# EDGAR Filing Document

**Accession Number:** 0000874501
**File Stem:** 0001628280-26-014653
**Filing Date:** 2026-3
**Character Count:** 766325
**Document Hash:** 15259e1974ab27d8221495ed1520bf97
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-014653.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001628280-26-014653

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 152

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OCTAVE SPECIALTY GROUP INC
- **CENTRAL INDEX KEY:** 0000874501
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURETY INSURANCE [6351]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 133621676
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-10777
- **FILM NUMBER:** 26721801

**BUSINESS ADDRESS:**
- **STREET 1:** 40 WALL STREET
- **STREET 2:** 55TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005
- **BUSINESS PHONE:** 2126587470

**MAIL ADDRESS:**
- **STREET 1:** 40 WALL STREET
- **STREET 2:** 55TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMBAC FINANCIAL GROUP INC
- **DATE OF NAME CHANGE:** 19980121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMBAC INC /DE/
- **DATE OF NAME CHANGE:** 19930328

?xml version='1.0' encoding='ASCII'? ambc-20251231

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i9cb0e1a24c9141e0943a78b7b32afc92_7)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

| | |
|:---|:---|
| **FORM** | **10-K** |

---

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Fiscal Year Ended December 31, 2025** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

---

| | |
|:---|:---|
| **Commission File Number:** | **1-10777** |

---

![Octave Logo.jpg](ambc-20251231_g1.jpg)

<u>OCTAVE SPECIALTY GROUP, INC.</u>

**(Exact name of Registrant as specified in its charter)**

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **Delaware** | **13-3621676** |
| **(State of incorporation)** | **(State of incorporation)** | **(State of incorporation)** | |
| **40 Wall Street** | **New York** | **NY** | **(I.R.S. employer identification no.)**<br>**10005** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip code)** |

---

---

| | |
|:---|:---|
| **(212)** | **658-7470** |
| **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** |

---

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act:  | Securities registered pursuant to Section 12(b) of the Act:  | Securities registered pursuant to Section 12(b) of the Act:  |
| **Title of each class** | **Trading Symbols** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | OSG | New York Stock Exchange |

---

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of "large accelerated filer", "accelerated filer", "smaller reporting company"and"emerging growth company" in Rule 12b-2 of the Exchange Act): (Check one):

Large accelerated filer ☐ Accelerated filer ☒ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive oﬃcers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The aggregate market value of voting stock held by non-affiliates of the Registrant as of the close of business on June 30, 2025 was $313,633,817. As of March 2, 2026, there were 44,951,913 shares of Common Stock, par value $0.01 per share, were outstanding.

**Documents Incorporated By Reference**

Portions of the Registrant's Proxy Statement related to its annual meeting of stockholders are incorporated by reference in this Form 10-K in response to Part III Items 10, 11, 12, 13, and 14.

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i9cb0e1a24c9141e0943a78b7b32afc92_7)

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**TABLE OF CONTENTS**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **<u>[Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995](#i9cb0e1a24c9141e0943a78b7b32afc92_10)</u>** | **<u>[Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995](#i9cb0e1a24c9141e0943a78b7b32afc92_10)</u>** | **<u>[Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995](#i9cb0e1a24c9141e0943a78b7b32afc92_10)</u>** | **<u>[Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995](#i9cb0e1a24c9141e0943a78b7b32afc92_10)</u>** | **<u>[Cautionary Statement Pursuant to the Private Securities Litigation Reform Act of 1995](#i9cb0e1a24c9141e0943a78b7b32afc92_10)</u>** | **<u>[1](#i9cb0e1a24c9141e0943a78b7b32afc92_10)</u>** |
| **Item Number** | **Item Number** | **Page** | **Item Number** | **Item Number** | **Page** |
| **[PART I](#i9cb0e1a24c9141e0943a78b7b32afc92_13)** | **[PART I](#i9cb0e1a24c9141e0943a78b7b32afc92_13)** |  | **PART II (CONTINUED)** | **PART II (CONTINUED)** |  |
| **1** | [Business](#i9cb0e1a24c9141e0943a78b7b32afc92_16) | **<u>[2](#i9cb0e1a24c9141e0943a78b7b32afc92_16)</u>** |  | <u>[Balance Sheet](#i9cb0e1a24c9141e0943a78b7b32afc92_133)</u> | **<u>[36](#i9cb0e1a24c9141e0943a78b7b32afc92_133)</u>** |
|  | <u>[Introduction](#i9cb0e1a24c9141e0943a78b7b32afc92_19)</u> | **<u>[2](#i9cb0e1a24c9141e0943a78b7b32afc92_19)</u>** |  | <u>[Accounting Standards](#i9cb0e1a24c9141e0943a78b7b32afc92_136)</u> | **<u>[38](#i9cb0e1a24c9141e0943a78b7b32afc92_136)</u>** |
|  | <u>Description of the Business</u> | **<u>[2](#i9cb0e1a24c9141e0943a78b7b32afc92_22)</u>** |  | <u>U.S. Insurance Basis Financial Results</u> | **<u>[38](#i9cb0e1a24c9141e0943a78b7b32afc92_139)</u>** |
|  | <u>[Enterprise Risk Management](#i9cb0e1a24c9141e0943a78b7b32afc92_34)</u> | **<u>[7](#i9cb0e1a24c9141e0943a78b7b32afc92_34)</u>** |  | <u>[Non-GAAP Financial Measures](#i9cb0e1a24c9141e0943a78b7b32afc92_142)</u> | **<u>[39](#i9cb0e1a24c9141e0943a78b7b32afc92_142)</u>** |
|  | <u>[Available Information](#i9cb0e1a24c9141e0943a78b7b32afc92_37)</u> | **<u>[9](#i9cb0e1a24c9141e0943a78b7b32afc92_37)</u>** | **7A** | <u>Quantitative and Qualitative Disclosures about Market Risk</u> | **<u>[41](#i9cb0e1a24c9141e0943a78b7b32afc92_145)</u>** |
|  | <u>[Insurance Regulatory Matters](#i9cb0e1a24c9141e0943a78b7b32afc92_40) and Other Restrictions</u> | **<u>[9](#i9cb0e1a24c9141e0943a78b7b32afc92_40)</u>** | **8** | <u>[Financial Statements and Supplementary Data](#i9cb0e1a24c9141e0943a78b7b32afc92_148)</u> | **<u>[43](#i9cb0e1a24c9141e0943a78b7b32afc92_148)</u>** |
|  | <u>[Investments and Investment Policy](#i9cb0e1a24c9141e0943a78b7b32afc92_52)</u> | **<u>[10](#i9cb0e1a24c9141e0943a78b7b32afc92_52)</u>** | **9** | <u>[Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](#i9cb0e1a24c9141e0943a78b7b32afc92_244)</u> | **<u>[93](#i9cb0e1a24c9141e0943a78b7b32afc92_244)</u>** |
|  | <u>[Employees](#i9cb0e1a24c9141e0943a78b7b32afc92_55)</u> | **<u>[10](#i9cb0e1a24c9141e0943a78b7b32afc92_55)</u>** | **9A** | <u>[Controls and Procedures](#i9cb0e1a24c9141e0943a78b7b32afc92_247)</u> | **<u>[93](#i9cb0e1a24c9141e0943a78b7b32afc92_247)</u>** |
| **1A** | <u>[Risk Factors](#i9cb0e1a24c9141e0943a78b7b32afc92_58)</u> | **<u>[10](#i9cb0e1a24c9141e0943a78b7b32afc92_58)</u>** | **9B** | <u>[Other Information](#i9cb0e1a24c9141e0943a78b7b32afc92_250)</u> | **<u>[94](#i9cb0e1a24c9141e0943a78b7b32afc92_250)</u>** |
| **1B** | <u>[Unresolved Staff Comments](#i9cb0e1a24c9141e0943a78b7b32afc92_85)</u> | **<u>[21](#i9cb0e1a24c9141e0943a78b7b32afc92_85)</u>** | **[PART III](#i9cb0e1a24c9141e0943a78b7b32afc92_253)** | **[PART III](#i9cb0e1a24c9141e0943a78b7b32afc92_253)** |  |
| **1C** | <u>[Cybersecurity](#i9cb0e1a24c9141e0943a78b7b32afc92_88)</u> | **<u>[21](#i9cb0e1a24c9141e0943a78b7b32afc92_88)</u>** | **10** | <u>[Directors, Executive Officers and Corporate Governance](#i9cb0e1a24c9141e0943a78b7b32afc92_256)</u> | **<u>[95](#i9cb0e1a24c9141e0943a78b7b32afc92_256)</u>** |
| **2** | <u>[Properties](#i9cb0e1a24c9141e0943a78b7b32afc92_91)</u> | **<u>[22](#i9cb0e1a24c9141e0943a78b7b32afc92_91)</u>** | **11** | <u>[Executive Compensation](#i9cb0e1a24c9141e0943a78b7b32afc92_259)</u> | **<u>[95](#i9cb0e1a24c9141e0943a78b7b32afc92_259)</u>** |
| **3** | <u>[Legal Proceedings](#i9cb0e1a24c9141e0943a78b7b32afc92_94)</u> | **<u>[23](#i9cb0e1a24c9141e0943a78b7b32afc92_94)</u>** | **12** | <u>[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i9cb0e1a24c9141e0943a78b7b32afc92_262)</u> | **<u>[95](#i9cb0e1a24c9141e0943a78b7b32afc92_262)</u>** |
| **4** | <u>[Mine Safety Disclosures](#i9cb0e1a24c9141e0943a78b7b32afc92_97)</u> | **<u>[23](#i9cb0e1a24c9141e0943a78b7b32afc92_97)</u>** | **13** | <u>[Certain Relationships and Related Transactions, and Director Independence](#i9cb0e1a24c9141e0943a78b7b32afc92_265)</u> | **<u>[95](#i9cb0e1a24c9141e0943a78b7b32afc92_265)</u>** |
| **[PART II](#i9cb0e1a24c9141e0943a78b7b32afc92_100)** | **[PART II](#i9cb0e1a24c9141e0943a78b7b32afc92_100)** |  | **14** | <u>[Principal Accountant Fees and Services](#i9cb0e1a24c9141e0943a78b7b32afc92_268)</u> | **<u>[95](#i9cb0e1a24c9141e0943a78b7b32afc92_268)</u>** |
| **5** | <u>[Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i9cb0e1a24c9141e0943a78b7b32afc92_103)</u> | **<u>[24](#i9cb0e1a24c9141e0943a78b7b32afc92_103)</u>** | **[PART IV](#i9cb0e1a24c9141e0943a78b7b32afc92_271)** | **[PART IV](#i9cb0e1a24c9141e0943a78b7b32afc92_271)** |  |
| **6** | <u>[Reserved](#i9cb0e1a24c9141e0943a78b7b32afc92_106)</u> | **<u>[25](#i9cb0e1a24c9141e0943a78b7b32afc92_106)</u>** | **15** | [Exhibits, Financial Statement Schedules](#i9cb0e1a24c9141e0943a78b7b32afc92_274) | **<u>[95](#i9cb0e1a24c9141e0943a78b7b32afc92_274)</u>** |
| **7** | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i9cb0e1a24c9141e0943a78b7b32afc92_109)</u> | **<u>[25](#i9cb0e1a24c9141e0943a78b7b32afc92_109)</u>** |  | <u>[Schedule I—Summary of Investment](#i9cb0e1a24c9141e0943a78b7b32afc92_280)[s](#i9cb0e1a24c9141e0943a78b7b32afc92_280)</u> | **<u>[99](#i9cb0e1a24c9141e0943a78b7b32afc92_280)</u>** |
|  | &nbsp;&nbsp;&nbsp;<u>Overview</u> | **<u>[26](#i9cb0e1a24c9141e0943a78b7b32afc92_115)</u>** |  | <u>[Schedule II—Condensed Financial Information of Registrant (Parent Company Only)](#i9cb0e1a24c9141e0943a78b7b32afc92_283)</u> | **<u>[100](#i9cb0e1a24c9141e0943a78b7b32afc92_283)</u>** |
|  | &nbsp;&nbsp;&nbsp;<u>Critical Accounting Policies and Estimates</u> | **<u>[27](#i9cb0e1a24c9141e0943a78b7b32afc92_118)</u>** |  | <u>[Schedule III—Supplementary Insurance Information](#i9cb0e1a24c9141e0943a78b7b32afc92_292)</u> | **<u>[105](#i9cb0e1a24c9141e0943a78b7b32afc92_292)</u>** |
|  | &nbsp;&nbsp;<u>[Results of Operations](#i9cb0e1a24c9141e0943a78b7b32afc92_121)</u> | **<u>[30](#i9cb0e1a24c9141e0943a78b7b32afc92_121)</u>** | **16** | Form 10-K Summary | **<u>[105](#i9cb0e1a24c9141e0943a78b7b32afc92_301)</u>** |
|  | &nbsp;&nbsp;<u>[Liquidity and Capital Resources](#i9cb0e1a24c9141e0943a78b7b32afc92_130)</u> | **<u>[35](#i9cb0e1a24c9141e0943a78b7b32afc92_130)</u>** | **<u>[SIGNATURES](#i9cb0e1a24c9141e0943a78b7b32afc92_304)</u>** | **<u>[SIGNATURES](#i9cb0e1a24c9141e0943a78b7b32afc92_304)</u>** | **<u>[106](#i9cb0e1a24c9141e0943a78b7b32afc92_304)</u>** |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>[&nbsp;&nbsp;&nbsp;&nbsp;](#i9cb0e1a24c9141e0943a78b7b32afc92_7)

**CAUTIONARY STATEMENT PURSUANT TO THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995** 

In this Annual Report, we have included statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "estimate," "project," "plan," "believe," "anticipate," "intend," "planned," "potential" and similar expressions, or future or conditional verbs such as "will," "should," "would," "could," and "may," or the negative of those expressions or verbs, identify forward-looking statements. We caution readers that these statements are not guarantees of future performance. Forward-looking statements are not historical facts, but instead represent only our beliefs regarding future events, which may by their nature be inherently uncertain and some of which may be outside our control. These statements may relate to plans and objectives with respect to the future, among other things which may change. We are alerting you to the possibility that our actual results may differ, possibly materially, from the expected objectives or anticipated results that may be suggested, expressed or implied by these forward-looking statements. Important factors that could cause our results to differ, possibly materially, from those indicated in the forward-looking statements include, among others, those discussed under "Risk Factors" in Part I, Item 1A in this Annual Report on Form 10-K.

Any or all of management's forward-looking statements, whether contained herein or in other publications may prove to be incorrect and are based on management's current belief or opinions. Octave Specialty Group's ("OSG") and its subsidiaries' (collectively, "Octave" or the "Company") actual results may differ materially from those expressed in, or implied by, these forward-looking statements,, and there are no guarantees about the performance of Octave's securities. Among events, risks, uncertainties or factors that could cause actual results to differ materially are: (1) the high degree of volatility in the price of OSG's common stock; (2) uncertainty concerning the Company's ability to achieve value for holders of its securities from the specialty property and casualty insurance business, the insurance distribution business, or related businesses; (3) greater than expected underwriting losses in the Company's specialty property and casualty insurance business resulting in inadequacy of loss and loss expense reserves and the possibility that changes in reserves may result in further volatility of earnings or financial results; (4) credit risk throughout Octave's business, including but not limited to issuers of securities in our investment portfolios, and exposures to reinsurers; (5) the Company's level of indebtedness, including its ability to generate sufficient cash to service obligations, refinance existing debt, or obtain additional financing on acceptable terms, and the resulting impact on financial condition and operating flexibility; (6) dependence on third parties, including specialty insurance program partners, reinsurers, distribution relationships, and other service providers, and the risk of failures or disruptions in their performance; (7) inability to obtain reinsurance coverage on economic terms; (8) loss of key relationships for production of business in specialty property and casualty and insurance distribution businesses or the inability to secure such additional relationships to produce expected results; (9) the impact of catastrophic public health, environmental or natural events, or political events, including as a result of global or regional conflicts; (10) restrictive covenants in agreements and instruments that impair Octave's ability to pursue or achieve its business strategies; (11) regulatory risks, including disagreements with insurance regulators, changes in laws or regulations, and the Company's ability to adapt to an evolving regulatory environment; (12) risks related to changes in the composition, valuation, or performance of the Company's investment portfolio, including interest rate and foreign currency exchange rate fluctuations; (13) events or circumstances that result in the impairment of our intangible assets and/or goodwill that was recorded in connection with Octave's acquisitions; (14) the risk of litigation, regulatory inquiries, investigations, claims or proceedings, and the risk of adverse outcomes in connection therewith; (15) system security risks, data protection breaches and cyber attacks; (16) our inability to attract and retain qualified executives, senior managers and other employees, or the loss of such personnel; (17) greater competition for our specialty property and casualty insurance business and/or our insurance distribution business; (18) loss or lowering of the AM Best rating for our property and casualty insurance company subsidiaries; (19) disintermediation within the insurance industry or greater competition from technology-based insurance solutions or non-traditional insurance markets; (20) changes in law or in the functioning of the healthcare market that impair the business model of our accident and health managing general agents; (21) failure to successfully execute business expansion initiatives, integrate acquired businesses, or realize anticipated benefits from such efforts and significant obligations under put rights granted in completed acquisitions; and (22) other risks and uncertainties that have not been identified at this time.

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>1</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**PART I**<br>

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Business**

**INTRODUCTION**

Octave Specialty Group, Inc. ("OSG"), headquartered in New York City, is a financial services holding company incorporated in the State of Delaware on April 29, 1991 and was formerly known as Ambac Financial Group, Inc. ("AFG"). In the fourth quarter of 2025, AFG changed its name and rebranded as OSG in connection with the sale of its Legacy Financial Guarantee business. References to "Octave," "OSG," the "Company," "we," "our," and "us" are to OSG and its subsidiaries, as the context requires. Octave operates two principal businesses:

&nbsp;&nbsp;&nbsp;&nbsp;• **Insurance Distribution —** Octave's specialty property and casualty ("P&C") insurance underwriting and distribution business, includes Managing General Agents and Underwriters (collectively "MGAs" or "MGA/Us"); an insurance broker; and other distribution, underwriting and related businesses. On October 31, 2025, the Company completed the acquisition of ArmadaCorp Capital, LLC and its subsidiaries (collectively, "ArmadaCorp"), a leading specialty accident and health MGA. Octave's insurance distribution platform operates in the following lines of business: property, niche specialty risk, accident & health, miscellaneous specialty, reinsurance, surety, marine & energy, specialty auto, E&S commercial package, professional lines and Directors & Officers ("D&O").

&nbsp;&nbsp;&nbsp;&nbsp;**• Specialty Property & Casualty Insurance** — Octave's Specialty Property & Casualty Insurance program insurer business currently includes five carriers (collectively, "Everspan"). Everspan carriers have an A.M. Best rating of 'A-' (Excellent) which was affirmed on July 17, 2025.

The Company reports these two business operations as segments; see *Note 3. Segment Information* for further information.

**Discontinued Operations**

On September 29, 2025, the Company completed the sale of its Legacy Financial Guarantee business, inclusive of Ambac Assurance Corporation ("AAC") and its wholly owned subsidiary Ambac Assurance UK Limited ("AUK"). The results of discontinued operations for all periods to the date of sale are reported separately as Net income (loss) from discontinued operations within the Consolidated Statements of Total Comprehensive Income for the current and prior periods. Assets and liabilities of AAC are presented on the Consolidated Balance Sheet as of December 31, 2024, under Assets of discontinued operations and Liabilities of discontinued operations. AAC's and AUK's cash flows for all periods to the date of sale are reflected as Net cash provided by (used in) discontinued operations within the Consolidated Statements of Cash Flows.

Refer to *Sale of Ambac Assurance Corporation* in Note 5. Discontinued Operations of the Notes to Consolidated Financial Statements under Part II, Item 8 of this Annual Report on Form 10-K for additional information.

OSG, on a standalone basis, had $76 million in net assets (excluding its investment in subsidiaries) and net operating loss carry-forwards of $1.7 billion at December 31, 2025. See Schedule II for more information on the holding company.

**Strategies to Enhance Shareholder Value**

The Company's primary goal is to maximize long-term shareholder value through the execution of targeted strategies for its Insurance Distribution and Specialty Property and Casualty Insurance businesses. Insurance Distribution and Specialty Property and Casualty Insurance strategic priorities include:

&nbsp;&nbsp;&nbsp;&nbsp;• Growing and expanding our Insurance Distribution business based on deep domain knowledge in specialty and niche classes of risk which generate attractive margins at scale. This will be achieved through establishing new businesses "de-novo," organic growth and diversification, and select acquisitions supported by a centralized technology-led shared services offering;

&nbsp;&nbsp;&nbsp;&nbsp;• Growing our Specialty Property and Casualty Insurance business to generate underwriting profits from a diversified portfolio of commercial and personal liability risks accessed primarily through affiliated and non-affiliated program administrators. In addition, we may seek strategic relationships and/or partnerships with unaffiliated parties in order to expand our product offerings, access to reinsurance capacity and other business or operational advantages.

**DESCRIPTION OF THE BUSINESS**

**Insurance Distribution ("ID")**

Octave's strategy is to build a diversified portfolio of MGA/Us and other insurance distributors covering various P&C products. Octave plans to grow its existing ID business using several strategies, including (i) organic growth, (ii) hiring experienced underwriting teams to incubate start-up ("de-novo") MGA/Us, and (iii) select acquisitions and/or partnerships. Octave continuously evaluates opportunities to acquire businesses and assets for its ID business, some of which may be material to our financial condition and operations and/or may involve raising capital to finance. Key criteria for acquisitions and underwriting teams include a track record of profitability and a seasoned management team. Insurance underwritten through Octave's MGA/Us may utilize Everspan as an insurance carrier, but are not required to do so, depending on strategic and operational considerations.

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>2</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

The following table sets forth ID's premiums placed by line of business:

---

| | | |
|:---|:---|:---|
| **($ in thousands)<br>Year ended December 31,** | **2025** | **2024** |
| Property | $**220879** | $64975 |
| Niche Specialty Risks | **144740** | 56203 |
| Accident & Health | **133352** | 127646 |
| Specialty Auto | **106721** | 93035 |
| Other professional | **77702** | 51698 |
| Misc. Specialty | **25429** | 5904 |
| Surety | **55912** | 27680 |
| Environmental | **50368** | 17793 |
| Marine & Energy | **44880** | 24864 |
| Reinsurance | **41717** | 10030 |
| Professional D&O | **50081** | 13545 |
| **Premiums placed** | $**951781** | $**493373** |

---

The ID's portfolio at December 31, 2025 includes the following entities:

**Xchange Benefits, LLC ("Xchange")** — Octave owns an 80% controlling interest in Xchange. Xchange operates through specialty producers in accident and health ("A&H") sectors across the U.S. which are typically not targeted by large direct writers and to whom Xchange can provide customized offerings. Xchange conducts business through approximately eleven insurance carriers and dozens of agents and other distributors. Under the terms of applicable agreements, the redeemable minority interest of 20% can be exercised beginning December 31, 2025.

Xchange's main products for which it is delegated underwriting authority by insurance carriers include: Employer Stop Loss ("ESL"), Limited Benefit Medical ("LM"), Short-term Medical ("STM"), and Travel and Reinsurance ("Xchange Re").

**All Trans Risk Solutions, LLC ("All Trans")** — Effective November 1, 2022, Octave acquired an 85% controlling interest in All Trans. All Trans is a full-service managing general underwriter with delegated underwriting authority in commercial automobile insurance for specific "for-hire" auto classes; principally private school bus operators. In 2024, All Trans launched a new program focussed on charter buses, livery and non-emergency medical vehicles. All Trans' track record of performance has allowed the company to maintain a consistent panel of insurance carriers and client relationships, several of which go back over 25 years. Under the terms of applicable agreements, the redeemable minority interest of 15% can be exercised beginning November 1, 2027.

**Capacity Marine Corporation ("Capacity Marine")** — Effective November 1, 2022, Octave acquired an 80% controlling interest in Capacity Marine. Capacity Marine is a wholesale and retail brokerage and reinsurance intermediary specializing in more sophisticated marine and international risk expsoures such as ports, terminals, and stevedores. Under the terms of applicable agreements, the redeemable minority interest of 20% can be exercised beginning November 1, 2027.

**Riverton Insurance Agency, Corp. ("Riverton")** — Effective August 1, 2023, Octave acquired an 80% controlling interest in Riverton. Riverton offers professional liability insurance

programs to licensed architects, engineers, construction managers and real estate professionals. Riverton's retail agency places professional liability for real estate agents with various markets. Under the terms of applicable agreements, the redeemable minority interest of 20% can be exercised beginning February 7, 2030.

**Tara Hill Insurance Services, LLC ("Tara Hill")** — Tara Hill is a de novo startup which began operations in October 2024. Tara Hill is 100% owned by Octave. Tara Hill is a program administrator focused on the underwriting of Management and Professional Liability exposures for non-public organizations ("Professional D&O"). Tara Hill helps to protect private companies' directors, officers and members of their management teams against possible financial loss.

**Octave Specialty Limited ("Octave Ventures") formerly Beat Capital Partners Limited** — Effective July 31, 2024, Octave acquired an approximately 60% controlling interest in Octave Ventures, a London-based insurance underwriting and MGA/U platform. Octave Ventures specializes in incubating de-novo MGA/Us by partnering with leading underwriting teams and providing such teams with funding, infrastructure and risk capital through access to two managed Lloyd's syndicates. Octave Ventures's 15 majority-owned MGA/Us (Octave Ventures typically owns between 60% and 80% of each MGA/U) offer alternative risk binders, as well as global direct and facultative property, directors and officers, credit, professional errors and omissions, energy, environmental and accident and health coverage. Under the terms of applicable agreements, the remaining 40% redeemable minority interest is exercisable each year beginning March 31, 2026 to March 31, 2029, with 25% of the option becomes exercisable each year.

**Pivix Specialty Insurance Services, Inc. ("Pivix")** — Effective September 1, 2025, OSG exercised an option to convert its $3.5 million convertible note investment in Pivix, an excess and surplus lines MGA/U, into common stock. As a result, Octave now has an approximately 74% controlling stake in Pivix and includes Pivix in its consolidated financial statements. Under the terms of applicable agreements, the redeemable minority interest of 26% can be exercised beginning October 7, 2029.

**ArmadaCorp Capital LLC ("ArmadaCorp")** — On October 31, 2025, the Company closed on the acquisition of ArmadaCorp for a purchase price of $250 million. The Company purchased all of the issued and outstanding limited liability company interests in ArmadaCorp from Sirius Re Holdings, Inc. and Sirius Acquisitions Holding Company, funded in part by $120 million of loans obtained under new credit facilities. See Note 1. Background and Business Description to the Consolidated Financial Statements included in this Annual Report on Form 10-K for further detail about the credit facility.

ArmadaCorp includes an MGA/U that focuses on supplemental health and benefit products for C-suite executives and other key talent. ArmadaCorp creates and distributes supplemental benefit solutions and insurance products. ArmadaCorp's differentiated product offering in the A&H market provides both line of business and product diversification to the Company, while also increasing exposure to non-correlated A&H business lines. ArmadaCorp also provides clients with tools to navigate the

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>3</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

healthcare system, including services that help match individuals with physicians suited to their personal needs, and maintains a provider of third-party administration services for insurance carriers that distribute the benefit products and handle claims.

In addition to existing MGA/Us and acquisitions, de-novo MGA/U formations, primarily through Octave Ventures, will be a core element of the ID segment's growth strategy.

ID's businesses are compensated for their services primarily by commissions paid by insurance carriers for underwriting, structuring and/or administering polices and, in some cases for managing claims under agency agreements. Commission revenues are usually based on a percentage of the premiums placed. The businesses are also eligible to receive profit sharing contingent commissions on certain programs based on the underwriting results of the policies they write, which may cause some variability in revenue and earnings recognition. Commission revenues experience seasonality during the year which can lead to concentrations of revenues and earnings in certain quarters, including the first and fourth quarters of each year. Given recent acquisitions and potential de-novo launches, seasonality patterns may change over time.

Expenses at the ID companies include commissions the businesses pay to their independent agents/producers, compensation for their management and staff, general overhead and intangible asset amortization from acquisitions. Commission expenses are a variable cost as we pay a percentage of premiums written to the agents/producers.

ID generated gross commission revenue and net commission revenue (commissions less commission expenses) during the years ended December 31, 2025 and 2024 as shown below.

---

| | | |
|:---|:---|:---|
| **($ in thousands)<br>December 31,** | **2025** | **2024** |
| Gross commissions | $**143381** | $92023 |
| Net Commissions | **106344** | 51147 |

---

Commission revenue and expense growth will be driven by the businesses' continued expansion and diversification of its products across regions, product, distribution partners and carriers.

**<u>Competitive Strengths:</u>**

&nbsp;&nbsp;&nbsp;&nbsp;**• Strategic operator —** Octave is a strategic operator with MGA/Us and Programs at the center of our business. This provides MGA/U principals the confidence and freedom to focus on building their businesses without the distraction of either subsequent ownership change or de-emphasis of the sector.

&nbsp;&nbsp;&nbsp;&nbsp;• **Partnership model —** Our partnership-based model is built around having MGA/U principals maintain ownership or direct economic alignment with the performance of their respective business. We believe this direct economic connection is valuable in both producing top-tier underwriting and attracting top underwriting talent who share an entrepreneurial mindset.

&nbsp;&nbsp;&nbsp;&nbsp;• **Aligned & managed capacity —** By maintaining direct access to rated and licensed insurance capacity our ID segment can accelerate the time to launch new MGA/Us.

&nbsp;&nbsp;&nbsp;&nbsp;**• Shared services platform —** One of the challenges new MGA/Us face while scaling their business is managing the increasing administrative burden. Our ID platform offers a range of shared services across IT, HR, and Finance which both provides economies of scale for these functions and allows for the principals to focus their efforts on building their franchises.

&nbsp;&nbsp;&nbsp;&nbsp;• **Deep specialty domain knowledge** — Our ID businesses are anchored by a deep specialty domain knowledge in their respective classes of business. This knowledge is key to generating the underwriting results necessary to maintain long-standing carrier relationships.

&nbsp;&nbsp;&nbsp;&nbsp;• **Strong distribution relationships** — Distribution relationships provide value in several ways. First, carrier and capital partners are looking for both underwriting expertise and distribution access when working with MGA/Us. In addition, the quality of distribution relationships helps provide our MGA/Us with access to higher quality risks from the wholesale and retail agents which we believe over time will help produce better underwriting results.

**<u>Competition:</u>**

The MGA/U insurance sector is highly fragmented and competitive, and firms actively compete with Octave's businesses for customers and insurance carrier capacity. Our main competitors in this segment include other MGA/U aggregators (such as Amynta), wholesale brokers (such as Ryan Specialty) and insurance carriers that choose to write insurance without the assistance of MGA/Us. Given our competitive strengths, we believe that we can compete effectively in this sector of the market.

**P&C Industry Overview**

We operate within the estimated $1 trillion U.S. P&C insurance market with a particular focus on the commercial MGA/U program market, both on an Admitted and Excess & Surplus Lines ("E&S") basis.

**<u>Admitted and E&S Insurance</u>**

Insurance carriers sell commercial P&C products in the United States through one of two markets: the Admitted market or the E&S market.

The Admitted insurance market, which has highly regulated rates and policy forms, is more consistent in price and coverage. In the E&S market, there is increased flexibility in pricing, terms and conditions in response to evolving market dynamics, and

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>4</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

E&S carriers can tailor insurance products to facilitate coverage that would not otherwise be attainable. This flexibility lends itself to the provision of solutions for unique risks, which has driven meaningful growth within the E&S market over the last decade, exceeding the growth rate of the Admitted market.

According to data from AM Best, the E&S market generated just under $130 billion of direct written premium in 2024, an increase of 12.3% over the prior year and represents 12.3% of the industry direct premium volume. The E&S market is more heavily focused in commercial lines and accounted for almost 26% of total commercial direct written premium in 2024. The E&S market has nearly doubled from $66 billion in 2019 to $130 billion in 2024, a 14.5% compound annual growth rate compared to 8.3% for the overall P&C industry.

Everspan presently has four admitted carriers, which are wholly-owned at December 31, 2025: Everspan Insurance Company; Greenwood Insurance Company; Consolidated Specialty Insurance Company and Providence Washington Insurance Company. Everspan Indemnity Insurance Company ("Everspan Indemnity"), an E&S carrier that is eligible to write business in all U.S. states and territories, is also part of Everspan.

**<u>MGA/U Program Market</u>**

It is estimated by Conning, Inc. ("Conning") that the U.S. MGA/Us market exceeded $110 billion in 2024. We believe there are significant advantages to the MGA/U business model when it comes to capturing the opportunity in the E&S market and propelling profitable growth. MGA/Us are specialized types of insurance agents or brokers that are vested with underwriting authority from an insurer, administering programs and negotiating contracts on their behalf. This is a particularly useful vehicle for P&C insurers as MGA/Us tend to participate in the E&S market where specialized expertise is needed to underwrite policies. Additionally, MGA/Us are cost-effective means for an insurer or reinsurer to access or grow a particular class of business they find attractive given that MGA/Us already possesses product expertise and distribution capabilities.

According to data from Conning, the MGA/U sector is one of fastest growing segments of the U.S. P&C insurance market with 2024 statutorily reported direct premium written of $92 billion, an increase of 15% over the prior year. In 2024, Conning identified over 850 MGAs in the U.S. market with around 250 small MGAs not counted in that group as their premium production falls below the 5% statutory filing threshold. We believe the growth in the MGA/U and program space is likely to continue as the industry continues its move towards increased specialization.

**Specialty Property and Casualty Insurance**

Everspan's strategy is to generate sustainable and profitable long-term specialty property and casualty program business with a focus on diverse classes of commercial and personal liability risks across an expanding roster of MGA/U partners.

As a specialty property and casualty program group, Everspan may retain a percentage of the business it underwrites. Everspan's management team has significant years of experience in the program insurance and reinsurance sectors and has long-standing and broad relationships with MGA/Us, reinsurers,

brokers, producers and third-party claims administrators ("TPAs"). Everspan sources business through program administrators and managing general agents, reinsurers, brokers, producers and others. Subject to Everspan's operational oversight, Everspan engages these third parties to market and administer policies and handle claims within defined authorities on Everspan's behalf.

Everspan is focused on generating strong underwriting results and stable fee income as part of its specialty program business model.

For the year ended December 31, 2025, Everspan generated $360,449 of gross written premium, of which Everspan retained approximately 20.5%, including assumed written premiums. Everspan retained approximately 12.9% of its direct written premiums, with the balance primarily ceded to quota share reinsurers.

Everspan may retain up to 30% of risk on each direct program and will reinsure the remainder to reinsurers and other providers of risk capital. These may be domestic or foreign reinsurers and institutional risk investors (capacity providers). On certain programs, Everspan may retain greater than 30%, however such programs generally include a sliding scale commission with the respective MGA/U that adjusts based on the performance of the program.

While underwriting direct business produced by MGA/Us is Everspan's primary means of distribution, Everspan also selectively assumes reinsurance to further its goal of writing a diversified book of specialty P&C business while managing its exposure limits. For example, the Company would evaluate, and may write certain lines, including those with catastrophe risk or workers' compensation on an assumed basis. Everspan may participate as a reinsurer on up to 30% of a program, which is in line with its strategy to retain up to 30% of risk per program. Participation as a reinsurer will affect the retention ratio as Everspan's portion of assumed premiums is reflected fully in both Gross and Net Written Premiums.

The following table sets forth gross written premiums (direct and assumed) by line of business for the years ended December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **($ in thousands)<br>Year Ended December 31,** | **2025** | **2024** |
| &nbsp;&nbsp;Excess liability | $**123727** | $95827 |
| &nbsp;&nbsp;Commercial auto liability | **64404** | 78238 |
| &nbsp;&nbsp;Multi-Peril / Business Owners (BOP) | **41290** | 1680 |
| &nbsp;&nbsp;Professional Lines | **35888** | 41534 |
| &nbsp;&nbsp;General liability | **30196** | 77767 |
| &nbsp;&nbsp;Surety | **29875** | 34794 |
| &nbsp;&nbsp;Workers Compensation | **28057** | 28294 |
| &nbsp;&nbsp;Commercial auto physical damage | **908** | 1480 |
| &nbsp;&nbsp;Non-standard auto | **21** | 20186 |
| &nbsp;&nbsp;Other | **6082** | 2970 |
| **Gross written premiums** | $**360449** | $**382770** |

---

Everspan purchases reinsurance to manage its net retention on individual risks and overall exposure to losses, while providing Everspan with the ability to offer policies with sufficient limits

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>5</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

to meet producer and policyholder needs. Generally, reinsurance contracts are specific to a program and are renewed annually, at which time they are subject to renegotiation. The key contractual provisions include, but are not limited to, those relating to the scope of business reinsured, ceding commissions, required reports to reinsurers, dispute resolution, any required collateral, and Everspan's termination rights in circumstances where, among other triggers, a reinsurer defaults (such as by failing to collateralize its obligations when required) or its financial strength falls below an agreed level. Everspan's ceded reinsurance contracts do not legally discharge Everspan from its primary liability for the full amount of the policies, and Everspan will be required to pay the loss and bear collection risk if a reinsurer fails to meet its obligations under the reinsurance agreement.

Everspan mitigates this credit risk by selecting well- capitalized, highly rated, authorized capacity providers, or requiring that the capacity provider post collateral, typically in the form of letters of credit issued by or trust accounts in the custody of National Association of Insurance Commissioners ("NAIC") qualified financial institutions, to secure the reinsured risks.

The following graph shows our reinsurance carriers' AM Best rating based on share of ceded premium for the year ended December 31, 2025:

![3993](ambc-20251231_g2.jpg)

(1)NR represents reinsurance carriers not rated by AM Best. Generally, under the terms of reinsurance contracts with such carriers the reinsurer is required to post collateral to Everspan.

See Note 8. Insurance Contracts to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K for further information on reinsurance recoverables, including the evaluation for credit impairments.

**<u>Competitive Strengths:</u>**

Specialty Property and Casualty Insurance is a competitive industry. Everspan believes that it can successfully operate in this industry in part based upon the following competitive strengths.

&nbsp;&nbsp;&nbsp;&nbsp;• **Experience** — Everspan has an experienced leadership team across underwriting, pricing, claims, and business development with an average tenure of over 30 years in the insurance industry.

&nbsp;&nbsp;&nbsp;&nbsp;• **Underwriting Focused Strategy** — Everspan is driven by underwriting performance, which is achieved via

evaluation and monitoring of MGA/U partners from our in-house pricing actuaries, claims executives, and program managers. This underwriting focus also aids in achieving and maintaining support from reinsurance partners.

&nbsp;&nbsp;&nbsp;&nbsp;• **Risk Appetite** — Everspan generally may retain up to 30% of the risk it underwrites. This meaningful participation serves to align interests with our reinsurers.

&nbsp;&nbsp;&nbsp;&nbsp;• **Commitment to Program Distribution** — Everspan does not have any direct distribution capability as it is committed to the program market distributed through MGA/Us. As a result, Everspan does not have channel conflicts which would compete with programs partners in underwriting business.

&nbsp;&nbsp;&nbsp;&nbsp;• **Nimble Platform** — A simplified organizational structure allows Everspan to be efficient and quick in responding to the needs of program partners as well as in finding customized solutions. We believe this provides a competitive advantage over the more traditional competitors in the market.

&nbsp;&nbsp;&nbsp;&nbsp;• **Aligned Ownership** — Everspan has a stable ownership structure which is focused on long-term value creation based on strong underwriting performance. This alignment of interest and strategic vision allows Everspan to leverage resources across Octave and access capital for future initiatives.

**<u>Competition:</u>**

Everspan faces competition from program business market participants such as Accelerant, Clear Blue, Core Specialty, Fortegra, Obsidian, Sutton National, State National, Transverse, and Trisura. Most of these entities have both admitted and E&S carriers. Competition may take the form of lower program fees, broader coverages, greater product flexibility, higher coverage limits, greater customer service or higher financial strength ratings by independent rating agencies. Few barriers exist to prevent existing insurers from entering target markets within the property and casualty industry. Market conditions and capital capacity influence the degree of competition at any point in time. A number of competitors to Everspan have announced or are rumored to be exploring plans for strategic alternatives. Exploring strategic alternatives may be triggered by the objectives of owners (like private equity funds), weak financial performance, capital and capacity shortfalls or valuation considerations, amongst a number of other reasons. The impact of consolidation amongst program market carriers on Everspan is hard to predict and may have adverse or favorable consequences.

During periods of excess underwriting capacity, as defined by the availability of capital, competition can result in lower pricing and less favorable policy terms and conditions for insurers. During periods of reduced underwriting capacity, pricing and policy terms and conditions are generally more favorable for insurers. Historically, the performance of the property and casualty insurance industry has tended to fluctuate in cyclical periods of price competition and excess underwriting capacity, followed by periods of high premium rates and shortages of underwriting capacity. At any given time, Everspan's portfolio of insurance products could experience varying combinations of these characteristics. This cyclical market pattern can be more pronounced in the specialty insurance and reinsurance markets

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>6</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

in which Everspan competes than in the standard insurance market. For the last several years, the property and casualty industry has been in a period of high premium rates with a shortage of underwriting capacity. While not anticipated to end in the short-term, this cyclical period will eventually end, perhaps unexpectedly. The end of this favorable cycle could have negative consequences for Everspan's growth and profitability prospects.

**<u>Business Acquisition and Program Partner Selection:</u>**

With our focus on generating long-term underwriting profitability, we are selective in adding new program partners. We look for program partners that share our vision of underwriting performance and return expectations and consequently are selective with whom we partner with. As of December 31, 2025, we have 25 programs with 21 MGA/Us. In 2025, approximately 106 submissions were evaluated and we agreed to contract 4 new programs including two new MGA/Us and two MGA/Us with an existing relationship, while renewing or extending twenty-one programs with seventeen incumbent MGA/Us. Included in 2025 renewed programs is one executed via assumed reinsurance. At times, it will be necessary to exit or discontinue certain programs when the risk profile or performance no longer meet our underwriting expectations or tolerances.

As noted above, most of Everspan's programs are sourced either from MGA/Us or through other third parties, such as reinsurance brokers, that are seeking to provide customized insurance solutions that require a carrier with a high rating from AM Best. Everspan works with MGA/Us that leverage both data and technology to streamline or improve the underwriting process.

Everspan may also source programs as a reinsurer. Accessing programs as a reinsurer provides Everspan with the ability to diversify its risk profile, efficiently manage its exposure limits and underwrite programs in a cost efficient manner, amongst other benefits.

For each new opportunity that Everspan chooses to evaluate, an initial evaluation of the MGA/U is conducted, including an assessment of its underwriting approach, philosophy, size, quality of management, past performance, future performance targets and, above all, compatibility with Everspan's operating model, risk appetite, and existing book of business. Everspan conducts substantial due diligence on all program partners led by the Underwriting Risk Committee, which is chaired by Everspan's Chief Underwriting Officer. As part of the diligence process, Everspan works closely with potential MGA/Us to design program underwriting guidelines, and ongoing reporting and auditing requirements. Everspan also typically requires the producing partner to retain underwriting risk or otherwise align incentives with program underwriting performance.

Additionally, as part of the diligence process for each program, Everspan will perform a review of the claims management function, typically performed by a TPA, which in some cases are managed by the MGA/U or producing partner. Diligence focuses on claims handling and litigation management, compliance, finance, governance, staff and vendor management, data and IT.

After due diligence is completed and acceptable reinsurers are identified, each program is presented to the Underwriting Risk Committee for final approval. The Underwriting Risk Committee will consider recommendations made by the credit subcommittee regarding the financial strength of the MGA/Us and/or reinsurers.

**<u>Ongoing Monitoring:</u>**

For active programs, Everspan authorizes MGA/Us to underwrite and bind coverages in accordance with approved underwriting guidelines and delegates authority to the TPA for claims adjustment and payment. Everspan monitors each MGA/U and TPA's adherence to the agreed upon underwriting and claims guidelines. Everspan will conduct periodic reviews of loss experience, rate levels, reserves and the overall financial health of the MGA/U and TPA and hold monthly underwriting meetings with both the MGA/U and TPA. Underwriting and claims data is provided by the MGA/Us and TPAs monthly. Additionally, Everspan conducts underwriting, claims and accounting audits, generally on-site, at least once a year for MGA/U and TPA partners which administer a material amount of Everspan's business. Everspan determines whether it will continue to participate on a program no less than annually, generally at the anniversary date of the program. The renewal process entails an assessment, with Underwriting Risk Committee participation, of the program's operating performance, profitability, and available reinsurance capacity. Everspan maintains the right to terminate relationships with its MGA/Us and TPAs. Reasons to terminate a relationship include an inability to produce targeted underwriting results, writing exposures outside of agreed upon risk tolerances, delinquency in meeting reporting requirements, a change of strategic direction, or failure to meet collateral or other commitments to Everspan.

**<u>Ratings:</u>**

Everspan carriers have an AM Best financial strength ratings ("FSR") of 'A-' (Excellent) and Financial Strength Category of Class VIII. Risk is shared among the Everspan carriers via a reinsurance agreement and an intercompany pooling agreement (the "Everspan Pool"). We view this rating and financial size category as a competitive advantage in the marketplace. Ratings are an important factor in assessing Everspan's competitive position, operating capabilities and risk management in the insurance industry.

**ENTERPRISE RISK MANAGEMENT**

The Company's policies and procedures relating to risk assessment and risk management are overseen by its Board of Directors. The Board of Directors takes an enterprise-wide approach to risk management oversight that is designed to support the Company's business plans at a level of risk considered by the Board to be reasonable. A fundamental part of risk assessment and risk management is not only understanding the risks the Company faces and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for the Company. The Board of Directors periodically reviews the Company's business plan, taking risk management into account. It also approves the Company's risk appetite statements, which articulate the Company's tolerance for certain risks and describe the general types of risk that the

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>7</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Company accepts, within certain parameters, or attempts to avoid.

While the Board of Directors has the ultimate oversight responsibility for the risk management process, various committees of the Board also have responsibilities related to risk assessment and risk management, and management has responsibility for managing the risks to which the Company is exposed and reporting on such matters to the Board of Directors and applicable Board committees.

&nbsp;&nbsp;&nbsp;&nbsp;• The Audit Committee oversees the management of risks associated with the integrity of Octave's financial statements and its compliance with legal and regulatory requirements. In addition, the Audit Committee discusses policies with respect to risk assessment and risk management, including major financial risk exposures and the steps management has taken to monitor and control such exposures. The Audit Committee reviews with management, internal auditors and independent auditors Octave's critical accounting policies, Octave's system of internal controls over financial reporting and the quality and appropriateness of disclosure and content of financial statements and other external financial communications.

&nbsp;&nbsp;&nbsp;&nbsp;• The Compensation Committee oversees the management of risk primarily associated with our ability to attract, motivate and retain quality talent (particularly executive talent) and with setting financial incentives that do not motivate undue risk-taking.

&nbsp;&nbsp;&nbsp;&nbsp;• The Governance and Nominating Committee oversees the management of risk primarily associated with Octave's ability to attract and retain quality directors, Octave's corporate governance programs and practices and our compliance therewith, including integration of ESG and sustainability policies, practices and goals into the Company's business strategy and decision making. Additionally, the Governance and Nominating Committee oversees the processes for evaluation of the performance of the Board of Directors and its committees each year and considers risk management effectiveness as part of its evaluation. This committee also reviews succession plans for Octave's executive officers, including the Chief Executive Officer. The Governance and Nominating Committee also performs oversight of the business ethics and compliance program and reviews compliance with Octave's Code of Business Conduct.

&nbsp;&nbsp;&nbsp;&nbsp;• The Strategy Committee oversees the management of strategic plans and initiatives.

The Board of Directors receives quarterly updates from Board committees and the Board provides guidance to individual committee activities, as appropriate.

In order to assist the Board of Directors in overseeing Octave's risk management, Octave uses enterprise risk management, a company-wide process that involves the Board of Directors, management and other personnel in an integrated effort to identify, assess and manage a broad range of risks (e.g., credit, financial, legal, liquidity, market, model, fraud, operational, regulatory, reputational and strategic) that may affect the Company's ability to execute on its corporate strategies and fulfill its business objectives. The Enterprise Risk Committee

("ERC"), which is a management committee, is comprised of executive and senior level management responsible for assisting in the management of the Company's risks on an individual and aggregate basis. The ERC produces the relevant risk management information for executive and senior management and the Board of Directors.

Octave management has established other management committees to assist in managing the risks throughout the enterprise. These committees will meet monthly or as needed on an ad hoc basis.

&nbsp;&nbsp;&nbsp;&nbsp;• The Disclosure Committee's objective is to assist the CEO and CFO in their responsibilities to design, establish, maintain and evaluate the effectiveness of disclosure controls and procedures. Members of the Disclosure Committee include the CEO, CFO, Chief Accounting Officer, General Counsel, Group Chief Operating Officer, who is also the Head of Risk Management, and senior managers from finance and legal.

&nbsp;&nbsp;&nbsp;&nbsp;• The Everspan Underwriting Risk Committee's objective is to provide oversight of the active underwriting operations of Everspan, develop underwriting parameters, and assist the Boards of the Everspan companies in overseeing the integrity and effectiveness of Everspan's underwriting risk management framework. Members of the committee include the CEO, key members of Everspan management and other senior managers or advisors of Octave. Additionally, a Reinsurance and Program Administrator Credit Risk sub-committee was established at the direction of the Underwriting Risk Committee to assist with the management of credit risk emanating from ceded reinsurance and program administrators.

&nbsp;&nbsp;&nbsp;&nbsp;• ***Subsidiary Boards of Directors***. Each of Octave's subsidiaries has an Octave management-led Board charged with overseeing the strategy, performance and operations of such subsidiary. These subsidiaries include Everspan as well as each of our MGA/Us. Many of these Boards are led by Executive Management of OSG and, in other instances, senior management from throughout the organization. Occasionally, our subsidiary boards may also include independent members that are not employees of Octave or its subsidiaries. Many of our MGA/U subsidiaries also maintain Underwriting Committees to oversee the underwriting quality and risk management of such underwriting unit. These Underwriting Committees provide regular updates to their respective Boards of Directors.

The Company's Enterprise Risk Management efforts build upon the foundation of an effective internal control environment. The design of any risk management or control system must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. As a result, the possibility of material financial loss remains regardless of the Company's Enterprise Risk Management efforts. An investor should carefully consider the risks and all of the other information set forth in this annual report, including the discussions included in Item 1A. Risk Factors, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, and Item 8. Financial Statements and Supplementary Data.

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>8</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**AVAILABLE INFORMATION**

Our Internet address is www.octavegroup.com. We make available through the investor relations section of our web site, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as well as proxy statements, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the U.S. Securities and Exchange Commission. Our Investor Relations Department can be contacted at Octave Specialty Group, Inc., 40 Wall Street, 55th Floor, New York, New York 10005, Attn: Investor Relations; telephone: 212-208-3277; email: ir@octavegroup.com. The reference to our website address does not constitute inclusion or incorporation by reference of the information contained on our website in this Annual Report on Form 10-K or other filings with the SEC and the information contained on our website is not part of this document.

**INSURANCE REGULATORY MATTERS AND OTHER RESTRICTIONS**

**Regulatory Matters**

Everspan Indemnity and its wholly owned subsidiary, Everspan Insurance Company ("Everspan Insurance"), and Everspan Insurance's wholly owned subsidiary, Consolidated Specialty Insurance Company are domiciled in the state of Arizona and are therefore subject to the insurance laws and regulations of the State of Arizona and regulated by the Arizona Department of Insurance and Financial Institutions as domestic insurers. Everspan Insurance's remaining subsidiaries, Greenwood Insurance Company and Providence Washington Insurance Company, are domiciled in the state of Pennsylvania and the state of Rhode Island, respectively, and are therefore subject to the insurance laws and regulations of their respective domiciliary States and regulated by the insurance departments of those States as domestic insurers. Everspan Insurance and its subsidiaries are also subject to the insurance laws and regulations of the other jurisdictions in which they are licensed and operate as foreign insurers in such jurisdictions. See Note 9. Insurance Regulatory Restrictions to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K for further information on regulatory restrictions.

The ID businesses, like other MGA/Us, program administrators and brokers, may be subject to licensing requirements and regulation by insurance regulators in various states and other applicable regulatory jurisdictions in which they conduct business.

Octave Ventures and its UK domiciled entities are subject to the UK Companies Act 2006 as well as to insurance laws and regulations of the UK and other jurisdictions in which they operate. Additionally, some of the Octave Ventures subsidiaries, while not regulated entities, must act in line with the regulations of the Financial Conduct Authority and Prudential Regulation Authority as appointed representatives of regulated entities.

Octave Ventures's subsidiary, Alcor Underwriting Bermuda, is domiciled in Bermuda and is subject to the insurance laws and regulations of Bermuda and regulated by the Bermuda Monetary Authority (the "BMA").

Octave Venture's subsidiary, Statera Managing Agency Limited, was authorized by the Prudential Regulation Authority to act as a Lloyd's managing agent in December 2025. It is regulated by the Prudential Regulation Authority and Financial Conduct Authority. The principal activity of the subsidiary is to manage syndicates at Lloyd's of London.

**<u>Regulation of Change in Control</u>**

Under applicable insurance law, any acquisition of control of OSG, or any other direct or indirect acquisition of control of its insurance carrier subsidiaries, requires the prior approval (or non-disapproval) of the domiciliary regulator of the acquired company (or, in the case of OSG, the domiciliary regulators of its insurance carrier subsidiaries). "Control" is generally defined as the direct or indirect power to direct or cause the direction of the management and policies of a person. Any purchaser of 10% or more of the outstanding voting stock of a corporation is presumed to have acquired control of that corporation and its subsidiaries unless the applicable insurance regulator, upon application, determines otherwise. For purposes of this test, OSG believes that a holder of common stock having the right to cast 10% or more of the votes which may be cast by the holders of all shares of common stock of OSG would be presumably deemed to have control of OSG's insurance carrier subsidiaries within the meaning of applicable insurance laws and regulations, although insurance regulators may in their discretion deem control not to exist where, for example, control is disclaimed by a passive investor.

Additionally, any change in control of Octave Ventures would need to be approved by Lloyds of London, the BMA and any applicable U.S. regulators.

**Dividend Restrictions, Including Contractual Restrictions** 

***Everspan Companies:***

Everspan Indemnity, Everspan Insurance and its subsidiaries are subject to regulatory restrictions on their ability to pay dividends. Certain subsidiaries do not have sufficient earned surplus at this time to pay ordinary dividends under the insurance laws and regulations of their respective states of domicile. Currently, the only Everspan Insurance subsidiaries that have sufficient earned surplus to pay dividends are Greenwood Insurance Company and Providence Washington Insurance Company. Octave does not have any plans to seek dividends from Everspan so that surplus may accumulate to support Everspan's growth.

***Insurance Distribution Companies:***

Octave's MGA/U subsidiaries are not restricted from paying dividends or partner distributions (collectively "Distributions") to their owners or partners, including Octave Partners, which is 100% owned by OSG. Most of Octave's established MGA/Us historically have paid Distributions equating to the majority of their individual EBITDA, subject to working capital, taxes and other capital needs. Newly formed de-novo MGA/Us are not expected to make regular distributions to their partners until they become profitable and generate free cash flow on a steady and/or predictable basis.

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>9</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Octave Venture's subsidiary, Statera Managing Agency Limited, has a minimum capital requirement determined by the Lloyd's Underwriting Byelaws. Its minimum capital requirement is dependent on the amount of managed syndicate capacity. Dividends can be made as long as it doesn't affect the minimum capital requirement for a Lloyd's managing agent.

**INVESTMENTS AND INVESTMENT POLICY** ($ in thousands)

As of December 31, 2025, the consolidated investments of Octave's continuing operations had an aggregate carrying value of $293,708, including $277,302 carried at fair value. Investments are primarily managed by third party investment management firms which are overseen internally. All investments are made in accordance with the general objectives, policies, and guidelines for investments approved by the Board of Directors of the applicable subsidiary. These policies and guidelines may include liquidity, credit quality, diversification and duration objectives and are periodically reviewed and revised as appropriate.

As of December 31, 2025, the Everspan group investment portfolio had an aggregate carrying value of approximately $193,428. Everspan's investment philosophy is liability driven and therefore seeks to maximize risk-adjusted returns while closely matching the cash flow profile and liquidity demands of its expected liabilities. In addition to internal investment policies and guidelines, the investment portfolio of each company is subject to limits on the types and quality of investments imposed by applicable insurance laws and regulations of the jurisdictions in which it is licensed. The Board of Directors of each respective subsidiary approves any changes to the respective investment policies.

As of December 31, 2025, OSG's (parent company only, excluding investments in subsidiaries) investment portfolio had an aggregate carrying value of approximately $64,468, including $39,344 of short-term investments carried at fair value. The primary investment objective is to preserve capital for strategic uses while maximizing income. The investment portfolio is subject to internal investment guidelines. Such guidelines set forth minimum credit rating requirements and credit risk concentration limits.

As of December 31, 2025, the ID investment portfolio had an aggregate carrying value of approximately $35,812, primarily consisting of money market funds.

The following table provide certain information concerning the consolidated investments of Octave:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2025** | **2025** | **2024** | **2024** |
| **Investment Category**<br>**($ in thousands)**<br>**December 31,** | **Carrying**<br>**Value** | **Weighted**<br>**Average**<br>**Yield** <sup>(1)</sup> | **Carrying**<br>**Value** | **Weighted**<br>**Average**<br>**Yield** <sup>(1)</sup> |
| Corporate securities | $**66573** | **3.4%** | $89192 | 3.3% |
| U.S. government obligations | **35424** | **3.6%** | 40995 | 3.3% |
| Municipal obligations | **11590** | **3.0%** | 14083 | 3.1% |
| Asset-backed securities | **3770** | **4.5%** | 8203 | 4.9% |
| Residential mortgage-backed securities | **1597** | **5.1%** | 2446 | 5.0% |
| Commercial mortgage-backed securities | **3341** | **5.3%** | 2101 | 5.8% |
| Short-term investments | **146442** | **2.8%** | 127601 | 3.7% |
| Total fixed maturity-available-for-sale | **268737** | **3.2%** | 284621 | 3.5% |
| Other investments <sup>(2)</sup> | **24971** | **— %** | 28294 | —% |
| **Total** | $**293708** | **2.9%** | $**312915** | **3.5%** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Yields are stated on a pre-tax basis, based on average amortized cost for both long and short term fixed-maturity investments.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Other investments consist of equity interests in development stage insurance MGA's and a limited partnership interest in a private equity fund. Refer to Note 6. Investments of the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K for further information about Other investments.

**EMPLOYEES**

As of December 31, 2025, Octave had 275 employees in the United States and Bermuda and 208 employees within the United Kingdom. Our 2025 voluntary turnover rate was approximately 17%. Octave considers its employee relations to be satisfactory.

Octave's focus has been on identifying and retaining key talent through individual development programs following skills assessments. Octave's succession planning has identified internal candidates that could fill executive management and senior management positions as the need arises. The Company continues to rely on compensation components (such as salary, long-term equity and cash incentive plans, and short-term incentive plan awards) to support employee retention and discourage excessive risk taking. The Company incorporates performance metrics as part of the annual short-term incentive bonus offering with increased bonus potential for exceptional results. We utilize third-party benchmark data to establish market-based compensation levels. We believe that our current compensation and incentive levels reflect high performance expectations as part of our merit pay philosophy. The targeted use of long-term equity incentive plan awards for key talent is an important element of Octave's long-term retention strategy.

**Item 1A.&nbsp;&nbsp;&nbsp;&nbsp;Risk Factors ($ in thousands)**

Capitalized terms used but not defined in this section shall have the meanings ascribed thereto in Part I, Item 1 in this Annual Report on Form 10-K or in Note 1. Background and Business Description to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K unless otherwise indicated.

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>10</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Our risk factors are organized in the following sections

---

| | |
|:---|:---|
| | ***Page*** |
| *<u>Risks Related to Octave Common Shares</u>* | <u>[11](#i9cb0e1a24c9141e0943a78b7b32afc92_61)</u> |
| *<u>Risks Related to the Company's Business</u>* | <u>[11](#i9cb0e1a24c9141e0943a78b7b32afc92_67)</u> |
| *<u>Risks Related to Capital, Liquidity and Credit Markets</u>* | <u>[19](#i9cb0e1a24c9141e0943a78b7b32afc92_70)</u> |

---

**Risks Related to OSG Common Shares**

***The price per share of OSG's common stock may be subject to a high degree of volatility, including significant price declines.***

Although OSG's common stock is listed on the New York Stock Exchange ("NYSE"), there can be no assurance as to the liquidity of the trading market or the price at which such shares can be sold. The price of the shares may decline substantially in response to a number of events or circumstances, including but not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;• adverse developments in our financial condition or results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;• changes to regulatory status;

&nbsp;&nbsp;&nbsp;&nbsp;• changes in investors' or analysts' valuation measures for our stock;

&nbsp;&nbsp;&nbsp;&nbsp;• adverse changes in analysts' recommendations regarding our stock;

&nbsp;&nbsp;&nbsp;&nbsp;• market perceptions of our success, or lack thereof, in building and managing our Specialty Property and Casualty Insurance and ID businesses and our business strategy and tactics more generally;

&nbsp;&nbsp;&nbsp;&nbsp;• perceptions regarding management guidance or forecast and changes to such guidance or forecasts;

&nbsp;&nbsp;&nbsp;&nbsp;• the impact or perceived impact of any acquisition, disposition or other strategic transaction, including entry into a new line of business or the value or long-term prospects of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;• adverse developments in the industries and markets in which we operate, including the property and casualty insurance, underwriting and brokerage industries, or the fixed income and equity capital markets;

&nbsp;&nbsp;&nbsp;&nbsp;• adverse market and/or economic conditions, such as those caused by a recession or inflation, which increase our risk of loss on insurance policies and depress the value and/or liquidity of our investments and other assets;

&nbsp;&nbsp;&nbsp;&nbsp;• adverse developments in current or future litigation; and

&nbsp;&nbsp;&nbsp;&nbsp;• results and actions of other participants in our industries.

The price of OSG's shares may also be affected by the risks described below. Investments in OSG's common stock may be subject to a high degree of volatility.

**Risks Related to the Company's Business**

***We are subject to reputational harm if companies with which we do business engage in negligent or fraudulent behaviors and damage to our reputation could materially adversely impact our business.***

Our business depends on contractual and working relationships with insurance distribution partners, insurance carriers,

reinsurers, policyholders and beneficiaries, third party administrators, and other agents and counterparties. We could suffer material financial loss, reputational harm and/or a loss of business prospects if a business partner, agent or counterparty engages in negligent or fraudulent conduct, whether directly in our relationship with them or indirectly as a result of their conduct in other business relationships.

***Octave may be adversely impacted by P&C industry market cycles.***

Octave's businesses are subject to market cycles. Premium pricing in the commercial property and casualty insurance markets has been historically based on underwriting capacity of insurance carriers, general economic conditions, inflation, and other factors. In recent years, we have been in a "hard" market whereby carriers and capacity/capital providers have been raising rates. However, in certain lines of business pricing has begun to decrease, while in others, the rate of pricing increase has begun to slow as competition has begun to increase. If carriers and capacity/capital providers lower premium rates more broadly this would be referred to as a "softening" or "soft" market. Given that Octave generates revenue from both insurance premiums and commissions that are based on insurance premiums, our revenues are affected by the cyclicality of the markets in which we operate. If we enter a soft market, absent mitigating factors, we may experience a reduction in revenues and profits.

***Catastrophic events may cause volatility of net income and comprehensive income primarily through changes to loss reserves, which may not be adequate to cover potential losses, and declines in revenues. Revenue may be adversely impacted by reduced business activity and lower sliding scale and profit commissions.***

Catastrophic events, whether natural or man-made, including natural disasters and environmental and public health events that result in material disruption of economic activity, loss of human life or significant property damage, can have a materially negative impact on our financial and operational performance. Such stresses could result in liquidity strains or permanent losses.

Everspan may be exposed to losses arising out of unpredictable catastrophic events. These include natural catastrophes and other disasters, such as hurricanes, earthquakes, windstorms, floods, wildfires, and severe winter weather. Catastrophes can also include man-made disasters, such as terrorist attacks and other destructive acts, war, political unrest, explosions, cyber-attacks, nuclear, biological, chemical or radiological events and infrastructure failures. A severe catastrophe or a series of catastrophes could result in losses exceeding Everspan's reinsurance protection and may have a material adverse impact on our results of operations or financial condition.

Changing weather patterns have added to the unpredictability, frequency and severity of weather-related catastrophes incurred by the property and casualty insurance industry in recent years. These changing weather patterns make it more difficult to predict and model catastrophic events, reducing our ability to accurately price exposure to such events and mitigate its risks.

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>11</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Catastrophic events may cause significant volatility in the markets in which we operate. Disruptions to these markets could result in a decline in business activity, increased claims, reduced underwriting capacity from insurance companies, reinsurers and other capital providers upon which our P&C businesses are reliant. Catastrophic events may also interrupt the operations of our agents and business partners that distribute our P&C insurance products. Profit commissions and contingent commissions related to certain of our P&C business lines may also be adversely impacted by catastrophic losses. Individually and/or collectively, these results may have a material adverse impact on our results of operations and financial condition.

Further, we use internally developed and third-party vendor tools and models to assess exposure to losses, including catastrophic losses. The models assume various conditions and probability scenarios and may not accurately predict future losses or measure losses currently incurred. Limitations in these tools and models may adversely affect our results of operations and financial condition.

***We could realize losses from our cash and investment accounts if one of the financial institutions we use fail or is taken over by regulators.***

We maintain cash and investment accounts, including premium trust accounts, at depository institutions in amounts in excess of the limits insured by the FDIC. If one or more of these institutions were to fail or be taken over by federal regulators, our access to these funds could be limited and we could experience liquidity problems and potential financial losses.

***Our risk management policies and practices may not adequately identify significant risks.***

As described in Part I, Item 1, "Risk Management" in our Annual Report on Form 10-K for the year ended December 31, 2025, we have established risk management policies and practices which seek to mitigate our exposure to a variety of risks. These policies and practices in the past have not insulated us from risks that were unforeseen and/or which had unanticipated loss severity, and such policies and practices may not do so in the future. There can be no assurance that these policies and practices will be adequate to avoid future losses. If we are not able to identify significant risks, we may not be able to timely mitigate such risks, thereby increasing the amount of losses to which we are exposed. An inability to identify significant risks could also result in the failure to timely establish loss reserves that are sufficient in relation to such risks.

We operate within an enterprise risk management ("ERM") framework designed to assess and monitor risks. However, no assurance can be given that we will effectively identify, review, monitor or manage all relevant risks. Nor can we provide assurance that our ERM framework will result in us accurately identifying all risks and adequately limiting our exposures based on our assessments. Any ineffectiveness in our controls or procedures or failure to manage these risks may have an adverse effect on our results of operations and financial condition.

***We are subject to the risk of litigation and the outcome of proceedings we are or may become involved in could have a material adverse effect on our business, operations, financial position, profitability or cash flows.***

Please refer to Note 19. Commitments and Contingencies of the Unaudited Consolidated Financial Statements located in Part I, Item 1 in this Form 10-Q and Note 19: Commitments and Contingencies in Part II, Item 8 in this Annual Report on Form 10-K for the year ended December 31, 2025, for a discussion on legal proceedings against Octave and its subsidiaries.

In the normal course of business, we are subject to regulatory and governmental investigations and civic actions, litigation and other forms of disputes in various domestic and foreign jurisdictions. It is not possible to predict the extent to which litigation against OSG or one or more subsidiaries will be filed, and it is also not possible to predict the outcome of litigation. It is possible that there could be unfavorable outcomes in existing or future proceedings. Management may be unable to make meaningful or reasonable estimates of the amount or range of losses that could result from unfavorable outcomes or of the expenses that will be incurred in connection with such lawsuits. Under some circumstances, adverse results in any such proceedings and/or the incurring of significant litigation or other expenses could be material to our business, operations, financial position, profitability or cash flows.

Everspan may be subject to disputes with policyholders regarding the scope and extent of coverage offered under Everspan's policies; be required to defend claimants in suits against its policyholders for covered liability claims; face allegations of improper claims handling; or enter into commercial disputes with its reinsurers, MGA/Us or TPAs regarding their respective contractual obligations and rights. Under some circumstances, the results of such disputes or suits may lead to liabilities beyond those which are anticipated or reserved, including liabilities in excess of policy limits.

***Regulatory developments may materially adversely affect our business.***

Our Specialty Property and Casualty Insurance subsidiaries are highly regulated as insurance carriers in the States of their domicile and the jurisdictions in which they are licensed. Our owned MGA/Us and insurance brokerage subsidiaries are also required to maintain certain entity-level licenses in those jurisdictions and/or the international countries in which they operate, as well as licenses of individual officers or representatives that are essential to their ability to conduct business. Each of the foregoing must also comply with laws generally applicable to insurance entities, including those relating to governance, capital, and operational requirements.

Government laws and regulations applicable to our businesses develop and change rapidly in response to consumer demands and public policies. State legislatures and insurance departments place increasing burdens on insurance carriers and producers with respect to matters such as cybersecurity, data privacy, artificial intelligence, management of technology, corporate governance, environmental and social issues, and enterprise risk management. Such laws and regulations require substantial resources to ensure that the Company has appropriate and

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>12</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

effective compliance programs in place. If we are unable to keep pace with changes in applicable law and regulations, or if we otherwise fail in our compliance efforts, the Company may be subject to fines, sanctions, governmental orders or modifications to business practices that individually or collectively impair our business or increase our costs, possibly materially.

In addition, the Company from time to time receives regulatory inquiries and requests for information, and its insurance carrier subsidiaries are subject to examination by regulatory authorities. It is not possible to predict the extent to which additional regulatory inquiries or requests for information will be made, nor the outcome of inquiries, requests for information or examination, which exposes the Company to potential fines, sanctions, governmental orders or modifications to business practices that individually or collectively impair our business or increase our costs, possibly materially.

***Our insurance subsidiaries are subject to minimum capital and surplus requirements, and our failure to meet these requirements could subject us to regulatory action.***

Our insurance subsidiaries are subject to risk-based capital standards and other minimum capital and surplus requirements imposed under applicable state laws. The risk-based capital standards, based upon the Risk-Based Capital Model Act adopted by the NAIC, require our insurance subsidiaries to report the results of risk-based capital calculations to state regulators and the NAIC. These risk-based capital standards provide for different levels of regulatory attention depending upon the ratio of an insurance company's total adjusted capital, as calculated in accordance with NAIC guidelines, to its authorized control level risk-based capital. Authorized control level risk-based capital is determined using the NAIC's risk-based capital formula, which measures the minimum amount of capital that an insurance company needs to support its overall business operations.

An insurance company with total adjusted capital that is less than 200% of its authorized control level risk-based capital is at a company action level, which would require the insurance company to file a risk-based capital plan that, among other things, contains proposals of corrective actions the company intends to take that are reasonably expected to result in the elimination of the company action level event. As of December 31, 2025, our insurance subsidiaries each maintained a risk-based capital ratio of over 700% and complied with the requirement of our state regulators.

In addition, our insurance subsidiaries are required to maintain certain minimum capital and surplus and to limit their written premiums to specified multiples of its capital and surplus. Our insurance subsidiaries could exceed these ratios if their volume increases faster than anticipated or if their surplus declines due to catastrophe or non-catastrophe losses or excessive underwriting and operational expenses.

Any failure by our insurance subsidiaries to meet the applicable risk-based capital or minimum statutory capital requirements or the writings ratio limitations imposed by state law could subject our insurance subsidiaries to further examination or corrective

action imposed by state regulators, including limitations on our writing of additional business, state supervision or liquidation.

Any changes in existing risk-based capital requirements, minimum statutory capital requirements or applicable writings ratios may require us to increase our statutory capital levels, which we may be unable to do.

***Everspan may not be successful in executing its business plans or may experience greater than expected insurance underwriting losses and/or reinsurance counterparty losses, which could result in losses material to Everspan's capital position, a downgrade of its AM Best rating and a loss of its franchise value. Such events could have a material adverse impact on the value of OSG's shares.***

Everspan is developing a portfolio of specialty insurance program business. Its business plan entails establishing programs with program administrators, MGA/Us, with claims handled by TPAs. The success of these programs is dependent upon the quality of insurance risk underwritten by the MGA/Us, the quality of underwriting and operational performance, as well as oversight, of the MGA/Us and TPAs by Everspan, the quality and creditworthiness of reinsurance obtained with respect to the underlying risks, loss experience over time, premium levels, competition and other factors, some of which are outside Everspan's control. Should Everspan fail in executing its business plans or experience greater than expected losses due to operational issues, poor risk selection, default or failure to perform by reinsurers, failure to timely realize ultimate loss exposure, a departure of qualified MGA/Us from the industry, enhanced scrutiny from regulators or ratings agencies specific to the program business model, failure to collect amounts due to it or other factors, Everspan may suffer losses that are material to its capital position, a downgrade in its AM Best rating and/or a loss of its franchise value. Any such outcomes could have a material adverse impact on the value of OSG's shares.

***A downgrade in the AM Best financial strength rating of Everspan may negatively affect our business.***

The financial strength of Everspan is evaluated by AM Best, which issues a Financial Strength Rating or "FSR," an important factor in establishing the competitive position of Everspan. The FSR reflects AM Best's opinion of Everspan's financial strength, operating performance, strategic position and ability to meet obligations to policyholders, and are not evaluations directed to investors. Everspan's FSR is subject to periodic review, and the criteria used in the rating methodologies are subject to change. All of the insurance companies that comprise Everspan are rated "A-" (Excellent). A downgrade in Everspan's FSR could make it more difficult to sell insurance policies and Everspan's distribution channels may cease to transact with them, which would adversely affect our business, financial condition and results of operations.

***Failure of Everspan's Program Partners to properly market, underwrite or administer policies could adversely affect us.***

The marketing, underwriting, administration and servicing of policies in our Specialty Property and Casualty Insurance

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>13</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

business have been contracted to the MGA/Us with which Everspan transacts. Any failure by the MGA/Us or TPAs to properly handle these functions could result in liability to us. Even though the MGA/Us and TPAs with which Everspan transacts may be required to indemnify Everspan for any such liability or monetary losses, there are risks for which indemnity may be insufficient or entirely unavailable if, for example, the relevant program partner becomes insolvent or is otherwise unable to pay us. Furthermore, any failure to properly handle the marketing, underwriting, administration and servicing of policies in our Specialty Property and Casualty Insurance business could also create regulatory issues or harm our reputation, which could materially and adversely affect our business, financial condition and results of operations.

***If, in our Specialty Property and Casualty Insurance business, we are unable to accurately underwrite risks and charge competitive yet profitable rates to our policyholders, our business, financial condition and results of operations may be adversely affected.***

In general, the premiums for our Specialty Property and Casualty Insurance policies are established at the time a policy is issued and, therefore, before all of our underlying costs are known. Everspan relies on estimates and assumptions in setting its premium rates. Establishing adequate premium rates is necessary, together with investment income, to generate sufficient revenue to offset losses, loss adjustment expenses, acquisition costs and general and administrative expenses in order to earn a profit. The rate environment is also subject to market cycles, which can be difficult to predict and make it difficult to adequately price risk. If Everspan does not accurately assess the risks that it assumes, it may not charge adequate premiums to cover its losses and expenses, which would adversely affect our results of operations and our profitability. Alternatively, Everspan could set its premiums too high, which could reduce its competitiveness and lead to lower policyholder retention, resulting in lower revenues. Pricing is a highly complex exercise involving the acquisition and analysis of historical loss data and the projection of future trends, loss costs, expenses, and inflation trends, among other factors, for each of Everspan's products in multiple risk tiers and many different markets. Everspan seeks to implement its pricing accurately in accordance with its assumptions. Everspan's ability to undertake these efforts successfully and, as a result, to accurately price its policies, is subject to a number of risks and uncertainties, including insufficient or unreliable data; incorrect or incomplete analysis of available data; uncertainties generally inherent in estimates and assumptions; failure to implement appropriate actuarial projections and ratings formulas or other pricing methodologies; regulatory constraints on rate increases; failure to accurately estimate investment yields and the duration of liabilities for losses and loss adjustment expenses; disagreements with reinsurers or the MGA/Us with whom Everspan transacts as to the adequacy of pricing assumptions; and unanticipated court decisions, legislation or regulatory action.

***If Everspan is unable to obtain reinsurance coverage at reasonable prices or on terms that adequately protect it, we may be required to bear increased risks or reduce the level of our underwriting commitments.***

Everspan purchases reinsurance as part of its overall risk management strategy. While reinsurance does not discharge our insurance subsidiaries from their obligations to pay claims for losses insured under their insurance policies, it does make the reinsurer liable to them for the reinsured portion of the risk. At the inception of a new program, Everspan generally acts as an issuing carrier and reinsures a majority of such risk to third parties in contracts that are generally subject to term limitations or termination rights. Everspan may be unable to maintain its current reinsurance arrangements or to obtain other reinsurance in adequate amounts and at favorable rates, particularly if reinsurers become unwilling or unable to support our specialty property and casualty business in the future. Additionally, market conditions beyond our control may impact the availability and cost of reinsurance and could have an adverse effect on our business, financial condition and results of operations. A decline in the availability of reinsurance may increase the cost of reinsurance and materially and adversely affect our business prospects. Everspan may, at certain times, be forced to incur additional costs for reinsurance or may be unable to obtain sufficient reinsurance on acceptable terms or from reinsurers which satisfy Everspan's criteria as acceptable security. In the latter case, Everspan would have to accept an increase in exposure to risk, reduce the amount of business written by it or seek alternatives in line with Everspan's risk limits, all of which could adversely affect our business, financial condition and results of operations.

***Our insurance carriers are subject to reinsurance counterparty credit risk. Their reinsurers may not pay on losses in a timely fashion, or at all.***

Our insurance carrier subsidiaries purchase reinsurance to transfer part of the risk they have underwritten to reinsurance companies in exchange for part of the premium they receive in connection with the risk. Although reinsurance makes reinsurers liable to our carriers for the risk transferred or ceded to the reinsurers, it does not relieve our insurance carrier subsidiaries of their liabilities to policyholders. Accordingly, our insurance carrier subsidiaries are exposed to credit risk with respect to their reinsurers, especially to the extent reinsurance receivables are not sufficiently secured by collateral or do not benefit from other credit enhancements. Our insurance carrier subsidiaries also bear the risk that they are unable to receive, or there is a substantial delay in receiving, the reinsurance recoverable for any reason, including that the terms of the reinsurance contract do not reflect the intent of the parties to the contract; there is a disagreement between the parties as to their intent; the terms of the contract cannot be legally enforced; the terms of the contract are interpreted by a court or arbitration panel differently than intended by our insurance carrier subsidiaries; the reinsurance transaction performs differently than our insurance carrier subsidiaries anticipated due to a flawed design of the reinsurance structure, terms or conditions; or changes in law and regulation, or in the interpretation of laws and regulations, affects a reinsurance transaction. These risks may be exacerbated to the extent that our insurance carrier subsidiaries'

---

| | |
|:---|:---|
| **Octave Specialty Group, Inc.**<sub>14</sub> | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

reinsurance recoverables are overly concentrated with one or a small subset of reinsurers.

The insolvency of one or more of our insurance carrier subsidiaries' reinsurers, or their inability or unwillingness to make timely payments if and when required under the terms of reinsurance contracts, could adversely affect our business, financial condition and results of operations.

***Everspan's insurance carriers may be subject to counterparty credit risk associated with its MGA/U distribution partners.***

Everspan may be subject to the risk that its MGA/U program partners fail to meet their financial obligations to Everspan or policyholders as it relates to premiums payable, return premiums, sliding scale commissions and return commissions. This risk may be exacerbated to the extent that Everspan has financial obligations to its reinsurers under reinsurance agreements that do not absolve Everspan of credit risk or non-payment by the MGA/U program partner.

The insolvency of one or more of our MGA/U program partners, or their inability or unwillingness to make timely payments if and when required under the terms of program agreements, could adversely affect our business, financial condition and results of operations.

***If actual claims exceed loss and loss adjustment expense reserves for Everspan, or if changes in the estimated level of loss and loss adjustment expense reserves are necessary, including as a result of, among other things, changes in the legal/tort, regulatory and economic environments in which Everspan operates, our financial results could be materially and adversely affected.***

The objective of establishing loss reserve estimates is not to, and our loss reserves do not, reflect worst possible outcomes. While our reserving is estimated based on experience and using various actuarial methods and assumptions, our loss reserves may change materially based on future developments. As a result of inherent uncertainties in the estimates and judgments made to determine loss reserves, there can be no assurance that actual losses will not exceed such reserves or that our reserves will not materially change over time as circumstances, events, our assumptions, or our models change.

Loss and loss adjustment expense reserves represent management estimates of what the ultimate settlement and administration of claims will cost. These estimates are developed using common and industry accepted actuarial techniques. Nevertheless, the process of estimating loss and loss adjustment expense reserves involves a high degree of judgment and is subject to a number of variables, which can be affected by internal and external events, such as changes in claims handling, changes in loss cost trends, catastrophic events and social inflation.

Elevated social inflation trends are likely to continue. Social inflation, which includes increased litigation, partially supported by access to litigation financing; changes in social norms; an erosion of the public sentiment towards insurers' interpretation of coverage levels and limits; and increased damage awards by juries, may make it difficult for Everspan to estimate loss

reserves, establish adequate product pricing, and maintain a strong competitive position with consumers.

Moreover, the impact of catastrophic events may not be adequately reflected in claims reserves and, accordingly, could adversely impact results. Catastrophic losses are caused by wind and hail, wildfires, tornadoes, hurricanes, tropical storms, earthquakes, severe freeze events, volcanic eruptions, terrorism, cyber-attacks, civil unrest, and industrial accidents and other such natural and man-made events.

We also face potential exposure to various types of new and emerging tort claims which were not known or anticipated when our insurance products were originally priced.

The impact of many of these items on ultimate costs for claims and claim adjustment expense reserves could be material and is difficult to estimate.

***Our ability to grow Everspan will depend in part on the addition of new Program Partners, and our ability to effectively onboard such new Program Partners could have an adverse effect on our business, financial condition and results of operations.***

Our ability to grow Everspan will depend in part on the addition of new MGA/U partners. If Everspan does not effectively and timely source, evaluate and onboard new MGA/Us, including assisting such MGA/Us to quickly resolve any post-onboarding matters and provide effective ongoing support, Everspan's ability to add new MGA/Us and its relationships with its existing Program Partners could be adversely affected. Additionally, Everspan's reputation with potential new MGA/Us could be damaged if it fails to effectively onboard MGA/Us with whom it has signed definitive legal agreements. Such reputational damage could make it more difficult for Everspan to attract new and retain existing program partners, which could have an adverse effect on our business, financial condition and results of operations.

***We compete with a large number of companies in the property and casualty insurance industry for underwriting premium.***

We compete with a large number of companies in the property and casualty insurance industry for underwriting premium. During periods of intense competition for premium, in particular, our Specialty Property and Casualty Insurance and ID businesses may be challenged to maintain competitiveness with other companies that may seek to write policies without the same regard for risk and profitability targeted by our Specialty Property and Casualty Insurance and ID businesses. During these times, it may be difficult for Everspan or our MGA/Us to grow or maintain premium volume without lowering underwriting standards, sacrificing income, or both.

In addition, our Specialty Property and Casualty Insurance and ID businesses face competition from a wide range of specialty insurance companies, underwriting agencies and intermediaries, as well as diversified financial services companies that are significantly larger than our Specialty Property and Casualty Insurance and ID businesses are and that have significantly larger financial, marketing, management and other resources.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **15** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Some of these competitors also have longer standing and better established market recognition than Octave's group companies. The greater resources or market presence that these competitors possess may enable them to avoid or defray particular costs, employ greater pricing flexibility, have a higher tolerance for risk or loss, or exploit other advantages that may make it more difficult for us to compete. We may incur increased costs in competing for underwriting revenues in this environment. If we are unable to compete effectively in the markets in which our Specialty Property and Casualty Insurance and ID businesses operate or expand into, our underwriting revenues may decline, as well as overall business results.

Other competitive concerns include the entrance of technology companies into the insurance distribution business and the direct-to-consumer insurance carriers that do not utilize third party agents and brokers as production sources. Additionally, the insurance industry may experience consolidation, and therefore we may experience increased competition from insurance companies and the financial services industry, as a growing number of larger financial institutions increasingly, and aggressively, offer a wider variety of financial services, including insurance distribution services. While we collaborate and compete in these segments on a fee-for-service basis, we cannot be certain that such alternative markets will provide the same level of insurance coverage or profitability as traditional insurance markets.

Technological changes to the way insurance is distributed, underwritten, and administered also present competitive risks. For example, our competitive position could be impacted if we are unable to cost-effectively deploy technology, such as machine learning and artificial intelligence, which collects and analyzes large sets of data to make underwriting or other decisions, or if our competitors collect and use data which we do not have the ability to access or use. In addition, usage-based methods of determining premiums (e.g., telematics) can impact product pricing and design and are becoming an increasingly important competitive factor. The landscape of law and regulation governing these areas presents additional risk to the extent we are unable to timely adapt to ensure compliance.

***We may be adversely affected by failures in services or products provided by third parties.***

We outsource and may further outsource certain technology and business process functions, and rely upon third-party vendors, agents and contractual counterparties for other essential services and information. Outsourcing functions to third parties exposes us to increased risk related to service disruptions. If we do not effectively develop, implement and monitor our vendor, agency and contractual counterparty relationships and the financial condition of such third parties, if third party providers do not perform as anticipated, if we experience technological or other problems, or if vendor, agency or other contractual relationships relevant to our business process functions are terminated, we may not realize expected productivity improvements or cost efficiencies and may experience operational difficulties, increased costs and a loss of business. Further, we may suffer financial losses if a counterparty defaults on a financial obligation to us, including with respect to insurance agency commissions which adjust over time. Moreover, policyholders and claimants may suffer delays or lapses in service levels

which may create extra-contractual exposures. The increased risks identified above could expose us to disruption of service, monetary and reputational damages, competitive disadvantage and significant increases in compliance costs. A material failure by an external service provider, information provider, agent or counterparty, or a material defect or default in the products, services or information provided thereby, could adversely affect our financial condition and results of operations.

Our outsourcing of certain technology and business process functions to third parties may expose us to increased risk related to data security, service disruptions or the effectiveness of our control system. These risks could increase as vendors increasingly offer cloud-based software services rather than software services which can be run within our data centers or as we choose to move additional functions to the cloud.

***Impairment of intangible assets and goodwill could adversely affect our results of operations.***

In connection with Octave's acquisition of insurance distribution businesses (MGA/Us and brokers), Octave records the fair value of identifiable intangible assets (primarily related to distribution relationships) and goodwill. The intangible assets are amortized over their remaining useful lives. The Company tests intangible assets for impairment if certain events occur or circumstances change indicating that the carrying amount of the intangible asset may not be recoverable. Goodwill is tested for impairment annually or whenever events occur or circumstances change that may indicate impairment. Intangible asset and goodwill impairments are driven by a variety of factors, which could include, among other things, declining future cash flows of the acquired business as addressed in other risk factors related to the ID Business. If we determine an impairment has occurred, we are required to record an impairment charge equal to the excess of the asset's carrying value over its estimated fair value. Any intangible asset or goodwill impairment could adversely affect the Company's operating results and financial condition.

***Our Insurance Distribution businesses derive a significant portion of their commission revenues from a limited number of insurance companies and Lloyd's syndicates, the loss of any of which could result in lower commissions or loss of business production.***

The commissions of our MGA/Us and insurance broker are derived from insurance policies underwritten on behalf of a limited number of capacity providers, including insurance and reinsurance companies, Lloyd's syndicates and other capital providers. Should one or more of these capacity providers terminate its arrangements with our ID businesses or otherwise decrease the amount of capacity provided, we may lose significant commission revenues or lose significant business production while seeking other sources of capacity.

A number of our MGA/Us have material relationships with Lloyd's Syndicate 4242, and to a lesser extent Cadenza Re Limited, which are risk carriers that are serviced by Octave group entities. A reduction in scale and/or appetite of these carriers, whether in response to underwriting performance, regulatory considerations, availability of underwriting capital support, or otherwise, may result in a loss of significant commission revenues. Furthermore, these carriers form the

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **16** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

cornerstone capacity for some of our MGA/Us new launches and hence a deterioration in their activities will further inhibit new MGA/U launches.

***Our Insurance Distribution businesses, results of operations, financial condition and liquidity may be materially adversely affected by certain potential claims or proceedings.***

Our owned MGA/Us and insurance brokerage operating subsidiaries are subject to various potential claims and other proceedings, including those relating to alleged errors and omissions in connection with the placement or servicing of insurance and/or the provision of services in the ordinary course of business, of which we cannot, and likely will not be able to, predict the outcome with certainty. Because our MGA/Us and insurance brokerage operating subsidiaries often assist customers with matters involving substantial amounts of money, including the placement of insurance and the handling of related claims that customers may assert, errors and omissions claims against it may arise alleging potential liability for all or part of the amounts in question. Also, the failure of an insurer with whom our MGA/Us and insurance brokerage operating subsidiaries place business could result in errors and omissions claims against it by its customers, which could adversely affect Octave's results of operations and financial condition. Claimants may seek large damage awards, and these claims may involve potentially significant legal costs and damages. In addition, regardless of monetary costs, these matters could have a material adverse effect on our reputation and cause harm to carrier, customer or employee relationships, or divert personnel and management resources.

***We may acquire additional MGA/Us as part of our Insurance Distribution business strategy. Risks associated with such endeavors could adversely affect our growth and results of operations.***

Acquisitions have been an important contributor of growth in the ID business and we believe that additional acquisitions may be important to future growth, building further operational scale and diversifying our sources of revenue. Failure to successfully identify and complete acquisitions may result in us achieving slower growth and less operating scale. Moreover, the failure of acquisition targets to achieve anticipated revenue and earnings levels could result in slower than anticipated growth and result in intangible asset or goodwill impairment charges.

***Future growth of our Insurance Distribution business is highly dependent upon, amongst other items, our ability to launch de novo MGA/MGUs, which is highly dependent on our ability to attract insurance talent, operationalize new MGA/MGUs and compete for business.***

The market for insurance underwriting talent and MGA/MGU leadership talent has become increasingly competitive. If we are not able to attract and/or retain such talent to launch and maintain de novo MGA/MGUs, our ability to grow may be materially constrained and the intangible and goodwill assets we recorded in connection with the acquisition of Octave Ventures may become impaired. Any such impairment could be materially adverse to our results of operations and financial

condition. Even if we are able to attract underwriting and leadership talent to launch de novo MGA/MGUs, there can be no guarantees that each de novo MGA/MGU will be successful or that we will be able to operationalize each business. Product and technological complexity have increased the challenges of starting de novo MGA/MGUs and could in the future increase the launch time and investment needed to improve the chances of success. Competition for premium has also increased, particularly as market conditions have begun to soften in certain segments. If markets continue to soften or such conditions spread to a broader set of risk classes, competition for premiums may increase further, making the launch of de novo MGA/MGU more challenging. While Octave has access to managed capacity, de novo MGA/MGUs rely on access to insurance capacity for the risks they write. If Octave were not able to source the capital needed to support the insurance risk underwritten by de novo MGA/MGUs, we would not be able to generate revenues to offset the expenses incurred to establish such de novo MGA/MGUs and we may experience losses.

***Octave may not be able to realize expected synergies from acquisitions.***

Octave's assessment of acquisitions often includes an estimate of the value of revenue, expense and operating synergies that may be created from the acquisition. If due to market, economic, technological, cultural, regulatory or other reasons Octave is not able to fully realize expected synergies or its valuation of such synergies otherwise proves incorrect, we may not realize the full expected value of an acquisition, which in turn may lead to lower than expected profits, material adverse results from operations and/or a weakened financial condition.

***Octave is planning to further develop and expand its Specialty Property and Casualty Insurance and Insurance Distribution businesses; however, such plans may not be realized, or if realized, may not create value and may negatively impact our financial results.***

Octave is planning to further develop and expand its Specialty Property and Casualty Insurance and ID businesses. Such plans may involve additional acquisitions of assets or existing businesses and the development of businesses through new or existing subsidiaries. Currently, it is not possible to fully predict the future prospects or other characteristics of such businesses. We may not be able to successfully identify opportunities, attract specialized underwriting and other talent, and operationalize new businesses in a timely or cost-efficient manner. While we expect to conduct business, financial and legal due diligence in connection with the evaluation of any future business or acquisition opportunities, there can be no assurance our due diligence will identify every matter that could have a material adverse effect on us. Efforts to pursue or develop certain business opportunities may be unsuccessful or require significant financial or other resources, which could have a negative impact on our growth plans, operating results and financial condition. To implement our growth strategy, we must be able to meet our capital needs, expand and refine our systems and our internal controls effectively, allocate our human resources optimally, identify and hire qualified employees and effectively integrate any acquisitions we make in our effort to achieve growth. No assurance can be given that Octave will successfully execute its plans for new business, generate any

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **17** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

earnings or value from new businesses or be able to successfully integrate any such business into our current operating structure. For example, on July 31, 2024, we acquired Beat Capital Partners (now known as Octave Ventures) and on October 31, 2025, we acquired ArmadaCorp Capital, LLC. We have devoted, and will continue to devote, significant management attention and resources to integrating these acquired businesses and any others that we may acquire. Potential challenges we may encounter as part of the integration process include the inability to achieve anticipated synergies and revenue growth, challenges in successfully managing customer relationships and integrating systems, the diversion of management attention and difficulties in integrating and retaining employees. The failure to manage our growth effectively and to integrate our acquired businesses successfully could have a material adverse effect on our business, financial condition and results of operations.

Our inability to successfully manage ongoing organizational changes could adversely impact our business results. We may experience higher levels of costs or disruption in managing these changes, which may cause the benefits derived from our business development strategy to be less than we originally expect.

Should changes in Octave's circumstances or financial condition or in the political, economic and/or legal environment occur, there can be no assurance that all or any part of our strategy and/or initiatives will not be abandoned or adjusted to take account of such changes. Any such adjustment or abandonment may have a material adverse effect on our securities.

***Changes in law or in the functioning of the healthcare market could significantly impair our Accident & Health insurance business and therefore negatively impact Octave's financial condition and results of operations.***

Adoption of a single payer healthcare system or a public health insurance option would likely adversely impact the entire healthcare industry. Our Accident & Health insurance business would likely be adversely impacted by such a material change in the U.S. healthcare system particularly if private health insurance is eliminated, materially limited, or is rendered noncompetitive. Material adverse developments to our Accident & Health insurance business would have a negative impact on Octave's financial condition and results of operations which could be material.

***Our Insurance Distribution businesses and their results of operations and financial condition may be adversely affected by conditions that result in reduced insurance capacity.***

Our ID business results of operations depend on the capacity of insurance carriers (including Lloyd's of London), reinsurers and other capital providers to assume risk and provide coverage. Capacity among insurance carriers, reinsurers and other capital providers may diminish because of our performance or due to factors outside our control. For example, capacity could be reduced by insurance companies failing or withdrawing from writing certain coverages that our ID businesses offer to their customers. To the extent that reinsurance becomes less widely available or significantly more expensive, we may not be able to procure the amount or types of coverage that our customers

desire and the coverage we are able to procure for our customers may be more expensive or limited.

***Variations in commission income that result from the timing of policy renewals and the net effect of new and lost business production may have unexpected effects on our results of operations.***

Commission income can vary quarterly or annually due to the timing of policy renewals and the net effect of new and lost business production. We do not solely control the factors that cause these variations. Specifically, customers' demand for insurance products can influence the timing of renewals, new business and lost business (which includes policies that are not renewed), and cancellations. Quarterly and annual fluctuations in revenues based upon increases and decreases associated with the timing of new business, policy renewals and payments from insurance companies may adversely affect our financial condition, results of operations and cash flows.

***Variations in contingent commissions that result from the effects of insurance loss activity on portfolios may result in significant variations in revenues.***

Profit-sharing contingent commissions are paid by insurance companies based upon the profitability of the business placed with such companies. In the past these commissions have accounted for a significant amount of total commissions and fees. Due to, among other things, the inherent uncertainty of loss and changes in underwriting criteria by insurance companies, there will be a level of uncertainty related to the payment of profit-sharing contingent commissions.

***Our P&C businesses rely on a limited number of retail and wholesale brokers to generate revenue and the loss of one or more of these key partners could adversely impact our results of operations and growth objectives.***

Our relationship with retail and wholesale brokers and other trading partners (collectively, "Brokers") are nonexclusive and may be discontinued at any time by either party. In addition, any of these parties may change the terms of our relationship which would cause our commission expense to increase.

The loss of a Broker could reduce the number of submissions we receive which could result in reduced commission revenue. Our business could also be harmed if we fail to develop relationships with new Brokers or other sources of business.

A reduction in the number of Brokers, whether as a result of the termination of relationships, consolidation or otherwise, may leave us more vulnerable to adverse changes in our relationships with other Brokers, particularly in geographies or lines of business where we offer insurance products through a relatively small number of Brokers.

***System security risks, data protection breaches and cyber-attacks could adversely affect our business and results of operations.***

We and our vendors and contractual counterparties rely on our information technology systems for many enterprise-critical functions and a prolonged failure or interruption of these systems for any reason could cause significant disruption to our

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **18** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

operations and have a material adverse effect on our business, financial condition and operating results. Our information technology and application systems, as well as those of our vendors and contractual counterparties, may be vulnerable to threats from computer viruses, natural disasters, unauthorized access, cyber-attack and other similar disruptions. Computer hackers may be able to penetrate our network's system security, or the network's security system of a vendor or contractual counterparty, and misappropriate or compromise confidential information, create system disruptions or cause shutdowns. The ability of hackers to infiltrate and compromise our and our vendors' and contractual counterparties' information systems or the contents thereof may be enhanced by generative artificial intelligence, which may be more difficult to detect and defend. In addition to our own confidential information, we and our vendors and contractual counterparties sometimes receive and are required to protect confidential information obtained from third parties (including us in the case of a vendor or contractual counterparty) and personally identifiable information of individuals. To the extent any disruption or security breach results in a loss or damage to our data (or the data of a vendor or contractual counterparty on which we rely), or inappropriate disclosure of our confidential information or that of others, or personally identifiable information of individuals, it could cause significant financial losses that are either not, or not fully, insured against, cause damage to our reputation, affect our relationships with third parties, lead to claims against us, result in regulatory action, or otherwise have a material adverse effect on our business or results of operations. In addition, we may be required to incur significant costs to mitigate the damage caused by any security breach, or to protect against future damage. Moreover, we may not be able to adequately execute our incident response, disaster recovery and business continuity plans in a timely fashion in the event of a disruption to our information technology and application systems. Additionally, we are an acquisitive organization and the process of integrating the information systems of the businesses we acquire is complex and exposes us to additional risk as we might not adequately identify weaknesses in the targets' information systems, which could expose us to unexpected liabilities or make our own systems more vulnerable to attack.

***The application of innovative and solution-based technology is required to facilitate effective operations and to realize internal efficiencies; however, the investment required in technology may not yield sufficient returns and the implementation of new or modified technology may be a material distraction to management.***

Our business performance and growth plans could be negatively affected if we are not able to, among other things, gain internal efficiencies through the application of effective technology across our businesses, integrate operations, and/or innovate product and operational solutions. Conversely, investments in internal systems or innovative product offerings may fail to yield sufficient return to cover their investment. To the extent our investments in technology fail to provide sufficient returns or achieve their stated business objectives, we may experience lower productivity and/or operational effectiveness, which could adversely impact our financial results and prevent us from meeting our strategic objectives.

***Our ability to attract and retain qualified executives, senior managers and other employees or the loss of any of these personnel could negatively impact our business.***

Our ability to execute on our business strategies depends on the retention and recruitment of qualified executives and other professionals. We rely substantially upon the services of our current executive and senior management teams. In addition to these officers, we rely on key staff with insurance, underwriting, business development, credit, risk management, investment, accounting, finance, legal, technology and other technical and specialized skills. The market for qualified executives, senior managers and other employees has become very competitive. As a result of competition for talent we may experience higher employee turnover and finding qualified replacements may be more difficult. The loss of the services of members of our executive and/or senior management teams, our inability to hire and retain other talented personnel and/or the absence of effective management succession plans could delay or prevent us from succeeding in executing our strategies, which could negatively impact our business.

***Our business could be affected by actions of stakeholders with differing interests or objectives.***

Octave could be affected by actions taken by stakeholders whose interests or objectives may differ from our strategic plans or from the interests of our stockholders, creditors or other stakeholders. Responding to such actions could be costly and time-consuming, disrupt operations and divert the attention of management and employees. In addition, these activities could interfere with our ability to execute on our strategic plans.

***We are exposed to foreign exchange risk, which may adversely affect our financial condition and results of operation.***

A significant portion of our ID business is operated out of the U.K where our functional currency is the British pound ("GBP"). However, the majority of our revenues are generated in U.S. dollars ("USD"). As a result, movements in the rate of exchange between GBP and USD may materially distort our financial results and cause losses that are not attributable to the underlying business. We frequently hedge this foreign exchange risk through forward contracts; however, these hedges may not completely negate the adverse impact of foreign exchange movements.

**Risks Related to Capital, Liquidity and Credit Markets**

***OSG and the Insurance Distribution business have outstanding indebtedness, resulting from the acquisition of ArmadaCorp on October 31, 2025, which could adversely affect our financial condition, operational flexibility and our ability to obtain financing in the future.***

The Company funded a significant portion of the purchase price of ArmadaCorp Capital, LLC and its subsidiaries through new term loan and revolving credit facilities (the "Credit Facilities"). The Credit Facilities are secured by substantially all of the assets of, and the Company's ownership interests in, our ID businesses, and are guaranteed by OSG.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **19** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

The Credit Facilities include covenants that restrict our ability to manage capital resources by requiring maintenance of certain financial ratios and restricting indebtedness, liens, mergers, sales of assets, investments, restricted payments (such as dividends), and affiliate transactions, among other restrictions. The Credit Facilities also require the prepayment of the borrowings thereunder with proceeds of certain asset sales, recovery events, issuances of indebtedness and indemnity payments. These requirements will impact our financial and operational flexibility while the Credit Facilities remains in place.

The Company's substantial indebtedness could have other significant consequences for our financial condition and operational flexibility. For example, it could:

&nbsp;&nbsp;&nbsp;&nbsp;• increase our vulnerability to general adverse economic, competitive and industry conditions;

&nbsp;&nbsp;&nbsp;&nbsp;• limit our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions, general corporate purposes or other purposes on satisfactory terms or at all;

&nbsp;&nbsp;&nbsp;&nbsp;• require the Company to dedicate a substantial portion of its cash flow from operations to the payment of interest on its indebtedness, thereby reducing the funds available for operations and to fund the execution of key strategies;

&nbsp;&nbsp;&nbsp;&nbsp;• limit or restrict the Company from making strategic acquisitions or cause us to make non-strategic divestitures;

&nbsp;&nbsp;&nbsp;&nbsp;• limit the Company's ability, or increase the costs, to refinance its indebtedness or repay indebtedness due to ongoing interest payment obligations; and

&nbsp;&nbsp;&nbsp;&nbsp;• limit our ability to attract and retain key employees.

While restrictive covenants in the Credit Facilities may limit the amount of additional indebtedness the Company may incur, we may obtain waivers of those restrictions and incur additional indebtedness in the future. In addition, our ability to make scheduled payments on, or refinance, any such indebtedness may depend on the ability of our subsidiaries to make distributions or pay dividends, which in turn will depend on their future operating performance and applicable contractual, legal and regulatory restrictions on the payment of distributions or dividends. There can be no assurance that any such dividends or distributions would be made. This could further exacerbate the risks associated with the Company's leverage.

The Company intends to service indebtedness under the Credit Facilities from earnings and cash flow generated by the ID businesses. In the event the ID businesses fail to produce sufficient earnings and cash flow to pay the Company's indebtedness when due, the Company would need to seek to modify the terms of the Credit Facilities, refinance or restructure its indebtedness, or raise additional capital. There can be no assurance that the Company will be able to adequately address a shortfall in its debt-servicing capacity through such measures on commercially reasonable terms or at all. Moreover, if the Company were able to address a shortfall in its debt servicing capacity through one or more of these measures, it may incur substantial additional costs or burdens, including additional collateral or restrictions on its business, which could cause a material adverse impact on the Company's results of operations and financial condition.

Furthermore, raising additional capital to pay down debt through the issuance of equity or other debt would depend on market and economic conditions, may dilute the ownership of existing stockholders and potentially diminish the ability of the Company to access the capital markets in the future. Moreover, raising additional capital through the sale of assets would depend on market and economic conditions; the availability of buyers; the requirements and conditions of local law, including regulatory restrictions; and other factors that may result in the Company or a party enforcing rights against the Company to be unable to receive proceeds sufficient to discharge the Company's obligations. Because of these and other factors beyond our control, the Company may be unable to pay or discharge the principal or interest on its indebtedness on economic terms or at all, which would materially impair the value of the Company.

***We may have future capital needs and may not be able to obtain third-party financing or raise additional third-party capital on acceptable terms, or at all.***

An inability to obtain third-party debt financing or raise additional third-party capital, when required by us or when business conditions warrant, could have a material adverse effect on our business, financial condition and results of operations, and could adversely impact our ability to achieve our strategic objectives. Our financial condition, the Risk Factors described elsewhere herein, as well as other factors, may constrain our financing abilities. Our ability to secure third-party financing will depend upon our future operating performance, regulatory conditions, the availability of credit generally, economic conditions and financial, business and other factors, many of which are beyond our control. The market conditions and the macroeconomic conditions that affect our business could have a material adverse effect on our ability to secure third-party financing on favorable terms, if at all.

If third-party financing is not available when needed, or is available on unfavorable terms, we may be unable to take advantage of business opportunities, respond to competitive pressures or effectively and efficiently manage our balance sheet, any of which could have a material adverse effect on our business, financial condition and results of operations.

***Octave has significant obligations as the counterparty to several put contracts related to redeemable minority interests in our Insurance Distribution business. Obligations under these put contracts may be material and may require Octave to raise third party capital to fund.***

If a counterparty exercises a put right, we would be required to make a cash payment, which could be substantial, at a time when we may not have sufficient cash resources to fund all or a portion of such obligation. As a result, we may be required to raise additional capital or liquidity to fund these obligations. Raising additional capital or liquidity may be dilutive to shareholders or may be otherwise very expensive. Raising the capital or liquidity to fund these obligations may have a material adverse effect on our results of operations and financial condition. Alternatively, to fund the put payment, we may be forced to liquidate other assets, which may be less liquid exposing us to the risk of loss. Our ability raise capital or liquidity would depend on market conditions at the time and

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **20** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

there can be no assurance that we will be able to raise the capital necessary to fund these put obligations.

***Adverse economic factors, including recession, inflation, periods of high unemployment or lower economic activity could result in the sale of fewer policies than expected or an increase in the frequency or severity of claims and premium defaults or both, which, in turn, could affect our growth and profitability.***

Factors such as business revenue, economic conditions, the volatility and strength of the capital markets, inflation and pandemics can all affect the business and economic environment. These same factors affect our ability to generate revenue and profits. In an economic downturn that is characterized by higher unemployment, declining spending and reduced corporate revenues, the demand for insurance products is adversely affected, which directly affects our premium levels and profitability. Negative economic factors may also affect our ability to receive the appropriate rate for the risk we insure with our policyholders and may adversely affect the number of policies we can write, including with respect to our opportunities to underwrite profitable business. In an economic downturn, our customers may have less need for insurance coverage, cancel existing insurance policies, modify their coverage, self-insure their risks, or not renew with us. Existing policyholders may exaggerate or even falsify claims to obtain higher claims payments, or not pay premiums on our policies when due. These outcomes would reduce our underwriting profit to the extent these factors are not reflected in the rates we charge.

***Changes in prevailing interest rate levels and market conditions could adversely impact our business results and prospects.***

Increases in prevailing interest rate levels can adversely affect the value of our investment portfolio and, therefore, our financial strength. In the event that investments must be sold in order to pay claims, to pay debt obligations, to meet collateral posting requirements or to meet other liquidity needs, such investments would likely be sold at discounted prices.

Our risk to changes in interest rates and market conditions could be magnified in the event that the US or UK were to enter into an economic recession. While interest rates may decline during a recession, credit and liquidity risks would be expected to increase which may cause us to experience losses in our investment portfolios. These losses may have a material adverse effect on our results of operations and financial condition, particularly if any economic rescission were prolonged.

**Item 1B.&nbsp;&nbsp;&nbsp;&nbsp;Unresolved Staff Comments** — No matters require disclosure.

**Item 1C.&nbsp;&nbsp;&nbsp;&nbsp;Cybersecurity.**

The Company is exposed to diverse cybersecurity risks that have the potential to significantly impact our business operations, financial standing, and reputation. We seek to identify, assess, and manage these risks, with the aim of safeguarding our critical systems and information and employing a documented process to respond in the event of a cybersecurity incident. This approach includes regular evaluations of our information

systems and infrastructure to identify vulnerabilities and potential weaknesses through the use of system monitoring tools, as well as monitoring of industry trends, threat intelligence, and emerging risks to anticipate and proactively assess potential threats. We engage third-party cybersecurity experts to conduct penetration testing, vulnerability scans, and risk assessments, informed by the NIST (National Institute of Standards and Technology) Cybersecurity Framework guidelines or ISO (International Organization for Standardization) 27001 standard, to increase the likelihood that system risks are identified.

To identify potential risks, Octave or a third party vendor engaged by the Company also assesses the security measures of vendors and third-party service providers that have access to the Company's information systems and sensitive data. Each review involves an initial risk assessment of the provider and initial and periodic reviews of the provider's cybersecurity program to evaluate security standards, access controls and security measures. The Company generally requires vendors and third party service providers to report to the Company any cybersecurity incidents involving the providers' systems that could affect the Company or to have cybersecurity incident notice requirements in their cybersecurity programs.

Our approach to managing cybersecurity risks includes implementing cybersecurity measures such as selective use of encryption, firewalls, data loss prevention, security monitoring, endpoint detection and response, anti-spam and anti-phishing email security, and intrusion detection systems to fortify our defenses. We conduct mandatory annual employee cybersecurity training programs and frequent simulated phishing campaigns to enhance cybersecurity knowledge and practices across the organization. Octave maintains an incident response plan that is updated regularly to respond to changes in the organization, risks and laws. Octave also conducts an annual test to restore business critical systems and data from back-ups. We have established reporting processes and escalation pathways for our business units and functions to identify, assess and manage potential cybersecurity incidents in a timely manner. Once an incident is identified, the Chief Information Security Officer ("CISO") (with the assistance of the IT team) will begin the investigation to determine the level of risk of the event and the appropriate response.

The Board of Directors of the Company oversees the management of risks from cybersecurity threats through its review of quarterly reports from the CISO on the status of the Company's cybersecurity preparedness; updates on information systems; and any cybersecurity threats of which management has become aware. In addition the Board receives periodic cybersecurity awareness training.

The CISO conducts weekly meetings with the Chief Information Officer, and as necessary with the Enterprise Architecture Committee, to discuss the implementation of new cybersecurity measures. Identified cybersecurity risks and newly disclosed software patch updates are escalated, as appropriate, for further assessment and remediation in accordance with the Company's vulnerability management procedures. The CISO also receives ongoing cybersecurity threat intelligence from external sources, including government and industry organizations such as the

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **21** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Cybersecurity and Infrastructure Security Agency, which is used to inform the Company's cybersecurity risk assessment and mitigation efforts. Cybersecurity risk is also included in the Company's Enterprise Risk Management ("ERM") process that involves senior management and other personnel in the identification, assessment and management of a broad range of risks (including cybersecurity risks) that could affect the Company's ability to execute on its corporate strategy and fulfill its business objectives. The Company's Chief Operating Officer and Chief Information Officer provide input and updates to the Enterprise Risk Committee (comprised of members of management) on cybersecurity preparedness and emerging risks. The Enterprise Risk Committee produces the relevant risk management information for executive and senior management and the Board of Directors, which receives ERM updates on a quarterly basis. The Chief Operating Officer and Chief Information Officer are also members of the Company's Disclosure Committee and provide updates on cybersecurity threats and emerging risks to the Disclosure Committee prior to the filing of each quarterly report on Form 10-Q and annual report on Form 10-K.

The Company's Chief Information Officer and CISO bring over 35 years of combined experience in the technology and cybersecurity space. The Chief Information Officer has served as a chief information officer and chief technology officer of both private and public institutions for the past 10 years and was responsible for the IT operations and cybersecurity practices of those institutions. The CISO is a certified cybersecurity professional and technologist. He holds an active ISO/ANSI-accredited cybersecurity certification and has experience managing security programs across multiple industries, including financial services and insurance.

Octave and its subsidiaries are subject to various U.S. federal and state laws and regulations with respect to privacy, data protection and cybersecurity that require financial institutions, including insurance companies and agencies, to safeguard personal and other sensitive information, and may provide for notice of their practices relating to the collection, disclosure and processing of personal information, disclosure of cybersecurity risk management practices, reporting of cybersecurity incidents, and implementation of governance practices. For example, the NAIC adopted the NAIC Insurance Data Security Model Law (#668) ("NAIC Model Law") that creates rules for insurers and other covered entities addressing data security and the investigation and notification of cybersecurity events involving unauthorized access to, or the misuse of, certain nonpublic information. This includes maintaining an information security program based on ongoing risk assessment, overseeing third-party service providers, investigating data breaches and notifying regulators of a cybersecurity event. Legislation based on the NAIC Model Law has been enacted in many states and may be enacted in other states. Certain of our subsidiaries, as insurance companies and agencies licensed in the State of New York, are also required to comply with the New York Department of Financial Services ("NYDFS") cybersecurity regulation, which establishes requirements for covered financial services institutions to implement a cybersecurity program designed to protect the confidentiality, integrity and availability of information systems of regulated entities, and information stored on those systems. The regulation imposes a governance

framework for cybersecurity programs, risk-based minimum standards for technology systems for data protection, monitoring and testing, third-party service provider reviews, security incident response and reporting to NYDFS of certain security incidents, annual certifications of regulatory compliance to NYDFS, and other requirements. Recent amendments to the NYDFS cybersecurity regulation impose additional security requirements and new governance obligations.

In the United States, portions of our business are subject to state laws that impose obligations with respect to personal information and grant consumers specific rights with respect to such information, For example, the California Consumer Privacy Act, went into effect in January 2020, and provides additional privacy rights for California residents, and in November 2020, California further expanded privacy rights for California residents by enacting the California Privacy Rights Act, which became effective January 1, 2023. Several other states have enacted similar comprehensive privacy laws. We anticipate that federal and state regulators will continue to enact legislation related to privacy and cybersecurity, which may require additional compliance investments and changes to policies, procedures and operations.

The federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations ("HIPAA") impose minimum standards on covered entities, such as health insurers, for the privacy and security of protected health information ("PHI"). The Health Information Technology for Economic and Clinical Health Act, enacted in 2009 ("HITECH") provides for the extension of certain privacy and security provisions of HIPAA to business associates of covered entities that handle electronic PHI. Xchange specializes in accident and health insurance and is a business associate of the health insurers carriers it partners with, making it subject to compliance with the provisions of HITECH and HIPAA applicable to business associates.

In the United Kingdom, data protection is governed by the UK General Data Protection Regulation 2016/679 and the UK Data Protection Act of 2018 (together the "UK GDPR"), which requires companies to manage the access and transfer of personal information of UK residents. The Company's affiliates licensed and doing business in the UK are subject to compliance with the provisions of the UK GDPR.

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Properties**

The executive office of Octave is located at 40 Wall Street, New York, New York 10005, and consists of 9,767 square feet of office space, under a lease agreement that expires in April 2031.

Operations of each of our segments are carried out either in our executive office at 40 Wall Street or in other leased offices under operating leases in Florida, New Jersey, New York, Indiana, North Carolina, Georgia, Maryland, Texas, Bermuda and England. The lease terms typically do not exceed ten years in length.

In the opinion of the Company's management, the Company's properties are adequate and suitable for its business as presently conducted and are adequately maintained.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **22** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings**

Refer to Notes to the Consolidated Financial Statements—Note 19. Commitments and Contingencies included in Part II, Item 8 in this Annual Report on Form 10-K for a discussion on legal proceedings against Octave.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Mine Safety Disclosures —** Not applicable.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **23** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**PART II**<br>

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities ($ in thousands, except per share amounts)**

**Market Information** 

The Company 's common stock trades on the NYSE under the symbol "OSG".

**Holders** 

On March 2, 2026, there were 20 stockholders of record of OSG's common stock.

**Dividends** 

The Company did not pay cash dividends on its common stock during 2025 and 2024. Information concerning restrictions on the payment of dividends from Octave's insurance subsidiaries is set forth in Item 1 above under the caption "Dividend Restrictions, Including Contractual Restrictions" and in Note 9. Insurance Regulatory Restrictions to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K.

**Purchases of Equity Securities By the Issuer and Affiliated Purchasers** 

When restricted and performance stock units issued by Octave settle, they become taxable compensation to employees. For certain awards, shares may be withheld to cover the employee's portion of withholding taxes. In the fourth quarter of 2025, Octave purchased 741,233 shares from employees that settled restricted or performance stock units to meet employee tax withholdings.

The following table includes information about the Company's purchases of its common shares during the fourth quarter of 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **($ in thousands, <br>except per share)** | **Oct-2025** | **Nov-2025** | **Dec-2025** | **Fourth Quarter 2025** |
| Shares Repurchased |  | 706244 | 34989 | 741233 |
| Average Price Paid Per Share | $— | $9.46 | $8.99 | $9.44 |
| Total Number of Shares Purchased as Part of Publicly Announced Plan | 3142554 |  |  | 3142554 |
| Maximum Dollar Value That may Yet be Purchased Under the Plan |  |  |  | $**8449** |

---

On November 12, 2024, Octave's Board of Directors authorized a share repurchase program, under which Octave may opportunistically repurchase up to $50,000 of the Company's common shares at management's discretion over the period ending on December 31, 2026. Shares purchased from employees to satisfy withholding taxes, as described above, do not count towards utilization under the Company's share repurchase program.

The following table shows shares repurchased by year under Octave's November 12, 2004 share repurchase program.

---

| | | |
|:---|:---|:---|
| **($ in thousands, <br>except per share)** | **December 31,** | **December 31,** |
| **($ in thousands, <br>except per share)** | **2024** | **2025** |
| Shares repurchased | 937141 | **3434745** |
| Total cost | $11678 | $**29873** |
| Average purchase price per share | $12.46 | $**8.70** |
| Unused authorization amount |  | $**8449** |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **24** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Stock Performance Graph**

The following graph compares the performance of an investment in our common stock from the close of business on December 31, 2020, through December 31, 2025, with the Russell 2000 Index and S&P Completion Index. The graph assumes $100 was invested on December 31, 2020, in our common stock at the closing price of $15.38 per share and at the closing price for the Russell 2000 Index and S&P Completion Index. It also assumes that dividends (if any) were reinvested on the date of payment without payment of any commissions. The performance shown in the graph represents past performance and should not be considered an indication of future performance.

![3122](ambc-20251231_g3.jpg)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **December 31,** | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
| | **2021** | **2022** | **2023** | **2024** | **2025** |
| Octave Specialty Group, Inc. | $104 | $113 | $107 | $82 | **$51** |
| Russell 2000 Index | $114 | $89 | $103 | $113 | **$128** |
| S&P Completion Index | $146 | $105 | $130 | $150 | **$165** |

---

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;[Reserved]**

**Item 7. &nbsp;&nbsp;&nbsp;&nbsp;Management's Discussion and Analysis of Financial Condition and Results of Operations ($ and £ in thousands)**

The objectives of our Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") are to provide users of our consolidated financial statements with the following:

&nbsp;&nbsp;&nbsp;&nbsp;• A narrative explanation from the perspective of management of our financial condition, results of operations, cash flows, liquidity and certain other factors that may affect future results;

&nbsp;&nbsp;&nbsp;&nbsp;• Context to the consolidated financial statements; and

&nbsp;&nbsp;&nbsp;&nbsp;• Information that allows assessment of the likelihood that past performance is indicative of future performance.

Unless otherwise noted, this Management's Discussion and Analysis of Financial Condition and Results of Operations relates solely to our continuing operations and does not include the operations of our Legacy Financial Guarantee business. See "Sale of AAC" below and Note 5. Discontinued Operations of the Notes to Consolidated Financial Statements under Part II, Item 8 of this Annual Report on Form 10-K for additional information about the divestiture of the Legacy Financial Guarantee business in September 2025.

The following discussion should be read in conjunction with our consolidated financial statements in Item 8 of this Report and the matters described under Item 1A. Risk Factors in this Annual Report on Form 10-K for the year ended December 31, 2025. Refer to Part I, Item 1. Introduction - Description of the Business, for a description of our business and our key strategies to achieve our primary goal to maximize shareholder value.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **25** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Organization of Information**

MD&A includes the following sections:

---

| | |
|:---|:---|
| | ***Page*** |
| *Strategies to Enhance Shareholder Value* | <u>[26](#i9cb0e1a24c9141e0943a78b7b32afc92_112)</u> |
| *Overview* | <u>[26](#i9cb0e1a24c9141e0943a78b7b32afc92_115)</u> |
| *<u>[Critical Accounting Policies and Estimates](#i9cb0e1a24c9141e0943a78b7b32afc92_118)</u>* | <u>[27](#i9cb0e1a24c9141e0943a78b7b32afc92_118)</u> |
| *<u>[Results of Operations](#i9cb0e1a24c9141e0943a78b7b32afc92_121)</u>* | <u>[30](#i9cb0e1a24c9141e0943a78b7b32afc92_121)</u> |
| *<u>[Liquidity and Capital Resources](#i9cb0e1a24c9141e0943a78b7b32afc92_130)</u>* | <u>[35](#i9cb0e1a24c9141e0943a78b7b32afc92_130)</u> |
| *<u>[Balance Sheet](#i9cb0e1a24c9141e0943a78b7b32afc92_133)</u>* | <u>[36](#i9cb0e1a24c9141e0943a78b7b32afc92_133)</u> |
| *<u>[Accounting Standards](#i9cb0e1a24c9141e0943a78b7b32afc92_136)</u>* | <u>[38](#i9cb0e1a24c9141e0943a78b7b32afc92_136)</u> |
| *<u>[Non-GAAP Financial Measures](#i9cb0e1a24c9141e0943a78b7b32afc92_142)</u>* | <u>[39](#i9cb0e1a24c9141e0943a78b7b32afc92_142)</u> |

---

**Strategies to Enhance Shareholder Value**

The Company's primary goal is to maximize long-term shareholder value through the execution of targeted strategies for its Insurance Distribution and Specialty Property and Casualty Insurance businesses.

Insurance Distribution and Specialty Property and Casualty Insurance strategic priorities include:

&nbsp;&nbsp;&nbsp;&nbsp;• Growing and expanding our Insurance Distribution business based on deep domain knowledge in specialty and niche classes of risk which generate attractive margins at scale. This will be achieved through establishing new businesses "de-novo," organic growth and diversification, and select acquisitions supported by a centralized technology-led shared services offering;

&nbsp;&nbsp;&nbsp;&nbsp;• Growing our Specialty Property and Casualty Insurance business to generate underwriting profits from a diversified portfolio of commercial and personal liability risks accessed primarily through affiliated and non-affiliated program administrators. In addition, we may seek strategic relationships and/or partnerships with unaffiliated parties in order to expand our product offerings, access to reinsurance capacity and other business or operational advantages.

**OVERVIEW** ($ in thousands)

The Company's continuing operations include two segments, financial highlights of which are summarized below along with other recent developments.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | **Specialty Property & Casualty Insurance** | **Insurance <br>Distribution** | **Corporate & Other** | **Total** | **Specialty Property & Casualty Insurance** | **Insurance <br>Distribution** | **Corporate & Other** | **Total** |
| Premiums placed |  | $**951781** |  | $**951781** |  | $493372 |  | $493372 |
| Gross premiums written | $**360449** |  |  | **360449** | $382771 |  |  | 382771 |
| Net premiums written | **73898** |  |  | **73898** | 88682 |  |  | 88682 |
| Total revenues | **88403** | **163726** | **(907)** | **251222** | 126320 | 99236 | 10259 | 235815 |
| Total expenses | **85073** | **184182** | **82981** | **352236** | 114098 | 107045 | 74516 | 295660 |
| Pretax income (loss) | **3330** | **(20456)** | **(83888)** | **(101014)** | 12222 | (7809) | (64257) | (59845) |
| Net income (loss) | **2956** | **(15353)** | **(83406)** | **(95803)** | 10469 | (6881) | (62509) | (58921) |
| EBITDA | **3330** | **36918** | **(80670)** | **(40422)** | 12222 | 19653 | (62393) | (30518) |
| Adjusted EBITDA | **3330** | **22411** | **(80670)** | **(54929)** | 5136 | 19901 | (16394) | 8643 |
| Net income (loss) attributable to Octave shareholders | **2956** | **(17954)** | **(83406)** | **(98404)** | 10471 | (7244) | (62509) | (59282) |
| EBITDA attributable to Octave shareholders | **3777** | **37041** | **(33789)** | **7028** | 12222 | 13205 | (62393) | (36966) |
| Adjusted EBITDA attributable to shareholders | **3777** | **22542** | **(33789)** | **(7471)** | 5136 | 13453 | (16394) | 2195 |

---

**Sale of AAC**

On September 29, 2025, the Company completed the sale of AAC pursuant to the June 4, 2024 stock purchase agreement (the "Purchase Agreement") with American Acorn Corporation (the "Buyer"), a Delaware corporation owned by funds managed by Oaktree Capital Management, L.P., pursuant to which OSG sold all of the issued and outstanding shares of common stock of AAC, a wholly-owned subsidiary of OSG, to Buyer for $420,000 in cash (the "Sale"). The Buyer also made an additional payment to OSG in an amount of $4,300. In the Sale, Buyer acquired complete common equity ownership of AAC and all of its wholly owned subsidiaries, including Ambac Assurance UK Limited. In connection with and pursuant to the Purchase Agreement, OSG issued to Buyer a warrant exercisable for 5,092,707 shares of common stock, par value $0.01, of OSG. Refer to Note 5. Discontinued Operations of the Notes to the

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **26** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

Consolidated Financial Statements under Part II, Item 8 in this Annual Report on Form 10-K for further details on the sale of AAC.

For all periods leading up to the Sale, AAC's results of operations and OSG's loss on sale are reported within Net income (loss) from discontinued operations before tax on the Consolidated Statement of Comprehensive Income (Loss). See Note 5. Discontinued Operations of the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Annual Report on Form 10-K for additional information.

**Acquisition of ArmadaCorp**

On October 31, 2025, the Company closed on the acquisition of ArmadaCorp for a purchase price of $250,000. The Company purchased all of the issued and outstanding limited liability company interests in ArmadaCorp from Sirius Re Holdings, Inc. and Sirius Acquisitions Holding Company, funded in part by $120,000 of loans obtained under new credit facilities. Refer to Note 4. Business Combination in Part II, Item 8 in this Annual Report on Form 10-K for further details on the acquisition of ArmadaCorp.

ArmadaCorp includes an MGA/U that focuses on supplemental health and benefit products for C-suite executives and other key talent. ArmadaCorp creates and distributes supplemental benefit solutions and insurance products. ArmadaCorp's differentiated product offering in the A&H market provides both line of business and product diversification to the Company, while also increasing exposure to non-correlated A&H business lines. ArmadaCorp also provides clients with tools to navigate the healthcare system, including services that help match individuals with physicians suited to their personal needs, and maintains a provider of third-party administration services for insurance carriers that distribute the benefit products and handle claims.

**Pivix**

Effective September 1, 2025, OSG's wholly owned subsidiary, Octave Partners, LLC exercised its option to convert its $3,500 convertible note investment in Pivix, an excess and surplus lines MGA/U, into common stock. As a result, Octave Partners now owns approximately 74% of Pivix, when combined with its previous 17% minority equity interest, and includes Pivix in its consolidated financial statements.

**Sale of Consolidated National Insurance Company**

On January 12, 2024, Everspan Insurance Company entered into a Stock Purchase Agreement with Hagerty Insurance Holdings, Inc., to sell its ownership interests in Consolidated National Insurance Company ("CNIC"), which was one of Everspan's admitted carriers. The closing of this transaction occurred on September 1, 2024, resulting in a gain of approximately $7,504. The sale of CNIC has not had any adverse impact on the group's operations or growth prospects.

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES ($ in thousands)**

Octave's Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in

the U.S. ("GAAP"). This section highlights accounting estimates management views as critical because they are most important to the portrayal of the Company's financial condition; and require management to make difficult and subjective judgments regarding matters that are inherently uncertain and subject to change. These estimates are evaluated on an ongoing basis considering historical developments, political events, market conditions, industry trends and other information. There can be no assurance that actual results will conform to estimates and that reported results of operations will not be materially adversely affected by the need to make future accounting adjustments to reflect changes in these estimates from time to time.

Management has identified the following critical accounting policies and estimates: (i) valuation of specialty property and casualty losses and loss adjustment expense reserves, (ii) business combinations including identification and valuation of intangible assets, and (iii) goodwill and intangible asset impairment analysis. Management has discussed each of these critical accounting policies and estimates with the Audit Committee, including the reasons why they are considered critical and how current and anticipated future events impact those determinations. Additional information about these policies can be found in Note 2. Basis of Presentation and Significant Accounting Policies to the Consolidated Financial Statements included in Part II, Item 8 in this Form 10-K.

**SPECIALTY PROPERTY AND CASUALTY LOSSES AND LOSS EXPENSE RESERVES** 

The specialty property and casualty insurance segment consists of Everspan-affiliated carriers. Loss and loss adjustment expense reserves represent management's estimate of the ultimate liability for unpaid losses and loss expenses for claims that have been reported and incurred but not yet reported ("IBNR") as of the balance sheet date.

Loss and loss adjustment expense reserves by line of business were as follows as of December 31, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **2025** | **Gross** | **Gross** | **Gross** | **Net** | **Net** | **Net** |
| **Line** | **Case** | **IBNR** | **Total** | **Case** | **IBNR** | **Total** |
| Commercial auto | $**67484** | $**91710** | $**159194** | $**10404** | $**12657** | $**23061** |
| Excess liability | **9771** | **106839** | **116610** | **1471** | **15427** | **16898** |
| General liability | **7534** | **56062** | **63596** | **2376** | **10196** | **12572** |
| Workers compensation | **9569** | **8229** | **17798** | **9569** | **8229** | **17798** |
| Non-standard personal auto | **2259** | **1567** | **3826** | **2231** | **1404** | **3635** |
| Professional liability | **6753** | **34094** | **40847** | **467** | **2383** | **2850** |
| Multi-peril / business owners (BOP) | **707** | **5478** | **6185** | **241** | **1278** | **1519** |
| Surety | **1128** | **11106** | **12234** | **—** | **94** | **94** |
| ULAE <sup>(1)</sup> | **—** | **14869** | **14869** | **—** | **5552** | **5552** |
| Other <sup>(2)</sup> | **11411** | **13420** | **24831** | **(102)** | **391** | **289** |
| **Loss and Loss Expense Reserves** | $**116616** | $**343374** | $**459990** | $**26657** | $**57611** | $**84268** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Unallocated loss adjustment expenses.&nbsp;&nbsp;&nbsp;&nbsp;

(2)&nbsp;&nbsp;&nbsp;&nbsp;Includes $23,530 and $0 total loss and loss expense reserves on a gross and net of reinsurance basis related to legacy liabilities obtained from the acquisitions of Providence Washington Insurance Company, Greenwood Insurance Company, and Consolidated Specialty Insurance Company. All legacy liabilities

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **27** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

remain obligations of affiliates of the sellers through reinsurance and contractual indemnities.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **2024** | **Gross** | **Gross** | **Gross** | **Net** | **Net** | **Net** |
| **Line** | **Case** | **IBNR** | **Total** | **Case** | **IBNR** | **Total** |
| Commercial auto | $66092 | $92379 | $158471 | $12532 | $16188 | $28720 |
| Excess and general liability | 7111 | 78348 | 85459 | 1317 | 13540 | 14857 |
| Workers compensation | 6640 | 7825 | 14465 | 6640 | 7825 | 14465 |
| Non-standard personal auto | 10393 | 2296 | 12689 | 10241 | 1943 | 12185 |
| Surety | 1176 | 10041 | 11217 |  |  |  |
| ULAE <sup>(1)</sup> |  | 12238 | 12238 |  | 6578 | 6578 |
| Other <sup>(2)</sup> | 8639 | 45884 | 54523 | 111 | 2066 | 2177 |
| **Loss and Loss Expense Reserves** | $**100051** | $**249011** | $**349062** | $**30831** | $**48139** | $**78981** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Unallocated loss adjustment expenses.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Includes $35,146 and $0 total loss and loss expense reserves on a gross and net of reinsurance basis related to legacy liabilities obtained from the acquisitions of Providence Washington Insurance Company, Greenwood Insurance Company, and Consolidated Specialty Insurance Company. All legacy liabilities remain obligations of affiliates of the sellers through reinsurance and contractual indemnities.

Loss and loss adjustment expense reserves, evaluated at a program and line of business level, are estimated based upon experience and using a variety of actuarial methods and are subject to the impact of future changes in factors such as claim severity and frequency, underwriting and claims practices, changes in social and economic conditions, including the impact of inflation, legal and judicial developments, medical cost trends and upward trends in damage awards. The key assumptions used to arrive at the best estimate of loss reserves are the expected loss ratios and loss development factors representing reported and paid loss emergence patterns. Our actuarial methods may also rely on external data, such as industry loss ratios, loss development factors, or trend factors. The initial estimate for an accident year is generally based on an exposure-based method using the loss ratio projection method. The loss ratio projection method develops an initial estimate of ultimate claims and claim adjustment expenses for an accident year by multiplying earned premium for the accident year by a projected loss ratio. The projected loss ratio is determined by analyzing prior period experience, and adjusting for loss cost trends, rate level differences, a mix of business changes and industry loss ratios and other known or observed factors influencing the accident year relative to prior accident years.

The loss and loss adjustment expense reserves estimate may be based on a judgmental weighting of estimates produced from multiple estimation and analysis methods considered. The method(s) selected and weighted are those that are believed to produce the most accurate estimate at that particular evaluation date. The following estimation and analysis methods are principally used by the Company's engaged independent actuarial specialists to estimate the ultimate cost of loss and loss adjustment expenses. These estimation and analysis methods are typically referred to as conventional actuarial methods.

&nbsp;&nbsp;&nbsp;&nbsp;• The paid loss development method assumes that the future change (positive or negative) in cumulative paid losses for a given cohort of claims will occur in a stable, predictable

pattern from year-to-year, consistent with the pattern observed in past cohorts.

&nbsp;&nbsp;&nbsp;&nbsp;• The case incurred development method is the same as the paid loss development method but is based on cumulative case-incurred losses rather than paid losses.

&nbsp;&nbsp;&nbsp;&nbsp;• The Bornhuetter-Ferguson method uses an initial estimate of ultimate losses for a given product line reserve component, typically expressed as a ratio to earned premium. The method assumes that the ratio of additional claim activity to earned premium for that component is relatively stable and predictable over time and that actual claim activity to date is not a credible predictor of further activity for that component. The method is used most often for more recent accident years where claim data is sparse and/or volatile, with a transition to other methods as the underlying claim data becomes more voluminous and therefore more credible.

The actuarial results provide a range of estimated losses by program and line of business including a low, central and high estimate of losses and loss expenses. At December 31, 2025, management selected the respective midpoint loss ratio between the actuarially determined central and high estimate for active and runoff programs and lines of business for each respective accident year when recording loss and loss adjustment expense reserves. In the prior year, management selected the high end of the respective actuarial range for programs in runoff, but due to (i) increased claims and actuarial oversight, (ii) further run-off of these programs and (iii) further evaluation of Everspan's aggregate reserve position it was determined to record both active and runoff programs at the midpoint loss ratio between the actuarial central and high estimate.

Since the reserves are based on estimates, the ultimate liability may be more or less than such reserves. Octave's actuarial evaluation at December 31, 2025, provided a range of losses incurred. Losses at the low end of the range would be below our recorded gross and net loss expense reserves by approximately $49,900 and $12,500, respectively at December 31, 2025, and losses at the high end of the range would exceed our recorded gross and net loss and loss adjustment expense reserve by approximately $14,600 and $2,200, respectively, at December 31, 2025. This range reflects low and high reasonable reserve estimates determined after using judgment to adjust the methods, factors, and assumptions selected within the internal reserve review. This approach produces a range of reasonable reserve estimates but does not represent a distribution of all possible outcomes.

Additionally, changes in assumptions such as loss development patterns and expected loss ratios can result in variability in actuarial estimates.

&nbsp;&nbsp;&nbsp;&nbsp;• For the loss development pattern we considered the impact of the reported incurred losses developing faster or slower than expected in our projections. For every 1.0% slower or faster the losses develop, we would expect our net indicated reserves to increase or decrease, respectively, by a range of 0.8% to 1.2%. If our reported loss development pattern was 5% slower, the net indicated reserves would be approximately 5% higher. If our reported loss development

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **28** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

pattern was 5% faster, the net indicated reserves would be approximately 4.3% lower.

&nbsp;&nbsp;&nbsp;&nbsp;• For the expected losses we utilize industry benchmark loss ratios and internal pricing loss ratios applied to earned premium. For every 1.0% higher or lower the expected losses are, we would expect our net indicated reserves to increase or decrease by approximately 0.6%. If our expected losses were 5% higher, the net indicated reserves would be approximately 3.2% higher. If our expected losses were 5% lower, the net indicated reserves would be approximately 3.2% lower.

Consequently, final outcomes may be greater or less than the estimates. The extent of the range and variability of loss and loss adjustment expense reserves could be further impacted by future changes in factors discussed above. See "Risk Factors" in Part I, Item 1A in this Annual Report on Form 10-K.

**BUSINESS COMBINATIONS**

The acquired entities comprising the ID segment primarily represent business combinations that were accounted for under the acquisition method of accounting. The acquisition method requires us to allocate the total consideration transferred for each acquisition to the assets acquired, liabilities assumed and noncontrolling interests ("NCI") based on their fair values as of the date of acquisition, including identifiable intangible assets. The allocation of the consideration utilizes significant estimates in determining the fair values of net assets acquired, which primarily consist of customer relationship intangible assets, but may include other finite-lived intangible assets including trade names or non-compete agreements. Measurement of the purchase balance sheet also requires valuation of redeemable NCI interests and nonredeemable NCI interests when applicable.

The valuation method used to determine customer relationship intangible assets was the multi-period excess earnings method "(MPEEM"), which quantifies the residual (or excess) cash flows generated by the intangible asset and discounts those cash flows to their present value. The significant assumptions used in determining the fair value of customer relationships include estimated revenue growth, customer attrition rates, operating margins, and discount rate. These estimates directly impact the amount of identified intangible assets recognized and the related amortization expense in future periods. As of December 31, 2025 and 2024, an aggregate of $463,785 and $333,562, respectively, of acquired intangible assets, net of accumulated amortization, was recorded on the Consolidated Balance Sheets, of which $446,835 and $323,720, respectively, represented customer relationships.

The valuation method used to determine the fair value of redeemable NCI interests and related put and call options was the Monte Carlo Simulation. The significant fair value assumptions used in the simulation include the exercise thresholds, EBITDA forecasts, discount rate and long-term growth rate. The valuation method to determine the fair value of nonredeemable NCI interests, which do not contain put or call options, was the discounted cash flow approach. The significant fair value assumptions used in the model include estimated long term revenue and expense forecasts and the discount rate.

The excess of purchase price over the fair value of assets acquired, liabilities assumed, and NCI interests (both redeemable and nonredeemable) is recorded as goodwill. We may refine our estimates and make adjustments to the assets acquired and liabilities assumed over a measurement period, not to exceed one year from the date of acquisition.

**GOODWILL AND INTANGIBLE IMPAIRMENT ANALYSIS**

***Goodwill impairment evaluation***

We perform the impairment assessment of goodwill at the reporting unit level within our ID segment on an annual basis or more frequently if circumstances indicate a possible impairment. We have determined that each of the entities acquired in the ID segment represent an individual reporting unit. The impairment test may first consider qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Examples of qualitative factors include, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, entity-specific events, events affecting reporting units and sustained changes in our stock price. If results of the qualitative assessment indicate a more likely than not determination or if we elect not to perform a qualitative assessment, a quantitative test is performed by comparing the estimated fair value using a weighted average of an income approach and market approach for each reporting unit to its carrying value. For the 2025 annual impairment evaluation, we elected to bypass the qualitative evaluation and perform quantitative tests on four reporting units containing $432,728 or 80% of the aggregate balance of goodwill as of December 31, 2025. For the remainder of our goodwill balance, including related to ArmadaCorp at year end, we performed a qualitative assessment. There was no goodwill impairment for any of the reporting units.

Under the quantitative assessment, the determination of fair value includes assumptions, which are considered Level 3 inputs, that are subject to risk and uncertainty. We consider different valuation approaches in the quantitative assessment. The income approach uses discounted cash flows which are dependent on subjective factors including the timing of future cash flows, the underlying margin projection assumptions, future growth rates and the discount rate. The market approach uses valuation multiples and is dependent on subjective factors including the determination of industry market multiples and EBITDA forecasts. These results are weighted to arrive at management's estimate of fair value for the reporting unit. Weight applied to each approach is based on the judgments about the extent that they reasonably reflect the value of the particular reporting unit that would be considered by a market participant. Additionally, to corroborate our estimated fair value, we perform a market capitalization reconciliation to determine if the implied control premium is reasonable.

For reporting units evaluated under the quantitative assessment, estimated fair values exceeded carrying values by between 1% and 19%. Market and income approaches were weighted 50% each, except for Octave Ventures where we applied 80% weight to the income approach, considering that the selected public companies used in the market approach do not adequately represent Octave Ventures's business as an MGA incubator

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **29** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

under a Lloyds consortium structure. Fair values are particularly sensitive to the discount rate used in the income approach and the multiple used in the market approach. With no other changes to inputs or assumptions, a 1% increase in the discount rate would have produced an aggregate 11% reduction to the fair value of the tested reporting units. With no other changes to inputs or assumptions, a 20% decrease in the market multiples used would have produced an aggregate 4% reduction to the fair value of the tested reporting units. Changes to these or other assumptions or estimates in our fair value calculations or variances to any of the above subjective factors from what was expected, could impact our impairment analysis and result in a decline in fair value that may trigger future impairment charges.

***Intangible asset impairment and useful life evaluation***

We review acquired finite-lived intangible assets that are being amortized for impairment whenever events or changes in circumstance indicate that their carrying amount may not be recoverable. Qualitative factors considered include any adverse developments in regulation, unfavorable market conditions, or the extent to which an asset will be utilized. We do not believe there will be a material change in the estimates or assumptions used to calculate impairments or useful lives of amortizable intangible assets. However, if actual results are not consistent with our estimates and assumptions, we may be exposed to an acceleration of amortization or impairment losses that could be material.

**RESULTS OF OPERATIONS**

The following is a discussion and analysis of the Company's financial condition and results of operations for the years ended December 31, 2025 and 2024, including year-to-year comparisons between 2025 and 2024. Year-to-year comparisons between 2024 and 2023 have been omitted from this Form 10-K, but may be found in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Net loss from continuing operations for the years ended December 31, 2025 and 2024, was $95,803 and $58,921, respectively. The net loss variance in 2025 compared to 2024 was primarily driven by: (i) higher restructuring costs of $15,524, (ii) higher intangible amortization of $20,442, (iii) higher interest expense on short-term debt of $9,261, and (iv) lower foreign exchange gains of $6,717, partially offset by lower acquisition costs of $19,213, investment impairments of $3,416, gains on sale of subsidiaries of $7,504, and higher ID revenue due to acquisitions and continuing growth of the business.

A summary of our financial results is shown below:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Revenues:** |  |  |  |
| &nbsp;&nbsp;Commissions | $**143381** | $92023 | $51281 |
| &nbsp;&nbsp;Servicing and other fees | **20419** | 6353 |  |
| &nbsp;&nbsp;Net premiums earned | $**67232** | $99005 | $51911 |
| &nbsp;&nbsp;Program fees | **14322** | 13506 | 8437 |
| &nbsp;&nbsp;Investment income | **10647** | 14448 | 13159 |
| &nbsp;&nbsp;Other | **(4780)** | 10480 | (60) |
| **Expenses:** |  |  |  |
| &nbsp;&nbsp;Commissions | **37037** | 40876 | 29465 |
| &nbsp;&nbsp;Losses and loss adjustment expenses | **47193** | 72626 | 36712 |
| &nbsp;&nbsp;Policy acquisition costs | **15790** | 23666 | 10557 |
| &nbsp;&nbsp;General and administrative | **191624** | 129166 | 66985 |
| &nbsp;&nbsp;Intangible amortization and depreciation | **41952** | 19947 | 5230 |
| &nbsp;&nbsp;Interest | **18640** | 9379 |  |
| &nbsp;&nbsp;Provision (benefit) for income taxes from continuing operations | **(5211)** | (924) | (989) |
| **Net income (loss) from continuing operations** | **(95803)** | (58921) | (23232) |
| Net income (loss) from discontinued operations, net of income taxes | **(163288)** | (497167) | 28183 |
| **Net income (loss)** | **(259091)** | **(556088)** | **4951** |
| &nbsp;&nbsp;Less: net (gain) loss attributable to NCI | **(2601)** | (361) | (1319) |
| **Net income (loss) attributable to shareholders** | $**(261692)** | $**(556449)** | $**3632** |

---

Octave's results for the year ended December 31, 2025 compared to the year ended December 31, 2024, were impacted by the following:

&nbsp;&nbsp;&nbsp;&nbsp;***•*** Acquisitions within the ID segment have had a significant impact on the comparability of results between 2025 and 2024.

–Effective October 31, 2025, Octave acquired 100% of ArmadaCorp.

–Effective September 1, 2025, Octave exercised its option to convert its $3,500 convertible note investment in Pivix and now owns approximately 74%.

–Effective July 31, 2024, Octave acquired 60% of Octave Ventures.

&nbsp;&nbsp;&nbsp;&nbsp;• The sale of AAC on September 29, 2025. AAC's results, including Octave's loss on the sale of AAC are reported within discontinued operations. Refer to Note 1. Background and Business Description and Note 5. Discontinued Operations of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K for further details on the Sale and results for the years ended December 31, 2025 and 2024. As a result of the Sale, Octave repaid all of the outstanding debt used to acquire Octave Ventures, amounting to $150,000, and purchased AAC's co-investment in Octave Ventures of $62,000. Concurrent with the Sale, OSG entered into a number of transactions as discussed herein, including transactions intended to lower the long term run-rate of corporate operating expenses.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **30** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

The following describes the consolidated results of continuing operations of Octave and its subsidiaries for 2025 and 2024.

**<u>Gross Premiums Written.</u>** Gross premiums written decreased $(22,322) for the year ended December 31, 2025, and increased $109,484 for the year ended December 31, 2024, compared to the comparable prior year periods, as shown below.

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Gross Premiums Written | $**360449** | $382771 | $273287 |

---

Changes are primarily driven by the number and size of active programs. As of December 31, 2025 and 2024 we had 25 and 27 programs, respectively, across approximately ten lines of business, with a focus on the casualty sector and minimal property exposure. The decline in active programs from 2024 was a strategic decision to improve capital allocation and return on capital.

**<u>Net Premiums Written.</u>** Net premiums written decreased $(14,784) for the year ended December 31, 2025, and increased $8,858 for the year ended December 31, 2024, compared to the comparable prior year periods, as shown below:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Net Premiums Written | $**73898** | $88682 | $79824 |

---

The decline in net premiums written will typically track gross premiums written but will also be impacted by the percentage of each program Everspan retains. Everspan typically retains up to 30% of each program. For the years ended December 31, 2025 and 2024, Everspan retained 20.5% and 23.2% of gross written premiums, respectively. The reduced retention rate in 2025 compared to 2024 was primarily driven by the managed non-renewal of certain programs.

**<u>Net Premiums Earned.</u>** Net premiums earned for the year ended December 31, 2025, decreased by $(31,773) or (32.1)% and increased by $47,094 or 90.7% for the year ended December 31, 2024, compared to the comparable prior year periods, as shown below.

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Net Premiums Earned | $**67232** | $99005 | $51911 |

---

The decrease in net premiums earned in 2025 compared to 2024 was driven by the changes in net premiums written and the managed non-renewal of certain programs.

**<u>Commission Income and Commission Expense.</u>** The ID business earns commission income as a percentage of the premium it places with insurance, reinsurance and other capacity providers. In some cases, the ID business will also earn profit commissions based on the underwriting performance of the business that it underwrites. Profit commissions by their nature may be volatile whereas base commissions tend to be more steady.

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Gross Commissions | $130982 | $82992 | $46792 |
| Profit commissions | 12400 | 9031 | 4489 |
| Commission expense | 37037 | 40876 | 29465 |

---

Commission income was $130,982 and $82,992 for the years ended December 31, 2025 and 2024, respectively. The increase was driven by organic growth in premiums placed as well as the acquisition of Octave Ventures in July 2024 and ArmadaCorp in October of 2025. Commission expense will largely track changes in gross commission.

Profit commissions were $12,400 and $9,031 for the years ended December 31, 2025 and 2024, respectively. The increase in profit commissions was due to the acquisitions of Octave Ventures and ArmadaCorp, offset by contraction at Xchange.

For the December 31, 2025 and 2024 commission expense was $37,037 and $40,876, respectively, representing approximately 26% and 43% of commission income in each respective period. The decrease in commission expense compared to commission income in 2025 relative to 2024 is primarily a result of the acquisition of Octave Ventures. Because third parties are paid commissions to obtain business, the majority of Octave Ventures's commission income is reported net of any distribution and commission expenses, due to the nature of its program agreements. The majority of the ID Segment's other MGA/Us report their commission income gross of distribution and commission expenses.

**<u>Program Fees.</u>** Program fee revenues were $14,322 and $13,506 for the years ended December 31, 2025 and 2024, respectively. Program fee revenues represent the recognition of ceding commissions in excess of direct acquisition costs received from reinsurers and minimum fees received from MGA/Us until related programs reach certain levels of premium ceded. Program fees are charged as a percentage of premiums ceded to reinsurers as a component of total ceding commissions. The growth is a function of premiums ceded to reinsurers; driven by changes in direct premiums written.

**<u>Net Investment Income.</u>** Net investment income consists of interest income, including the net effect of discount accretion and premium amortization, from fixed maturity securities classified as available-for-sale and net gains (losses) on pooled investment funds which are reported under the equity method. These funds and certain other investments are reported in Other investments on the Consolidated Balance Sheets. For further information about investment funds held, refer to Note 6. Investments to the Consolidated Financial Statements, included in Part II, Item 8 in this Annual Report on Form 10-K.

Net investment income was $10,647 and $14,448 for the years ended December 31, 2025 and 2024, respectively. The decline is due to lower Corporate short-term yields and lower average investment balances resulting primarily from assets used for the acquisition of Octave Ventures, partially offset by the impact of higher average investment balances in the Insurance Distribution segment and at Everspan.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **31** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**<u>Servicing and Other Fees.</u>** Servicing and Other Fees increased $14,066 for the year ended December 31, 2025. Servicing and Other Fees include revenues earned for providing operational and administrative services to the Lloyd's syndicates managed by Octave Ventures, and its Managing Agency (Statera Managing Agency Limited). This was previously managed by a third party managing agency and as of December 31, 2025 it is now managed by Statera Managing Agency Limited. Other policy and brokerage fees are also included relating to the MGAs within Octave Ventures. Servicing and other fees also include program administration (TPA), health connections, set-up and renewal fees related to ArmadaCorp.

**<u>Other Revenues</u>**. Other revenues include (i) net investment gains (losses) on securities sold or called, net of investment impairment charges; (ii) foreign exchange gains (losses) from the ID segment; and (iii) net gains on derivative contracts, including FX forward contracts used to manage currency risk within the ID segment. Other revenues for the years ended December 31, 2025 and 2024, was $(4,780) compared to $10,480 in the prior year. The decrease in Other revenue resulted primarily from higher foreign exchange losses from the ID segment, together with certain items impacting the 2024 results including gains on FX forward contracts used by Octave to mitigate currency risk leading up to the acquisition of Octave Ventures, a gain on Everspan's sale of one of its shell insurance companies and its licenses, and a realized gain on conversion of notes receivable to a preferred stock position at Corporate. The decrease was partially offset by reduction in Corporate investment impairment charges.

**<u>Losses and Loss Adjustment Expenses (Benefit).</u>** Losses and loss adjustment expenses decreased $25,433 for the year ended December 31, 2025, compared to December 31, 2024. The decrease was primarily due to the reduction in premium related to non-renewal of certain programs. Everspan's loss and loss adjustment expense ("LAE") ratio was 70.2% and 73.4% for the years ended December 31, 2025 and 2024, respectively, inclusive of prior years' adverse development of 7.4% and 4.7%, respectively. Excluding prior period development, Everspan's loss and LAE ratio were 62.8% and 68.6%, respectively. The shift in the overall loss and LAE and the loss and LAE ratios, excluding prior period development, was primarily due to the managed non-renewal of certain programs.

Prior year adverse development was driven primarily by higher excess liability and commercial auto loss experience in the prior accident years for year ended December 31, 2025, whereas the year ended December 31, 2024, included higher commercial auto loss experience in the prior accident years and a higher selected loss ratio for programs in runoff. Additionally, in 2024 management set loss reserves for programs that are runoff at the high end of the actuarial loss range, given these programs can experience greater loss volatility than active programs. This change to set runoff reserves at the high end of the range resulted in a 1 percentage point increase in the loss and LAE ratio for the year ended December 31, 2024.

Everspan's loss and LAE ratio will vary based on changes in the lines of business underwritten and retained, loss reserving policy, loss development trends, inflation rates and other economic and industry specific factors.

The decrease in the loss and LAE ratio for the year ended December 31, 2025, compared to December 31, 2024, additionally had further improvement driven by benefits within acquisition costs as a result of sliding scale commission arrangements with program partners. Certain Everspan programs were structured to include sliding scale commission arrangements within a loss ratio range. These sliding scale arrangements help to partially mitigate net income volatility. Such benefit reduced the Specialty Property and Casualty Insurance segments expense ratio by 2.1% and 0.8% for the years ended December 31, 2025 and 2024.

Everspan's insurance risk is primarily concentrated via casualty insurance, primarily related to commercial auto, workers compensation, excess and general liability lines of business. Everspan continuously monitors its diversification in lines of business and manages its concentration via MGA/U program oversight of policy limits and premium caps and via reinsurance to third parties. Loss and loss adjustment expenses incurred may be adversely impacted by increasing economic and social inflation, particularly within the commercial auto business. The impact of inflation on ultimate loss reserves is difficult to estimate, particularly in light of recent disruptions to the judicial system, supply chain, labor markets and the potential impact of the imposition of trade tariffs. In addition, going forward, we may not be able to offset the impact of inflation on our loss costs with sufficient price increases. The estimation of loss reserves may also be more difficult during extreme events, such as a pandemic, or during the persistence of volatile or uncertain economic conditions, due to, amongst other reasons, unexpected changes in behavior of judicial decisions, claimants and policyholders, including fraudulent reporting of exposures and/or losses. Additionally, Everspan may be subject to disputes with policyholders regarding the scope and extent of coverage offered under Everspan's policies or may be subject to disputes which may lead to liabilities beyond those which are anticipated or reserved, including liabilities in excess of policy limits. Due to the inherent uncertainty underlying loss reserve estimates, the final resolution of the estimated liability for loss and loss adjustment expenses will likely be higher or lower than the related loss reserves at the reporting date. In addition, our estimate of losses and loss expenses may change. These additional liabilities or increases in estimates, or a range of either, could vary significantly from period to period.

**<u>General and Administrative Expenses ("G&A").</u>** The following table provides a summary of G&A expenses for the periods presented:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Compensation | $**109847** | $64346 | $48468 |
| Non-compensation | **81777** | 64820 | 18517 |
| Total | $**191624** | $129166 | $66985 |

---

The increase in 2025 compared to 2024 was primarily due to the following:

&nbsp;&nbsp;&nbsp;&nbsp;• Higher compensation costs of $45,501 were primarily due to (i) the acquisition of ArmadaCare as well we the launch of new (de-novo) MGAs such as Pivix (ii) the inclusion of a full year of Octave Ventures in 2025 compared to a partial year in 2024, and (iii) severance and accelerated

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **32** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

incentive compensation expenses incurred in relation to the sale of AAC.

&nbsp;&nbsp;&nbsp;&nbsp;• Higher non-compensation costs of $16,957, driven primarily by higher restructuring costs of $15,524 in relation to the sale of AAC, the inclusion of a full year of Octave Ventures in 2025 and the acquisition of ArmadaCorp in 2025, partially offset by decrease in Corporate costs associated with acquisitions of $17,906.

**<u>Intangible Amortization and Depreciation.</u>** Intangible amortization and depreciation for the years ended December 31, 2025 and 2024 was $41,952 compared to $19,947 in the prior year. The increases are due to intangible amortization for the year ended December 31, 2025, related to the ArmadaCorp and Octave Ventures acquisition.

**<u>Interest Expense.</u>** Interest expense for the years ended December 31, 2025 and 2024 was $18,640 and $9,379, respectively, due to higher average debt outstanding in 2025. Octave borrowed under a credit facility to partially fund the Octave Ventures acquisition in the third quarter of 2024. This debt was repaid on September 29, 2025. Octave borrowed under a new credit facility, at a lower rate, on October 31, 2025, to partially fund the ArmadaCorp acquisition.

**<u>Provision for Income Taxes.</u>** The provision for income tax (benefit) for the years ended December 31, 2025 and 2024, was $(5,211) and $(924), respectively. The tax benefit recognized in the current year includes current tax expense associated with Octave Ventures operations in the U.K. offset by deferred tax benefits related to the recognition of deferred tax assets generated by Octave Ventures operations in the U.S. and amortization of finite-lived intangible assets associated with Octave Ventures operations both in the U.K. and U.S.

At December 31, 2025, the OSG had approximately $1,690,842 of U.S. federal net ordinary operating loss carryforwards.

**Results of Operations by Segment**

---

| | | | |
|:---|:---|:---|:---|
| **Insurance Distribution** | **Insurance Distribution** | **Insurance Distribution** | |
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Premiums placed | $**951781** | $493372 | $230606 |
| Commission income | $**143381** | $92023 | $51281 |
| Commission expense | **37037** | 40876 | 29465 |
| Net commissions | **106344** | 51147 | 21816 |
| Servicing and other fees | 20419 | 6353 |  |
| Net investment income | 1514 | 787 | 64 |
| Other income (expense) | (1588) | 73 | 200 |
| **Expenses:** |  |  |  |
| &nbsp;&nbsp;General and administrative | **89771** | 38707 | 10598 |
| **EBITDA** | **36918** | **19653** | **11483** |
| &nbsp;&nbsp;Interest Expense | **18640** | 9379 |  |
| &nbsp;&nbsp;Depreciation | **690** | 481 | 42 |
| &nbsp;&nbsp;Intangible amortization | **38044** | 17602 | 4152 |
| **Pretax income (loss)** | $**(20456)** | $(7809) | $7289 |
| **Octave's stockholders equity** <sup>(1)</sup> | $**757850** | $218344 | $102473 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Represents the share of Octave stockholders equity for each subsidiary within the ID segment, including intercompany eliminations.

Octave's ID companies are compensated for their services primarily by commissions paid by insurance carriers for underwriting, structuring and/or administering polices and, in some cases, the managing of claims under an agency agreement. Commission revenues are usually based on a percentage of the premiums placed. In addition, we are eligible to receive profit sharing contingent commissions ("Profit Commissions") based on the underwriting results of certain programs underwritten by our MGA/Us. These profit commissions may fluctuate from period to period resulting in some variability in revenue and earnings.

The ID segment placed premiums for were approximately $951,781 for the year ended December 31, 2025, up $458,409 or 93% as compared to the year ended December 31, 2024. The increase was primarily driven by the inclusion of a full year of Octave Ventures, the acquisition of ArmadaCorp and organic growth.

The ID pretax loss for the year ended December 31, 2025 and 2024, was $(20,456) and $(7,809), respectively, up $(12,647) or 162%, compared to year ended December 31, 2024. The increase was primarily driven by higher intangible amortization and interest expense related to acquisitions.

The ID EBITDA for the years ended December 31, 2025 and 2024 was $36,918 and $19,653, respectively, up $17,265 or 88%. The increase was primarily driven by increase in commission income due to acquisitions and organic growth.

ID businesses may experience seasonal impacts on their revenues and net results. For example, Employer Stop Loss business and other A&H lines produce the majority of their business in January and July, which results in revenue and earnings concentrations in the first and third quarters of each

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **33** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

calendar year. Seasonal impacts on the ID segment, and therefore Octave's results, may increase or decrease and shift over time depending on the relative growth of certain classes of business as well as the impact of acquisitions.

**<u>G&A Expenses</u>** G&A expenses for the year ended December 31, 2025, were $89,771 compared to the year ended December 31, 2024, of $38,707 For the current year, compensation expense increased by $35,408 and non-compensation expenses increased by $15,656 primarily due to the addition of the operating expenses of ArmadaCorp and Octave Ventures, which were acquired in October 2025 and July 2024, respectively, and the consolidation of Pivix in September 2025.

---

| | | | |
|:---|:---|:---|:---|
| **Specialty Property and Casualty Insurance** | **Specialty Property and Casualty Insurance** | **Specialty Property and Casualty Insurance** | |
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Gross premiums written | $**360449** | $382771 | $273287 |
| Net premiums written | **73898** | 88682 | 79824 |
| **Revenues:** |  |  |  |
| &nbsp;&nbsp;Net premiums earned | $**67232** | $99005 | $51911 |
| &nbsp;&nbsp;Investment income | **6811** | 6400 | 3795 |
| &nbsp;&nbsp;Program fees | **14322** | 13506 | 8437 |
| &nbsp;&nbsp;Other income | **38** | 7409 | (42) |
| Total | **88403** | 126320 | 64101 |
| **Expenses:** |  |  |  |
| &nbsp;&nbsp;Losses and loss adjustment expenses | **47193** | 72626 | 36712 |
| &nbsp;&nbsp;Policy acquisition costs | **15790** | 23666 | 10557 |
| &nbsp;&nbsp;General and administrative | **22090** | 17806 | 16449 |
| &nbsp;&nbsp;Net (gain) loss attributable to NCI interest | **—** | 2 | (1) |
| **Pretax income (loss)** | $**3330** | $12222 | $383 |
| **EBITDA** | **3330** | $12222 | $383 |
| **Retention Ratio** <sup>(1)</sup> | **20.5%** | 23.2% | 29.2% |
| **Loss and LAE Ratio** <sup>(2)</sup> | **70.2%** | 73.4% | 70.7% |
| **Expense Ratio** <sup>(3)</sup> | **35.0%** | 28.2% | 35.8% |
| **Combined Ratio** <sup>(4)</sup> | **105.2%** | 101.6% | 106.5% |
| **Octave's stockholders equity** <sup>(5)</sup> | $**140278** | $133266 | $121678 |

---

(1)Retention ratio is defined as net premiums written divided by gross premiums written.

(2)Loss and LAE ratio is defined as losses and loss expenses incurred divided by net premiums earned.

(3)Expense Ratio is defined as acquisition costs and general and administrative expenses, reduced by program fees, divided by net premiums earned.

(4)Combined ratio is defined as Loss and LAE ratio plus Expense Ratio.

(5)Represents Octave stockholders equity in the Specialty Property and Casualty Insurance segment, including intercompany eliminations.

The Specialty Property and Casualty Insurance segment has grown significantly since underwriting its first program in May 2021. Twenty-five programs were authorized to issue policies as of December 31, 2025, a decrease compared to twenty-seven as of December 31, 2024. Program counts and premium production, including gross and net premiums written and net premiums earned declined in 2025 from 2024 primarily due to

managed non-renewals of certain programs to improve capital allocation and return on capital. Partially offsetting this decline in premium production is lower losses and LAE and lower policy acquisition costs. Additionally, EBITDA and pre-tax income has decreased as compared to year ended December 31, 2024. This is primarily due to the gain on sale of CNIC recognized in 2024 of approximately $7,500. The combined ratio increased in 2025 versus 2024 due to higher general and administrative expenses as Everspan continues to build out its staffing and operations combined with the impact of the lower net premiums earned base. Lower premiums earned results in greater sensitivity to changes in losses and expenses.

**<u>G&A Expenses</u>** G&A costs increased for the year ended December 31, 2025, relative to the year ended December 31, 2024, primarily due to net growth in Everspan's staffing, outside services and expanded business operations.

**Corporate**

Corporate consists of our holding company and shared services operations ("Corporate"). Corporate provides financial, technological and human resources to Octave's two segments and is responsible for the function of OSG as a publicly-traded company.

Corporate revenues totaled $(907) and $10,259 for the years ended December 31, 2025 and 2024, respectively.

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Investment income | **2323** | 7261 | 9298 |
| Net derivative gains (losses) | **—** | 3910 | (279) |
| Other | **(3230)** | (912) | 61 |
| Total revenue | **(907)** | 10259 | 9080 |

---

Investment income decreased for the year ended December 31, 2025, relative to year ended December 31, 2024, primarily due to lower average invested assets due to the use of funds for the (i) acquisition of Octave Ventures in the third quarter 2024, (ii) the acquisition of ArmadaCorp in the fourth quarter of 2025, and (iii) the repurchase of our stock in October 2025, as well as lower yields on short-term invested assets in 2025.

Both years included write-downs in the carrying value on investments in preferred securities that are carried at cost less impairment.

Corporate revenues in 2024 included net derivative gains related to FX hedging of the purchase price of Octave Ventures, together with realized gains from the conversion and early settlement of certain convertible notes, including make-whole payments, which are included in Other revenue.

Corporate expenses were $82,981 for the year ended December 31, 2025, up $8,465 from the year ended December 31, 2024. Corporate expenses for the years ended December 31, 2025 and 2024 included compensation expenses of $33,841 and $25,791, respectively, and non-compensation expense of $49,140 and $48,725, respectively. Compensation expense is higher mostly due to (i) impact of incentive costs for $5,079 related to compensation restructuring and (ii) severance costs of $4,878. Non-compensation expenses were relatively flat but included increases of $6,481 from an early lease termination payment,

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **34** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

restructuring fees of $15,712 from the sale of AAC and disposal of software of $1,017, offset by decreases in acquisition costs of $18,282 and franchise tax expense of $1,323.

**LIQUIDITY AND CAPITAL RESOURCES**

**Holding Company Liquidity**

OSG is a holding company organized as a legal entity separate and distinct from its operating subsidiaries. OSG's liquidity is primarily dependent on its net assets, excluding the operating subsidiaries that it owns, totaling $76,484 and $119,214 as of December 31, 2025 and December 31, 2024, respectively, and secondarily on investment income, distributions, tax and expense-sharing payments and third-party capital (e.g. from credit facilities and equity issuance).

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| Cash and short-term investments | $**49471** | $74423 |
| Other investments <sup>(1)</sup> | **25124** | 28117 |
| Other net assets | **1889** | 16674 |
| **Total** | $**76484** | $**119214** |

---

(1)Includes minority equity investments in insurance services businesses of $17,517 and $20,618 at December 31, 2025 and December 31, 2024, respectively.

The decrease in OSG net assets, excluding its equity investments in subsidiaries, during the 2025 was driven primarily by net cash outflows from operating expenses, contributions to subsidiaries, open market stock repurchases, and the purchase of ArmadaCorp, partially offset by net proceeds from the sale of AAC, interest income, and distributions received from subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;• OSG acquired ArmadaCorp for $250,000 which was funded by cash and $120,000 of loans from a global bank.

&nbsp;&nbsp;&nbsp;&nbsp;• OSG received $420,000 of proceeds from the sale of AAC, plus an additional $4,300, less applicable legal, advisory and other expenses incurred in connection with the Sale.

&nbsp;&nbsp;&nbsp;&nbsp;• In connection with the 2024 Octave Ventures acquisition, Octave Partners incurred $150,000 of debt funded by a global bank. Upon the closing of the sale of AAC in 2025, OSG repaid the $150,000 loan.

&nbsp;&nbsp;&nbsp;&nbsp;• OSG's acquisition of Octave Ventures was partially funded by AAC's co-investment in the amount of $62,000. Upon the close of the AAC sale in 2025, OSG purchased AAC's co-investment at a price resulting in a 7.5% rate of return per annum to AAC.

&nbsp;&nbsp;&nbsp;&nbsp;• OSG repurchased 3.4 million of its common shares for $29,942 under a share repurchase program.

Everspan's ability to make future dividend payments will mostly depend on its future profitability relative to its capital needs to support growth. Everspan did not pay dividends to OSG in 2025 and is not expected to pay dividends in 2026; however, it does make tax payments to OSG in accordance with a Tax Sharing Agreement. For the year ended December 31, 2025, Everspan paid $2,014 in tax payments to OSG.

Octave Partners does not have any regulatory restrictions on its ability to make distributions. OSG received distributions from

Octave Partners of $15,363 and $10,739 during the years ended December 31, 2025 and 2024, respectively.

OSG's principal uses of liquidity are: (i) the payment of G&A expenses, including costs to explore opportunities to grow and diversify Octave, (ii) making capital investments to acquire, grow and/or capitalize new and/or existing businesses, including through the acquisition of noncontrolling interests ("NCI") as a result of the exercise of outstanding puts and/or calls, and (iii) making investments in technology and other operational infrastructure to improve the operational effectiveness and efficiency of our business and to support its growth. Funding puts, calls and other capital commitments would require payments from OSG, the magnitude of which will ultimately depend on the performance of the underlying businesses, whether or not the puts or calls are exercised, FX rates and other considerations. OSG would expect the funding requirements for such obligations not to exceed approximately $50,000 in 2026, but such amount could be higher based on those considerations outlined above. In 2026 OSG intends to fund potential NCI puts using additional debt. OSG is seeking to fund future NCI puts and calls using internal funding, but may also seek additional debt or other funding sources. OSG may satisfy certain put/call obligation using common equity for up to 35% of the amount of the exercise value. The need for additional capital to fund future NCI puts and calls will depend on a number of considerations, including distribution levels from subsidiaries, the potential for additional acquisitions, other capital investment demands, and stock repurchases. In addition, the value of the NCI puts and calls at the time of exercise will also have an impact on our need for additional funding. OSG may also provide short-term financial support, primarily in the form of loans, to its operating subsidiaries to support their operating requirements.

In the opinion of the Company's management the net assets and expected funding sources of OSG are currently sufficient to meet OSG's current liquidity requirements. However, events, opportunities, acquisitions, the exercise of puts and calls, the need to refinance outstanding debt, share repurchases or other circumstances could require OSG to seek additional capital (e.g. through loans or the issuance of debt, equity, convertible or hybrid securities).

In connection with the ArmadaCorp acquisition on October 31, 2025, the Company borrowed $120,000 in the form of a five-year $100,000 term loan and a five-year $20,000 revolving credit facility (together, the "Credit Facilities"). The Credit Facilities include covenants that restrict our ability to manage capital resources by requiring maintenance of certain financial ratios and restricting indebtedness, liens, mergers, sales of assets, investments, restricted payments (such as dividends), and affiliate transactions, among other restrictions. The Credit Facility also requires the prepayment of the borrowings thereunder with proceeds of certain asset sales, recovery events, issuances of indebtedness and indemnity payments. These requirements will impact our financial and operational flexibility while the Credit Facility remains in place. See Note 12. Debt to the Consolidated Financial Statements included in this Annual Report for further detail about the Credit Facilities.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **35** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Operating Companies' Liquidity**

**<u>Insurance:</u>**

Sources of liquidity for Everspan are primarily through funds generated from premiums, reinsurance recoveries, fees, investment income and maturities and sales of investments.

Cash provided from these sources is used primarily for claim payments, loss expenses, acquisition costs, operating expenses, reinsurance payments and purchases of securities and other investments.

Everspan manages its liquidity risk by projecting cash flows and maintaining specified levels of cash and short-term investments at all times. It is the opinion of the Company's management that the insurance subsidiaries' near term liquidity needs will be adequately met from the sources described above.

**<u>Insurance Distribution:</u>**

The liquidity requirements of our ID subsidiaries are met primarily by funds generated from commission (both base and profit commissions) and fees. Base commissions and fees are generally received monthly, whereas profit commissions are received only if the business underwritten is profitable. Cash provided from these sources is used primarily for commissions paid to sub-producers, operating expenses and distributions to OSG and other members.

**Cash Held at Banks**

Octave maintains cash and investment accounts, including premium trust accounts, at depository institutions in amounts in excess of the limits insured by the FDIC and in countries other than the U.S. Octave's cash balances held at banks were $68,440 as of December 31, 2025, including cash of Octave's insurance distribution subsidiaries held in regional banks of $33,263 as of December 31, 2025.

**Consolidated Cash Flow Statement Discussion**

The following table summarizes the net cash flows for continuing operations for the periods presented.

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Cash provided by (used in):** |  |  |  |
| &nbsp;&nbsp;Operating activities | $**(52283)** | $762 | $36948 |
| &nbsp;&nbsp;Investing activities | **199936** | (166371) | (26679) |
| &nbsp;&nbsp;Financing activities | **(126298)** | 194219 | (10986) |
| **Net cash flow** | $**21355** | $**28610** | $**(717)** |

---

**<u>Operating Activities for Continuing Operations</u>**

Operating cash flows during the year ended December 31, 2025 were adversely impacted by transaction-related costs for the acquisition of Octave Ventures and the sale of AAC, together with interest payments on Octave Partners's short-term borrowing.

Future operating cash flows will primarily be impacted by net premium collections, investment coupon receipts, fee and net commission revenues, operating expenses, net claim and loss expense payments and debt interest payments.

**<u>Investing Activities for Continuing Operations</u>**

Investing activities for the year ended December 31, 2025 included net cash used in the ArmadaCorp acquisition of $217,940 and net cash proceeds from the sale of AAC of $407,300.

**<u>Financing Activities for Continuing Operations</u>**

Financing activities for the year ended December 31, 2025 included net borrowings of $117,470 under five year credit facilities for the ArmadaCorp acquisition and concurrent with the AAC Sale, repayment $150,000 of short term borrowing, the repurchase of AAC's co-investment used to partially fund the purchase of Octave Ventures for $67,309 and share repurchases of $29,942.

Financing activities for the year ended December 31, 2024 included borrowing of $147,000 under a short-term credit facility, receipt of a $62,000 co-investment from AAC to fund the acquisition of Octave Ventures and share repurchases of $11,698.

Future financing cash flows will be primarily impacted by paydowns and maturities of debt; share repurchases; acquisitions of noncontrolling interest shares; other capital management activity and distributions to noncontrolling interests.

**<u>Cash Flows from Discontinued Operations</u>**

Cash flows pertaining to discontinued operations are reported separately on the Consolidated Statements of Cash Flows. The primary driver of the cash flows from discontinued operations was the continued runoff of the financial guarantee business, including the collection of premiums, interest income and subrogation, and the payment of claims, expenses and foreign taxes. Since the agreement to sell AAC, the operations were substantially separated and with the Sale having been completed in September 2025, reporting periods after September 30, 2025 will exclude any discontinued operations activity.

**BALANCE SHEET**

Total assets decreased by approximately $5,835,061 from December 31, 2024 to $2,223,317 at December 31, 2025 (decrease of $6,267,200 related to discontinued operations, partially offset by an increase of $432,139 from continuing operations).

Total liabilities decreased by approximately $5,725,706 from December 31, 2024 to $1,137,151 as of December 31, 2025 (decrease of $5,887,685 relating to discontinued operations, partially offset by an increase of $161,979 from continuing operations).

As of December 31, 2025, total stockholders' equity was $833,185, compared with total stockholders' equity of $996,119 at December 31, 2024. This decrease was primarily the result of the net loss attributable to common stockholders for the year ended December 31, 2025, of $261,692, decreases to Octave Ventures nonredeemable NCI of $44,023 , adjustments to the redemption value of redeemable NCI of $7,899, and cost of shares repurchased of $29,942. The decrease was partially offset by translation gains of $176,166, including changes associated with Discontinued Operations of $158,505.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **36** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Discontinued Operations:**

**<u>Assets and Liabilities Held-for-Sale.</u>** Assets held-for-sale decreased to $0 at December 31, 2025, from $6,267,200 at December 31, 2024. The decrease results from the completion of the sale of AAC. Liabilities held-for-sale decreased to $— at December 31, 2025 from $5,887,685 at December 31, 2024 due to the completion of the sale of AAC. Refer to Note 5. Discontinued Operations in this Annual Report on Form 10-K.

**Continuing Operations:**

The following discusses changes in assets, liabilities and stockholders' equity as of December 31, 2025 compared to December 31, 2024. Octave's acquisition of ArmadaCorp impacted the comparability of the balance sheet between December 31, 2025 and December 31, 2024. Refer to Note 4. Business Combination to the Consolidated Financial Statements included in this Annual Report on Form 10-K for details of the assets and liabilities acquired at the acquisition date.

**Assets:**

***Investment Portfolio***

Octave's investment portfolio is managed under established guidelines designed to meet the investment objectives of the Everspan Group and OSG. Everspan's fixed maturity and short-term investment portfolio had a weighted average credit rating of AA and AA- at December 31, 2025 and 2024, respectively. The ID businesses investments are limited to cash sweep products, treasuries, certificates of deposit and money market funds. Refer to "Description of the Business — Investments and Investment Policy" in this Annual Report on Form 10-K located in Part I. Item 1, for further description of Octave's investment policies and applicable regulations.

The following table summarizes the composition of Octave's investment portfolio, at carrying value at December 31, 2025 and 2024:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Consolidated** | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Consolidated** |
| Fixed maturity securities | $**122141** | $**—** | $**153** | $**122294** | $157020 | $— | $— | $157020 |
| Short-term | **71287** | **35812** | **39344** | **146443** | 35727 | 27435 | 64439 | 127601 |
| Other investments | **—** | **—** | **24971** | **24971** |  | 177 | 28117 | 28294 |
| **Total investments** | $**193428** | $**35812** | $**64468** | $**293708** | $**192247** | $**27612** | $**92556** | $**312915** |

---

Octave invests in various asset classes in its fixed maturity securities portfolio. Refer to Note 6. Investments to the Consolidated Financial Statements in this Annual Report on Form 10-K located in Part II. Item 8 for information about the composition of fixed maturity securities and other investments by asset class.

***Premium Receivables.*** Octave's premium receivables increased to $75,085 at December 31, 2025, from $57,222 at December 31, 2024. As further discussed in Note 8. Insurance Contracts to the Consolidated Financial Statements, in this Annual Report on Form 10-K located in Part II. Item 8, the increase is primarily due to growth in certain programs within the Specialty Property and Casualty Insurance Segment. All premium receivables are in a payment currency of U.S. Dollars.

***Commission and Fees Receivable*** Octave's commission and fee receivables increased to $86,549 at December 31, 2025, from $55,377 at December 31, 2024. The increase is primarily due to growth in the ID Segment, specifically at Octave Ventures as well as the inclusions of ArmadaCorp and Pivix.

Reinsurance Recoverable on Paid and Unpaid Losses. Octave has reinsurance in place pursuant to surplus share treaties and facultative agreements. As of December 31, 2025 and December 31, 2024, reinsurance recoverable on paid and unpaid losses were $436,092 and $306,191, respectively, increasing due to continued production in the Specialty P&C Insurance Segment. To minimize its exposure to losses from reinsurers, Octave (i) monitors the financial condition of its reinsurers; (ii) is entitled to receive collateral from its reinsurance counterparties under certain reinsurance contracts; and (iii) has certain cancellation rights that can be exercised in the event of rating agency downgrades of a reinsurer (among other events and

circumstances). Those reinsurance counterparties that do not currently post collateral are well-capitalized, highly rated, authorized capacity providers. Octave benefited from letters of credit and collateral amounting to approximately $88,732 from its reinsurers at December 31, 2025. Additionally, while legacy liabilities from Specialty P&C acquisitions were fully ceded to certain reinsurers, Everspan also benefits from an unlimited, uncapped indemnity from the respective sellers to mitigate any residual risk to these reinsurers.

***Intangible Assets, net of Accumulated Depreciation.*** Intangible assets primarily include (i) intangible assets established as part of acquisitions in the ID business of $463,790 at December 31, 2025 and (ii) indefinite-lived intangible assets in the Specialty P&C business as part of its acquisition of admitted shell carriers of $11,213 at December 31, 2025.

As of December 31, 2025 and December 31, 2024, intangible assets were $474,998 and $344,775, respectively. The increase is driven by the ArmadaCorp acquisition of $146,000, Pivix consolidation of $667, and foreign exchange rates of $21,591 (appreciation of the British pound), partially offset by amortization of $38,044.

***Goodwill.*** As of December 31, 2025 and December 31, 2024, goodwill totaled $540,345 and $418,234 respectively. The

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **37** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

increase is primarily driven by the acquisition of ArmadaCorp and foreign exchange rates (appreciation of the British pound). All of the goodwill was assigned to the ID segment.

**Liabilities:**

***Loss and Loss Adjustment Expense Reserves.*** Loss and LAE reserves are estimates of the ultimate liability for unpaid losses and loss expenses for claims that have been reported and incurred but not yet reported as of the balance sheet date.

Loss and LAE reserves by line of business were as follows as of December 31, 2025 and 2024

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **December 31,<br>2025** | **December 31,<br>2025** | **December 31,<br>2024** | **December 31,<br>2024** |
| **Line** | **Gross** | **Net** | **Gross** | **Net** |
| Commercial auto | $**159194** | $**23062** | $158472 | $28720 |
| Excess liability | **116610** | **16897** | 50248 | 6571 |
| General liability | **63596** | **12572** | 35211 | 8286 |
| Workers compensation | **17798** | **17798** | 14465 | 14465 |
| Non-standard personal auto | **3826** | **3635** | 12689 | 12185 |
| Professional liability | **40846** | **2851** | 17698 | 1807 |
| Surety | **12233** | **94** | 11217 | 6 |
| Unallocated loss adjustment expense reserves | **14869** | **5552** | 12238 | 6578 |
| Other <sup>(1)</sup> | **24834** | **289** | 36551 | 320 |
| **Loss and Loss Expense Reserves** | $**453806** | $**82750** | $**348789** | $**78937** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Includes $23,530 and $0 loss and loss expense reserves on a gross and net of reinsurance basis at December 31, 2025, and $35,146 and $0 loss and loss expense reserves on a gross and net of reinsurance basis at December 31, 2024, related to legacy liabilities obtained from the acquisitions of Providence Washington Insurance Company, Greenwood Insurance Company and Consolidated Specialty Insurance Company. All legacy liabilities remain obligations of affiliates of the sellers through reinsurance.

The process for determining the level of loss and LAE reserves is subject to certain estimates and judgments. Refer to the "Critical Accounting Policies and Estimates" and "Results of Operations" sections of Management's Discussion and Analysis of Financial Condition and Results of Operations, in addition to Basis of Presentation and Significant Accounting Policies and Loss Reserves sections included in Note 2. Basis of Presentation and Significant Accounting Policies and Note 8. Insurance Contracts, respectively, to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report on Form 10-K, for further information on loss and loss adjustment expenses.

***Short and Long-term Debt.*** Octave borrowed under a short-term credit facility to provide partial funding of the acquisition of Octave Ventures in 2024. This $150,000 short-term debt facility was repaid from the proceeds of the sale of AAC.

In connection with the acquisition of ArmadaCorp on October 31, 2025, Octave Partners LLC and certain of its subsidiaries (including ArmadaCorp) entered into $120,000 of the Credit Facilities, which were fully drawn to pay part of the purchase price for ArmadaCorp.

***Commission Payable***. Commission payables are commissions due to sub producers for placing insurance contracts on behalf of the MGAs and amounts due to UK Syndicates that provide advanced commissions to fund short-term liquidity needs for MGAs. Commission payable at December 31, 2025 and

December 31, 2024 was $115,555 and $71,431, respectively. The increase is primarily due to higher advance commissions due to Syndicates.

**Redeemable Noncontrolling Interest (NCI):** 

The minority equity interests of Octave Ventures's majority-owned MGA/Us were classified within nonredeemable NCI at December 31, 2024. During the three months ended March 31, 2025, Octave entered into put options on certain of these minority interests that are embedded in the underlying equity instruments. As a result, the minority interests were reclassified from nonredeemable to redeemable and remeasured at fair value including the put options, increasing redeemable NCI by $42,180. Other changes to redeemable NCI during the year ended December 31, 2025, relate primarily to the allocation of financial results to the minority interests, revaluation to redemption value where applicable, reclassification of certain interests to nonredeemable due to the expiration of related put options, the exercise of certain put options and the impact of foreign currency translation.

**ACCOUNTING STANDARDS**

Please refer to Note 2. Basis of Presentation and Significant Accounting Policies to the Consolidated Financial Statements, included in Part II, Item 8 in this Annual Report Form 10-K for a discussion of the impact of recent accounting pronouncements on Octave's financial condition and results of operations.

**U.S. INSURANCE BASIS FINANCIAL RESULTS**

OSG's U.S. insurance subsidiaries prepare financial statements under accounting practices prescribed or permitted by its domiciliary state regulator ("SAP") for determining and reporting the financial condition and results of operations of an insurance company. The NAIC Accounting Practices and Procedures manual ("NAIC SAP") is adopted as a component of prescribed practices by each domiciliary state. For further information, see Note 9. Insurance Regulatory Restrictions to the Consolidated Financial Statements included in Part II, Item 8 in this Annual Report Form 10-K.

**Everspan Indemnity Insurance Company**

Everspan Indemnity Insurance Company's (EIIC) statutory policyholder surplus was $128,031 at December 31, 2025, as compared to $125,202 at December 31, 2024. The increase in surplus was driven by net income at EIIC, including its subsidiaries, of $2,285 during the year ended December 31, 2025. Each of Everspan's insurance carriers are a direct or indirect wholly-owned subsidiary of EIIC and therefore are included in EIIC's statutory policyholder surplus.

The significant differences between GAAP and SAP are that under SAP:

&nbsp;&nbsp;&nbsp;&nbsp;• Investment grade fixed maturity investments are stated at amortized cost and certain below-investment-grade fixed maturity investments are reported at the lower of amortized cost or fair value. Under GAAP, all fixed maturity investments are reported at fair value.

&nbsp;&nbsp;&nbsp;&nbsp;• Majority-owned subsidiaries are not consolidated; rather, the equity basis of accounting is utilized and the carrying

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **38** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

values of these investments are subject to admissibility tests. The carrying values of Providence Washington Insurance Company, Greenwood Insurance Company, and Consolidated Specialty Insurance Company include a goodwill component representing the acquisition cost in excess of the related entity's statutory surplus. Goodwill is amortized over ten years under SAP. Under GAAP, the initial acquisitions of the companies were recorded as asset acquisitions, which required i) all net assets to initially be recorded at fair value and ii) the acquisition costs in excess of the fair value of net assets to be allocated to the bases of certain types of assets based on their relative fair values, if applicable. Acquired assets include intangible assets with indefinite lives. Such assets are not amortized, but their estimated useful lives are reevaluated each reporting period. No goodwill is recorded for asset acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;• Acquisition costs and ceding commissions, other than excess ceding commissions, are expensed or recognized at the time of a transaction. Under GAAP, acquisition costs and ceding commissions are deferred and recognized over the life of the related transaction.

&nbsp;&nbsp;&nbsp;&nbsp;• Unearned premiums and loss reserves are presented net of ceded amounts, while under GAAP, they are reflected gross of ceded amounts.

**NON-GAAP FINANCIAL MEASURES**

In addition to reporting the Company's quarterly financial results in accordance with GAAP, the Company is reporting non-GAAP financial measures: EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin, Organic Revenue Growth Rate (Insurance Distribution segment only), Adjusted Net Income and Adjusted Net Income Margin. These amounts are derived from our consolidated financial information, but are not presented in our consolidated financial results.

We present non-GAAP supplemental financial information because we believe such information is of interest to the investment community, and that it provides greater transparency and enhanced visibility into the underlying drivers and performance of our businesses on a basis that may not be otherwise apparent on a GAAP basis. We view these non-GAAP financial measures as important indicators when assessing and evaluating our performance on a segmented and consolidated basis and they are presented to improve the comparability of our results between periods by eliminating the impact of the items that may not be representative of our core operating performance. These non-GAAP financial measures are not substitutes for the Company's GAAP reporting, should not be viewed in isolation and may differ from similar reporting provided by other companies, which may define non-GAAP measures differently.

Beginning December 31, 2024, Octave replaced the non-GAAP measure Adjusted Net Income with new non-GAAP measures Adjusted Net Income and Adjusted Net Income Margin and added Adjusted EBITDA and Adjusted EBITDA Margin to better align with other participants in the Property & Casualty insurance industry, including insurance carriers and other peers in the insurance distribution business.

The following paragraphs define each non-GAAP financial measure. A tabular reconciliation of the non-GAAP financial measure and the most comparable GAAP financial measure is also presented below.

EBITDA — EBITDA is net income (loss) from continuing operations before interest expense, income taxes, depreciation and amortization of intangible assets.

**Adjusted EBITDA and Adjusted EBITDA Margin *—*** We define Adjusted EBITDA as net income (loss) from continuing operations before interest expense, income taxes, depreciation, amortization of intangible assets, change in fair value of contingent consideration and certain items of income and expense, including share-based compensation expense, acquisition and integration-related expenses, severance, and other exceptional or non-recurring items, including those related to raising capital. We believe that Adjusted EBITDA is an appropriate measure of operating performance because it eliminates the impact of income and expenses that may obfuscate business performance, and that the presentation of this measure enhances an investor's understanding of our financial performance.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **39** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** | **2023** |
| | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Total** | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Total** | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Total** |
| **Net income (loss) from continuing operations** | $**2956** | $**(15353)** | $**(83406)** | $**(95803)** | $**10469** | $**(6881)** | $**(62509)** | $**(58921)** | $**335** | $**7133** | $**(30701)** | $**(23232)** |
| Adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Interest expense | **—** | **18640** | **—** | **18640** |  | 9379 |  | 9379 |  |  |  |  |
| &nbsp;&nbsp;Income taxes | **374** | **(5103)** | **(482)** | **(5211)** | 1753 | (928) | (1748) | (924) | 48 | 156 | (1193) | (989) |
| &nbsp;&nbsp;Depreciation | **—** | **690** | **3218** | **3908** |  | 481 | 1864 | 2345 |  | 42 | 1036 | 1078 |
| &nbsp;&nbsp;Intangible amortization | **—** | **38044** | **—** | **38044** |  | 17602 |  | 17602 |  | 4152 |  | 4152 |
| **EBITDA** | **3330** | **36918** | **(80670)** | **(40422)** | **12222** | **19653** | **(62393)** | **(30518)** | **383** | **11483** | **(30858)** | **(18991)** |
| Add: Impact of noncontrolling interests | **—** | **(14507)** | **—** | **(14507)** |  | (6448) |  | (6448) |  | (2102) |  | (2102) |
| **EBITDA attributable to shareholders** | **3330** | **22411** | **(80670)** | **(54929)** | **12222** | **13205** | **(62393)** | **(36966)** | **383** | **9381** | **(30858)** | **(21094)** |
| Net income margin |  |  | NM |  |  |  | NM |  |  |  | NM |  |
| Net income margin attributable to shareholders |  |  | NM |  |  |  | NM |  |  |  | NM |  |
| EBITDA margin |  |  | NM |  |  |  | NM |  |  |  | NM |  |
| EBITDA margin attributable to shareholders |  |  | NM |  |  |  | NM |  |  |  | NM |  |
| Add: Acquisition and integration related expenses | **—** | **375** | **9106** | **9481** |  |  | 27388 | 27388 |  |  | 567 | 567 |
| Add: Equity-based compensation expense | **447** | **368** | **11494** | **12309** | 414 |  | 8941 | 9355 | 634 |  | 11632 | 12266 |
| Add: Severance and restructuring expense | **—** | **60** | **21173** | **21233** |  | 248 | 7352 | 7600 |  |  |  |  |
| Add: Other non-operating (income) losses | **—** | **(591)** | **5108** | **4517** | (7500) |  | 2318 | (5182) |  |  | 279 | 279 |
| **Adjusted EBITDA** | **3777** | **37041** | **(33789)** | **7028** | **5136** | **19901** | **(16394)** | **8643** | **1017** | **11483** | **(18380)** | **(5879)** |
| **Adjusted EBITDA attributable to shareholders** | $**3777** | $**22542** | $**(33789)** | $**(7471)** | $**5136** | $**13453** | $**(16394)** | $**2195** | $**1017** | $**9381** | $**(18380)** | $**(7981)** |
| Adjusted EBITDA Margin | **4.3%** | **22.6%** | **NM** | **2.8%** | **4.1%** | **20.1%** | **NM** | **3.7%** | **1.6%** | **22.3%** | **NM** | **(4.7)%** |
| Adjusted EBITDA Margin attributable to shareholders | **4.3%** | **13.8%** | **NM** | **(3.0)%** | **4.1%** | **13.6%** | **NM** | **0.9%** | **1.6%** | **18.2%** | **NM** | **(6.2)%** |

---

**Organic Revenue Growth (Insurance Distribution only)**

Organic revenue is based on commissions and fees for the relevant period by excluding (i) the first twelve months of commissions and fees generated from acquisitions, (ii) commissions and fees from divestitures and (iii) other items such as contingent commissions, profit commissions and the impact of changes in foreign exchange rates.

Organic revenue growth is the change in organic revenue period-to-period, with prior period results adjusted to (i) include commissions and fees that were excluded from organic revenue in the prior period and reached the twelve-month owned mark in the current period and (ii) exclude commissions and fees related to divestitures from organic revenue.

Organic revenue growth rate to Total revenue growth rate, the most directly comparable GAAP measure, for each of the periods indicated is as follows (in percentages):

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | | **Year Ended December 31,** | **Year Ended December 31,** | |
| | **2025** | **2024** | **% Growth** | **2024** | **2023** | **% Growth** |
| Total Insurance Distribution revenue <sup>(1)</sup> | $**163855** | $99236 | 65.1% | $99236 | $51546 | 92.5% |
| Less: Acquired revenues <sup>(2)</sup> | **(50102)** | (1200) |  | (45202) |  |  |
| Less: Profit commission and contingent commission income | **(11898)** | (9031) |  | (4273) | (4489) |  |
| Less: Impact of F.X. rates | **2572** | (183) |  |  |  |  |
| Total Organic Revenue & Growth Percentage | $**104427** | $88822 | 17.6% | $49761 | $47057 | 5.7% |

---

(1)Total ID revenue includes investment income.

(2)Organic revenue growth includes a $1.2m reduction to 4Q24 revenue to adjust for a revenue recognition accounting policy adjustment made in 4Q24 in connection with the acquisition of Octave Ventures to recognize revenues that otherwise should have been recorded in 3Q24.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **40** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Adjusted Net Income and Adjusted Net Income Margin —** We define Adjusted Net Income as net income (loss) from continuing operations attributable to Octave adjusted for amortization of intangible assets, change in fair value of contingent consideration and certain items of income and expense, including share-based compensation expense, acquisition and integration -related expenses, severance and non-recurring income and loss items that, in the opinion of management, significantly affect the period-over-period assessment of operating results, and the related tax effect of those adjustments. Per share amounts exclude any impact of revaluing non-controlling interests as otherwise reported under GAAP earnings per share. We believe that Adjusted Net Income is an appropriate measure of operating performance because it eliminates the impact of income and expenses that may obfuscate business performance.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** | **2023** |
| | Specialty Property & Casualty Insurance | Insurance Distribution | Corporate & Other | Consoli-dated | Specialty Property & Casualty Insurance | Insurance Distribution | Corporate & Other | Consoli-dated | Specialty Property & Casualty Insurance | Insurance Distribution | Corporate & Other | Consoli-dated |
| **Net income (loss) (Continuing Operations)** | $**2956** | $**(15353)** | $**(83406)** | $**(95802)** | $**10469** | $**(6881)** | $**(62509)** | $**(58921)** | $**335** | $**7133** | $**(30701)** | $**(23232)** |
| Adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Add: Acquisition and integration related expenses | **—** | **375** | **9106** | **9481** |  |  | 27388 | **27388** | **—** | **—** | **567** | **567** |
| &nbsp;&nbsp;Add: Intangible amortization | **—** | **38044** | **—** | **38044** |  | 17602 |  | **17602** | **—** | **4152** | **—** | **4152** |
| &nbsp;&nbsp;Add: Equity-based compensation expense | **447** | **368** | **11494** | **12309** | 414 |  | 8941 | **9355** | **634** | **—** | **11632** | **12266** |
| &nbsp;&nbsp;Add: Severance and restructuring expense | **—** | **60** | **23065** | **23125** |  | 248 | 7352 | **7600** | **—** | **—** | **—** | **—** |
| &nbsp;&nbsp;Add: Other non-operating (income) losses <sup>(1)</sup> | **—** | **(591)** | **5108** | **4517** | (7500) |  | 2318 | **(5182)** | **—** | **—** | **279** | **279** |
| Adjusted net income (loss) before tax and NCI | **3403** | **22903** | **(34633)** | **(8328)** | 3383 | 10969 | (16510) | **(2158)** | **969** | **11285** | **(18223)** | **(5968)** |
| Income tax effects | **(58)** | **(6009)** | **58** | **(6009)** |  |  |  | **—** | **—** | **—** | **—** | **—** |
| Adjusted net income (loss) before NCI | **3345** | **16894** | **(34575)** | **(14337)** | 3383 | 10969 | (16510) | **(2158)** | **969** | **11285** | **(18223)** | **(5968)** |
| Net (income) loss attributable to NCI | **—** | **(13394)** | **—** | **(13394)** |  | (6448) |  | **(6448)** | **—** | **(2102)** | **—** | **(2102)** |
| **Adjusted net income (loss) attributable to shareholders** | $**3345** | $**3500** | $**(34575)** | $**(27731)** | $**3383** | $**4521** | $**(16510)** | $**(8606)** | $**969** | $**9183** | $**(18223)** | $**(8070)** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Other non-operating expense includes one-time add-backs related to gain on sale of CNIC, partially offset by losses related to minority interest strategy and write-down of certain capitalized software. costs.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** | **2024** | **2023** | **2023** | **2023** | **2023** |
| | Specialty Property & Casualty Insurance | Insurance Distribution | Corporate & Other | Consoli-dated | Specialty Property & Casualty Insurance | Insurance Distribution | Corporate & Other | Consoli-dated | Specialty Property & Casualty Insurance | Insurance Distribution | Corporate & Other | Consoli-dated |
| Net income (loss) margin | **3.3%** | **(9.4)%** | **NM** | **(38.1)%** | 8.3% | (6.9)% | NM | (25.0)% | 0.5% | 13.8% | NM | (18.6)% |
| Adjusted net income (loss) margin | **3.8%** | **14.0%** | **NM** | **(3.3)%** | 2.7% | 11.1% | NM | (0.9)% | 1.5% | 21.9% | NM | (4.8)% |

---

**Item 7A. &nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures about Market Risk ($ in thousands)**

Market risk represents the potential for loss due to adverse changes in the fair value of financial instruments, as a result of changes in market rates and prices, such as interest rates (inclusive of credit spreads), foreign currency exchange rates and other relevant market rate or price changes. Market risk is, in part, a function of the markets in which the underlying assets are traded. The Company's market-risk-sensitive financial instruments are primarily entered into for purposes other than trading. As discussed further below, the Company's primary market risk exposures include those from changes in interest rates, foreign currency exchange rates and equity market values.

&nbsp;&nbsp;&nbsp;&nbsp;• The primary market risks for fixed maturity and short-term investment securities are interest rate risk and foreign exchange rate risk. Octave's investment portfolio includes securities denominated both in U.S. dollars and foreign currencies, which are sensitive to changes in interest rates and foreign currency exchange rates. Our fixed maturity investments are generally classified as available-for-sale, with the effect of market movements recognized immediately through Other comprehensive income, or through Net income when securities are sold or when an impairment charge is recorded.

&nbsp;&nbsp;&nbsp;&nbsp;• Octave invests in a limited partnership reported within Other investments. This fund is subject to equity value changes driven primarily by changes to their respective net

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **41** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

asset value ("NAV"). Octave's share of the changes of the equity value of the fund is reported through Net income.

Octave utilizes various systems, models and sensitivity scenarios to monitor and manage market risk. These models include estimates, made by management, which utilize current and historical market information. This market information is considered in management's judgments about adverse sensitivity scenarios that are reasonably possible to occur in the near-term. The impact of these scenarios does not consider the possibility of simultaneous movement in other market rates or prices, actions of management or other factors that could lessen or worsen actual results. For these reasons, the valuation results from these models could differ materially from amounts actually realized in the market.

**Market Risk Sensitivities**

**<u>Interest Rate Risk.</u>** Financial instruments within Octave's continuing operations for which fair value may be affected by changes in interest rates consist primarily of fixed maturity investment securities. Increases to interest rates would result in declines in the fair value of our fixed maturity investment portfolio. Octave performs scenario testing to measure the potential for losses in volatile markets. These scenario tests include parallel and non-parallel shifts in the benchmark interest rate curve.

The following table summarizes the estimated change in fair value of our fixed maturity investment portfolio from a hypothetical immediate increase in interest rates of 100 basis points across the yield curve as of December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| Fair value of fixed maturity and short-term investments | $**268737** | $284621 |
| Pre-tax impact of 100 basis point increase in interest rates |  |  |
| &nbsp;&nbsp;Decrease in dollars | $**(4143)** | $(4952) |
| &nbsp;&nbsp;As a percent of fair value | **2%** | 2% |

---

**<u>Foreign Currency Risk.</u>** Octave's ID subsidiary, Octave Ventures, has short-term investments denominated in British pounds sterling and is a party to foreign exchange forward contracts at December 31, 2025. These financial instruments would experience fair value losses if the U.S. dollar strengthened relative to the British pounds sterling. The following table summarizes the estimated decrease in fair value of these financial instruments assuming immediate 20% strengthening of the U.S. dollar relative to the British pounds sterling as of December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| Fair value of investments denominated in currencies other than the U.S. dollar | $**18750** | $16604 |
| Pre-tax loss from 20% strengthening of the U.S. dollar | $**(3750)** | $(3321) |
| Fair value of FX forward contracts | $**(8)** | $(317) |
| Pre-tax loss from 20% strengthening of the U.S. dollar | $**(4800)** | $(3936) |

---

**<u>Equity Sensitivity.</u>** Octave's investment portfolio includes a partnership interest in a private equity fund. The table below summarizes the decrease in fair value of Octave's pooled fund investment that would occur assuming an immediate and uniform 10% decline in NAV of the fund. The selection of a 10% fair value stress is made only as an illustration of the hypothetical impact of adverse market movements on Octave's investments with equity value sensitivity. Actual market shocks could have materially different results.

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| Fair value of investments in pooled funds | $**7454** | $7499 |
| Pre-tax impact of 10% decline in NAV of the funds | $**(745)** | $(750) |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **42** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Item 8. &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Supplementary Data**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**

Reports of Independent Registered Public Accounting Firm KPMG LLP, New York, NY, PCAOB ID 185**&nbsp;&nbsp;&nbsp;&nbsp;**<u>[44](#i9cb0e1a24c9141e0943a78b7b32afc92_154)</u>

---

| | | | |
|:---|:---|:---|:---|
| **Consolidated Financial Statements** | **Consolidated Financial Statements** | **Consolidated Financial Statements** | **Consolidated Financial Statements** |
| <u>[Consolidated Balance Sheets](#i9cb0e1a24c9141e0943a78b7b32afc92_160)</u> | <u>[47](#i9cb0e1a24c9141e0943a78b7b32afc92_160)</u> | <u>Consolidated Statements of Stockholders' Equity</u> | <u>[49](#i9cb0e1a24c9141e0943a78b7b32afc92_166)</u> |
| <u>[Consolidated Statements of Total Comprehensive Income (Loss)](#i9cb0e1a24c9141e0943a78b7b32afc92_163)</u> | <u>[48](#i9cb0e1a24c9141e0943a78b7b32afc92_163)</u> | <u>[Consolidated Statements of Cash Flows](#i9cb0e1a24c9141e0943a78b7b32afc92_169)</u> | <u>[50](#i9cb0e1a24c9141e0943a78b7b32afc92_169)</u> |
| **Notes to Consolidated Financial Statements** | **Notes to Consolidated Financial Statements** | **Notes to Consolidated Financial Statements** | **Notes to Consolidated Financial Statements** |
| Note 1. Background and Business Description | <u>[51](#i9cb0e1a24c9141e0943a78b7b32afc92_175)</u> | Note 11. Goodwill and Intangible Assets | <u>[82](#i9cb0e1a24c9141e0943a78b7b32afc92_211)</u> |
| Note 2. Basis of Presentation and Significant Accounting Policies | <u>[51](#i9cb0e1a24c9141e0943a78b7b32afc92_181)</u> | Note 12. Debt | <u>[82](#i9cb0e1a24c9141e0943a78b7b32afc92_214)</u> |
| Note 3. Segment Information | <u>[61](#i9cb0e1a24c9141e0943a78b7b32afc92_184)</u> | Note 13. Revenues From Contracts with Customers | <u>[83](#i9cb0e1a24c9141e0943a78b7b32afc92_217)</u> |
| Note 4. Business Combination | <u>[64](#i9cb0e1a24c9141e0943a78b7b32afc92_187)</u> | Note 14. Comprehensive Income (Loss) | <u>[84](#i9cb0e1a24c9141e0943a78b7b32afc92_220)</u> |
| Note 5. Discontinued Operations | <u>[65](#i9cb0e1a24c9141e0943a78b7b32afc92_190)</u> | Note 15. Net Income Per Share | <u>[84](#i9cb0e1a24c9141e0943a78b7b32afc92_223)</u> |
| Note 6. Investments | <u>[69](#i9cb0e1a24c9141e0943a78b7b32afc92_193)</u> | Note 16. Income Taxes | <u>[85](#i9cb0e1a24c9141e0943a78b7b32afc92_226)</u> |
| Note 7. Fair Value Measurements | <u>[71](#i9cb0e1a24c9141e0943a78b7b32afc92_196)</u> | Note 17. Employment Benefit Plans | <u>[87](#i9cb0e1a24c9141e0943a78b7b32afc92_232)</u> |
| Note 8. Insurance Contracts | <u>[74](#i9cb0e1a24c9141e0943a78b7b32afc92_202)</u> | Note 18. Leases | <u>[90](#i9cb0e1a24c9141e0943a78b7b32afc92_235)</u> |
| Note 9. Insurance Regulatory Restrictions | <u>[79](#i9cb0e1a24c9141e0943a78b7b32afc92_205)</u> | Note 19. Commitments and Contingencies | <u>[91](#i9cb0e1a24c9141e0943a78b7b32afc92_238)</u> |
| Note 10. Derivative Instruments | <u>[81](#i9cb0e1a24c9141e0943a78b7b32afc92_208)</u> |  |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **43** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Report of Independent Registered Public Accounting Firm**

To the Stockholders and Board of Directors

Octave Specialty Group, Inc.:

*Opinion on Internal Control Over Financial Reporting*

We have audited Octave Specialty Group, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of total comprehensive income (loss), stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes and financial statement schedules I, II and III (collectively, the consolidated financial statements), and our report dated March 4, 2026 expressed an unqualified opinion on those consolidated financial statements.

The Company acquired ArmadaCorp Capital, LLC during 2025, and management excluded from its assessment of the effectiveness of the Company's internal control over financial reporting as of December 31, 2025, ArmadaCorp Capital, LLC's internal control over financial reporting associated with total assets of 2% and total revenues of 2% included in the consolidated financial statements of the Company as of and for the year ended December 31, 2025. Our audit of internal control over financial reporting of the Company also excluded an evaluation of the internal control over financial reporting of ArmadaCorp Capital, LLC.

*Basis for Opinion* 

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control

over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

*Definition and Limitations of Internal Control Over Financial Reporting* 

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ **KPMG LLP**

New York, New York

March 4, 2026

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **44** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**Report of Independent Registered Public Accounting Firm**

To the Stockholders and Board of Directors

Octave Specialty Group, Inc.:

*Opinion on the Consolidated Financial Statements*

We have audited the accompanying consolidated balance sheets of Octave Specialty Group, Inc. and subsidiaries (the Company) as of December 31, 2025 and 2024, the related consolidated statements of total comprehensive income (loss), stockholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes and financial statement schedules I, II and III (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated March 4, 2026 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.

*Basis for Opinion*

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

*Critical Audit Matters*

The critical audit matters communicated below are matters arising from the current period audit of the consolidated

financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

*Estimate of loss and loss adjustment expense reserves*

As discussed in Notes 2 and 8 to the consolidated financial statements, the loss and loss adjustment expense reserves (reserves) for Specialty Property and Casualty policies represent the Company's estimate of the ultimate liability for unpaid losses and loss expenses for claims that have been reported and claims that have been incurred but not yet reported as of the balance sheet date. The reserves are estimated based upon experience and using a variety of actuarial methods. The Company's reserves balance at December 31, 2025 was $459,990 thousand.

We identified the assessment of the estimate of reserves for Specialty Property and Casualty policies as a critical audit matter. The assessment of the Company's selected methods and key assumptions used to develop the estimate of reserves required complex auditor judgment due to the significant measurement uncertainty. Key assumptions included loss development factors, expected loss ratios, and the weighting of actuarial methods when more than one was used. Specialized actuarial skills and knowledge were required to evaluate the actuarial method or methods and key assumptions used.

The following are the primary procedures we performed to address the critical audit matter. With the assistance of actuarial professionals, when appropriate, we evaluated the design and tested the operating effectiveness of certain internal controls over the Company's reserving process. This included controls over the Company's process to develop the Company's estimate of reserves based on actuarial methodologies and key assumptions employed by the Company's actuaries. We involved actuarial professionals with specialized skills and knowledge, who assisted in:

&nbsp;&nbsp;&nbsp;&nbsp;• for certain programs, evaluating the Company's key assumptions and methods for consistency with actuarial standards of practice

&nbsp;&nbsp;&nbsp;&nbsp;• for certain programs, developing an independent range of reserves using methods and assumptions consistent with actuarial standards of practice and comparing it to the Company's recorded reserves

&nbsp;&nbsp;&nbsp;&nbsp;• for certain programs, assessing the position in the range and the year-over-year movements of the Company's recorded reserves within the independent range of reserves.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **45** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

*Valuation of customer relationship intangibles for the ArmadaCorp Capital, LLC reporting unit*

As discussed in Note 4 to the consolidated financial statements, on October 31, 2025, the Company completed the acquisition of of ArmadaCorp Capital, LLC for a purchase price of $250,000 thousand. The acquisition was accounted for as a business combination using the acquisition method of accounting, which required the Company to allocate the total consideration transferred to the assets acquired and liabilities assumed based on their fair values at the date of acquisition. As part of the transaction, the Company acquired a customer relationships intangible asset with an acquisition date fair value of $138,000 thousand, which was valued using the multi-period excess earnings method.

We identified the assessment of the acquisition date fair value of the customer relationships intangible asset as a critical audit matter. Subjective auditor judgment and the involvement of valuation professionals with specialized skills and knowledge were required to assess the discount rate assumption used to estimate the acquisition date fair value for the customer relationships intangible asset due to the degree of measurement uncertainty associated with this assumption.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company's acquisition date valuation process. This included a control over the development of the discount rate assumption used to value the customer relationships intangible asset. We involved valuation professionals with specialized skills and knowledge, who assisted in evaluating the Company's discount rate assumption used for the valuation of the customer relationships intangible asset by independently developing a range of discount rates based on publicly available market data for comparable entities and comparing that range to the Company's discount rate.

*Fair Value of the Octave Ventures reporting unit*

As discussed in Notes 2 and 11 to the consolidated financial statements, the Company's consolidated goodwill balance as of December 31, 2025 was $540,345 thousand, a portion of which relates to the Octave Ventures reporting unit. Goodwill impairment tests are performed annually, as of October 1 of each year, or more frequently, if circumstances indicate possible impairment. The quantitative evaluation compares the estimated fair value using a combination of an income approach and market approach. The income approach uses discounted cash flows which are dependent on subjective factors including the timing of future cash flows, the underlying margin projection assumptions, future growth rates, and the discount rate. The market approach uses valuation multiples and is dependent on subjective factors including the determination of industry market multiples and EBITDA forecasts.

We identified the evaluation of fair value for the Octave Ventures reporting unit used to assess goodwill for impairment as a critical audit matter. Subjective and challenging auditor judgment and professionals with specialized skills and knowledge were required to evaluate the discount rate assumption used in the income approach to determine the fair

value of Octave Ventures reporting unit due to the degree of measurement uncertainty associated with this assumption.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company's goodwill impairment assessment process for the Octave Ventures reporting unit. This included a control over the development of the discount rate assumption used in the fair value estimate. We involved valuation professionals with specialized skills and knowledge, who assisted in:

&nbsp;&nbsp;&nbsp;&nbsp;• Assessing the reasonableness of the Company's discount rate, including the company-specific risk premium, by comparing it to an independently developed discount rate using publicly available market data

&nbsp;&nbsp;&nbsp;&nbsp;• Comparing the Octave Ventures reporting unit fair value estimate to an independently developed range of fair value estimates developed using the Company's significant assumptions and our independently developed discount rate.

/s/ **KPMG LLP**

We have served as the Company's auditor since 1985.

New York, New York

March 4, 2026

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **46** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
| **(Dollars in thousands, except share data) December 31,** | **2025** | **2024** |
| **Assets:** |  |  |
| Investments: |  |  |
| &nbsp;&nbsp;Fixed maturity securities, at fair value (amortized cost of $123,414 and $162,124) | $**122295** | $157020 |
| &nbsp;&nbsp;Short-term investments, at fair value (amortized cost of $146,434 and $127,588) | **146442** | 127601 |
| &nbsp;&nbsp;Other investments (at cost, except for $7,454 and $7,499 at fair value) | **24971** | 28294 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total investments | **293708** | 312915 |
| Cash and cash equivalents (including $40,754 and $17,669 of restricted cash) | **68440** | 47275 |
| Premium receivables | **75085** | 57222 |
| Commission and fees receivable | **86549** | 55377 |
| Reinsurance recoverable on paid and unpaid losses | **436092** | 306191 |
| Deferred ceded premium | **146365** | 148300 |
| Policy acquisition costs | **9732** | 8572 |
| Intangible assets, less accumulated amortization | **474998** | 344775 |
| Goodwill | **540345** | 418234 |
| Other assets | **92003** | 92317 |
| Assets of discontinued operations | **—** | 6267200 |
| **Total assets** | $**2223317** | $**8058378** |
| **Liabilities and Stockholders' Equity:** |  |  |
| **Liabilities:** |  |  |
| Unearned premiums | $**187178** | $182446 |
| Loss and loss adjustment expense reserves | **459990** | 349062 |
| Ceded premiums payable | **80561** | 53002 |
| Deferred program fees and reinsurance commissions | **6978** | 7500 |
| Commissions payable | **115555** | 71431 |
| Deferred taxes | **65217** | 70135 |
| Short-term debt | **—** | 150000 |
| Long-term debt | **117558** |  |
| Accrued interest payable | **1343** | 2560 |
| Other liabilities | **102771** | 89036 |
| Liabilities of discontinued operations | **—** | 5887685 |
| **Total liabilities** | **1137151** | **6862857** |
| **Commitments and contingencies (See Note 19)** |  |  |
| Redeemable noncontrolling interest | **252981** | 199402 |
| **Stockholders' equity:** |  |  |
| &nbsp;&nbsp;Preferred stock, par value $0.01 per share; 20,000,000 shares authorized shares; issued and outstanding shares—none | **—** |  |
| &nbsp;&nbsp;Common stock, par value $0.01 per share; 130,000,000 shares authorized; issued shares: 48,876,882 and 48,875,167 | **489** | 489 |
| &nbsp;&nbsp;Additional paid-in capital | **369860** | 331007 |
| &nbsp;&nbsp;Accumulated other comprehensive income (loss) | **8483** | (188436) |
| &nbsp;&nbsp;Retained earnings | **370431** | 683643 |
| &nbsp;&nbsp;Treasury stock, shares at cost: 3,871,598 and 2,368,194 | **(33473)** | (28339) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Octave Specialty Group, Inc. stockholders' equity | **715790** | 798364 |
| &nbsp;&nbsp;Nonredeemable noncontrolling interest | **117395** | 197755 |
| **Total stockholders' equity** | **833185** | **996119** |
| **Total liabilities, redeemable noncontrolling interest and stockholders' equity** | $**2223317** | $**8058378** |

---

*See accompanying Notes to Consolidated Financial Statements*

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **47** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Consolidated Statements of Total Comprehensive Income (Loss)**

---

| | | | |
|:---|:---|:---|:---|
| **(Dollars in thousands, except share data) Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Revenues:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Commissions | $**143381** | $92023 | $51281 |
| &nbsp;&nbsp;Servicing and other fees | **20419** | 6353 |  |
| &nbsp;&nbsp;Net premiums earned | **67232** | 99005 | 51911 |
| &nbsp;&nbsp;&nbsp;Program fees | **14322** | 13506 | 8437 |
| &nbsp;&nbsp;Investment income | **10647** | 14448 | 13159 |
| &nbsp;&nbsp;Other | **(4780)** | 10480 | (60) |
| &nbsp;&nbsp;**Total revenues** | **251222** | **235815** | **124728** |
| **Expenses:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Commissions | $**37037** | $40876 | $29465 |
| &nbsp;&nbsp;Losses and loss adjustment expenses | **47193** | 72626 | 36712 |
| &nbsp;&nbsp;&nbsp;Policy acquisition costs | **15790** | 23666 | 10557 |
| &nbsp;&nbsp;General and administrative | **191624** | 129166 | 66985 |
| &nbsp;&nbsp;Intangible amortization and depreciation | **41952** | 19947 | 5230 |
| &nbsp;&nbsp;Interest | **18640** | 9379 |  |
| &nbsp;&nbsp;**Total expenses** | **352236** | **295660** | **148949** |
| **Pretax income (loss) from continuing operations** | **(101014)** | **(59845)** | **(24221)** |
| Provision (benefit) for income taxes from continuing operations | **(5211)** | (924) | (989) |
| **Net income (loss) from continuing operations** | **(95803)** | **(58921)** | **(23232)** |
| &nbsp;&nbsp;Net income (loss) from discontinued operations, net of tax (including loss on disposal of $117,468 in 2025 and $570,145 in 2024) | **(163288)** | (497167) | 28183 |
| **Net income (loss)** | **(259091)** | **(556088)** | **4951** |
| Net (gain) loss attributable to noncontrolling interest | **(2601)** | (361) | (1319) |
| **Net income (loss) attributable to shareholders** | $**(261692)** | $**(556449)** | $**3632** |
| **Net income (loss) attributable to shareholders** |  |  |  |
| &nbsp;&nbsp;Continuing operations | $**(98404)** | $(59282) | $(24551) |
| &nbsp;&nbsp;Discontinued operations | **(163288)** | (497167) | 28183 |
| **Total** | $**(261692)** | $**(556449)** | $**3632** |
| **Other comprehensive income (loss), after tax** |  |  |  |
| **Net income (loss)** | $**(259091)** | $**(556088)** | $**4951** |
| Unrealized gains (losses) on securities, net of income tax provision (benefit) of $0, $1,295 and $2,095 | **19643** | (939) | 51184 |
| Gains (losses) on foreign currency translation, net of income tax provision (benefit) of $0, $0 and $0 | **201367** | (22156) | 40132 |
| Credit risk changes of fair value option liabilities, net of income tax provision (benefit) of $0, $(118) <br>and $177 | **1108** | (356) | (88) |
| Changes to postretirement benefit, net of income tax provision (benefit) of $0, $0 and $0 | **—** | (4939) | 1569 |
| Total other comprehensive income (loss), net of income tax | **222118** | (28390) | 92797 |
| **Total comprehensive income (loss), net of income tax** | **(36973)** | (584478) | 97748 |
| Less: net (gain) loss attributable to noncontrolling interest | **(2601)** | (361) | (1319) |
| Less: (gain) loss on foreign currency translation attributable to noncontrolling interest | **(25200)** | 3074 |  |
| **Total comprehensive income (loss) attributable to shareholders** | $**(64774)** | $**(581765)** | $**96429** |
| **Net income (loss) from continuing operations per share attributable to stockholders** |  |  |  |
| &nbsp;&nbsp;**Basic** | $**(2.47)** | $**(1.37)** | $**(0.43)** |
| &nbsp;&nbsp;**Diluted** | $**(2.47)** | $**(1.37)** | $**(0.43)** |
| **Net income (loss) from discontinued operations per share attributable to stockholders** |  |  |  |
| &nbsp;&nbsp;**Basic** | $**(3.46)** | $**(10.58)** | $**0.62** |
| &nbsp;&nbsp;**Diluted** | $**(3.46)** | $**(10.58)** | $**0.62** |
| **Net income (loss) per share attributable to stockholders** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Basic** | $**(5.93)** | $**(11.96)** | $**0.18** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Diluted** | $**(5.93)** | $**(11.96)** | $**0.18** |
| **Weighted average number of common shares outstanding:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Basic** | **47181227** | **46969708** | **45636649** |
| &nbsp;&nbsp;&nbsp;&nbsp;**Diluted** | **47181227** | **46969708** | **45636649** |

---

*See accompanying Notes to Consolidated Financial Statements*

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **48** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>, &nbsp;&nbsp;&nbsp;&nbsp;

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Consolidated Statements of Stockholders' Equity**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** | **Years Ended December 31, 2023, 2024 and 2025** |
| | **Stockholders' Equity** | **Stockholders' Equity** | **Stockholders' Equity** | **Stockholders' Equity** | **Stockholders' Equity** | **Stockholders' Equity** | **Stockholders' Equity** | **Stockholders' Equity** | **Mezzanine**<br>**Equity**<br>**Redeemable** <br>**NCI** <sup>(1)</sup> |
| | | **Octave Specialty Group, Inc.** | **Octave Specialty Group, Inc.** | **Octave Specialty Group, Inc.** | **Octave Specialty Group, Inc.** | **Octave Specialty Group, Inc.** | **Octave Specialty Group, Inc.** | | **Mezzanine**<br>**Equity**<br>**Redeemable** <br>**NCI** <sup>(1)</sup> |
| **($ in thousands)** | **Total** | **Preferred Stock** | **Common Stock** | **Additional Paid-in<br>Capital** | **Accumulated<br>Other<br>Comprehensive<br>Income (Loss)** | **Retained Earnings** | **Common Stock Held in Treasury, at Cost** | **Non-redeemable NCI**<sup>(1)</sup> | **Mezzanine**<br>**Equity**<br>**Redeemable** <br>**NCI** <sup>(1)</sup> |
| **Balance at December 31, 2022** | $**1305250** | $**—** | $**467** | $**274486** | $**(252843)** | $**1245491** | $**(15270)** | $**52919** | $**19983** |
| &nbsp;&nbsp;Net income (loss) | 3634 |  |  |  |  | 3632 |  | 2 | 1317 |
| &nbsp;&nbsp;Total other comprehensive income (loss) | 92797 |  |  |  | 92797 |  |  |  |  |
| &nbsp;&nbsp;Stock-based compensation | 17275 |  |  | 17275 |  |  |  |  |  |
| &nbsp;&nbsp;Cost of shares (acquired) issued under equity plan | (4665) |  |  |  |  | (7872) | 3207 |  |  |
| &nbsp;&nbsp;Cost of shares repurchased | (4510) |  |  |  |  |  | (4510) |  |  |
| &nbsp;&nbsp;Changes to noncontrolling interest | 4834 |  |  |  |  | 4797 |  | 37 | (6671) |
| &nbsp;&nbsp;Purchase of All Trans and Capacity Marine |  |  |  |  |  |  |  |  | 2450 |
| **Balance at December 31, 2023** | $**1414615** | $**—** | $**467** | $**291761** | $**(160046)** | $**1246048** | $**(16573)** | $**52958** | $**17079** |
| &nbsp;&nbsp;Net income (loss) | (554806) |  |  |  |  | (556449) |  | 1643 | (1282) |
| &nbsp;&nbsp;Total other comprehensive income (loss) | (28390) |  |  |  | (28390) |  |  |  | (4805) |
| &nbsp;&nbsp;Stock-based compensation | 8995 |  |  | 8995 |  |  |  |  |  |
| &nbsp;&nbsp;Cost of shares (acquired) issued under equity plan | (701) |  |  |  |  | (634) | (67) |  |  |
| &nbsp;&nbsp;Cost of shares repurchased | (11699) |  |  |  |  |  | (11699) |  |  |
| &nbsp;&nbsp;Changes to noncontrolling interest | (9225) |  |  |  |  | (5322) |  | (3903) | 2941 |
| &nbsp;&nbsp;Purchase of Octave Ventures | 149095 |  |  |  |  |  |  | 149095 | 185469 |
| &nbsp;&nbsp;Acquisition of noncontrolling interest in subsidiary | (994) |  |  | 1044 |  |  |  | (2038) |  |
| &nbsp;&nbsp;Issuance of common stock in connection with purchase of Octave Ventures | 29229 |  | 22 | 29207 |  |  |  |  |  |
| **Balance at December 31, 2024** | $**996119** | $**—** | $**489** | $**331007** | $**(188436)** | $**683643** | $**(28339)** | $**197755** | $**199402** |
| &nbsp;&nbsp;Net income (loss) | **(257084)** |  |  |  |  | **(261692)** |  | **4608** | **(2007)** |
| &nbsp;&nbsp;Total other comprehensive income (loss) | **206892** |  |  |  | **196919** |  |  | **9973** | **15227** |
| &nbsp;&nbsp;Stock-based compensation | **9707** |  |  | **9707** |  |  |  |  |  |
| &nbsp;&nbsp;Cost of shares (acquired) issued under equity plan | **(8535)** |  |  |  |  | **(33343)** | **24808** |  |  |
| &nbsp;&nbsp;Cost of shares repurchased | **(29942)** |  |  |  |  |  | **(29942)** |  |  |
| &nbsp;&nbsp;Changes to noncontrolling interest | **(50054)** |  |  | **12146** |  | **(18177)** |  | **(44023)** | **39000** |
| &nbsp;&nbsp;Purchase of Pivix |  |  |  |  |  |  |  |  | **1359** |
| &nbsp;&nbsp;Issuance of warrants in connection with sale of AAC | **17000** |  |  | **17000** |  |  |  |  |  |
| &nbsp;&nbsp;Impact of sale of discontinued operations | **(50918)** |  |  |  |  |  |  | **(50918)** |  |
| **Balance at December 31, 2025** | $**833185** | $**—** | $**489** | $**369860** | $**8483** | $**370431** | $**(33473)** | $**117395** | $**252981** |

---

(1) NCI = Noncontrolling interest

*See accompanying Notes to Consolidated Financial Statements*

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **49** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>,

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Consolidated Statements of Cash Flows**

---

| | | | |
|:---|:---|:---|:---|
| **($ in thousands) Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Cash flows from operating activities:** |  |  |  |
| Net income (loss) | $**(259091)** | $(556088) | $4951 |
| Net income (loss) from discontinued operations | **(163288)** | (497167) | 28183 |
| Net income (loss) from continuing operations | **(95803)** | (58921) | (23232) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible amortization and depreciation | **41952** | 19947 | 5230 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | **9707** | 9356 | 12266 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unearned premiums, net | **6667** | (10324) | 27913 |
| &nbsp;&nbsp;&nbsp;&nbsp;Losses and loss expenses, net | **(18973)** | 10779 | 23737 |
| &nbsp;&nbsp;&nbsp;&nbsp;Ceded premiums payable | **27559** | 23337 | 9721 |
| &nbsp;&nbsp;&nbsp;&nbsp;Premium and commissions receivables | **(49578)** | (11329) | (30225) |
| &nbsp;&nbsp;&nbsp;&nbsp;Commissions payable | **30743** | (3160) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate costs reallocated to continuing operations | **6786** | 14919 | 19367 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | **(11343)** | 6158 | (7829) |
| **Net cash provided by (used in) operating activities from continuing operations** | **(52283)** | 762 | 36948 |
| **Cash flows from investing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of bonds | **27366** | 5994 | 1378 |
| &nbsp;&nbsp;&nbsp;Proceeds from matured bonds | **37658** | 21580 | 15078 |
| &nbsp;&nbsp;&nbsp;Purchases of bonds | **(25577)** | (60470) | (33243) |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of other invested assets | **—** | 625 |  |
| &nbsp;&nbsp;&nbsp;Purchases of other investments | **(66)** | (2522) | (2242) |
| &nbsp;&nbsp;&nbsp;Change in short-term investments | **(18752)** | 101829 | 4157 |
| &nbsp;&nbsp;&nbsp;Acquisitions, net of cash acquired | **(217940)** | (243776) | (6953) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of subsidiary | **407300** | 14119 |  |
| &nbsp;&nbsp;&nbsp;Other, net | **(10053)** | (3750) | (4854) |
| **Net cash provided by (used in) investing activities from continuing operations** | **199936** | **(166371)** | **(26679)** |
| **Cash flows from financing activities:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from long-term debt | **117470** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from short-term debt | **—** | 147000 |  |
| &nbsp;&nbsp;&nbsp;Issuance of equity interest in subsidiary | **—** | 62000 |  |
| &nbsp;&nbsp;&nbsp;Payments for purchases of common stock held in treasury | **(29942)** | (11698) | (4510) |
| &nbsp;&nbsp;&nbsp;Payments for extinguishment of short-term debt | **(150000)** |  |  |
| &nbsp;&nbsp;&nbsp;Tax payments related to shares withheld for share-based compensation plans | **(5307)** | (692) | (4585) |
| &nbsp;&nbsp;&nbsp;Issuance of warrants | **17000** |  |  |
| &nbsp;&nbsp;&nbsp;Distributions to noncontrolling interest holders | **(4174)** | (2391) | (1891) |
| &nbsp;&nbsp;&nbsp;Acquisitions of noncontrolling interest shares | **(71345)** |  |  |
| **Net cash provided by (used in) financing activities from continuing operations** | **(126298)** | **194219** | **(10986)** |
| **Net cash provided by (used in) continuing operations** | **21355** | 28610 | (717) |
| Effect of foreign exchange on cash and cash equivalents - continuing operations | **1460** | (558) |  |
| **Net cash provided by (used in) continuing operations** | **22815** | **28052** | **(717)** |
| Cash, cash equivalents, and restricted cash at beginning of period - continuing operations | **47275** | 19223 | 19940 |
| **Cash, cash equivalents, and restricted cash at end of period - continuing operations** | $**70090** | $**47275** | $**19223** |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities from discontinued operations | **71728** | 33536 | 163376 |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities from discontinued operations | **69712** | (7911) | 461870 |
| &nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities from discontinued operations | **(143144)** | (214606) | (411947) |
| **Net cash provided by (used in) discontinued operations** | **(1704)** | (188981) | 213299 |
| Effect of foreign exchange on cash and cash equivalents - discontinued operations | **—** | (126) | 529 |
| **Net cash provided by (used in) discontinued operations** | **(1704)** | **(189107)** | **213828** |
| Cash, cash equivalents, and restricted cash at beginning of period - discontinued operations | **66076** | 255183 | 41355 |
| **Cash, cash equivalents, and restricted cash at end of period - discontinued operations** | $**—** | $**66076** | $**255183** |
| **Cash paid during the period for:** |  |  |  |
| &nbsp;&nbsp;Interest on debt | $**19775** | $3821 | $— |
| **Non-cash investing and financing activities:** |  |  |  |
| &nbsp;&nbsp;Octave common stock issued as partial consideration to acquire Octave Ventures | **—** | 29229 |  |

---

*See accompanying Notes to Consolidated Financial Statements*

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **50** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**1.&nbsp;&nbsp;&nbsp;&nbsp;BACKGROUND AND BUSINESS DESCRIPTION**

Octave Specialty Group, Inc. ("OSG"), headquartered in New York City, is a financial services holding company incorporated in the state of Delaware on April 29, 1991. OSG is formerly known as Ambac Financial Group, Inc. ("AFG"). In the fourth quarter of 2025 AFG changed its name to OSG in connection with the sale of its legacy financial guarantee business to reflect the Company's position as a P&C only business. References to "Octave," "OSG," the "Company," "we," "our," and "us" are to OSG and its subsidiaries, as the context requires. Octave operates two principal businesses:

&nbsp;&nbsp;&nbsp;&nbsp;• **Insurance Distribution —** Octave's specialty property and casualty ("P&C") insurance underwriting and distribution business, includes Managing General Agents and Underwriters (collectively "MGAs" or "MGA/Us"); an insurance broker; and other distribution, underwriting and related businesses. On October 31, 2025, the Company completed the acquisition of ArmadaCorp Capital, LLC and its subsidiaries (collectively, "ArmadaCorp"), a leading specialty accident and health MGA. Octave's insurance distribution platform operates in the following lines of business: property, niche specialty risk, accident & health, miscellaneous specialty, reinsurance, surety, marine & energy, specialty auto, E&S commercial package, professional lines and Directors & Officers ("D&O").

&nbsp;&nbsp;&nbsp;&nbsp;**• Specialty Property & Casualty Insurance** — Octave's Specialty Property & Casualty Insurance program insurer business currently includes five carriers (collectively, "Everspan"). Everspan carriers have an A.M. Best rating of 'A-' (Excellent) which was affirmed on July 17, 2025.

The Company reports these two business operations as segments; see *Note 3. Segment Information* for further information.

Octave's financial guarantee business, which is being reported as a discontinued operations due to its sale in 2025, includes the activities of Ambac Assurance Corporation ("AAC") and its wholly owned subsidiaries, including Ambac Assurance UK Limited ("Ambac UK") and Ambac Financial Services LLC ("AFS"). See *Note 5. Discontinued Operations* for information related to the sale of AAC.

**Limitations on Voting and Transfer of Common Stock**

OSG's Amended and Restated Certificate of Incorporation limits voting and transfer rights of stockholders in significant ways. Article IV contains voting restrictions applicable to any person owning at least 10% of OSG's common stock so that such person (including any group consisting of such person and any other person with whom such person or any affiliate or associate of such person has any agreement, contract, arrangement or understanding with respect to acquiring, voting, holding or disposing of OSG's common stock) shall not be entitled to cast votes in excess of one vote less than 10% of the

votes entitled to be cast by all common stock holders, except as otherwise approved by the insurance commissioners of the states of domicile of the insurance companies controlled by OSG. Article XII contains substantial restrictions on the ability to transfer OSG's common stock. In order to preserve certain tax benefits, subject to limited exceptions, any attempted transfer of common stock shall be prohibited and void to the extent that, as a result of such transfer (or any series of transfers of which such transfer is a part), either (i) any person or group of persons shall become a holder of 5% or more of OSG's common stock or (ii) the percentage stock ownership interest in OSG of any holder of 5% or more of OSG's common stock shall be increased (a "Prohibited Transfer"). These restrictions shall not apply to an attempted transfer if the transferor or the transferee obtains the written approval of OSG's Board of Directors prior to such transfer. A purported transferee of a Prohibited Transfer shall not be recognized as a stockholder of OSG for any purpose whatsoever in respect of the securities which are the subject of the Prohibited Transfer (the "Excess Securities"). Until the Excess Securities are acquired by another person in a transfer that is not a Prohibited Transfer, the purported transferee of a Prohibited Transfer shall not be entitled with respect to such Excess Securities to any rights of stockholders of OSG, including, without limitation, the right to vote such Excess Securities and to receive dividends or distributions, whether liquidating or otherwise, in respect thereof, if any. Once the Excess Securities have been acquired in a transfer that is not a Prohibited Transfer, the securities shall cease to be Excess Securities. If the Board determines that a transfer of securities constitutes a Prohibited Transfer then, upon written demand by OSG, the purported transferee shall transfer or cause to be transferred any certificate or other evidence of ownership of the Excess Securities within the purported transferee's possession or control, together with any distributions paid by OSG with respect to such Excess Securities, to an agent designated by OSG. Such agent shall thereafter sell such Excess Securities and the proceeds of such sale shall be distributed as set forth in the Amended and Restated Certificate of Incorporation. If the purported transferee of a Prohibited Transfer has resold the Excess Securities before receiving such demand, such person shall be deemed to have sold the Excess Securities for OSG's agent and shall be required to transfer to such agent the proceeds of such sale, which shall be distributed as set forth in the Amended and Restated Certificate of Incorporation.

**2.&nbsp;&nbsp;&nbsp;&nbsp;BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES** 

Octave's consolidated financial statements have been prepared on the basis of U.S. generally accepted accounting principles ("GAAP"). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and disclosures. There can be no assurance that actual results will conform to such estimates and any future changes in estimates could be material to the financial statements.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **51** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**Consolidation**

The consolidated financial statements include the accounts of OSG and all other entities in which OSG (directly or through its subsidiaries) has a controlling financial interest. All significant intercompany balances have been eliminated. The usual condition for a controlling financial interest is ownership of a majority of the voting interests of an entity.

**OSG Unconsolidated Financial Information**

Financial information of OSG is presented in Schedule II in this Annual Report on Form 10-K as of December 31, 2025 and 2024 and for the years ended December 31, 2025, 2024 and 2023. Investments in subsidiaries are accounted for using the equity method of accounting in Schedule II.

**Discontinued Operations**

On September 29, 2025, the Company completed the sale of its Legacy Financial Guarantee business, inclusive of Ambac Assurance Corporation ("AAC") and its wholly owned subsidiary Ambac Assurance UK Limited. The results of discontinued operations for all periods to the date of sale are reported separately as Net income (loss) from discontinued operations within the Consolidated Statements of Total Comprehensive Income for the current and prior periods. Assets and liabilities of AAC are presented on the Consolidated Balance Sheet as of December 31, 2024, under Assets of discontinued operations and Liabilities of discontinued operations. AAC's cash flows for all periods to the date of sale are reflected as Net cash provided by (used in) discontinued operations within the Consolidated Statements of Cash Flows.

Refer to *Sale of Ambac Assurance Corporation* in *Note 5. Discontinued Operations* for further information.

**Acquisition of ArmadaCorp** 

On October 31, 2025, the Company closed on the acquisition of ArmadaCorp for a purchase price of $250,000. The Company purchased all of the issued and outstanding limited liability company interests in ArmadaCorp from Sirius Re Holdings, Inc. and Sirius Acquisitions Holding Company.

**Credit Facilities**

Proceeds from the sale of AAC were used, in part, by the Company to repay the $150,000 credit facility that was used to partially finance the acquisition of Octave Specialty Limited ("Octave Ventures") .

In connection with the acquisition of ArmadaCorp on October 31, 2025, Octave Partners LLC and certain of its subsidiaries (including ArmadaCorp) entered into a credit facility providing for a $100,000 term loan and a $20,000 revolving credit facility. The term loan and revolving loans were fully drawn to pay part of the purchase price for ArmadaCorp.

Refer to *Note 12. Debt* for further information regarding these credit facilities.

**Pivix Conversion**

Effective September 1, 2025, OSG's wholly owned subsidiary, Octave Partners, LLC ("Octave Partners"), exercised its option to convert its $3,500 convertible note investment in Pivix Specialty Insurance Services ("Pivix"), an excess and surplus lines MGA/U, into common stock. As a result, Octave Partners has a 74% controlling stake in Pivix when combined with its previous 17% minority equity interest and includes Pivix in its consolidated financial statements.

**Measurement of Credit Losses on Financial Instruments (CECL)**

Octave measures credit losses on financial assets that are not accounted for at fair value through net income in accordance with the Current Expected Credit Loss standard or "CECL".

The credit loss impairment evaluation process for available-for-sale debt securities is discussed in the Investments sub-section below. CECL does not apply to equity method investments accounted for under ASC 323.

Credit loss impairment for amortized cost assets reflect management's current estimate of all expected lifetime credit losses. The estimate of expected lifetime credit losses considers historical information, current information, as well as reasonable and supportable forecasts. Expected lifetime credit losses for amortized cost assets are recorded as an allowance for credit losses, with subsequent increases or decreases in the allowance reflected in net income each period. The credit loss impairment evaluation process for amortized cost assets is addressed in the applicable subsections below. The total allowance for credit losses for amortized cost assets recorded under CECL related to continuing operations was $950 at December 31, 2025.

**Investments**

The Investments — Debt Securities Topic of the ASC requires that all debt instruments be classified in Octave's Consolidated Balance Sheets according to their purpose and, depending on that classification, be carried at either cost or fair market value.

Octave's debt investment portfolio is accounted for on a trade-date basis and consists primarily of investments in fixed maturity securities that are either classified as available-for-sale or trading as defined by the Investments - Debt Securities Topic of the ASC. Available-for-sale debt securities are reported in the financial statements at fair value with unrealized gains and losses, net of deferred taxes, reflected in Accumulated Other Comprehensive Income (Loss) in Stockholders' Equity and computed using amortized cost as the basis. For purposes of computing amortized cost, premiums and discounts are accounted for using the effective interest method over the term of the security. For structured debt securities with a large underlying pool of homogenous loans, such as mortgage-backed and asset-backed securities, premiums and discounts are adjusted for the effects of actual and anticipated prepayments. For other fixed maturity securities, such as corporate and municipal bonds, discounts are amortized or accreted over the remaining term of the securities and premiums are amortized to the earliest call date.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **52** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

Short-term investments consist of investments in money market funds, fixed maturity investments having maturities of less than one year and greater than three months when purchased, cash sweep products, and certificates of deposit.

Other investments primarily consist of:

&nbsp;&nbsp;&nbsp;&nbsp;• Equity interests in limited partnership which are accounted for in accordance with the Investments — Equity Securities Topic of the ASC and reported as Other investments on the Consolidated Balance Sheet with income reported through Net investment income on the Statement of Total Comprehensive Income (Loss). Equity interests in limited partnership are reported using the equity method.

&nbsp;&nbsp;&nbsp;&nbsp;• Preferred equity investments that do not have readily determinable fair values are carried at cost, less any impairments as permitted under the Investments — Equity Securities Topic of the ASC.

Fair value is based primarily on quotes obtained from independent market sources. When quotes for fixed maturity securities are not available or cannot be reasonably corroborated, valuation models are used to estimate fair value. These models include estimates, made by management, which utilize current market information. When fair value is not readily determinable for pooled investment funds, the investments are valued using net asset value ("NAV") as a practical expedient as permitted under the Fair Value Measurement Topic of the ASC. Investment valuations could differ materially from amounts that would actually be realized in the market. Realized gains and losses on the sale of investments are determined on the basis of specific identification. Refer to *Note 7. Fair Value Measurements* for further description of the methodologies used to determine the fair value of investments, including model inputs and assumptions where applicable.

Octave has a formal impairment review process for fixed maturity available-for-sale securities in its investment portfolio. Octave conducts a review each quarter to identify and evaluate investments that have indications of impairment in accordance with the Investments — Debt Securities Topic of the ASC.

If management either: (i) has the intent to sell its investment in an impaired debt security or (ii) determines that the Company more likely than not will be required to sell the debt security before its anticipated recovery of the amortized cost basis less any current period credit impairment, then an impairment charge is recognized in earnings, with the amortized cost of the security written-down to fair value.

If management does not intend to sell, or will not be required to sell the debt security, the security is reviewed for credit impairment. Factors considered to identify and assess securities for credit impairment include: (i) fair values that have declined by 20% or more below amortized cost; (ii) recent downgrades by rating agencies; (iii) the financial condition of the issuer and financial guarantor, as applicable, and an analysis of projected defaults on the underlying collateral; and (iv) whether scheduled interest payments are past due. The recognition of credit impairment losses for available-for-sale debt securities are recorded as an allowance for credit losses with an offsetting

charge to net income. Improvements to estimated credit losses for available-for-sale debt securities are recognized immediately in net income. If we believe a decline in the fair value of a particular fixed maturity available-for-sale investment is not credit impaired, we record the decline as an unrealized loss net of tax in Accumulated Other Comprehensive Income (Loss) in Stockholders' Equity on our Consolidated Balance Sheets.

The evaluation of securities for credit impairment is a quantitative and qualitative process, which is subject to risks and uncertainties and is intended to determine whether, and to what extent, declines in the fair value of investments should be recognized in current period earnings. The risks and uncertainties include changes in general economic conditions, the issuer's or guarantor's financial condition and/or future prospects, the impact of regulatory actions on the investment portfolio, the performance of the underlying collateral, the effects of changes in interest rates or credit spreads and the expected recovery period.

Octave has made certain accounting policy elections related to accrued interest receivable ("AIR") for available-for-sale investments under CECL. Elections include: (i) not measuring AIR for credit impairment, instead AIR is written off when it becomes 90 days past due; (ii) writing off AIR by reversing interest income; (iii) presenting AIR separately in Other Assets on the balance sheet and (iv) excluding AIR from amortized cost balances in required CECL disclosures found in *Note 6. Investments*. AIR at December 31, 2025 and 2024 was $1,432 and $1,703, respectively.

Refer to *Note 6. Investments* for further credit impairment disclosures.

**Specialty Property and Casualty Insurance Premiums**

Gross written premiums on insurance policies are recorded at the inception of the policy and can be received on an upfront or installment basis. Certain gross written premiums are written as assumed reinsurance. Assumed reinsurance can attach on a risk-attaching or loss-occurring basis. On risk attaching, assumed written premiums are recorded at the inception of the policy and can be received on an upfront or installment basis. On loss-occurring, assumed written premium includes the transfer of unearned premiums for in-force policies at the effective date of the respective reinsurance agreements and ongoing premium written activity of policies inforce during the respective contract period. At end of the contract period, the remaining unearned premiums of inforce policies are returned to the carrier. Collections of loss occurring assumed written premiums are generally on an installment basis. Ceded premiums written are based on contractual terms applied against related gross written premiums. Premiums, net of reinsurance, are recognized as revenue on a daily pro-rata basis over the term of the insured risk. Unearned premiums and deferred ceded premiums represents the portion of gross and ceded premiums written that relate to unexpired risk, respectively.

Premium receivables represent balances currently due and amounts not yet due from policyholders, insurance carriers, managing general agents or producers issuing insurance policies on Everspan's behalf. Premium receivables are reported net of

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **53** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

an allowance for expected credit losses. The allowance is based upon Everspan's ongoing review of amounts outstanding, including delinquencies and write-offs, and other relevant factors. Credit risk is partially mitigated by the managing general agent's ability to cancel the policy on behalf of Everspan if the policyholder does not pay the premium, thereby reducing the related policy's premium written and Everspan's premium receivable.

**Derivative Contracts**

The Company has used derivative contracts to hedge foreign exchange or other economic risks in connection with certain strategic investments. None of Octave's derivative contracts were designated as hedges under the Derivatives and Hedging Topic of the ASC.

All derivatives are recorded on the Consolidated Balance Sheets at fair value and are included in Other assets and Other liabilities, as appropriate. Refer to *Note 10. Derivative Instruments* for further discussion of the Company's use of derivative instruments and their impact on the consolidated financial statements. Refer to *Note 7. Fair Value Measurements* for further description of the methodologies used to determine the fair value of derivative contracts.

**Deferred Acquisition Costs, Ceding Commissions and Deferred Program Fees**

The Specialty Property and Casualty Program business defers acquisition costs incurred that are related directly to the successful acquisition of new or renewal insurance contracts, including commissions paid to managing general agents for direct business and paid to insurance carriers when acquired via assumed reinsurance. Ceding commissions received from reinsurers represent a recovery of related acquisition costs. Deferred acquisition costs, net of ceding commissions, are amortized over the related policy period, generally one year, and recognized in amortization of deferred acquisition costs on the Statement of Total Comprehensive Income (Loss). Ceding commissions received in excess of the related direct acquisition costs are deferred and amortized over the related policy period, and recognized as program fees on the Statement of Total Comprehensive Income (Loss).

A legal right of offset exists for (i) premiums received and commissions paid to managing general agents on direct business, (ii) premiums received and ceding commission paid on assumed business and (iii) premiums paid and ceding commissions received on ceded business.

**Goodwill** 

Goodwill is attributable to acquisitions in the ID segment and represents the acquisition cost in excess of the fair value of net assets acquired, including identifiable intangible assets. Goodwill is assigned at acquisition to the applicable reporting unit of the acquired entity giving rise to the goodwill. Goodwill is not amortized but is subject to impairment testing. Goodwill impairment tests are performed annually or more frequently if circumstances indicate a possible impairment. The annual test of goodwill impairment is as of October 1st of each year. The impairment test for each reporting unit may first consider

qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Examples of qualitative factors include macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, entity-specific events, events affecting reporting units and sustained changes in our stock price. If results of the qualitative assessment indicate a more likely than not determination, or if we elect not to perform a qualitative assessment, then a quantitative impairment evaluation is performed as described below.

The quantitative evaluation compares the estimated fair value using a combination of an income approach and market approach for each reporting unit with its respective carrying value (including goodwill and identifiable intangible assets). The income approach uses discounted cash flows which are dependent on subjective factors including the timing of future cash flows, the underlying margin projection assumptions, future growth rates and the discount rate. The market approach uses valuation multiples and is dependent on subjective factors including the determination of industry market multiples and EBITDA forecasts. Additionally, to corroborate our estimated fair value, we perform a market capitalization reconciliation to determine if the implied control premium is reasonable. If our assumptions or estimates in our fair value calculations change or if any of the above subjective factors vary from what was expected, this may impact our impairment analysis and result in a decline in fair value that may trigger future impairment charges.

**Intangible Assets**

**<u>Finite-lived intangibles</u>**

Octave acquired identifiable intangible assets attributable to the ID segment. The intangible assets primarily relate to distribution relationships, non-compete agreements and trade names, all of which have finite lives and are amortized over their estimated useful lives using the straight-line method. The acquisition date valuation method used to determine the fair value of customer relationships, which were the most significant intangible assets acquired, was the multi period excess earnings method "(MPEEM"), which quantifies the residual (or excess) cash flows generated by the intangible asset and discounts those cash flows to their present value. The significant assumptions used in determining the fair value of customer relationships include estimated revenue growth, customer attrition rates, operating margins, and discount rate.

The Company tests finite-lived acquired intangible assets for impairment if certain events occur or circumstances change indicating that the carrying amount of the intangible asset may not be recoverable. The carrying amount of the intangible asset is not recoverable if it exceeds the projected undiscounted cash flows expected to result from the use and eventual disposal of the asset or asset group. If deemed unrecoverable, an impairment loss is recognized for the excess carrying amount over the fair value. There have been no accumulated impairment losses since these finite-lived intangible assets were established.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **54** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**<u>Indefinite-lived intangibles</u>**

Octave acquired identifiable intangible assets attributable to its acquisitions of licensed insurance carriers in both 2021 and 2022, which were accounted for as asset acquisitions (Specialty Property and Casualty Insurance segment). The intangible assets relate to insurance licenses which have indefinite lives and therefore are not amortized. The useful lives are re-evaluated each period to determine whether facts and circumstances continue to support an indefinite life. The Company tests indefinite-lived acquired intangible assets for impairment annually or more frequently if circumstances indicate a possible impairment. Octave tests indefinite-lived intangibles for impairment as of October 1st of each year. If, after assessing qualitative factors, management believes it is more likely than not that the intangible assets are impaired, a quantitative impairment evaluation is performed. Management also has the option to bypass the qualitative evaluation and proceed directly to the quantitative evaluation. The quantitative test compares the estimated fair value of the intangible asset with its carrying value. An impairment is recognized for the excess of the carrying amount of the intangible asset over it estimated fair value. If the asset's estimated fair value exceeds its carrying value, the intangible asset is not impaired. There have been no accumulated impairment losses since these indefinite-lived intangible assets were established.

**Cash and Cash Equivalents**

Cash and cash equivalents principally consist of demand deposits with financial institutions and highly liquid fixed maturity investments having maturities of three months or less when purchased.

**<u>Restricted Cash including Fiduciary Funds</u>**

Cash that we do not have the right to use for general purposes is recorded as restricted cash in our consolidated balance sheets. Restricted cash includes fiduciary cash held by Octave's insurance distribution subsidiaries as described below.

As an intermediary, we hold funds, generally in a fiduciary capacity, for the account of third parties, typically as the result of premiums received from retail brokers or insureds that are in transit to insurers and claims due that are in transit from insurers. Since fiduciary assets are not available for corporate use, they are shown in the consolidated balance sheets as restricted cash and we present an equal and corresponding fiduciary liability relating to these funds representing amounts or claims or premiums due on our consolidated balance sheets (included in Other liabilities).

Fiduciary funds are generally required to be kept in bank accounts subject to guidelines which emphasize capital preservation and liquidity. The Company is entitled to retain investment income earned on certain of these fiduciary funds in accordance with industry custom and practice and, in some cases, as supported by agreements with insureds.

Restricted cash for net uncollected premiums and claims and the related fiduciary liabilities were $40,754 and $17,669 at December 31, 2025 and 2024, respectively.

**Specialty Property and Casualty Loss and Loss Adjustment Expenses**

Loss and loss adjustment expense reserves for Specialty Property and Casualty policies represent management's estimate of the ultimate liability for unpaid losses and loss expenses for claims that have been reported and claims that have been incurred but not yet reported ("IBNR") as of the balance sheet date.

Loss and loss adjustment expense reserves represent management estimates, primarily utilizing actuarial expertise and projection methods that develop estimates for the ultimate cost of claims and claim adjustment expenses. The reserves are estimated based upon experience and using a variety of actuarial methods. These estimates are reviewed and are subject to the impact of future changes in factors such as claim severity and frequency, underwriting and claims practices, changes in social and economic conditions including the impact of inflation, legal and judicial developments, medical cost trends and upward trends in damage awards. Our actuarial methods may also rely on external data, such as industry loss ratios, loss development factors, or trend factors. Such data, while more mature than Everspan's own data, may not be perfectly representative of the particular business written by Everspan. The ultimate amount for loss and loss adjustment expenses may be in excess, or less than, the amounts recorded on our financial statements. Because the establishment of claims and claim adjustment expense reserves is an inherently uncertain process involving estimates and judgment, currently estimated claims and claim adjustment expense reserves may change. Adjustments will be reflected as part of the net increase or reduction in loss and loss adjustment expense reserves in the periods in which they become known.

Cumulative amounts paid and case reserves held as of the balance sheet date are subtracted from the estimate of the ultimate cost of claims and claim adjustment expenses to derive incurred but not reported (IBNR) reserves. There were no changes in methodology in the past year.

Detailed claim data is typically insufficient to produce a reliable indication of the initial estimate for ultimate claims and claim adjustment expenses for an accident year. As a result, the initial estimate for an accident year is generally based on an exposure-based method using the loss ratio projection method. The loss ratio projection method develops an initial estimate of ultimate claims and claim adjustment expenses for an accident year by multiplying earned premium for the accident year by a projected loss ratio. The projected loss ratio is determined by analyzing prior period experience, and adjusting for loss cost trends, rate level differences, a mix of business changes and other known or observed factors influencing the accident year relative to prior accident years.

The following estimation and analysis methods are principally used by the Company's actuaries to estimate the ultimate cost of claims and claim adjustment expenses. These estimation and analysis methods are typically referred to as conventional actuarial methods.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **55** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

&nbsp;&nbsp;&nbsp;&nbsp;• The paid loss development method assumes that the future change (positive or negative) in cumulative paid losses for a given cohort of claims will occur in a stable, predictable pattern from year-to-year, consistent with the pattern observed in past cohorts.

&nbsp;&nbsp;&nbsp;&nbsp;• The case incurred development method is the same as the paid loss development method, but is based on cumulative case-incurred losses rather than paid losses.

&nbsp;&nbsp;&nbsp;&nbsp;• The Bornhuetter-Ferguson method uses an initial estimate of ultimate losses for a given product line reserve component, typically expressed as a ratio to earned premium. The method assumes that the ratio of additional claim activity to earned premium for that component is relatively stable and predictable over time and that actual claim activity to date is not a credible predictor of further activity for that component. The method is used most often for more recent accident years where claim data is sparse and/or volatile, with a transition to other methods as the underlying claim data becomes more voluminous and therefore more credible.

While these are the principal methods utilized, the Company's actuaries have available to them the full range of actuarial methods developed by the casualty actuarial profession. Most actuarial methods assume that past patterns demonstrated in the data will repeat themselves in the future.

The Company performs a continuing review of its loss and loss adjustment expense reserves, including its reserving techniques and the impact of reinsurance. Since the reserves are based on estimates, the ultimate liability may be more or less than such reserves.

**Reinsurance Recoverable**

The Company uses ceded reinsurance to transfer certain insurance risk, along with premiums written and earned, to other insurance carriers that agree to share in such risks. The primary purpose of the reinsurance is to (i) protect the Company, at a cost, from losses in excess of amounts it is willing to accept, (ii) protect the Company's capital, and (iii) to manage the Company's net retention on individual risks and overall exposure to losses while providing the Company the ability to offer policies with sufficient limits to meet policyholder needs. The Company generally enters into quota share reinsurance agreements whereby it cedes to the capacity providers (reinsurers) a substantial amount (generally 70% or more) of its gross liability under all policies issued by and on behalf of the Company by the MGA/U.

Everspan is exposed to the credit risk of the reinsurer, or the risk that one of its reinsurers becomes insolvent or otherwise unable or unwilling to pay policyholder claims. This credit risk is generally mitigated by either selecting well-capitalized, highly rated authorized capacity providers or requiring that the capacity provider post collateral to secure the reinsured risks, which in some instances, exceeds the related reinsurance recoverable.

Amounts recoverable from reinsurers are estimated in a manner consistent with the associated loss and loss adjustment expense

reserves. The Company reports reinsurance recoverables net of an allowance for amounts that are estimated to be uncollectible.

The reinsurance of risk does not legally relieve Everspan of its original liability to its policyholders. In the event that any of Everspan's reinsurers are unable to meet their obligations under reinsurance contracts, Everspan would, nonetheless, be liable to its policyholders for the full amount of its policy.

To minimize credit exposure to losses from reinsurer insolvencies, Everspan (i) is entitled to receive collateral from certain reinsurance counterparties pursuant to the terms of the relevant reinsurance contracts and (ii) has certain cancellation rights that can be exercised by Everspan in the event of rating agency downgrades of a reinsurer (among other events and circumstances). For those reinsurance counterparties that do not currently post collateral, Everspan's reinsurers are well-capitalized, highly rated, authorized capacity providers.

Everspan has a formal quarterly credit impairment review process whereby it has elected to use the practical expedient of considering the fair value of collateral posted by reinsurers when evaluating credit impairment. To determine the total unsecured recoverable to be evaluated for credit impairment, we net the reinsurance recoverable amount by ceded premiums payable and the fair value of collateral posted, if any.

The key factors in assessing credit impairment for reinsurance recoverables are independent rating agency credit ratings and loss severities. Management utilizes a probability of default/loss given default ("PD/LGD") approach, which is applied to the net unsecured reinsurance recoverable amount. Refer to *Note 8. Insurance Contracts* for credit impairment disclosures.

**Short and Long-term Debt**

Short and long-term debt are carried at par value less unamortized discount. Accrued interest and discount accretion on short and long-term debt is reported as Interest expense on the Consolidated Statements of Total Comprehensive Income (Loss).

**Noncontrolling Interests ("NCI")**

**<u>Nonredeemable NCI</u>**

For Octave Ventures, the Nonredeemable NCI of $117,395 and $146,837 as of December 31, 2025 and 2024, includes the NCI share in certain operating units which are minority owned by the units' respective management teams that do not have associated put options. As of December 31, 2024, there were no put options associated with any of these minority interests and as such, the aggregate amount was classified as nonredeemable NCI on the balance sheet. During the year ended December 31, 2025, certain NCI shares were reclassified between nonredeemable and redeemable NCI as further described under "Redeemable NCI" below. The acquisition date valuation method to determine the fair value of nonredeemable NCI was the discounted cash flow approach. The significant fair value assumptions used in the model included estimated long term revenue and expense forecasts and the discount rate. When redeemable NCI shares are no longer redeemable, such as when

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **56** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

put options expire unused, the NCI shares are reclassified to nonredeemable NCI with no change in carrying value.

During the year ended December 31, 2025, Octave paid $2,967 to purchase certain nonredeemable shares from minority interest owners, resulting in a $14,362 decrease to Nonredeemable noncontrolling interest. The difference between the consideration paid and carrying value of the nonredeemable NCI is recorded as an adjustment to additional paid-in capital.

**<u>Redeemable noncontrolling interests</u>**

The Xchange, All Trans, Capacity Marine, Riverton, Octave Ventures, and Pivix acquisitions resulted in the ownership percentages of the acquired entities by Octave as shown in the following table

---

| | |
|:---|:---|
| **Company** | **Ownership Percentage** |
| Xchange | **80%** |
| All Trans | **85%** |
| Capacity Marine | **80%** |
| Riverton | **80%** |
| Octave Ventures <sup>(1)</sup> | **60%** |
| Pivix | **74%** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Octave Ventures's majority interests in its underlying MGAs ranges from 60% to 100% at December 31, 2025, resulting in Octave's interest ranging from 36% to 60% in each underlying MGA/U.

Under the terms of applicable agreements, Octave has call options to purchase the remaining interests from the minority owners (i.e., noncontrolling interests) and the minority owners have put options to sell their interests to Octave, which certain put obligations can be settled in equity and up to a maximum of 35% of the redemption value. Because the exercise of the put options are outside the control of Octave, in accordance with the Distinguishing Liabilities from Equity Topic of the ASC, Octave reports redeemable NCI in the mezzanine section of its consolidated balance sheet. In addition, during the three months ended March 31, 2025, Octave entered into put options with certain minority owners of the MGA/U operating entities that are majority owned by Octave Ventures. These put options are embedded in the associated NCI shares ("Option Shares"), resulting in remeasurement of the shares at fair value inclusive of the put options and reclassification of the Option Shares from nonredeemable NCI to redeemable NCI. The change in carrying value resulting from revaluation of $10,276 is recorded as an offset to retained earnings, with a corresponding impact on earnings per share for the year ended December 31, 2025. During the year ended December 31, 2025, Octave paid $1,068 as a result of exercise of put options on the Option Shares, acquiring redeemable NCI with a carrying value of $1,815. The difference between the consideration paid and carrying value of the redeemable NCI is recorded as an adjustment to additional paid-in capital. During the three months ended December 31, 2025, there was no activity related the exercise of the put options on the Option Shares.

The acquisition date valuation method to determine the fair value of redeemable NCI and related put and call options was Monte Carlo Simulation. The significant fair value assumptions

used in the simulation include the exercise thresholds, EBITDA forecasts, discount rate and long-term growth rates. The redeemable NCI is remeasured each period as the greater of:

&nbsp;&nbsp;&nbsp;&nbsp;i.the carrying value under ASC 810, which attributes a portion of consolidated net income (loss) to the redeemable NCI, and

&nbsp;&nbsp;&nbsp;&nbsp;ii.the redemption value of the put option under ASC 480 as if it were exercisable at the end of the reporting period.

Management calculates the redemption value of the put options under ASC 480 on an annual basis. At each reporting period, the redeemable noncontrolling interest increases or decreases due to activity related to net income and distributions. The Company remeasures such interests to redemption value when required based on the terms of the redemption provisions. Where redemption value is determined using prior-year EBITDA or associated calculations, management evaluates the redemption value and records adjustments only when contractual terms change.

Any increase (decrease) in the carrying amount of the redeemable NCI as a result of adjusting to the redemption value of the put option is recorded as an offset to retained earnings. The impact of such differences on earnings per share are presented in *Note 15. Net Income Per Share.*

Following is a rollforward of redeemable NCI.

---

| | | |
|:---|:---|:---|
| **Years ended December 31,** | **2025** | **2024** |
| Beginning balance | $**199402** | $17079 |
| Net income (loss) attributable to redeemable noncontrolling interest (ASC 810) | **(2007)** | (1282) |
| Gain (loss) on foreign currency translation attributable to redeemable NCI | **15227** | (4805) |
| Fair value of acquired redeemable noncontrolling interest at acquisition date | **1359** | 185469 |
| Reclassification from nonredeemable noncontrolling interest including remeasurement at fair value | **42180** |  |
| Reclassification to nonredeemable noncontrolling interest | **(5136)** |  |
| Put / call option exercise | **(1815)** |  |
| Distributions | **(4128)** | (2391) |
| Adjustment to redemption value (ASC 480) | **7899** | 5332 |
| **Ending Balance** | $**252981** | $**199402** |

---

The following table outlines the aggregate amounts of redeemable NCI according to the next earliest year in which a NCI put option becomes exercisable over the next five years as of December 31, 2025:

---

| | |
|:---|:---|
| 2026 | $**69387** |
| 2027 | **77002** |
| 2028 | **55309** |
| 2029 | **48833** |
| 2030 | **2450** |
| **Total** | $**252981** |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **57** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

Per ASC 480, the redeemable NCI is to be recorded as the greater of the carrying value or redemption value, therefore, the options in any issue year could be exercised at a lower amount.

**Revenue Recognition**

Revenues for the ID business operations are recognized in accordance with the Revenue from Contracts with Customers Topic of the ASC. The following steps are applied to recognize revenue: (i) identify the contract(s) with the customer, (ii) identify the performance obligations in the contract(s), (iii) determine the transaction price, and (iv) allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. A performance obligation is satisfied either at a point in time or over time depending on the nature of the product or service provided and the specific terms of the contract with customers.

Performance obligations consist of underwriting and placing policies with insurers and, for certain products, providing claims servicing. Revenue from employer stop loss policies ("ESL") is apportioned to policy placement and claims servicing based on the relative stand-alone selling price of the respective performance obligations with policy placement revenue recognized upfront while claims servicing revenue is recognized over the claim adjustment period. Revenue from other insurance policies are recognized up front as no further performance obligations exist after policy placement.

Revenue consists of base and profit-sharing commissions.

&nbsp;&nbsp;&nbsp;&nbsp;• Base commissions, associated with policy placement and claims servicing, are estimated by applying the contractual commission percentages to estimated gross premiums placed.

&nbsp;&nbsp;&nbsp;&nbsp;• Profit-sharing commissions represent variable consideration associated with policy placement only and are estimated based on expected loss ratios and the estimated gross premium for base commissions.

Base and profit-sharing commissions are estimated with a constraint applied such that a significant reversal of revenue in the future is not probable. Revenue is reported in Commissions income on the Consolidated Statement of Total Comprehensive Income.

Contract assets represent the Company's right to future consideration for services it has already transferred to the customer, which is subject to certain contingencies. Once the right to consideration becomes unconditional, it is reported as a receivable. Contract assets are evaluated for credit loss under CECL using a probability of default / loss given default ("PD/LGD") method which measures credit impairment as the product of the carrying value, default probability and loss given default, considering the asset's credit rating and average life. Contract liabilities represent the Company's obligation to transfer services for which it has already received consideration from the customer. Contract assets and receivables are reported as other assets, and contract liabilities are reported as other liabilities, on the Consolidated Balance Sheet.

The Company's costs to obtain customer contracts relate to certain commissions paid to independent agents for procuring policies. As these costs relate to the Company's policy placement performance obligation to its customers, they are expensed as incurred. These costs are reported in Commission expenses on the Consolidated Statement of Total Comprehensive Income (Loss).

**Incentive Compensation**

Incentive compensation is a key component of our compensation strategy. Incentive compensation has two components: short-term incentive compensation (consisting of an annual cash bonus) and long-term incentive plan awards (consisting of deferred cash and stock-based awards described further below). Annual decisions with regard to incentive compensation are generally made in the first quarter of each year and are based on the prior year's performance for the Company, the employee and the employee's business unit.

In 2024, the Octave 2020 Incentive Compensation Plan (the "2020 Incentive Plan") was superseded by the 2024 Incentive Compensation Plan ("2024 Incentive Plan"). Both plans allow for the granting of stock options, restricted stock, stock appreciation rights, restricted and performance units and other awards to employees, directors and consultants that are valued or determined by reference to Octave's common stock. Under these plans, Octave has issued both cash and equity awards to US and UK employees and consultants.

In connection with the adoption of the 2024 Incentive Plan, all shares reserved but unissued under the 2020 Incentive Plan were transferred to the 2024 Incentive Plan in addition to any shares underlying outstanding awards under the 2020 Incentive Plan as of June 5, 2024, that subsequently terminate by expiration or forfeiture, cancellation, or otherwise are not issued.

Under the 2020 and 2024 Incentive Compensation Plans Octave recognizes compensation costs for all equity classified awards granted at fair value, which is measured on the grant date, and records forfeitures for unvested shares only when they occur. For awards that only include service and performance conditions, the fair value is the market price of Octave stock on the grant date. For awards that also contain a market condition, including a total shareholder return ("TSR") modifier or achievement of Octave common stock price hurdles, the fair value is estimated using a Monte Carlo simulation.

The types of equity awards granted to employees are as follows:

&nbsp;&nbsp;&nbsp;&nbsp;• Restricted stock units — only require future service and accordingly the respective fair value is recognized as compensation expense over the relevant service period.

&nbsp;&nbsp;&nbsp;&nbsp;• Performance stock units — require both future service and achieving specified performance targets to vest. Performance stock unit grants also include a market condition TSR modifier that will cause the total payout at the end the performance period to increase or decrease depending on Octave's stock performance relative to a peer group. Compensation costs for all performance stock units are only recognized when the achievement of the

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **58** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

performance conditions are considered probable. Once deemed probable, such compensation costs are recognized as compensation expense over the relevant service period. Compensation costs are initially based on the probable outcome of the performance conditions and adjusted for subsequent changes in the estimated or actual outcome each reporting period as necessary. Changes in the estimated or actual outcome of a performance condition are recognized by reflecting a retrospective adjustment to compensation cost in the current period.

&nbsp;&nbsp;&nbsp;&nbsp;• Performance stock options ("PSOs") — require both future service and achieving specified market price targets to vest. The PSOs vest upon the achievement of an explicit one-year service period from grant and OSG stock reaching specified market price targets. Compensation costs for PSOs are initially recognized over the period from grant date to the end of the derived service period estimated from the Monte Carlo valuation process. If market conditions are achieved prior to the derived service period, the remaining compensation expense is recognized immediately.

**Operating Leases**

A contract contains a lease if it conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Octave's evaluation of whether certain contracts contain leases requires judgment regarding what party controls the asset and whether the asset is physically distinct.

Octave is the lessee in leases which are classified as operating leases. Octave recognizes a single lease cost, calculated so that the cost is allocated generally on a straight-line basis over the lease term within operating expenses in the Consolidated Statements of Total Comprehensive Income (Loss). The lease term commences on the earlier of the date when we become legally obligated for the rent payments or the date on which we take possession of the property. For such operating leases, Octave recognizes a right-of-use ("ROU") asset and a lease liability, initially measured at the present value of the lease payments. The discount rate used to initially measure the ROU assets and lease liabilities reflects the estimated secured borrowing rate of the applicable Octave subsidiary, which considers the rate of existing or recent debt obligations of the entity. All cash payments are classified within operating activities in the statement of cash flows.

For contracts where Octave is the lessee, we have elected the short-term lease recognition exemption for all leases that qualify. For those leases that qualify for that exemption, we will not recognize ROU assets or lease liabilities. For all contracts where Octave is the lessee and lessor, we have also elected the practical expedient to not separate lease and non-lease components.

**Depreciation and Amortization of Fixed Assets**

Depreciation of furniture and fixtures, certain information technology development costs and electronic data processing equipment is charged over the estimated useful lives of the respective assets, ranging from three to five years, using the

straight-line method. Amortization of leasehold improvements is charged over the remaining term of the respective operating lease using the straight-line method. Changes to estimated useful lives are accounted for prospectively from the period of change. Fixed assets are evaluated for impairment whenever events or changes in circumstances indicate their carrying value may not be recoverable.

**Foreign Currency**

Financial statement accounts expressed in foreign currencies are translated into U.S. dollars in accordance with the Foreign Currency Matters Topic of the ASC. The functional currencies of Octave's subsidiaries are the local currencies of the country where the respective subsidiaries are based, which are also the primary operating environments in which the subsidiaries operate.

**<u>Foreign currency translation:</u>** Functional currency assets and liabilities of Octave's foreign subsidiaries are translated into U.S. dollars using exchange rates in effect at the balance sheet dates and the related translation adjustments, net of deferred taxes, are included as a component of Accumulated Other Comprehensive Income (Loss) in Stockholders' Equity. Functional currency operating results of foreign subsidiaries are translated using average exchange rates.

**<u>Foreign currency transactions:</u>** The impact of non-functional currency transactions and the remeasurement of non-functional currency assets and liabilities into the respective subsidiaries' functional currency (collectively "foreign currency transactions gains/(losses)") are $(3,864), $101 and $0 for the years ended December 31, 2025, 2024 and 2023, respectively. Foreign currency transaction gains/(losses) are primarily the result of Octave Ventures transactions in currencies (primarily the U.S. dollar) other than its functional currency (the British Pound Sterling).

**Commitments and Contingencies**

The Company and its subsidiaries are defendants in or parties to actual, pending and threatened lawsuits and proceedings. A liability is accrued for such contingencies when a loss is both probable and reasonably estimable. If a loss is not "probable and reasonably estimable," but is reasonably possible, disclosure of the contingency and an estimate of the loss or range of loss is required if such an estimate can be determined. Significant management judgment is required to apply this guidance. As a legal contingency develops, the Company, in conjunction with outside counsel, evaluates what level of accrual and/or disclosure is required under the guidance. See *Note 19. Commitments and Contingencies* for additional information about our legal contingencies and related accounting evaluation.

**Income Taxes**

Octave files a consolidated U.S. federal income tax return with its subsidiaries, except for Octave Ventures which files a separate tax return. Octave and its subsidiaries also file separate or combined income tax returns in various states, local and foreign jurisdictions. Current tax assets and liabilities are recognized for taxes refundable or payable for the current year.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **59** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on current and deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date.

The Income Taxes Topic of the ASC requires that companies assess whether valuation allowances should be established against their deferred tax assets based on management's assessment and consideration of all available evidence using a 'more likely than not' standard. In making such judgments, significant weight is given to evidence that can be objectively verified. The level of deferred tax asset recognition is influenced by management's assessment of future profitability, which depends on the existence of sufficient taxable income within the carry forward periods available under the tax law.

**Net Income Per Share**

Basic net income per share is computed by dividing net income attributable to common stockholders, including the adjustment to redemption value of the redeemable NCI, by the weighted-average number of common shares outstanding and vested restricted stock units (together, "Basic Weighted Average Shares Outstanding"). Diluted net income per share is computed by dividing net income attributable to common stockholders, including the adjustment to redemption value of the redeemable controlling interest, by the Basic Weighted-Average Shares Outstanding plus all potentially dilutive common shares outstanding during the period. All potentially dilutive common shares outstanding consider common stock deliverable pursuant to warrants, unvested restricted stock units and performance stock units granted under existing compensation plans.

**Immaterial Correction of Prior Period Error**

The Company identified an immaterial prior period error in the Consolidated Stockholders' Equity statement related to the redeemable non-controlling interest associated with the redemption value adjustment recorded under ASC 810-10. The Company assessed the materiality of this change in presentation on the prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, "Materiality," (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that this error correction in its Consolidated Balance Sheet, Stockholders Equity and Earnings Per share are not material to any previously presented consolidated financial statements. The corrections had no impact any previously presented interim or annual consolidated financial statements. Accordingly, the Company corrected the previously reported immaterial errors for the years ended December 31, 2024, in this Annual Report on Form 10-K.

A summary of the immaterial corrections to the Company's previously reported audited consolidated financial statements follows.

**Corrected Consolidated Balance Sheet:**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | As Reported | Immaterial Correction | As Corrected |
| Redeemable noncontrolling interest | $140860 | $58542 | $199402 |
| Retained earnings | 742185 | (58542) | 683643 |
| Total liabilities, redeemable noncontrolling interest and stockholders' equity | $8058378 | $— | $8058378 |

---

**Corrected Consolidated Statement of Stockholders' Equity:**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | As Reported | Immaterial Correction | As Corrected |
| Retained earnings | 742185 | (58542) | 683643 |

---

**Corrected Earnings Per Share:**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | As Reported | Immaterial Correction | As Corrected |
| Net income (loss) from continuing operations per share attributable to stockholders |  |  |  |
| &nbsp;&nbsp;Basic | $(0.13) | $(1.24) | $(1.37) |
| &nbsp;&nbsp;Diluted | $(0.13) | $(1.24) | $(1.37) |
| Net income (loss) per share attributable to shareholders |  |  |  |
| &nbsp;&nbsp;Basic | $(10.71) | $(1.25) | $(11.96) |
| &nbsp;&nbsp;Diluted | $(10.71) | $(1.25) | $(11.96) |

---

***Note 2. Basis of Presentation and Significant Accounting Policies***

**Corrected rollforward of redeemable NCI:**

---

| | | | |
|:---|:---|:---|:---|
| | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | As Reported | Immaterial Correction | As Corrected |
| Beginning balance | $17079 | $— | $17079 |
| Fair value of redeemable NCI at acquisition date | 185469 |  | 185469 |
| Net income attributable to redeemable NCI (ASC 810) | (1282) |  | (1282) |
| Distributions | (2391) |  | (2391) |
| Adjustment to redemption value (ASC 480) | (53210) | 58542 | 5332 |
| Foreign exchange | (4805) |  | (4805) |
| Ending balance | $140860 | $58542 | $199402 |

---

**Reclassifications and Rounding**

Reclassifications have been made to prior years' amounts to conform to the current year's presentation. This includes reclassifying held-for-sale assets and liabilities of Octave's financial guarantee business which is being reported as a discontinued operation. Certain amounts and tables in the consolidated financial statements and associated notes may not add due to rounding.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **60** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**Adopted Accounting Standards**

**<u>Income Taxes:</u>**

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740) - Improvements to Income Tax Disclosures*. The enhancements in the ASU include the following:

&nbsp;&nbsp;&nbsp;&nbsp;• Within the rate reconciliation table, disclosure of additional categories of information about federal, state, and foreign income taxes and provision of more details about reconciling items in some categories if the items meet a quantitative threshold.

&nbsp;&nbsp;&nbsp;&nbsp;• Annual disclosure of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes and further disaggregated by jurisdiction based on a quantitative threshold.

&nbsp;&nbsp;&nbsp;&nbsp;• Other disclosures include: (i) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign amounts and (ii) income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.

Octave has adopted this ASU prospectively for the annual reporting period ending December 31, 2025.

There have been no other new accounting standards adopted during the year ended December 31, 2025.

**Future Application of Accounting Standards and Required Disclosures**

**<u>Credit Losses for Accounts Receivable and Contract Assets:</u>**

In July 2025, the FASB issued ASU 2025-05, *Financial Instruments— Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets.* The amendments in the ASU provide all entities with a practical expedient when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions under Topic 606. The practical expedient allows entities to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset.

The ASU is effective for interim and annual periods beginning after December 15, 2025. The standard is not expected to have a material impact on Octave's financial statements.

**<u>Goodwill and Other — Internal-Use Software</u>**

In September 2025, the FASB issued ASU 2025-06, *Intangibles— Goodwill and Other— Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal Use Software.* This standard is intended to increase the operability of the accounting guidance for internal-use software development costs considering the evolution of software development methods. Amendments remove references to prescriptive and sequential project stages, requiring entities to start capitalizing costs when: (i) management has authorized and committed to funding the project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended.

The ASU is effective for interim and annual periods beginning after December 15, 2027 with early adoption permitted. Octave has not determined if it will early adopt this ASU and is evaluating its impact on Octave's financial statements.

**<u>Expense Disaggregation Disclosures:</u>**

In November 2024, the FASB issued ASU 2024-03, *Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures* (Subtopic 220-40). The enhanced disclosures requirements include the following:

&nbsp;&nbsp;&nbsp;&nbsp;• Disclose the amounts of certain expense categories included in each relevant expense caption. Those categories applicable to Octave include employee compensation, depreciation, and intangible asset amortization. A relevant expense caption is an expense caption presented on the face of the income statement within continuing operations that contains any of the expense categories listed above.

&nbsp;&nbsp;&nbsp;&nbsp;• Include certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements.

&nbsp;&nbsp;&nbsp;&nbsp;• Disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively.

&nbsp;&nbsp;&nbsp;&nbsp;• Disclose the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses.

The ASU is effective for annual periods beginning after December 15, 2026 and for interim reporting periods after December 15, 2027 with early adoption permitted. Octave has not determined if it will early adopt this ASU and is evaluating the impact on Octave's financial statements.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **61** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**3.&nbsp;&nbsp;&nbsp;&nbsp;SEGMENT INFORMATION**

The Company reports its results of continuing operations in two segments: Specialty Property and Casualty Insurance and ID. These reportable segments offer distinct products and services as further described in Note 1. Background and Business Description. The operating entities within each segment are wholly or majority owned by separate intermediate holding companies: Everspan Holdings, LLC for Specialty Property and Casualty Insurance and Octave Partners LLC for ID. The Company's segments have separate management teams with incentive compensation structures based on segment level performance. Financial reporting for each segment is regularly provided to the Company's Chief Executive Officer, who is the chief operating decision maker ("CODM"), for purposes of monitoring the businesses, assessing performance and allocating resources.

The following tables summarize the components of the Company's total revenues and expenses and pretax income (loss) by reportable business segment. Information provided below for "Corporate and Other" primarily relates to the operations of OSG, which will include investment income on its investment portfolio and costs to maintain the operations of OSG, including public company reporting, capital management and business development costs for the acquisition and development of new business initiatives. As a result of the Company reporting the results of operations of AAC as discontinued operations, certain corporate costs charged to AAC totaling $6,786, $14,919, and $19,367 for the years ended December 31, 2025, 2024 and 2023, respectively, have been reported in Net income from continuing operations on the Consolidated Statements of Total Comprehensive Income and included in Corporate and Other in the tables below.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **62** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2025** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** | **Year Ended December 31, 2024** |
| | **Reportable Segments** | **Reportable Segments** | | | **Reportable Segments** | **Reportable Segments** | | |
| | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Total** | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Total** |
| **Revenues:** | | | | | | | | |
| &nbsp;&nbsp;Commissions |  | $**143381** |  | **143381** |  | $92023 |  | $92023 |
| &nbsp;&nbsp;Servicing and other fees |  | **20419** |  | **20419** |  | 6353 |  | 6353 |
| &nbsp;&nbsp;Net premiums earned | $**67232** |  |  | **67232** | $99005 |  |  | 99005 |
| &nbsp;&nbsp;Program fees | **14322** |  |  | **14322** | 13506 |  |  | 13506 |
| &nbsp;&nbsp;Investment income | **6811** | **1514** | $**2323** | **10647** | 6400 | 787 | $7261 | 14448 |
| &nbsp;&nbsp;Other | **38** | **(1588)** | **(3230)** | **(4780)** | 7409 | 73 | 2998 | 10480 |
| **Total revenues from Continuing Operations** <sup>(1)</sup> | **88403** | **163726** | **(907)** | **251222** | **126320** | **99236** | **10259** | **235815** |
| **Less:** |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Commissions |  | **37037** |  | **37037** |  | 40876 |  | 40876 |
| &nbsp;&nbsp;Loss and loss adjustment expenses | **47193** |  |  | **47193** | 72626 |  |  | 72626 |
| &nbsp;&nbsp;Policy acquisition costs | **15790** |  |  | **15790** | 23666 |  |  | 23666 |
| &nbsp;&nbsp;Intangible amortization and depreciation |  | **38734** | 3218 | **41952** |  | 18083 | 1864 | 19947 |
| &nbsp;&nbsp;Interest expense |  | **18640** |  | **18640** |  | 9379 |  | 9379 |
| &nbsp;&nbsp;Compensation expense | **12245** | **63761** | **33841** | **109847** | 10201 | 28353 | 25791 | 64346 |
| &nbsp;&nbsp;Non Compensation expense | **9845** | **26010** | **45922** | **81777** | 7605 | 10354 | 46861 | 64820 |
| &nbsp;&nbsp;**Total expenses from continuing operations** | **85073** | **184182** | **82981** | **352236** | **114098** | **107045** | **74516** | **295660** |
| **Segment pretax income (loss)** | **3330** | **(20456)** | **(83888)** | **(101014)** | **12222** | **(7809)** | **(64257)** | **(59845)** |
| Segment income tax expense (benefit) | **374** | **(5103)** | **(482)** | **(5211)** | 1753 | (928) | (1748) | (924) |
| Segment net income (loss) | **2956** | **(15353)** | **(83406)** | **(95803)** | 10469 | (6881) | (62509) | (58921) |
| Segment net (income) loss attributable to NCI | **—** | **(2601)** |  | **(2601)** | 2 | (363) |  | (361) |
| **Net income (loss) attributable to shareholders** | $**2956** | $**(17954)** | $**(83406)** | $**(98404)** | $**10471** | **(7244)** | **(62509)** | $**(59282)** |
| **<u>Reconciliation to consolidated net income (loss) attributable to shareholders</u>** | **<u>Reconciliation to consolidated net income (loss) attributable to shareholders</u>** | **<u>Reconciliation to consolidated net income (loss) attributable to shareholders</u>** | **<u>Reconciliation to consolidated net income (loss) attributable to shareholders</u>** |  |  |  |  |  |
| Discontinued operations |  |  |  | **(163288)** |  |  |  | (497167) |
| Net income (loss) attributable to shareholders |  |  |  | $**(261692)** |  |  |  | $**(556449)** |
| **<u>Reconciliation of segment assets to consolidated total assets</u>** | **<u>Reconciliation of segment assets to consolidated total assets</u>** | **<u>Reconciliation of segment assets to consolidated total assets</u>** |  |  |  |  |  |  |
| Total assets | $**894692** | $**1243979** | $**84646** | $**2223317** | $**751272** | $**900222** | $**139684** | $**1791178** |
| Discontinued operations |  |  |  | $**—** |  |  |  | $**6267200** |
| Total consolidated assets |  |  |  | $**2223317** |  |  |  | $**8058378** |
| **EBITDA Reconciliation** |  |  |  |  |  |  |  |  |
| Segment net income (loss) | $**2956** | $**(15353)** | $**(83406)** | $**(95803)** | $**10469** | $**(6881)** | $**(62509)** | $**(58921)** |
| Adjustments: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Interest expense |  | **18640** |  | **18640** |  | 9379 |  | 9379 |
| &nbsp;&nbsp;Income taxes | **374** | **(5103)** | **(482)** | **(5211)** | 1753 | (928) | (1748) | (924) |
| &nbsp;&nbsp;Depreciation | **—** | **690** | **3218** | **3908** |  | 481 | 1864 | 2345 |
| &nbsp;&nbsp;Intangible amortization |  | **38044** |  | **38044** |  | 17602 |  | 17602 |
| **EBITDA** | **3330** | **36918** | **(80670)** | **(40422)** | **12222** | **19653** | **(62393)** | **(30518)** |
| Add: Impact of noncontrolling interests |  | **(14507)** |  | **(14507)** |  | (6448) |  | (6448) |
| **EBITDA attributable to shareholders** | $**3330** | $**22411** | $**(80670)** | $**(54929)** | $**12222** | $**13205** | $**(62393)** | $**(36966)** |

---

(1)Inter-segment revenues and inter-segment pre-tax income (loss) amounts are insignificant and are not presented separately.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **63** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** | **Year Ended December 31, 2023** |
| | **Reportable Segments** | **Reportable Segments** | | |
| | **Specialty Property & Casualty Insurance** | **Insurance Distribution** | **Corporate & Other** | **Total** |
| **Revenues:** | | | | |
| &nbsp;&nbsp;Commissions |  | $51281 |  | 51281 |
| &nbsp;&nbsp;Net premiums earned | $51911 |  |  | $51911 |
| &nbsp;&nbsp;Program fees | 8437 |  |  | 8437 |
| &nbsp;&nbsp;Investment income | 3795 | 64 | $9298 | 13159 |
| &nbsp;&nbsp;Other | (42) | 200 | (218) | (60) |
| **Total revenues from continuing operations** | **64101** | **51546** | **9080** | **124728** |
| **Less:** |  |  |  |  |
| &nbsp;&nbsp;Loss and loss adjustment expenses | 36712 |  |  | 36712 |
| &nbsp;&nbsp;Policy acquisition costs | 10557 |  |  | 10557 |
| &nbsp;&nbsp;Commissions |  | 29465 |  | 29465 |
| &nbsp;&nbsp;Intangible amortization and depreciation |  | 4194 | 1036 | 5230 |
| &nbsp;&nbsp;Interest expense |  |  |  |  |
| &nbsp;&nbsp;Compensation expense | 10853 | 7951 | 29664 | 48468 |
| &nbsp;&nbsp;Non Compensation expense | 5596 | 2647 | 10274 | 18517 |
| **Total expenses from Continuing Operations** <sup>(1)</sup> | **63718** | **44257** | **40974** | **148949** |
| **Segment pretax income (loss)** | **383** | **7289** | **(31894)** | **(24221)** |
| Segment income tax expense (benefit) | 48 | 156 | (1193) | (989) |
| Segment net income (loss) | 335 | 7133 | (30701) | (23232) |
| Segment net (income) loss attributable to NCI | (1) | (1318) |  | (1319) |
| **Net income (loss) attributable to shareholders** | $**334** | $**5815** | $**(30701)** | $**(24551)** |
| **Reconciliation to consolidated net income (loss) attributable to shareholders** | **Reconciliation to consolidated net income (loss) attributable to shareholders** | **Reconciliation to consolidated net income (loss) attributable to shareholders** | **Reconciliation to consolidated net income (loss) attributable to shareholders** |  |
| Discontinued operations |  |  |  | 28183 |
| **Net income (loss) attributable to shareholders** | **Net income (loss) attributable to shareholders** | **Net income (loss) attributable to shareholders** | **Net income (loss) attributable to shareholders** | $**3632** |
| **Reconciliation of segment assets to consolidated total assets** | **Reconciliation of segment assets to consolidated total assets** | **Reconciliation of segment assets to consolidated total assets** | **Reconciliation of segment assets to consolidated total assets** |  |
| **Total assets** | **523179** | **154846** | **233839** | $**911864** |
| **Discontinued operations** |  |  |  | **7516456** |
| **Total consolidated assets** |  |  |  | $**8428320** |
| Segment net income (loss) | $**335** | $**7133** | $**(30701)** | $**(23232)** |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;Interest expense |  |  |  | **—** |
| &nbsp;&nbsp;Income taxes | 48 | 156 | (1193) | **(989)** |
| &nbsp;&nbsp;Depreciation |  | 42 | 1036 | **1078** |
| &nbsp;&nbsp;Intangible amortization |  | 4152 |  | **4152** |
| **EBITDA** | **383** | **11483** | **(30858)** | **(18991)** |
| Add: Impact of noncontrolling interests |  | (2102) |  | (2102) |
| **EBITDA attributable to shareholders** | $**383** | $**9381** | $**(30858)** | $**(21093)** |

---

(1)Inter-segment revenues and inter-segment pre-tax income (loss) amounts are insignificant and are not presented separately.

**Geographic Information**

Revenue is primarily recognized based on the country in which the services are performed. The following table shows the geographic breakdown of revenue:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| United States | $**172321** | $212605 | $124728 |
| United Kingdom | **78901** | 23210 |  |
| **Total revenues** | $**251222** | $**235815** | $**124728** |

---

**4.&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS COMBINATION**

On October 31, 2025, Octave Specialty Group, (the "Company") completed its previously announced acquisition of ArmadaCorp Capital, LLC ("ArmadaCorp) pursuant to the Membership Interest Purchase Agreement dated October 31, 2025, for total consideration of approximately $250,000 in cash, financed in part with borrowings of $120,000 made concurrent with the acquisition (the "Transaction").

The acquisition was accounted for as a business combination using the acquisition method of accounting. The Company has finalized its fair value estimates of the acquired asset and assumed liabilities as of December 31, 2025 and no subsequent adjustments will be made within the permitted measurement period as defined by ASC 805.

The following table summarizes the consideration transferred for this acquisition and the estimated fair values of the identified assets acquired and liabilities assumed at the acquisition date:

---

| | |
|:---|:---|
| **Fair value of consideration transferred:** | **Fair value of consideration transferred:** |
| Cash | $**250000** |
| Less: incentive payments | **(6491)** |
| Net cash consideration | $**243509** |
| **Recognized amounts of assets acquired and liabilities assumed:** | **Recognized amounts of assets acquired and liabilities assumed:** |
| Cash and equivalents | $**27549** |
| Accounts receivable | **6246** |
| Other assets | **4092** |
| Intangible assets | **146000** |
| Goodwill | **94044** |
| Premium payable | **(16377)** |
| Other liabilities | **(18045)** |
| Total | $**243509** |

---

Incentive payments represent amounts netted against the purchase prince to fund short-term and long-term incentive compensation and retention payments to the management of ArmadaCare.

Goodwill was recorded to reflect the excess purchase consideration over net assets acquired and primarily consists of the future economic benefits that we expect to receive as a result of the acquisition, driven by the value of potential future distribution and carrier relationships and synergies with other Octave business operations. All of the $94,044 of goodwill was assigned to the ID segment. The goodwill is deductible for tax purposes over 15 years.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **64** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

The fair values assigned to tangible and identifiable intangible assets acquired and liabilities assumed were based on management's estimates and assumptions at the time of the acquisitions.

The following table sets forth the estimated fair values of identifiable intangible assets acquired and their estimated useful lives as of the date of acquisition:

---

| | | |
|:---|:---|:---|
| | **Fair Value** | **Useful Life in Years** |
| **<u>Armada</u>** | | |
| Customer relationships | $**138000** | **15.0** |
| Trade names | $**8000** | **15.0** |
| **Total** | $**146000** |  |

---

The customer relationships intangible represents existing relationships ArmadaCorp maintains with a variety of existing distributors and customers across its product. It excludes the value of potential future distribution relationships that may be developed, which is included in goodwill. The trade name intangible represents the rights to the Armada trade name which is well known in the marketplace in which ArmadaCorp operates.

The overall weighted average useful life of the identified amortizable intangible assets acquired is 7.9 years for ArmadaCorp.

The acquired business contributed revenues of $4,998 and net income of $378 to Octave for the period from November 1, 2025, to December 31, 2025. The following unaudited pro forma summary presents consolidated information of Octave as if the business combination had occurred on January 1, 2024.

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| **Pro forma (unaudited)** | **2025** | **2024** |
| Revenues | $**292022** | $274816 |
| Net (loss) from continuing operations | $**(50687)** | $(75809) |

---

Octave did not have any material, nonrecurring pro forma adjustments directly attributable to the business combination included in the reported pro forma revenue and net income.

These pro forma amounts have been calculated after applying Octave's accounting policies and adjusting the results of the acquired company to reflect amortization that would have been charged assuming the fair value adjustments to intangible assets had been applied from January 1, 2024 with the consequential tax effects.

In 2025 and 2024, Octave incurred $7,796 and $27,388 of acquisition-related costs. These expenses are included in general and administrative expense on Octave's consolidated statement of comprehensive income (loss) for the years ended December 31, 2025 and 2024. In the table above, these expenses are reflected in the pro forma net income for the years ended December 31, 2025 and 2024.

**5.&nbsp;&nbsp;&nbsp;&nbsp;DISCONTINUED OPERATIONS**

**Sale of Ambac Assurance Corporation ("AAC")**

On September 29, 2025, pursuant to the stock purchase agreement dated as of June 4, 2024, as amended by the First Amendment thereto dated as of July 3, 2025, (the "Purchase Agreement") and the Letter Agreements dated July 3, 2025, and September 22, 2025 with American Acorn Corporation (the "Buyer"), a Delaware corporation owned by funds managed by Oaktree Capital Management, L.P., OSG sold all of the issued and outstanding shares of common stock of AAC, a wholly-owned subsidiary of OSG, to the Buyer for $420,000 in cash (the "Sale"). The Buyer acquired complete ownership of the common stock of AAC and all of its wholly owned subsidiaries, including Ambac Assurance UK Limited. In connection with and pursuant to the Purchase Agreement, OSG issued to Buyer a warrant exercisable for 5,092,707 shares of common stock, par value $0.01, of OSG. The warrant has an exercise price per share of $18.50 and expires March 29, 2032. Under the terms of the Letter Agreement dated July 3, 2025 between the parties to the Purchase Agreement, the Buyer may convert the warrant at a value equal to its Black-Sholes value, over specified time periods, with the conversion value delivered in shares of OSG common stock or cash at OSG's election. In addition, the Buyer made an incremental payment to OSG totaling $4,300 to resolve other agreed upon matters.

OSG recorded an expected loss on sale in the Statement of Comprehensive Income (Loss) for the year ended December 31, 2024 of $(570,145), equal to the difference between the sale proceeds (net of the value of the warrants to be issued) and the carrying value of AAC's net assets held-for-sale, less expected closing costs. OSG recorded adjustments to the loss on sale of AAC equal to $(117,468) for the year ended December 31, 2025, reflecting remeasurement of net assets held-for-sale, changes in fair value of the warrant issued to Buyer, other agreed upon payments, and re-estimation of closing costs during the periods leading up to the final Sale closing. The loss on sale for the year ended December 31, 2025, included the reclassification of net unrealized gains (losses) on available-for-sale investment securities, cumulative foreign currency translation adjustments and cumulative credit risk changes of fair value option liabilities attributable to AAC and subsidiaries, totaling $(85,096), from Accumulated Other Comprehensive Income (Loss) ("AOCI") to Net income (loss) from discontinued operations at Sale closing.

The components of the loss on sale, reflected in the valuation allowance on net assets of discontinued operations as of

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **65** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

December 31, 2024 and at Sale closing on September 29, 2025, are summarized below:

---

| | | |
|:---|:---|:---|
| | **Sale Closing on September 29, 2025** | **December 31,<br>2024** |
| Fair value of net consideration to be received | $**407300** | $399727 |
| Less: estimated closing costs | **7098** | 7235 |
|  | **400202** | 392492 |
| Carrying amount of net assets held-for-sale | **1002719** | 962637 |
| Reclassification of AOCI | $**(85096)** |  |
| **Loss on disposal** | $**(687613)** | $**(570145)** |

---

The following table summarizes the major classes of assets and liabilities of discontinued operations on the Consolidated Balance Sheet at December 31, 2024 after elimination of intercompany balances:

---

| | |
|:---|:---|
| | **December 31,<br>2024** |
| **ASSETS:** | |
| &nbsp;&nbsp;Total investments | $**2226505** |
| &nbsp;&nbsp;Cash and equivalents | **8322** |
| &nbsp;&nbsp;Premiums receivable | **217096** |
| &nbsp;&nbsp;Reinsurance recoverable on paid and unpaid losses | **25274** |
| &nbsp;&nbsp;Deferred ceded premiums | **79074** |
| &nbsp;&nbsp;Subrogation recoverable | **113962** |
| &nbsp;&nbsp;Intangible assets | **213457** |
| &nbsp;&nbsp;Other assets, net | **49396** |
| &nbsp;&nbsp;VIE assets (including restricted cash of $57,754) | **3904259** |
| &nbsp;&nbsp;Valuation allowance on assets held-for-sale | **(570145)** |
| **Total assets held-for-sale** | $**6267200** |
| **LIABILITIES:** |  |
| &nbsp;&nbsp;Unearned premiums | $**228177** |
| &nbsp;&nbsp;Loss and loss adjustment reserves | **577167** |
| &nbsp;&nbsp;Ceded premiums payable | **56404** |
| &nbsp;&nbsp;Long-term debt and accrued interest | **1046658** |
| &nbsp;&nbsp;Other liabilities, net | **105772** |
| &nbsp;&nbsp;VIE liabilities | **3873507** |
| **Total liabilities held-for-sale** | $**5887685** |

---

The following table summarizes the major line items constituting net income (loss) from discontinued operations reconciled to net income (loss) from discontinued operations presented in the Consolidated Statement of Comprehensive Income (Loss):

---

| | | | |
|:---|:---|:---|:---|
| | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** |
| | **2025** | **2024** | **2023** |
| **REVENUES:** |  |  |  |
| &nbsp;&nbsp;Net premiums earned | $**15145** | $23879 | $26040 |
| &nbsp;&nbsp;Net investment income | **100203** | 133933 | 126957 |
| &nbsp;&nbsp;Net investment gains (losses), including impairments | **(12616)** | 4416 | (22507) |
| &nbsp;&nbsp;Net gains (losses) on derivative contracts | **302** | 3958 | (699) |
| &nbsp;&nbsp;Other revenues | **18016** | 31096 | 14533 |
| &nbsp;&nbsp;**Total revenues** | **121050** | 197282 | **144324** |
| **EXPENSES:** |  |  |  |
| &nbsp;&nbsp;Loss and loss adjustment expenses (benefit) | **10444** | (45767) | (69320) |
| &nbsp;&nbsp;Intangible amortization | **17097** | 30508 | 24736 |
| &nbsp;&nbsp;General & administrative and other expenses | **81034** | 57491 | 88306 |
| &nbsp;&nbsp;Interest expense | **47617** | 63587 | 64025 |
| &nbsp;&nbsp;**Total expenses** | **156192** | 105819 | **107747** |
| **Pretax income (loss)** | **(35142)** | 91463 | **36577** |
| Provision for income taxes | **10678** | 18485 | 8394 |
| Loss on disposal | **(117468)** | (570145) |  |
| **Net income (loss) from discontinued operations** | $**(163288)** | $(497167) | $**28183** |

---

**Significant Accounting Policies**

The held-for-sale assets and liabilities and results of operations were subject to certain additional significant accounting policies to those described in Note 2. *Basis of Presentation and Significant Accounting Policies*.

**<u>Fair value of assets held-for-sale:</u>**

Total assets held-for-sale are carried at fair value as of December 31, 2024. The Fair Value Measurement Topic of the ASC specifies a fair value hierarchy based on whether the inputs to valuation techniques used to measure fair value are observable or unobservable. Measurement of fair value of assets held-for-sale was based on information from the purchase agreement and other unobservable information and was considered by management to be a Level 3 valuation under the Fair Value Measurement Topic of the ASC.

**<u>Investments:</u>**

Equity interests in pooled investment funds which are accounted for in accordance with the Investments - Equity Securities Topic of the ASC include equity interests in the form of common stock or in-substance common stock which are classified as trading securities and reported at fair value with changes in fair value reported through income.

Investments in fixed maturity securities classified at trading are reported within Assets held-for-sale at fair value with unrealized gains and losses reported through income.

**<u>Consolidation of Variable Interest Entities:</u>**

The consolidated financial statements include the accounts of VIEs for which AAC or Ambac UK was deemed the primary beneficiary in accordance with the Consolidation Topic of the ASC. A VIE is an entity: (a) that lacks enough equity investment at risk to permit the entity to finance its activities

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **66** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

without additional subordinated financial support from other parties; or (b) where the group of equity holders does not have: (1) the power, through voting rights or similar rights, to direct the activities of an entity that most significantly impact the entity's economic performance; (2) the obligation to absorb the entity's expected losses; or (3) the right to receive the entity's expected residual returns. The determination of whether a variable interest holder was the primary beneficiary involved performing a qualitative analysis of the VIE that includes, among other factors, its capital structure, contractual terms including the rights of each variable interest holder, the activities of the VIE, whether the variable interest holder had the power to direct the activities of a VIE that most significantly impact the VIE's economic performance, whether the variable interest holder had the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, related party relationships and the design of the VIE. An entity that was deemed the primary beneficiary of a VIE was required to consolidate the VIE.

We determined that AAC or Ambac UK generally had the obligation to absorb a Legacy Financial Guarantee ("LFG") VIE's expected losses given that they had issued financial guarantees supporting certain liabilities (and in some cases certain assets). AAC consolidated certain LFG VIEs in cases where we also have the power to direct the activities that most significantly impact the VIE's economic performance. A VIE was generally deconsolidated in the period that AAC or Ambac UK no longer had such control rights.

The impact of consolidating such LFG VIEs on Octave's balance sheet was the elimination of transactions between the consolidated LFG VIEs and AAC or Ambac UK and the inclusion of the LFG VIE's third party assets and liabilities. For a financial guarantee insurance policy issued to a consolidated VIE, Octave did not reflect the financial guarantee insurance policy in accordance with the related insurance accounting rules under the Financial Services — Insurance Topic of the ASC. Consequently, upon consolidation, Octave eliminated the insurance assets and liabilities associated with the policy from the Consolidated Balance Sheets, including premium receivables, unearned premiums, loss and loss expense reserves, and insurance intangible assets. For investment securities owned by AAC or Ambac UK that were debt instruments issued by the VIE, the associated debt and investment balances were eliminated upon consolidation.

Generally, AAC had elected the fair value option for consolidated LFG VIE financial assets and financial liabilities, except in cases where AAC or Ambac UK was involved in the design of the VIE and was granted control rights at its inception or when the financial liabilities are primarily supported by non-financial assets. The election to use the fair value option was made on an instrument by instrument basis.

In cases where the fair value option had not been elected, the LFG VIE's invested assets were fixed maturity securities and were classified as either available-for-sale or trading as defined by the Investments - Debt Securities Topic of the ASC.

When the fair value option was elected for LFG VIE long-term debt, changes in the fair value of the long-term debt was reported in income on the Consolidated Statements of Total Comprehensive Income (Loss), except for the portion of the total change in fair value of financial liabilities caused by changes in the instrument-specific credit risk which was presented separately in Other comprehensive income (loss). In cases where the fair value option was not elected, the LFG VIEs' long-term debt was carried at par less unamortized discount, with interest expense reported in income on the Consolidated Statements of Total Comprehensive Income (Loss).

Consolidated VIE assets and liabilities were presented in VIE assets and VIE liabilities in the above table. Results of consolidated VIEs were included in other revenues above.

**<u>Financial Guarantee Insurance Intangible:</u>**

Upon Octave's emergence from bankruptcy in 2013, an insurance intangible asset was recorded which represented the difference between the fair value and aggregate carrying value of the financial guarantee insurance and reinsurance assets and liabilities. The carrying values of financial guarantee insurance and reinsurance contracts continue to be reported and measured in accordance with their existing accounting policies. Pursuant to the Financial Services-Insurance Topic of the ASC, the insurance intangible was to be measured on a basis consistent with the related financial guarantee insurance and reinsurance contracts. The initial insurance intangible asset was assigned to groups of insurance and reinsurance contracts with similar characteristics and has been amortized using a level-yield method based on par exposure of the related groups.

**<u>Legacy Financial Guarantee Loss and Loss Adjustment Expenses:</u>**

The loss and loss adjustment expense reserve ("loss reserve") policy related only to Octave's non-derivative financial guarantee insurance business for insurance policies issued to beneficiaries, including VIEs, for which we do not consolidate the VIE. Losses and loss expenses were based upon estimates of the ultimate aggregate losses inherent in the insured portfolio as of the reporting date.

A loss reserve was recorded on the balance sheet on a policy-by-policy basis based upon the present value ("PV") of expected net claim cash outflows or expected net recovery cash inflows, discounted at risk-free rates. The estimate for future net cash flows consider the likelihood of all possible outcomes that may occur from missed principal and/or interest payments on the insured obligation. This estimate also considered future recoveries related to remediation strategies and other contractual or subrogation-related cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;▪ Net claim cash *outflow* policies represented contracts where the PV of expected cash outflows are greater than the PV of expected recovery cash inflows. For such policies, a "loss and loss adjustment expense reserves" liability was recorded for the excess of the PV of expected net claim cash outflows over the unearned premium revenue.

&nbsp;&nbsp;&nbsp;&nbsp;▪ Net recovery cash *inflow* policies represented contracts where the PV of expected recovery cash inflows were

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **67** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

greater than the PV of expected claim cash outflows. For such policies, a "Subrogation recoverable" asset was recorded.

The evaluation process for determining expected losses was subject to certain judgments based on our assumptions regarding the probability of default by the issuer of the insured security, probability of settlement outcomes (which may include commutation settlements, refinancing and/or other settlement outcomes) and expected severity of credits for each insurance contract. Octave's loss reserves are based on management's ongoing review of the financial guarantee credit portfolio. Active surveillance of the insured portfolio enables Octave's Risk Management Group ("RMG") to track credit migration of insured obligations from period to period and update internal classifications and credit ratings for each transaction. Non-adversely classified credits are assigned a Class I rating while adversely classified credits are assigned a rating ranging from Class IA ("<u>Potential Problem with Risks to be Dimensioned")</u> through Class V (<u>"Fully Reserved")</u>. The criteria for an exposure to be assigned an adversely classified credit rating includes the deterioration of an issuer's financial condition, underperformance of the underlying collateral (for collateral dependent transactions such as mortgage-backed or student loan securitizations), poor performance by the servicer of the underlying collateral and other adverse economic events or trends. The servicer of the underlying collateral of an insured securitization transaction was a consideration in assessing credit quality because the servicer's performance can directly impact the performance of the related issue. All credits were assigned risk classifications by RMG using established guidelines.

The population of credits evaluated in Octave's loss reserve process were: (i) all adversely classified credits and (ii) non-adversely classified credits which had an internal Octave rating downgrade since the transaction's inception. One of two approaches is then utilized to estimate losses to ultimately determine if a loss reserve should be established.

&nbsp;&nbsp;&nbsp;&nbsp;▪ The first approach was a statistical expected loss approach, which considers the likelihood of all possible outcomes. The "base case" statistical expected loss was the product of: (i) the par outstanding on the credit; (ii) internally developed default information (taking into consideration internal ratings and average life of an obligation); (iii) internally developed loss severities; and (iv) a discount factor. The loss severities and default information were based on rating agency information, were specific to each bond type and were established and approved by senior RMG officers. For certain credit exposures, Octave's additional monitoring, loss remediation efforts and probabilities of potential settlement outcomes may provide information relevant to adjust this estimate of "base case" statistical expected losses. RMG may accept the "base case" statistical expected loss as the best estimate of expected loss or assign multiple probability weighted scenarios to determine an adjusted statistical expected loss that better reflects management's view of a given transaction's expected losses, as well as the potential for additional remediation activities (e.g., commutations).

&nbsp;&nbsp;&nbsp;&nbsp;▪ The second approach entails the use of cash-flow based models to estimate expected losses (future claims, net of potential recoveries, expected to be paid to the holder of the insured financial obligation). Octave's RMG group will consider the likelihood of all possible outcomes and develop appropriate cash flow scenarios. This approach can include the utilization of internal or third party models and tools to project future losses and resultant claim payment estimates. We utilize cash flow models for RMBS, student loans and other exposures. RMBS and student loan models use historical performance of the collateral pools in order to then derive future performance characteristics, such as default and voluntary prepayment rates, which in turn determine projected future claim payments. In other cases, such as many public finance exposures we do not specifically forecast resources available to pay debt service in the cash flow model itself. Rather, we consider the issuers' overall ability and willingness to pay, including the fiscal, economic, legal and political framework to develop projected future claim payment estimates. In this approach, a probability-weighted expected loss estimate was developed based on assigning probabilities to multiple claim payment scenarios and applying an appropriate discount factor. Additionally, we consider the issuer's ability to refinance an insured issue, Octave's ability to execute a potential settlement (i.e., commutation) of the insurance policy, including the impact on future installment premiums, and/or other restructuring possibilities in our scenarios. The commutation scenarios and the related probabilities of occurrence vary by transaction, depending on our view of the likelihood of negotiating such a transaction with issuers and/or investors.

The discount factor applied to the statistical expected loss approach was based on a risk-free discount rate corresponding to the remaining expected weighted-average life of the exposure and the exposure currency. For the cash flow scenario approach, discount factors were applied based on a risk-free discount rate term structure and correspond to the date of each respective cash flow payment or recovery and the exposure currency. Discount factors were updated for the current risk-free rate each reporting period.

Octave establishes loss expense reserves based on our estimate of expected net cash outflows for loss expenses, such as legal and consulting costs.

**Long-term Debt**

Long-term debt issued was carried at par value less unamortized discount. Accrued interest and discount accretion on long-term debt was reported through income on the Consolidated Statements of Total Comprehensive Income (Loss). To the extent Octave repurchases or redeems its long-term debt, such repurchases or redemptions may be settled for an amount different than the carrying value of the obligation. Any difference between the payment and carrying value of the obligation was reported in income on the Consolidated Statements of Total Comprehensive Income (Loss). For surplus note repurchases, the pro-rata purchase price related to principal

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **68** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

and accrued interest was reported as a financing and operating activity, respectively, on the Statement of Cash Flows.

On September 29, 2025, the Company completed the sale of AAC, and accordingly, the Company no longer had surplus notes outstanding as they are obligations of AAC.

Ambac UK debt, issued in connection with the commutation of an exposure on June 18, 2019, had a par value of $40,600 and a carrying value of $18,079 at December 31, 2024. The Ambac UK debt had a legal maturity of May 2, 2036. Interest on the Ambac UK debt was at an annual rate of 0.0%. The Ambac UK

debt was recorded at its fair value at the date of issuance with the discount amortizing at an effective interest rate of 7.4%.

**NOL & Investment Interest Carryforward**

As of December 31, 2024, AAC had (i) $1,952,621 of NOLs, which if not utilized will begin expiring in 2030, and will fully expire in 2045, and (ii) $110,494 of interest expense tax deduction carryover, which had an indefinite carryforward period but was limited in any particular year based on certain provisions. AAC had maintained a full valuation allowance since 2010.

**6.&nbsp;&nbsp;&nbsp;&nbsp;INVESTMENTS** 

Octave's invested assets are primarily comprised of (i) fixed maturity securities classified as either available-for-sale, (ii) investment in limited partnership which is reported within Other investments on the Consolidated Balance Sheets and (iii) preferred equity investments which are reported within Other investments on the Consolidated Balance Sheets. Interests in pooled investment funds are limited partner interests and are reported using the equity method.

**Fixed Maturity Securities**

The amortized cost and estimated fair value of available-for-sale investments, at December 31, 2025 and 2024 were as follows:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Amortized<br>Cost** | **Allowance for Credit Losses** | **Gross Unrealized** | **Gross Unrealized** | **Estimated<br>Fair Value** | **Amortized<br>Cost** | **Allowance for Credit Losses** | **Gross Unrealized** | **Gross Unrealized** | **Estimated<br>Fair Value** |
| | **Amortized<br>Cost** | **Allowance for Credit Losses** | **Gains** | **Losses** | **Estimated<br>Fair Value** | **Amortized<br>Cost** | **Allowance for Credit Losses** | **Gains** | **Losses** | **Estimated<br>Fair Value** |
| **Fixed maturity securities:** | | | | | | | | | | |
| Municipal obligations | $**11697** | $**—** | $**121** | $**228** | $**11590** | $14646 |  | 7 | 570 | 14083 |
| Corporate obligations | **67881** | **—** | **634** | **1942** | **66573** | 92990 |  | 107 | 3905 | 89192 |
| U.S. government obligations | **35190** | **—** | **365** | **131** | **35424** | 41706 |  | 98 | 809 | 40995 |
| Residential mortgage-backed securities | **1604** | **—** | **—** | **7** | **1597** | 2475 |  |  | 29 | 2446 |
| Commercial mortgage-backed securities | **3307** | **—** | **42** | **8** | **3341** | 2127 |  | 8 | 34 | 2101 |
| Collateralized debt obligations | **1963** | **—** | **12** | **—** | **1975** | 3131 |  | 13 | 2 | 3142 |
| Other asset-backed securities | **1772** | **—** | **23** | **—** | **1795** | 5049 |  | 14 | 2 | 5061 |
|  | **123414** | **—** | **1197** | **2316** | **122295** | 162124 |  | 247 | 5351 | 157020 |
| Short-term | **146434** | **—** | **8** | **—** | **146442** | 127588 |  | 13 |  | 127601 |
| **Total available-for-sale investments** | $**269848** | $**—** | $**1205** | $**2316** | $**268737** | $**289712** | $**—** | $**260** | $**5351** | $**284621** |

---

The amortized cost and estimated fair value of available-for-sale investments, at December 31, 2025, by contractual maturity, were as follows:

---

| | | |
|:---|:---|:---|
| | **Amortized<br>Cost** | **Estimated<br>Fair Value** |
| Due in one year or less | $**180013** | $**179824** |
| Due after one year through five years | **32409** | **31588** |
| Due after five years through ten years | **47801** | **47619** |
| Due after ten years | **979** | **998** |
|  | **261202** | **260029** |
| Residential mortgage-backed securities | **1604** | **1597** |
| Commercial mortgage-backed securities | **3307** | **3341** |
| Collateralized debt obligations | **1963** | **1975** |
| Other asset-backed securities | **1772** | **1795** |
| **Total** | $**269848** | $**268737** |

---

Expected maturities will differ from contractual maturities because borrowers may have the right to call or prepay certain obligations with or without call or prepayment penalties.

**Unrealized Losses on Fixed Maturity Securities**

The following table shows gross unrealized losses and fair values of Octave's available-for-sale investments, which at December 31, 2025, did not have an allowance for credit losses under the CECL standard. This information is aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, at December 31, 2025 and 2024:

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **69** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Less Than 12 Months** | **Less Than 12 Months** | **12 Months or More** | **12 Months or More** | **Total** | **Total** | **Less Than 12 Months** | **Less Than 12 Months** | **12 Months or More** | **12 Months or More** | **Total** | **Total** |
| | **Fair<br>Value** | **Gross<br>Unrealized<br>Loss** | **Fair Value** | **Gross<br>Unrealized<br>Loss** | **Fair Value** | **Gross<br>Unrealized<br>Loss** | **Fair<br>Value** | **Gross<br>Unrealized<br>Loss** | **Fair Value** | **Gross<br>Unrealized<br>Loss** | **Fair Value** | **Gross<br>Unrealized<br>Loss** |
| **Fixed maturity securities:** | | | | | | | | | | | | |
| &nbsp;&nbsp;Municipal obligations | $**535** | $**16** | $**5820** | $**212** | $**6355** | $**228** | 6042 | 112 | 6582 | 458 | $12624 | $570 |
| &nbsp;&nbsp;Corporate obligations | **1807** | **10** | **30751** | **1932** | **32558** | **1942** | 23784 | 269 | 46612 | 3636 | 70396 | 3905 |
| &nbsp;&nbsp;U.S. government obligations | **2206** | **14** | **9491** | **117** | **11697** | **131** | 15919 | 344 | 14818 | 465 | 30737 | 809 |
| &nbsp;&nbsp;Residential mortgage-backed securities | **—** | **—** | **1596** | **7** | **1596** | **7** | 2446 | 29 |  |  | 2446 | 29 |
| &nbsp;&nbsp;Commercial mortgage-backed securities | **763** | **8** | **—** | **—** | **763** | **8** | 738 | 34 |  |  | 738 | 34 |
| &nbsp;&nbsp;Collateralized debt obligations | **—** | **—** | **—** | **—** | **—** | **—** | 655 | 2 |  |  | 655 | 2 |
| &nbsp;&nbsp;Other asset-backed securities | **—** | **—** | **—** | **—** | **—** | **—** | 1428 | 2 |  |  | 1428 | 2 |
| Total temporarily impaired securities | **5311** | **48** | **47658** | **2268** | **52969** | **2316** | $51012 | $792 | $68012 | $4559 | $119024 | $5351 |

---

Management has determined that the securities in the above table do not have credit impairment as of December 31, 2025 and 2024 based upon (i) no actual or expected principal and interest payment defaults on these securities and (ii) analysis of the creditworthiness of the issuer.

Octave's assessment about whether a security is credit impaired reflects management's current judgment regarding facts and circumstances specific to the security and other factors. If that judgment changes, Octave may record a charge for credit impairment in future periods.

The declines in fair value and resultant unrealized losses across asset classes as of December 31, 2025 included in the above table resulted primarily from the impact of increasing interest rates since the securities were purchased. Management has determined that the securities with unrealized losses are not credit impaired. Further discussion of management's assessment with respect to security categories with larger unrealized loss balances is below.

***Corporate obligations***

The gross unrealized losses on corporate obligations as of December 31, 2025, resulted primarily from an increase in interest rates since the securities were purchased. Management believes that the full and timely receipt of all principal and interest payment on corporate obligations with unrealized losses as of December 31, 2025, is probable.

**Investment Income (Loss)**

Net investment income (loss) was comprised of the following for the affected periods:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| &nbsp;&nbsp;Fixed maturity securities | $**5175** | $4895 | $3696 |
| &nbsp;&nbsp;Short-term investments | **6014** | 10033 | 9287 |
| &nbsp;&nbsp;Investment expense | **(273)** | (365) | (296) |
| Securities available-for-sale and short-term | **10916** | 14563 | 12687 |
| &nbsp;&nbsp;Other investments | **(269)** | (115) | 472 |
| **Total net investment income (loss)** | $**10647** | $**14448** | $**13159** |

---

Net investment income (loss) from Other investments primarily represents changes in fair value on equity securities including

income from investment limited partnership and other equity interests accounted for under the equity method.

**Net Investments Gains (Losses), including Impairments**

The following table details amounts included in net investment gains (losses) and impairments included in earnings for the affected periods and are included in Revenues, other on the Statements of Total Comprehensive Income (Loss):

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Gross realized gains on securities | $**526** | $6068 | $57 |
| Gross realized losses on securities | **(3)** | (47) | (38) |
| Credit impairments | (3100) | (6517) |  |
| **Net investment gains (losses), including impairments** | $**(2577)** | $**(496)** | $**19** |

---

Octave had an allowance for credit losses $0 and $0 at December 31, 2025 and 2024, respectively.

Octave did not purchase any financial assets with credit deterioration for the years ended December 31, 2025 and 2024.

**Deposits with Regulators and Other Restrictions**

Securities carried at $34,016 and $22,861 at December 31, 2025 and 2024, respectively, were deposited by Octave's insurance subsidiaries with governmental authorities or designated custodian banks as required by laws affecting insurance companies. Investments in fixed maturity securities of OSG carried at $153 as of December 31, 2025, were deposited as security in connection with a letter of credit issued for a corporate office lease. Fiduciary funds held by Octave's insurance distribution subsidiaries, carried at $2,656 and $2,845 at December 31, 2025 and 2024, respectively, are included in invested assets.

**Other Investments**

Octave's investment portfolio includes a limited partnership interest in a private equity fund which seeks to generate long-term capital appreciation through investments in private equity, equity-related and other instruments. The fair value of Octave's investment in the fund was $7,454 and $7,499 as of December 31, 2025 and 2024, determined using net asset value ("NAV") as a practical expedient. Redemptions may be made quarterly with 90 days notice subject to withdrawal limitations

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **70** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

and/or redemption fees which vary with the timing and notification of withdrawal provided by the investor. Octave's unfunded commitments total $1,501 on this private equity fund at December 31, 2025.

Other investments also include preferred equity investments with a carrying value of $17,517 and $20,618 as of December 31, 2025 and 2024, respectively, that do not have readily determinable fair values and are carried at cost, less any impairments as permitted under the Investments — Equity Securities Topic of the ASC. There were $(3,100), $(6,517), and $0 impairments recorded on these investments in the years ended December 31, 2025, 2024 and 2023, respectively.

**7.&nbsp;&nbsp;&nbsp;&nbsp;FAIR VALUE MEASUREMENTS** 

The Fair Value Measurement Topic of the ASC establishes a framework for measuring fair value and disclosures about fair value measurements.

**Fair Value Hierarchy**

The Fair Value Measurement Topic of the ASC specifies a fair value hierarchy based on whether the inputs to valuation techniques used to measure fair value are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect Company-based assumptions. The fair value hierarchy has three broad levels as follows:

---

| | | |
|:---|:---|:---|
| ● | Level 1 | Quoted prices for identical instruments in active markets. Assets and liabilities classified as Level 1 include US Treasury and other foreign government obligations traded in highly liquid and transparent markets, and money market funds. |
| ● | Level 2 | Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets. Assets and liabilities classified as Level 2 generally include investments in fixed maturity securities and certain derivatives valued using only market observable data. |
| ● | Level 3 | Model derived valuations in which one or more significant inputs or significant value drivers are unobservable. This hierarchy requires the use of observable market data when available. Financial instruments classified as Level 3 include certain investments in fixed maturity securities, loans and derivatives. |

---

The Fair Value Measurement Topic of the ASC permits, as a practical expedient, the estimation of fair value of certain investments in funds using the net asset value per share of the investment or its equivalent ("NAV"). Investments in funds valued using NAV are not categorized as Level 1, 2 or 3 under the fair value hierarchy. The Investments — Equity Securities Topic of the ASC permits the measurement of certain equity securities without a readily determinable fair value at cost, less impairment, and adjusted to fair value when observable price changes in identical or similar investments from the same issuer occur (the "measurement alternative"). The fair values of investments measured under this measurement alternative are not included in the below disclosures of fair value of financial instruments.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **71** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

The following table sets forth the carrying amount and fair value of Octave's financial assets and liabilities as of December 31, 2025 and 2024, including the level within the fair value hierarchy at which fair value measurements are categorized. As required by the Fair Value Measurement Topic of the ASC, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2024:** | **December 31, 2024:** | **December 31, 2024:** | **December 31, 2024:** | **December 31, 2024:** |
| | **Carrying<br>Amount** | **Total Fair<br>Value** | **Fair Value Measurements Categorized as:** | **Fair Value Measurements Categorized as:** | **Fair Value Measurements Categorized as:** | **Carrying<br>Amount** | **Total Fair<br>Value** | **Fair Value Measurements Categorized as:** | **Fair Value Measurements Categorized as:** | **Fair Value Measurements Categorized as:** |
| | **Carrying<br>Amount** | **Total Fair<br>Value** | **Level 1** | **Level 2** | **Level 3** | **Carrying<br>Amount** | **Total Fair<br>Value** | **Level 1** | **Level 2** | **Level 3** |
| ***Financial assets:*** | | | | | | | | | | |
| **Fixed maturity securities:** | | | | | | | | | | |
| &nbsp;&nbsp;Municipal obligations | $**11590** | $**11590** | $**—** | $**11590** | $**—** | $14083 | $14083 | $— | $14083 | $— |
| &nbsp;&nbsp;Corporate obligations | **66573** | **66573** | **—** | **66573** | **—** | 89192 | 89192 |  | 89192 |  |
| &nbsp;&nbsp;U.S. government obligations | **35424** | **35424** | **35424** | **—** | **—** | 40995 | 40995 | 40995 |  |  |
| &nbsp;&nbsp;Residential mortgage-backed securities | **1597** | **1597** | **—** | **1597** | **—** | 2446 | 2446 |  | 2446 |  |
| &nbsp;&nbsp;Commercial mortgage-backed securities | **3341** | **3341** | **—** | **3341** | **—** | 2101 | 2101 |  | 2101 |  |
| &nbsp;&nbsp;Collateralized debt obligations | **1975** | **1975** | **—** | **1975** | **—** | 3142 | 3142 |  | 3142 |  |
| &nbsp;&nbsp;Other asset-backed securities | **1795** | **1795** | **—** | **1795** | **—** | 5061 | 5061 |  | 5061 |  |
| **Fixed maturity securities, pledged as collateral:** |  |  |  |  |  |  |  |  |  |  |
| **Short term investments** | **146442** | **146442** | **146442** | **—** | **—** | 127601 | 127601 | 127601 |  |  |
| **Other investments** <sup>(1)</sup> | **24971** | **7454** | **—** | **—** | **—** | 28294 | 7499 |  |  |  |
| **Cash, cash equivalents and restricted cash** | **68440** | **68440** | **68440** | **—** | **—** | 47275 | 47275 | 47275 |  |  |
| **Other assets-Loans** | **—** | **—** | **—** | **—** | **—** | 3434 | 3434 |  |  | 3434 |
| **Total financial assets** | $**362148** | $**344631** | $**250306** | $**86871** | $**—** | $**363624** | $**342829** | $**215871** | $**116025** | $**3434** |
| ***Financial liabilities:*** |  |  |  |  |  |  |  |  |  |  |
| **Short-term debt, including accrued interest** | $**—** | $**—** | $**—** | $**—** | $**—** | $152560 | $152560 | $— | $— | $152560 |
| **Long term debt, including accrued interest** | **118901** | **121343** | **—** | **—** | **121343** |  |  |  |  |  |
| **Derivative liabilities:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;FX forward contracts | **8** | **8** | **—** | **8** | **—** | 317 | 317 |  | 317 |  |
| **Total financial liabilities** | $**118909** | $**121351** | $**—** | $**8** | $**121343** | $**152877** | $**152877** | $**—** | $**317** | $**152560** |

---

(1)Excluded from the fair value measurement categories in the table above are investment funds of $7,454 and $7,499 as of December 31, 2025 and 2024, respectively, which are measured using NAV as a practical expedient. Also excluded from the fair value measurements in the table above are equity securities with a carrying value of $17,517 and $20,618 as of December 31, 2025 and 2024, respectively, that do not have readily determinable fair values and have carrying amounts determined using the measurement alternative.

**Determination of Fair Value**

When available, Octave uses quoted active market prices specific to the financial instrument to determine fair value and classifies such items within Level 1. The determination of fair value for financial instruments categorized in Level 2 or 3 involves judgment due to the complexity of factors contributing to the valuation. Third-party sources from which we obtain independent market quotes also use assumptions, judgments and estimates in determining financial instrument values and different third parties may use different methodologies or provide different values for financial instruments. In addition, the use of internal valuation models may require assumptions about hypothetical or inactive markets. As a result of these factors, the actual trade value of a financial instrument in the market, or exit value of a financial instrument position by Octave, may be significantly different from its recorded fair value.

Octave's financial instruments carried at fair value are mainly comprised of investments in fixed maturity securities, equity interests in pooled investment funds, and derivative instruments. Valuation of financial instruments is performed by Octave's finance group using methods approved by senior financial management with consultation from risk management and third-party portfolio managers as appropriate. Preliminary valuation results are discussed internally and with third-party portfolio managers as necessary quarterly to assess consistency with

market transactions and trends as applicable. Market transactions such as trades or negotiated settlements of similar positions, if any, are reviewed to validate fair value model results. However, financial instruments valued using significant unobservable inputs have very little or no observable market activity. Methods and significant inputs and assumptions used to determine fair values across portfolios are reviewed quarterly by senior financial management. Other valuation control procedures specific to particular portfolios are described further below.

**<u>Fixed Maturity Securities</u>**

The fair values of fixed maturity investment securities are based primarily on market prices received from independent pricing sources. Because many fixed maturity securities do not trade on a daily basis, pricing sources apply available market information through processes such as matrix pricing to calculate fair value. Such prices generally consider a variety of factors, including recent trades of the same and similar securities. In those cases, the items are classified within Level 2. For those fixed maturity investments where quotes were not available or cannot be reasonably corroborated, fair values are based on internal valuation models. Key inputs to the internal valuation models generally include maturity date, coupon and yield curves for asset-type and credit rating characteristics that closely match those characteristics of the specific investment securities being valued. Items valued using valuation models are classified

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **72** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

according to the lowest level input or value driver that is significant to the valuation. Thus, an item may be classified in Level 3 even though there may be significant inputs that are readily observable. Longer (shorter) expected maturities or higher (lower) yields used in the valuation model will, in isolation, result in decreases (increases) in fair value. Generally, lower credit ratings or longer expected maturities will be accompanied by higher yields used to value a security.

Octave performs various review and validation procedures to quoted and modeled prices for fixed maturity securities, including price variance analyses, missing and static price reviews, overall valuation analysis by portfolio managers and finance managers and reviews associated with our ongoing impairment analysis. Unusual prices identified through these procedures will be evaluated further against alternative third-party quotes (if available), internally modeled prices and/or other relevant data, and the pricing source values will be challenged as necessary. Price challenges generally result in the use of the pricing source's quote as originally provided or as revised by the source following their internal diligence process. A price challenge may result in a determination by either the pricing source or Octave management that the pricing source cannot provide a reasonable value for a security or cannot adequately support a quote, in which case Octave would resort to using either other quotes or internal models. Results of price challenges are reviewed by portfolio managers and finance managers.

**<u>Other Investments</u>**

Other investments includes investments in pooled investment funds carried under the equity method valued using NAV as a practical expedient as permitted under the Fair Value Measurement Topic of the ASC. Refer to *Note 6. Investments* for additional information about such investments in pooled funds that are reported at fair value using NAV as a practical expedient.

**<u>Derivative Instruments</u>**

As of December 31, 2025, Octave has foreign currency forward contracts and holds warrants to purchase preferred stock of a development stage company. The fair value of foreign currency forwards are determined using valuation models with observable market inputs. Fair value of the warrants are determined using a standard warrant valuation model with internally developed input assumptions.

**<u>Debt</u>**

Both the long-term and short-term debt as of December 31, 2025 and 2024 consists of SOFR indexed borrowing under credit facilities and are classified as Level 3.

**<u>Other Financial Assets</u>**

Included in Other assets are loans carried at amortized cost, the fair values of which are estimated based upon internal valuation models and are classified as Level 3.

**Additional Fair Value Information for Financial Assets and Liabilities Accounted for at Fair Value**

The following tables present the changes in the Level 3 fair value category for the periods presented in 2025, 2024 and 2023. Octave classifies financial instruments in Level 3 of the fair value hierarchy when there is reliance on at least one significant unobservable input to the valuation model. In addition to these unobservable inputs, the valuation models for Level 3 financial instruments typically also rely on a number of inputs that are readily observable either directly or indirectly. Thus, the gains and losses presented below include changes in the fair value related to both observable and unobservable inputs.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Level-3 Financial Assets and Liabilities Accounted for at Fair Value** | **Level-3 Financial Assets and Liabilities Accounted for at Fair Value** | **Level-3 Financial Assets and Liabilities Accounted for at Fair Value** | **Level-3 Financial Assets and Liabilities Accounted for at Fair Value** | **Level-3 Financial Assets and Liabilities Accounted for at Fair Value** | **Level-3 Financial Assets and Liabilities Accounted for at Fair Value** | | | | |
| **Year Ended** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2023** | **December 31, 2023** | **December 31, 2023** |
| | **Investments** | **Derivatives** | **Total** | **Investments** | **Derivatives** | **Total** | **Investments** | **Derivatives** | **Total** |
| ***Balance, beginning of period*** | $**—** | $**—** | $**—** | $**13920** | $**656** | $**14576** | $**12341** | $**935** | $**13276** |
| Total gains/(losses) realized and unrealized: |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Included in earnings | **—** | **—** | **—** | 6016 | (656) | 5360 |  | (279) | (279) |
| &nbsp;&nbsp;Included in other comprehensive income | **—** | **—** | **—** | 125 |  | 125 | 784 |  | 784 |
| Purchases | **—** | **—** | **—** |  |  |  | 795 |  | 795 |
| Issuances | **—** | **—** | **—** |  |  |  |  |  |  |
| Sales | **—** | **—** | **—** |  |  |  |  |  |  |
| Settlements | **—** | **—** | **—** | (20061) |  | (20061) |  |  |  |
| ***Balance, end of period*** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**13920** | $**656** | $**14576** |
| *The amount of total gains/(losses) included in earnings attributable to the change in unrealized gains or losses relating to assets and liabilities still held at the reporting date* | $**—** | $**—** | $**—** | $— | $(656) | $(656) | $— | $(279) | $(279) |
| *The amount of total gains/(losses) included in other comprehensive income attributable to the change in unrealized gains or losses relating to assets and liabilities still held at the reporting date* | $**—** | $**—** | $**—** | $— | $— | $— | $784 | $— | $784 |

---

Invested assets are transferred into Level 3 when internal valuation models that include significant unobservable inputs are used to estimate fair value. All such securities that have internally modeled fair values have been classified as Level 3. Derivative instruments are transferred into Level 3 when the use of unobservable inputs becomes significant to the overall valuation. There were no transfers of financial instruments into or out of Level 3 in the periods disclosed.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **73** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

Gains and losses (realized and unrealized) relating to Level 3 assets and liabilities included in earnings for the affected periods are reported as follows:

---

| | | |
|:---|:---|:---|
| | **Net<br>Investment<br>Income** | **Net Gains<br>(Losses) on<br>Derivative Contracts** |
| **<u>Year Ended December 31, 2025</u>** | | |
| Total gains (losses) included in earnings for the period | $**—** | $**—** |
| Changes in unrealized gains (losses) relating to financial instruments still held at the reporting date | **—** | **—** |
| **<u>Year Ended December 31, 2024</u>** |  |  |
| Total gains (losses) included in earnings for the period | $6016 | $(656) |
| Changes in unrealized gains (losses) relating to financial instruments still held at the reporting date |  | (656) |
| **<u>Year Ended December 31, 2023</u>** |  |  |
| Total gains (losses) included in earnings for the period | $— | $(278) |
| Changes in unrealized gains (losses) relating to financial instruments still held at the reporting date |  | (278) |

---

**8.&nbsp;&nbsp;&nbsp;&nbsp;INSURANCE CONTRACTS**

**Premiums**

The effect of reinsurance on premiums written and earned was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Year Ended<br>December 31,** | **Direct** | **Assumed** | **Ceded** | **Net<br>Premiums** |
| **2025:** | | | | |
| &nbsp;&nbsp;Written | $**329089** | $**31360** | $**286551** | $**73898** |
| &nbsp;&nbsp;Earned | **325493** | **30225** | **288486** | **67232** |
| **2024:** |  |  |  |  |
| &nbsp;&nbsp;Written | $334311 | $48459 | $294088 | $88682 |
| &nbsp;&nbsp;Earned | 298121 | 57081 | 256197 | 99005 |
| **2023:** |  |  |  |  |
| &nbsp;&nbsp;Written | $233702 | $39585 | $193462 | $79825 |
| &nbsp;&nbsp;Earned | 185470 | 18354 | 151913 | 51911 |

---

**<u>Premium Receivables, including Credit Impairments</u>**

Premium receivables at December 31, 2025 and 2024, were $75,085 and $57,222, respectively. Management evaluates premium receivables for expected credit losses ("credit impairment") in accordance with the CECL standard, which is further described in *Note 2. Basis of Presentation and Significant Accounting Policies*.

Below is a rollforward of the premium receivable allowance for credit losses as of December 31, 2025 and 2024:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Beginning balance** | $**142** | $69 | $— |
| Current period provision | **358** | 73 | 69 |
| Write-offs of the allowance | **—** |  |  |
| Recoveries of previously written-off amounts | **—** |  |  |
| **Ending balance** | $**500** | $**142** | $**69** |

---

At December 31, 2025 and 2024, $6,781 and $5,690 of premiums, respectively, were past due.

**Loss and Loss Adjustment Expense Reserves**

Below is the loss and loss reserve expense roll-forward, recoverable and reinsurance, for the affected periods.

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Beginning gross loss and loss adjustment expense reserves** | $**349062** | $197089 | $89907 |
| &nbsp;&nbsp;Reinsurance recoverable | **270081** | 156301 | 80155 |
| Beginning balance of net loss and loss adjustment expense reserves | **78981** | 40788 | 9752 |
| **Losses and loss expenses incurred:** |  |  |  |
| &nbsp;&nbsp;Current year | **42242** | 67937 | 36569 |
| &nbsp;&nbsp;&nbsp;Prior years | **4951** | 4689 | 143 |
| &nbsp;&nbsp;Total <sup>(1)</sup> | **47193** | 72626 | 36712 |
| **Loss and loss adjustment expenses (recovered) paid:** |  |  |  |
| &nbsp;&nbsp;Current year | **9939** | 16202 | 3798 |
| &nbsp;&nbsp;&nbsp;Prior years | **31967** | 18231 | 1878 |
| &nbsp;&nbsp;**Total** | **41906** | **34433** | **5676** |
| Ending net loss and loss adjustment expense reserves | **84268** | 78981 | 40788 |
| Reinsurance recoverable <sup>(2)</sup> | **375722** | 270081 | 156301 |
| **Ending gross loss and loss adjustment expense reserves** | $**459990** | $**349062** | $**197089** |

---

(1)Total losses and loss expenses (benefit) is net of $(214,987), $(191,151) and $(113,622) for the years ended December 31, 2025, 2024 and 2023, respectively, related to ceded reinsurance.

(2)Represents reinsurance recoverable on future loss and loss adjustment expenses. Additionally, the Balance Sheet line "Reinsurance recoverable on paid and unpaid losses" includes reinsurance recoverables of $60,470, $36,210 and $8,765 as of December 31, 2025, 2024 and 2023, respectively, related to previously paid loss and loss adjustment expenses.

Prior accident years losses incurred development for the year ended December 31, 2025, was primarily driven by commercial auto loss experience, primarily related to programs currently in runoff, and excess liability claims activity. Commercial auto prior accident year loss experience primarily relates to 2022 and 2023 accident years, whereas excess liability loss experience primarily relates to claims activity in the 2024 accident year.

Prior accident years losses incurred development for the year end December 31, 2024, was primarily driven by commercial auto loss experience and a higher selected loss ratio for programs in runoff. In the fourth quarter of 2024 management decided to set loss reserves for programs that were in runoff at

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **74** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

the high end of the actuarial loss range, given these program can experience greater loss volatility than active programs.

**Specialty Property & Casualty Loss Reserves**

**<u>Claims Development</u>**

The following is a summary of loss and loss adjustment expense reserves, including certain components, for the Company's major product lines by reporting segment at December 31, 2025 and 2024.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
| | **Net Claims and Claim Adjustment Expense Reserves** | **Reinsurance Recoverables on Unpaid Losses** | **Loss and Loss Adjustment Reserves** | **Net Claims and Claim Adjustment Expense Reserves** | **Reinsurance Recoverables on Unpaid Losses** | **Loss and Loss Adjustment Reserves** |
| Commercial auto | $**23062** | $**136132** | $**159194** | $28720 | $129752 | $158472 |
| Excess liability | **16897** | **99713** | **116610** | 6571 | 43677 | 50248 |
| General liability | **12572** | **51024** | **63596** | 8286 | 26925 | 35211 |
| Workers compensation | **17798** | **—** | **17798** | 14465 |  | 14465 |
| Non-standard personal auto | **3635** | **191** | **3826** | 12185 | 504 | 12689 |
| Professional liability | **2851** | **37996** | **40846** | 1807 | 15891 | 17698 |
| Multi-peril / business owners (BOP) | **1519** | **4666** | **6185** | 43 | 230 | 273 |
| Surety | **94** | **12140** | **12233** | 6 | 11211 | 11217 |
| Unallocated loss adjustment expense reserves | **5552** | **9317** | **14869** | 6578 | 5660 | 12238 |
| Other <sup>(1)</sup> | **289** | **24544** | **24834** | 320 | 36231 | 36551 |
| **Total** | $**84268** | $**375722** | $**459991** | $**78981** | $**270081** | $**349062** |

---

(1)Other includes $23,530 and $35,146 at December 31, 2025 and 2024, respectively, related to legacy liabilities obtained from the acquisitions of Providence Washington Insurance Company, Greenwood Insurance Company, and Consolidated Specialty Insurance Company. All legacy liabilities remain obligations of affiliates of the sellers through reinsurance and contractual indemnities.

The claim development tables that follow present, by accident year, incurred and cumulative paid claims and allocated claim adjustment expense on a historical basis. This claim development information is presented on an undiscounted, net of reinsurance basis since 2021, Everspan's entry into the Specialty P&C business. The claim development tables also provide the historical average annual percentage payout of incurred claims by age, net of reinsurance, as supplementary information (identified as unaudited in the tables below). The historical average annual percentage payout for incurred claims is subject to variability due to the impact of both large claim activity and subrogation recoveries, among other items.

***Commercial Auto***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  |  |  |
| 2021 | $432 | $468 | $978 | $962 | $**1212** | $**88** | **82** |
| 2022 |  | 8225 | 7866 | 9099 | **9832** | **1292** | **1162** |
| 2023 |  |  | 19459 | 23309 | **25345** | **4279** | **3282** |
| 2024 |  |  |  | 15217 | **14851** | **4027** | **3243** |
| 2025 |  |  |  |  | **4783** | **2972** | **1564** |
|  |  |  |  | Total | $**56024** |  |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **75** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **2021 -** | **Before** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  | **2025** | **2021** |
| 2021 | $7 | $45 | $150 | $681 | $**1013** |  |  |
| 2022 |  | 555 | 2325 | 4701 | **6450** |  |  |
| 2023 |  |  | 3914 | 10984 | **17056** |  |  |
| 2024 |  |  |  | 3554 | **7885** |  |  |
| 2025 |  |  |  |  | **557** |  |  |
|  |  |  |  | Total | $**32962** | $23062 | $— |
|  |  |  |  |  |  | Total net liability | $23062 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** |
| | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |
| **Years** | **1** | **2** | **3** | **4** | **5** |
|  | **11.4%** | **19.6%** | **19.0%** | **30.8%** | **27.4%** |

---

***Excess Liability***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  |  |  |
| 2021 | $3 | $3 | $13 | $**15** | $**16** | **2** | **2** |
| 2022 |  | 146 | 129 | **161** | **149** | **58** | **4** |
| 2023 |  |  | 1579 | **1573** | **1344** | **1162** | **76** |
| 2024 |  |  |  | $**5285** | **7373** | **4106** | **95** |
| 2025 |  |  |  |  | **10519** | **10098** | **41** |
|  |  |  |  | Total | $**19400** |  |  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **2021 -** | **Before** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  | **2025** | **2021** |
| 2021 | $— | $— | $— | $— | $**—** |  |  |
| 2022 |  |  | 1 | 104 | **104** |  |  |
| 2023 |  |  | 6 | 258 | **158** |  |  |
| 2024 |  |  |  | 101 | **2079** |  |  |
| 2025 |  |  |  |  | **162** |  |  |
|  |  |  |  | Total | $**2503** | $16897 | $— |
|  |  |  |  |  |  | Total net liability | $16897 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** |
| | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |
| **Years** | **1** | **2** | **3** | **4** | **5** |
|  | **0.7%** | **11.6%** | **20.6%** | **— %** | **— %** |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **76** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

***General Liability***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  |  |  |
| 2021 | $— | $— | $— | $— | $**—** | **—** | **—** |
| 2022 |  | 223 | 217 | 425 | **374** | **109** | **4** |
| 2023 |  |  | 2019 | 1328 | **1784** | **886** | **26** |
| 2024 |  |  |  | $6915 | **6955** | **5205** | **194** |
| 2025 |  |  |  |  | **5311** | **3996** | **45** |
|  |  |  |  | Total | $**14423** |  |  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **2021 -** | **Before** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  | **2025** | **2021** |
| 2021 | $— | $— | $— | $— | $**—** |  |  |
| 2022 |  |  | 1 | 265 | **266** |  |  |
| 2023 |  |  | 24 | 57 | **791** |  |  |
| 2024 |  |  |  | 60 | **780** |  |  |
| 2025 |  |  |  |  | **15** |  |  |
|  |  |  |  | Total | $**1852** | $12572 | $— |
|  |  |  |  |  |  | Total net liability | $12572 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** |
| | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |
| **Years** | **1** | **2** | **3** | **4** | **5** |
|  | **0.6%** | **4.2%** | **55.9%** | **0.3%** | **— %** |

---

***Workers Compensation***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  |  |  |
| 2021 | $— | $— | $— | $**—** | $**—** | $**—** | **—** |
| 2022 |  |  |  | **—** | **—** | **—** | **—** |
| 2023 |  |  | 6053 | 6056 | **7362** | **2675** | **2384** |
| 2024 |  |  |  | 16486 | **15146** | **5150** | **4889** |
| 2025 |  |  |  |  | $**16752** | **404** | **4252** |
|  |  |  |  | Total | $**39260** |  |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **77** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** | **Cumulative Paid Claims and Allocated Claim Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Year ended December 31,** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **2021 -** | **Before** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  | **2025** | **2021** |
| 2021 | $— | $— | $— | $— | $**—** |  |  |
| 2022 |  |  |  |  | **—** |  |  |
| 2023 |  |  | 807 | 3938 | **6230** |  |  |
| 2024 |  |  |  | 4139 | **10692** |  |  |
| 2025 |  |  |  |  | **4541** |  |  |
|  |  |  |  | Total | $**21463** | $17798 | $— |
|  |  |  |  |  |  | Total net liability | $17798 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** |
| | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |
| **Years** | **1** | **2** | **3** | **4** | **5** |
|  | **21.8%** | **42.9%** | **31.1%** | **— %** | **— %** |

---

***Other*** <sup>(1)</sup>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** | **Incurred Claims and Allocated LAE, Net of Reinsurance** |
| **Accident Year** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **IBNR Reserves at December 31, 2025** | **Cumulative Number of Reported Claims** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  |  |  |
| 2021 | $— | $— | $— | $— | $**—** | $**—** | **—** |
| 2022 |  | 1 | 1 | 3 | **1** | **1** | **788** |
| 2023 |  |  | 6142 | 5907 | **5884** | **2441** | **18743** |
| 2024 |  |  |  | 23475 | **24292** | **1513** | **57524** |
| 2025 |  |  |  |  | **3652** | **1595** | **2307** |
|  |  |  |  | Total | $**33829** |  |  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** | **Cumulative Paid Claims and Allocated LAE, Net of Reinsurance** |
| **Accident Year** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** | **Liability for Loss and Loss Adjustment Expenses, Net of Reinsurance** |
| **Accident Year** | **2021** | **2022** | **2023** | **2024** | **2025** | **2021 -** | **Before** |
|  | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |  | **2025** | **2021** |
| 2021 | $— | $— | $— | $— | $**—** |  |  |
| 2022 |  |  |  |  | **—** |  |  |
| 2023 |  |  | 966 | 4342 | **5522** |  |  |
| 2024 |  |  |  | 10802 | **19489** |  |  |
| 2025 |  |  |  |  | **430** |  |  |
|  |  |  |  | Total | $**25441** | $8388 | $— |
|  |  |  |  |  |  | Total net liability | $8388 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** | **Average Annual Percentage Payout of Incurred Claims by Age, <br>Net of Reinsurance** |
| | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** | **Unaudited** |
| **Years** | **1** | **2** | **3** | **4** | **5** |
|  | **18.2%** | **31.1%** | **10.1%** | **— %** | **— %** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<sup>(1)</sup> Other includes non-standard personal auto, professional liability, business owners products, travel and surety

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **78** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**<u>Methodology for Determining Cumulative Number of Reported Claims</u>**

A claim file is created when the Company or the third party claims administrator is notified of an actual demand for payment, notified of an event that may lead to a demand for payment or when it is determined that a demand for payment could possibly lead to a future demand for payment on another coverage on the same policy or on another policy. Claim files are generally created at the claimant by coverage type, depending on the particular facts and circumstances of the underlying event.

For purposes of the claims development tables above, claims reported for direct business are counted even if they eventually close with no loss payment. Note that claims with zero claim dollars may still generate some level of claim adjustment expenses. Claim counts for assumed business are included only to the extent such counts are available. The methods used to summarize claim counts have not changed significantly over the time periods reported in the tables above.

The Company cautions against using the summarized claim count information provided in this disclosure in attempting to project ultimate loss payouts by product line. The Company generally finds claim count data to be useful only on a more granular basis than the aggregated basis disclosed in the claim development tables above, as the risks, average values and other dynamics of the claim process can vary materially by the cause of loss and coverage within product line.

**Reinsurance Recoverables, Including Credit Impairments:**

Everspan's reinsurance assets, including deferred ceded premiums and reinsurance recoverables on losses, amounted to $582,457 at December 31, 2025. Credit exposure existed at December 31, 2025, with respect to reinsurance recoverables to the extent that any reinsurer may not be able to reimburse Everspan under the terms of these reinsurance arrangements. At December 31, 2025, there were ceded reinsurance balances payable of $80,561 offsetting this credit exposure. Contractually ceded reinsurance payables can only be offset against amounts owed from the same reinsurer in the event that such reinsurer is unable to meet its obligations to reimburse Everspan.

To minimize its credit exposure to losses from reinsurer insolvencies, Everspan (i) is entitled to receive collateral from its reinsurance counterparties in certain reinsurance contracts and (ii) has certain cancellation rights that can be exercised by Everspan in the event of rating agency downgrades of a reinsurer (among other events and circumstances). Everspan held letters of credit and collateral amounting to $88,732 from its reinsurers at December 31, 2025. For those reinsurance counterparties that do not currently post collateral, Everspan's reinsurers are well-capitalized, highly rated, authorized capacity providers. Additionally, while legacy liabilities from the Providence Washington Insurance Company acquisition and the admitted carriers acquired by Everspan on January 3, 2022, (Greenwood Insurance Company and Consolidated Specialty Insurance Company), were fully ceded to certain reinsurers,

Everspan also benefits from an unlimited, uncapped indemnity from Enstar Holdings (US) and 21st Century Premier Insurance Company to mitigate any residual risk to these reinsurers.

For 2025, our top five reinsurers represented 54% our total reinsurance recoverables on paid and unpaid losses. These reinsurance recoverables were primarily from reinsurers with applicable ratings of A or better. The following table sets forth our five most significant reinsurers by amount of reinsurance recoverables as of December 31, 2025.

---

| | | | |
|:---|:---|:---|:---|
| **Reinsurers** | **Rating**<br><sup>(1)</sup> | **Reinsurance**<br>**Recoverable**<br><sup>(2)</sup> | **Unsecured** <br>**Recoverable**<br><sup>(3)</sup> |
| General Reinsurance Company | A++ | $**124602** | $**100165** |
| Munich Reinsurance Company | A+ | **57036** | **55196** |
| QBE Insurance Corporation | A | **19791** | **19791** |
| Everest Reinsurance Company | A+ | **17524** | **17932** |
| Swiss Reinsurance America Corporation | A+ | **15507** | **14657** |
| All other reinsurers |  | **201632** | **104054** |
| **Total recoverables** |  | $**436092** | $**311795** |

---

(1)Represents financial strength ratings from AM Best.

(2)Represents reinsurance recoverables on paid and unpaid losses. Unsecured amounts from QBE Insurance Corporation is also supported by an unlimited, uncapped indemnity from Enstar Holdings (US).

(3)Reinsurance recoverables reduced by ceded premiums payables due to reinsurers, letters of credit, and collateral posted for the benefit of Everspan.

Everspan has uncollateralized credit exposure to reinsurers of $311,795 and $232,310 and has recorded an allowance for credit losses of $100 and $100 at December 31, 2025 and 2024, respectively. The uncollateralized credit exposure to reinsurers includes legacy liabilities obtained from the acquisitions of Providence Washington Insurance Company and the admitted carriers acquired by Everspan on January 3, 2022, of $23,530 and $35,146 at December 31, 2025 and 2024, respectively. All legacy liabilities remain with affiliates of the sellers through reinsurance and contractual indemnities.

**9.&nbsp;&nbsp;&nbsp;&nbsp;INSURANCE REGULATORY RESTRICTIONS** 

Everspan Indemnity and its wholly owned subsidiary, Everspan Insurance Company ("Everspan Insurance"), as well as Consolidated Specialty Insurance Company, a wholly-owned subsidiary of Everspan Insurance, are domiciled in Arizona and are subject to the insurance laws and regulations of Arizona (the "Arizona Insurance Laws") and are regulated by the Arizona Department of Insurance and Financial Institutions as domestic insurers. The other subsidiaries of Everspan Insurance, Providence Washington Insurance Company and Greenwood Insurance Company (together with Everspan Insurance, the "Everspan Admitted Carriers") are domiciled in Rhode Island and Pennsylvania, respectively, and are therefore subject to the insurance laws and regulations of their respective States of domicile (together with Arizona Insurance Laws, the "State Insurance Laws") and regulated by the insurance departments of those States as domestic insurers. In addition, the Everspan

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **79** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

Admitted Carriers are subject to the insurance laws and regulations of the other jurisdictions in which they are licensed and operate as foreign insurers.

Insurance laws and regulations applicable to insurers vary by jurisdiction, but the insurance laws and regulations applicable to our insurance carriers generally require them to maintain minimum standards of business conduct and solvency; to meet certain financial tests; and to file policy forms, premium rate schedules and certain reports with regulatory authorities, including information concerning capital structure, ownership, financial condition (such as risk-based capital), corporate governance and enterprise risk.

Regulated insurance companies are also required to file quarterly and annual statutory financial statements in each jurisdiction in which they are licensed. The State Insurance Laws also require prior approval (or non-disapproval) of certain transactions between an insurance carrier and its affiliates. The level of supervisory authority that may be exercised by non-domiciliary insurance regulators varies by jurisdiction. Generally, however, non-domiciliary regulators are authorized to suspend or revoke the insurance license they issued and to impose restrictions on that license in the event that laws or regulations are breached by a regulated insurance company or in the event that continued or unrestricted licensing of the regulated insurance company constitutes a "hazardous condition" (or meets a similar standard) in the opinion of the non-domiciliary regulator.

The domiciliary regulators have primary regulatory authority, including with respect to the initiation and administration of rehabilitation or liquidation proceedings. Additionally, the accounts and operations of Everspan Indemnity and the Everspan Admitted Carriers are subject to individual periodic comprehensive financial examinations by their domestic regulators, and may be examined collectively by the lead regulator of the affiliated insurance company group.

Everspan Indemnity is a domestic surplus lines insurer and is eligible to write property and casualty insurance as an excess and surplus lines insurance in all states by virtue of the U.S. Nonadmitted and Reinsurance Reform Act of 2010.

Everspan Insurance, Greenwood Insurance Company, Consolidated Specialty Insurance Company, and Providence Washington Insurance Company are admitted property and casualty insurers. Collectively, they have broad authority to write property and casualty insurance throughout the United States.

Everspan Indemnity and the Everspan Admitted Carriers (collectively, "Everspan") are subject to risk-based capital requirements.

All of Octave's insurance subsidiaries are in compliance with the minimum capital and surplus levels required under the State Insurance Laws required to transact all business written to date.

Our ID businesses, like some other managing general agents, brokerages and program administrators, may be subject to

licensing requirements and regulation by insurance regulators in various regulatory jurisdictions in which they conduct business.

The financial statements Everspan are prepared on the basis of accounting practices prescribed or permitted by the State Insurance Laws and the actions of regulatory authorities thereunder. Everspan uses such statutory accounting practices prescribed or permitted by the applicable regulatory authorities for determining and reporting their financial condition and results of operations, including for determining solvency under the State Insurance Laws. The States in which Everspan are domiciled have adopted the National Association of Insurance Commissioners ("NAIC") accounting practices and procedures manual ("NAIC SAP") as a component of prescribed practices as codified in each State's applicable law or regulation.

Statutory policyholder surplus differs from stockholder's equity determined under GAAP principally due to statutory accounting rules that treat investments, acquisition costs and consolidation of subsidiaries differently.

Everspan Indemnity has statutory policyholder surplus of $128,031 as of December 31, 2025, as compared to $125,202 as of December 31, 2024.

Everspan does not have any permitted or additional prescribed practices at December 31, 2025 or December 31, 2024.

**Dividend Restrictions, Including Contractual Restrictions**

**<u>United States</u>**

State Insurance Regulators prescribe rules that determine if Everspan may declare dividends. In addition, Everspan is subject to certain restrictions in their respective articles of incorporation with regards to the payment of dividends. Board action authorizing a distribution by an insurance company must generally be reported to the applicable domiciliary regulator prior to payment. In addition, State Insurance Laws generally require regulatory approval for the payment of extraordinary dividends, which are distributions in amounts that would exceed certain thresholds, such as a percentage of surplus or net income for the prior year or number of years.

Everspan does not have sufficient earned surplus at this time to pay ordinary dividends under the State Insurance Laws. Furthermore, certain subsidiaries of Everspan Insurance were restricted from paying dividends to Everspan Insurance until January 1, 2025. Currently, Everspan Insurance's subsidiaries, other than Greenwood Insurance Company and Providence Washington Insurance Company, do not have sufficient surplus to pay dividends.

Octave's MGA/U subsidiaries are not restricted from paying dividends or partner distributions (collectively "Distributions") to their owners or partners, including Octave Partners, which is 100% owned by OSG. Octave's established MGA/Us historically have paid Distributions equating to the majority of their individual EBITDA, subject to working capital, taxes and other capital needs, on a quarterly basis. Newly formed de-novo MGA/Us are not expected to make regular distributions to their

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **80** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

partners until they become profitable and generate free cash flow on a steady and/or predictable basis.

**<u>United Kingdom</u>**

Octave Ventures's UK subsidiaries are subject to certain restrictions in their articles of association and shareholder agreements with regards to the payment of dividends. The Board of Octave Ventures and each subsidiary can approve the payment of a dividend (subject to repayment of any funding agreements). Octave Ventures and its UK subsidiaries historically have paid Distributions equating to the majority of their distributable reserves, being principally profit after taxation.

**<u>Bermuda</u>**

Octave Venture's Bermuda subsidiary is subject to certain restrictions in their articles of association and shareholder agreements with regards to the payment of dividends. The Board of the Bermuda subsidiary can approve the payment of a dividend (subject to repayment of any funding agreement). The Board of the Bermuda subsidiary historically has paid Distributions equating to the majority of their distributable reserves, being principally profit after taxation.

**10.&nbsp;&nbsp;&nbsp;&nbsp;DERIVATIVE INSTRUMENTS**

The following tables summarize the location and gross fair values of individual derivative instruments and the impact of legal rights of offset as reported in the Consolidated Balance Sheets, as of December 31, 2025 and 2024.

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2025:** | **December 31, 2024:** | **December 31, 2024:** | **December 31, 2024:** | **December 31, 2024:** | **December 31, 2024:** |
| | **Gross<br>Amounts of<br>Recognized<br>Assets /<br>Liabilities** | **Gross<br>Amounts<br>Offset in the<br>Consolidated<br>Balance Sheet** | **Net Amounts<br>of Assets/<br>Liabilities<br>Presented<br>in the<br>Consolidated<br>Balance Sheet** | **Gross Amount<br>of Collateral<br>Received /<br>Pledged not<br>Offset in the<br>Consolidated<br>Balance<br> Sheet** | **Net Amount** | **Gross<br>Amounts of<br>Recognized<br>Assets /<br>Liabilities** | **Gross<br>Amounts<br>Offset in the<br>Consolidated<br>Balance Sheet** | **Net Amounts<br>of Assets/<br>Liabilities<br>Presented<br>in the<br>Consolidated<br>Balance Sheet** | **Gross Amount<br>of Collateral<br>Received /<br>Pledged not<br>Offset in the<br>Consolidated<br>Balance<br> Sheet** | **Net Amount** |
| **Other assets:** | | | | | | | | | | |
| &nbsp;&nbsp;Warrants | $**—** | $**—** | $**—** | $**—** | $**—** | $— | $— | $— | $— | $— |
| **Total derivative assets** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** | $**—** |
| **Other liabilities:** |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;FX forwards | $**8** | $**—** | $**8** | $**—** | $**8** | $317 | $— | $317 | $— | $317 |
| **Total derivative liabilities** | $**8** | $**—** | $**8** | $**—** | $**8** | $**317** | $**—** | $**317** | $**—** | $**317** |

---

The following tables summarize the location and amount of gains and losses of derivative contracts in the Consolidated Statements of Total Comprehensive Income (Loss) for the years ended December 31, 2025, 2024 and 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Location of Gain (Loss) Recognized<br>in Consolidated Statements of<br>Total Comprehensive Income (Loss)** | **Amount of Gain (Loss) Recognized in Consolidated Statement of Total Comprehensive Income (Loss) – <br>Year Ended December 31,** | **Amount of Gain (Loss) Recognized in Consolidated Statement of Total Comprehensive Income (Loss) – <br>Year Ended December 31,** | **Amount of Gain (Loss) Recognized in Consolidated Statement of Total Comprehensive Income (Loss) – <br>Year Ended December 31,** |
| | **Location of Gain (Loss) Recognized<br>in Consolidated Statements of<br>Total Comprehensive Income (Loss)** | **2025** | **2024** | **2023** |
| **Derivative type:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Warrants | Other revenue | $**—** | $(656) | $(279) |
| &nbsp;&nbsp;&nbsp;&nbsp;FX forwards | Other revenue | **1019** | 4672 |  |
| &nbsp;&nbsp;**Total derivatives** |  | $**1019** | $4016 | $(279) |

---

**Other Derivatives:**

Octave Ventures utilizes foreign exchange forward contracts to partially hedge its foreign currency exposure. Octave Ventures's functional currency is the British Pound, but a significant portion of its revenues are generated in currencies other than the British Pound, particularly the US Dollar. Octave Ventures, therefore, typically enters into forward contracts to partially hedge its exposure to fluctuations in exchange rates relative to the British Pound. OSG used FX forward contracts to mitigate British Pound to US Dollar exchange risk leading up to its purchase of Octave Ventures in August 2024.

Octave also holds warrants to purchase equity shares of a development stage company and was party to foreign exchange (FX) forward contracts in 2024.

Information about FX forward contracts as of December 31, 2025 and December 31, 2024, is summarized below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Derivative Type** | **Weighted<br>Average<br>Remaining<br>Term<br>(years)** | **Face<br>Amount<br>(Buy)** | **Face<br>Amount<br>(Sell)** | **Fair Value<br>Asset<br>(Liability)** |
| **<u>December 31, 2025</u>** | | | | |
| FX Forwards-Buy GBP/Sell USD | 1.39 | 17876 | 24000 | (6) |
| FX Forwards-Buy GBP/Sell CAD | 0.73 | 1530 | 2800 | (2) |
| **<u>December 31, 2024</u>** |  |  |  |  |
| FX Forwards-Buy GBP/Sell USD | 0.61 | 15720 | 20000 | (317) |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **81** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**11.&nbsp;&nbsp;&nbsp;&nbsp;GOODWILL AND INTANGIBLE ASSETS**

The following table presents a rollforward of goodwill at December 31, 2025 and 2024.

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| Beginning balance | $**418234** | $69694 |
| &nbsp;&nbsp;Business acquisitions | **95357** | 357316 |
| &nbsp;&nbsp;Gain (loss) on foreign currency translation | **26754** | (8776) |
| &nbsp;&nbsp;Impairments | **—** |  |
| **Ending balance** | $**540345** | $**418234** |

---

Intangible asset and accumulated amortization are included in the Consolidated Balance Sheets, as shown below.

---

| | | | |
|:---|:---|:---|:---|
| | **Cost** | **Accumulated Amortization** | **Net Carrying Amount** |
| **<u>December 31, 2025</u>** | | | |
| **Finite-lived Intangible Assets:** | | | |
| Customer relationships | $**509197** | $**62362** | $**446835** |
| Non-compete agreements | **1350** | **1350** | **—** |
| Trade names | **19383** | **2433** | **16950** |
| **Total finite-lived intangible assets** | **529930** | **66145** | **463785** |
| **Indefinite-lived Intangible Assets:** |  |  |  |
| Insurance licenses | **11213** | **—** | **11213** |
| **Total intangible assets** | $**541143** | $**66145** | $**474998** |
| **<u>December 31, 2024</u>** |  |  |  |
| **Finite-lived Intangible Assets:** |  |  |  |
| Customer relationships | $348350 | $24630 | $323720 |
| Non-compete agreements | 1350 | 1080 | 270 |
| Trade names | 10767 | 1195 | 9572 |
| **Total finite-lived intangible assets** | **360467** | **26905** | **333562** |
| **Indefinite-lived Intangible Assets:** |  |  |  |
| Insurance licenses | $11213 | $— | $11213 |
| **Total intangible assets** | $**371680** | $**26905** | $**344775** |

---

**Amortization Expense:**

Amortization expense is included in the Consolidated Statements of Total Comprehensive Income (Loss), as shown below.

---

| | | | |
|:---|:---|:---|:---|
| **Year ended December 31,** | **2025** | **2024** | **2023** |
| Customer relationships | **36578** | 16739 | 3622 |
| Non-compete | **270** | 270 | 270 |
| Trade names | **1196** | 593 | 260 |
| **Total** <sup>(1)</sup> | $**38044** | $**17602** | $**4152** |

---

(1)The weighted-average amortization period is 4.7 years.

The estimated future amortization expense for finite-lived intangible assets is as follows:

---

| | |
|:---|:---|
| **Amortization Expense** | **Total** |
| 2026 | $**44647** |
| 2027 | **44308** |
| 2028 | **44308** |
| 2029 | **44304** |
| 2030 | **43859** |
| Thereafter | **242359** |

---

**12.&nbsp;&nbsp;&nbsp;&nbsp;DEBT** 

**2025 Credit Facility**

In connection with the acquisition of ArmadaCorp on October 31, 2025, Octave Partners LLC (f.k.a. Cirrata Group LLC) and certain of its subsidiaries (including ArmadaCorp) entered into a credit facility providing for a $100,000 term loan and a $20,000 revolving credit facility (the "2025 Credit Facility"). The term loan and revolving loans were fully drawn as SOFR loans to pay part of the purchase price for ArmadaCorp. The term loan will amortize in equal quarterly installments beginning March 31, 2026, in an aggregate amount equal to 2.5% per annum of the original principal amount, with the remaining principal balance due October 31, 2030. Unless earlier terminated, the revolver matures October 31, 2030. Optional prepayments are permitted without premium or penalty. Mandatory prepayments will be due with net cash proceeds from certain asset sales, recovery events (such as insurance recoveries), issuances of indebtedness and indemnity payments. As of December 31, 2025, outstanding borrowings under the term loan were $100,000 and under the revolving credit facility were $20,000. Borrowings under the Credit Facility bear interest at a rate per annum equal to 3-month term SOFR plus an applicable margin of 2.25% to 2.75%. The applicable margin adjusts automatically at the end of each fiscal quarter based on the borrowers' reported Consolidated Total Net Leverage Ratio for the most recently ended fiscal quarter. The Company's applicable margin in effect as of December 31, 2025, was 2.75%. Debt issuance costs incurred in connection with the 2025 Credit Facility of $2,530 are being amortized to interest expense over the contractual term of the facility and are presented as a reduction to the carrying amount of the borrowings reported within Long-term debt on the Consolidated Balance Sheets.

The 2025 Credit Facility includes customary representations and warranties and covenants applicable to the ID businesses, including (without limitation) maintenance of certain financial ratios and limitations on indebtedness, liens, mergers, sales of assets, investments, restricted payments (such as dividends), and affiliate transactions. Pursuant to a separate guaranty and pledge agreement, OSG guarantees the payment and performance of all obligations under the credit agreement and other loan documents and pledges its ownership interest in Octave Partners LLC as collateral. OSG makes customary representations and warranties and covenants and agrees to always maintain minimum cash liquidity of $10,000. Pursuant to a separate guaranty and security agreement, the borrowers and other wholly-owned subsidiaries of Octave Partners LLC guarantee the payment and performance of all obligations under the credit

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **82** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

agreement and other loan documents and grant security interests in substantially all of the assets of the borrowers and such other subsidiaries, including their respective ownership interests in their subsidiaries, as collateral. These requirements will impact our financial and operational flexibility while the 2025 Credit Facility remains in place.

**2024 Credit Facility**

In the third quarter of 2024, OSG funded a portion of the acquisition of Octave Ventures (f.k.a. Beat) with a $150,000 credit facility (the "2024 Credit Facility"). On June 10, 2025, OSG entered into an amendment (the "Amendment") to the $150,000 2024 Credit Facility. Pursuant to the Amendment, the maturity date for amounts owed with respect to the loans made under the 2024 Credit Facility was extended from July 31, 2025 to the earlier of (a) December 31, 2025 and (b) the date that is the three-month anniversary of the termination of the Stock Purchase Agreement, dated June 4, 2024, between OSG and American Acorn Corporation. Borrowing under the Credit Facility as amended bears interest at 3-month term SOFR plus a margin initially equal to 4.50%, increasing to 5.50% on November 1, 2024, 6.50% on February 1, 2025, and 7.50% on May 1, 2025. A duration fee equal to 1.00% of the then outstanding Credit Facility was due on each of February 1, 2025, and May 1, 2025, to the extent the borrowing under the Credit Facility is not repaid earlier. OSG paid an extension fee in an amount equal to 1.00% of the aggregate principal amount of loans outstanding under the Credit Agreement on June 10, 2025. The 2024 Credit Facility was repaid in full on September 29, 2025 with a portion of the proceeds from the sale of AAC.

Obligations under the 2024 Credit Facility as amended were guaranteed by OSG and were secured on a first-priority basis by (i) a pledge by OSG of all of the capital stock of Everspan Holdings, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company and (ii) a pledge by the Purchaser of all of the capital stock of Octave Ventures held by Purchaser. The 2024 Credit Facility as amended included financial and other covenants that restricted our ability to manage capital resources by limiting, among other actions, the issuance of debt or capital stock; the creation of liens; the disposition of assets; transactions with affiliates; restricted payments, including dividends and the purchase or redemption of capital stock; and acquisitions and other investments.

**13.&nbsp;&nbsp;&nbsp;&nbsp;REVENUES FROM CONTRACTS WITH CUSTOMERS**

As further described in the Revenue Recognition section of Note 2. Basis of Presentation and Significant Accounting Policies, the ID businesses have contracts that are subject to the Revenue from Contracts with Customers Topic of the ASC ("ASC 606").

The following table presents ID commission income recognized disaggregated by policy type for the years ended December 31, 2025, 2024 and 2023:

---

| | | | |
|:---|:---|:---|:---|
| **Year ended December 31,** | **2025** | **2024** | **2023** |
| Accident & Health | $**29640** | $30123 | $32836 |
| Property | **22565** | 5116 |  |
| Specialty Auto | **17370** | 17851 | 11929 |
| Reinsurance | **15713** | 1641 | 147 |
| Other Professional | **13294** | 10076 | 3097 |
| Niche Specialty Risks | **13263** | 5268 |  |
| Surety | **10307** | 2948 |  |
| Professional D&O | **6995** | 1422 |  |
| Misc. Specialty | **5406** | 1696 | 363 |
| Marine & Energy | **4577** | 2829 | 2909 |
| Environmental | **4251** | 13053 |  |
| **Total** | $**143381** | $**92023** | $**51281** |

---

For the years ended December 31, 2025, 2024 and 2023, income of $20,419, $6,353 and $0, respectively, was recognized in accordance with ASC 606 and reported as Servicing and other fees on the Consolidated Statement of Comprehensive Income.

During the years ended December 31, 2025, 2024 and 2023, the amount of revenue recognized related to performance obligations satisfied in a previous period, inclusive of changes due to estimates was approximately $2,984, $5,325 and $5,241, respectively.

**Receivables, Contract Assets and Liabilities**

The balances of receivables, contract assets and contract liabilities with customers were as follows:

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| Receivables | $**86609** | $55377 |
| Contract assets | **31757** | 15967 |
| Contract liabilities | **2954** | 2705 |

---

Contract assets and Contract liabilities is reported in Other Assets and Other Liabilities on the Balance Sheet

***Insurance Distribution***

Contract assets represent estimated future consideration related to base commissions and profit-sharing commissions that were recognized as revenue upon the placement of the policy, but are not yet billable or collectable. The Company does not have the right to bill or collect payment on (i) base commissions until the related premiums from policyholders have been collected nor (ii) profit-sharing commissions until after the contract year is completed.

Contract liabilities represent advance consideration received from customers related to Employer stop loss base commissions that will be recognized over time as claims servicing is performed, which typically occurs between 17 and 20 months from contract inception. During the years ended December 31, 2025, 2024 and 2023, the Company recognized revenue that was included in the contract liability balance as of the beginning of the period of $679, $479 and $583, respectively.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **83** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**14.&nbsp;&nbsp;&nbsp;&nbsp;COMPREHENSIVE INCOME (LOSS)** 

The following tables detail the changes in the balances of each component of accumulated other comprehensive income for the affected periods:

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Year Ended December 31, 2025:** | **Year Ended December 31, 2025:** | **Year Ended December 31, 2025:** | **Year Ended December 31, 2025:** | **Year Ended December 31, 2025:** | **Year ended December 31, 2024:** | **Year ended December 31, 2024:** | **Year ended December 31, 2024:** | **Year ended December 31, 2024:** | **Year ended December 31, 2024:** |
| | **Unrealized Gains (Losses) on Available- for Sale Securities** <sup>(1)</sup> | **Amortization** <br>**of Postretirement Benefit**<br><sup>(1)</sup> | **Gain (Loss)** <br>**on Foreign** <br>**Currency**<br>**Translation**<br><sup>(1)</sup> | **Credit Risk**<br>**Changes of Fair Value Option**<br>**Liabilities** <br><sup>(1) (2)</sup> | **Total** | **Unrealized Gains (Losses) on Available- for Sale Securities** <sup>(1)</sup> | **Amortization** <br>**of Postretirement Benefit**<br><sup>(1)</sup> | **Gain (Loss)** <br>**on Foreign** <br>**Currency**<br>**Translation**<br><sup>(1)</sup> | **Credit Risk**<br>**Changes of Fair Value Option**<br>**Liabilities** <br><sup>(1) (2)</sup> | **Total** |
| Beginning Balance | $**(21136)** | $**—** | $**(166191)** | $**(1109)** | $**(188436)** | $(20197) | $4939 | $(144035) | $(753) | $(160046) |
| &nbsp;&nbsp;Other comprehensive income (loss) before reclassifications | **23259** | **—** | **76812** | **—** | **100071** | 3583 | (67) | (22156) |  | (18640) |
| &nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income (loss) | **(3615)** | **—** | **99354** | **1109** | **96848** | (4522) | (4872) |  | (356) | (9750) |
| Net current period other comprehensive income (loss) | **19643** | **—** | **176166** | **1109** | **196919** | (939) | (4939) | (22156) | (356) | (28390) |
| **Ending balance** | $**(1493)** | $**—** | $**9975** | $**—** | $**8483** | $**(21136)** | $**—** | $**(166191)** | $**(1109)** | $**(188436)** |

---

(1)All amounts are net of tax and NCI. Amounts in parentheses indicate reductions to Accumulated Other Comprehensive Income.

(2)Represents the changes in fair value attributable to instrument-specific credit risk of liabilities for which the fair value option is elected.

The following table details the significant amounts reclassified from each component of accumulated other comprehensive income, shown in the above rollforward tables, for the affected periods:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Details about Accumulated Other**<br>**Comprehensive Income Components** | | **Amount Reclassified from Accumulated<br>Other Comprehensive Income** | **Amount Reclassified from Accumulated<br>Other Comprehensive Income** | **Affected Line Item in the**<br>**Consolidated Statement of**<br>**Total Comprehensive Income** |
| **Details about Accumulated Other**<br>**Comprehensive Income Components** | | **Year Ended December 31,** | **Year Ended December 31,** | **Affected Line Item in the**<br>**Consolidated Statement of**<br>**Total Comprehensive Income** |
| **Details about Accumulated Other**<br>**Comprehensive Income Components** |  | **2025** | **2024** | **Affected Line Item in the**<br>**Consolidated Statement of**<br>**Total Comprehensive Income** |
| **Details about Accumulated Other**<br>**Comprehensive Income Components** | **Unrealized Gains (Losses) on Available-for-Sale Securities** <sup>(1)</sup> |  |  | **Affected Line Item in the**<br>**Consolidated Statement of**<br>**Total Comprehensive Income** |
|  |  | $**15193** | $(3919) | Other income |
|  |  | **(3851)** | (603) | Provision for income taxes |
|  |  | **(14957)** |  | Net loss on discontinued operations |
|  |  | $**(3615)** | $(4522) | Net of tax and noncontrolling interest |
| **Amortization of Postretirement Benefit** |  |  |  |  |
| Prior service cost |  | $**—** | $(210) | Other income |
| Actuarial gains (losses) |  | **—** | (67) | Other income |
| Curtailment gain |  | **—** | (4662) | Other income |
|  |  | **—** | (4939) | Total before tax |
|  |  | **—** |  | Provision for income taxes |
|  |  | $**—** | $(4939) | Net of tax and noncontrolling interest |
| **Gain (loss) on foreign currency translation** |  |  |  |  |
|  |  | $**99354** | $— | Net loss on discontinued operations |
|  |  | $**99354** | $— | Net of tax and noncontrolling interest |
| **Credit Risk Changes of Fair Value Option Liabilities** |  |  |  |  |
|  |  | $**590** | $(474) | Credit risk changes of fair value option liabilities |
|  |  | **(179)** | 118 | Provision for income taxes |
|  |  | **698** |  | Net loss on discontinued operations |
|  |  | **1109** | (356) | Net of tax and noncontrolling interest |
| **Total reclassifications for the period** |  | $**96848** | $**(9817)** | **Net of tax and noncontrolling interest** |

---

(1)Net unrealized investment gains (losses) on available-for-sale securities are included in Octave's Consolidated Statements of Comprehensive Income as a component of Accumulated Other Comprehensive Income. Changes in these amounts include reclassification adjustments to exclude from "Other comprehensive income (loss)" those items that are included as part of "Net income" for a period that has been part of "Other comprehensive income (loss)" in earlier periods.

**15.&nbsp;&nbsp;&nbsp;&nbsp;NET INCOME PER SHARE** 

As of December 31, 2025, 45,005,284 shares of OSG's common stock (par value $0.01) and a warrant entitling the holder to acquire up to 5,092,707 shares of common stock at an exercise price of $18.50 per share were issued and outstanding. The warrant was issued September 29, 2025, and allows the holder to convert the warrant at its Black-Sholes value, settleable in shares of OSG common stock or cash at OSG's election. Common shares outstanding decreased by 1,501,689 during the year ended December 31, 2025, primarily due to share repurchases partially offset by shares issued in connection with employee stock compensation.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **84** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**Share Repurchases**

On November 12, 2024, Octave's Board of Directors authorized a share repurchase program, under which Octave may opportunistically repurchase up to $50,000 of the Company's common shares at management's discretion over the period ending on December 31, 2026.

The following table shows shares repurchased by year.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **($ in thousands,** <br>**except per share)** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| **($ in thousands,** <br>**except per share)** | **2022** | **2023** | **2024** | **2025** |
| Shares repurchased | 1605316 | 325068 | 937141 | **3434745** |
| Total cost | $14217 | $4510 | $11699 | $**29942** |
| Average purchase price per share | $8.86 | $13.88 | $12.48 | $**8.72** |
| Unused authorization amount | Unused authorization amount |  |  | $**8449** |

---

**Earnings Per Share Calculation**

The numerator of the basic and diluted earnings per share computation represents net income (loss) attributable to common stockholders adjusted by the retained earnings impacts of the noncontrolling adjustment to redemption value under ASC 480 or amendments resulting in revaluation to fair value and reclassification of NCI shares to redeemable NCI. Adjustments to the carrying value of redeemable noncontrolling interest are further described in the Redeemable NCI section of *Note 2. Basis of Presentation and Significant Accounting Policies*.

The following table provides a reconciliation of net income (loss) from continuing operations attributable to common stockholders to the numerator in the basic and diluted earnings per share calculation, together with the resulting earnings per share amounts:

---

| | | | |
|:---|:---|:---|:---|
| **Year ended December 31,** | **2025** | **2024** | **2023** |
| Net income (loss) attributable to Octave common stockholders | $**(98404)** | $(59282) | $(24551) |
| Adjustment to redemption value (ASC 480) | **(18175)** | (5222) | 4792 |
| Numerator of basic and diluted EPS | $**(116579)** | $(64504) | $(19759) |
| Per Share: |  |  |  |
| &nbsp;&nbsp;Basic | $**(2.47)** | $(1.37) | $(0.43) |
| &nbsp;&nbsp;Diluted | $**(2.47)** | $(1.37) | $(0.43) |

---

The denominator of the basic earnings per share computation represents the daily weighted average common shares outstanding plus vested restricted stock units and performance stock units (together, "Basic Weighted Average Shares Outstanding"). The denominator of diluted earnings per share adjusts the basic weighted average shares outstanding for all potential dilutive common shares outstanding during the period. All potential dilutive common shares outstanding consider common stock deliverable pursuant to warrants, employee options, unvested restricted stock units and unvested performance stock units granted under existing compensation plans.

In determining diluted net income (loss) per share, whether net income from continuing operations is positive or negative

controls whether dilutive shares are included in the determination. For all periods presented, net income from continuing operations was negative, a net loss. Accordingly, since including dilutive shares would dilute the loss from continuing operations, no dilutive shares are included in any of the per share calculations. The following table provides a reconciliation of the common shares used for basic net income per share to the diluted shares used for diluted net income per share:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Basic weighted average shares outstanding | **47181227** | 46969708 | 45636649 |
| Effect of potential dilutive <br>shares <sup>(1)</sup>: |  |  |  |
| &nbsp;&nbsp;Restricted stock units | **—** |  |  |
| &nbsp;&nbsp;Performance stock units <sup>(1)</sup> | **—** |  |  |
| Diluted weighted average shares outstanding | **47181227** | 46969708 | 45636649 |
| **Anti-dilutive shares excluded from the above reconciliation** |  |  |  |
| &nbsp;&nbsp;Warrants <sup>(2)</sup> | **1311546** |  |  |
| &nbsp;&nbsp;Options <sup>(2)</sup> | **279740** |  |  |
| &nbsp;&nbsp;Restricted stock units | **164101** | 479781 | 550255 |
| &nbsp;&nbsp;Performance stock units <sup>(1)</sup> | **8273** | 817483 | 900964 |

---

(1)Performance stock units are reflected based on the performance metrics through the balance sheet date. Vesting of these units is contingent upon meeting certain performance metrics. Although a portion of these performance metrics have been achieved as of the respective period end, it is possible that awards may no longer meet the metric at the end of the performance period.

(2)Options require the OSG's stock price to exceed certain market price hurdles to vest, none of which have been met. Warrants have an exercise price above the market price of OSG stock during the year. Amounts shown reflect the maximum number of shares issuable upon exercise, weighted for the time outstanding during the periods.

**16.&nbsp;&nbsp;&nbsp;&nbsp;INCOME TAXES**

OSG files a consolidated U.S. federal income tax return with its 80% or more owned domestic subsidiaries ("Consolidated Tax Subsidiaries"). Octave Ventures's US subsidiaries file separate U.S. federal income tax returns as they are not directly owned by OSG for tax purposes. OSG and its Consolidated Tax Subsidiaries also file separate or combined income tax returns in various states, local and foreign jurisdictions. The following are the major jurisdictions in which Octave and its subsidiaries, including its foreign subsidiaries, operate and the earliest tax years subject to examination:

---

| | |
|:---|:---|
| **Jurisdiction** | **Tax Year** |
| United States | 2009 |
| New York State | 2015 |
| New York City | 2019 |
| United Kingdom | 2021 |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **85** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**Consolidated Pretax Income (Loss)**

U.S. and foreign components of pre-tax income (loss) from continuing operations were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| U.S. | $**(81400)** | $(58014) | $(24221) |
| Foreign | **(19614)** | (1831) |  |
| **Total** | $**(101014)** | $**(59845)** | $**(24221)** |

---

**Provision (Benefit) for Income Taxes**

The components of the provision (benefit) for income taxes from continuing operations were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| **<u>Current taxes</u>** |  |  |  |
| &nbsp;&nbsp;U.S. state and local | $**—** | $108 | $— |
| &nbsp;&nbsp;Foreign | **5103** | 2090 |  |
| &nbsp;&nbsp;Total current taxes | **5103** | 2198 | 431 |
| **<u>Deferred taxes</u>** |  |  |  |
| &nbsp;&nbsp;U.S. federal | **(2464)** | (633) | (1509) |
| &nbsp;&nbsp;U.S. state and local | **(37)** |  |  |
| &nbsp;&nbsp;Foreign | **(7813)** | (2489) |  |
| &nbsp;&nbsp;Total deferred taxes | $**(10314)** | $**(3122)** | $**(1509)** |
| **Provision for income taxes** | $**(5211)** | $**(924)** | $**(989)** |

---

The total effect of income taxes on net income and stockholders' equity for the years ended December 31, 2025, 2024 and 2023 is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Total income taxes charged to net income | $**(5211)** | $(924) | $(989) |
| Income taxes charged (credited) to stockholders' equity: |  |  |  |
| &nbsp;&nbsp;Unrealized gains (losses) on investment securities, including foreign exchange | **(867)** | 144 | 918 |
| &nbsp;&nbsp;Unrealized gains (losses) on foreign currency translations | **4985** | (1922) |  |
| &nbsp;&nbsp;Valuation allowance to equity | **867** | 1778 | (918) |
| &nbsp;&nbsp;Total charged to stockholders' equity: | **4985** |  |  |
| **Total effect of income taxes** | $**(226)** | $**(924)** | $**(989)** |

---

**Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate**

The tax provisions for continuing operations in the accompanying Consolidated Statements of Total Comprehensive Income (Loss) reflect effective tax rates differing from prevailing federal corporate income tax rates. As allowed by ASU 2023-09, *Improvements to Income Tax Disclosures*, Management has elected to apply the enhanced disclosure requirements of the ASU prospectively. This results in non-comparable rate reconciliation disclosures between the current and prior years. Below is a reconciliation of these differences for the year ended December 31, 2025, followed by a reconciliation of these differences for the years ended December 31, 2024 and 2023:

---

| | | |
|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2025** |
| Tax on income from continuing operations at statutory rate | $**(21213)** | **21.0%** |
| Changes in expected tax resulting from: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Nondeductible executive compensation | **2939** | **(2.9)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **(811)** | **0.8%** |
| &nbsp;&nbsp;&nbsp;Cross-border tax laws | **1286** | **(1.3)%** |
| &nbsp;&nbsp;Changes in valuation allowance | **(31790)** | **31.5%** |
| &nbsp;&nbsp;Other |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Outside basis differences | **41712** | **(41.3)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjust DTA related to intangibles | **1497** | **(1.5)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **(440)** | **0.4%** |
| Domestic state income taxes, net of federal | **261** | **(0.3)%** |
| Foreign jurisdictions |  |  |
| &nbsp;&nbsp;United Kingdom |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign tax effects | **(1228)** | **1.2%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in valuation allowance | **4322** | **(4.3)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **(1746)** | **1.7%** |
| **Tax expense on income from continuing operations** | $**(5211)** | **5.2%** |

---

For the year ended December 31, 2025, activity in California, Florida, Illinois, New Jersey, New York state, New York City and New Jersey account for the majority of the amounts in the Domestic state income taxes, net of federal tax effect category.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Year Ended December 31,** | **2024** | **2024** | **2023** | **2023** |
| Tax on income/(loss) at statutory rate | $(12567) | 21.0% | $(5086) | 21.0% |
| State DTA tax rate change | 4554 | (7.6)% |  | —% |
| Tax-exempt interest | (4) | —% | (5) | —% |
| Foreign taxes | 787 | (1.3)% |  | —% |
| State income taxes | 79 | (0.1)% | 411 | (1.7)% |
| Outside basis differences <sup>(1)</sup> | 21076 | (35.2)% |  | —% |
| Acquisition costs | 2017 | (3.4)% | 1497 | (6.2)% |
| Changes in valuation allowance <sup>(1)</sup> | (17044) | 28.5% | 1602 | (6.6)% |
| Other | 178 | (0.3)% | 592 | (2.4)% |
| **Tax expense on income from continuing operations** | $**(924)** | **1.5%** | $**(989)** | **4.1%** |

---

(1)These amounts have been revised from the amounts previously disclosed to accurately reflect the outside basis difference in the subsidiary held for sale.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **86** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**Unrecognized Tax Positions**

The Company had no material unrecognized tax positions at December 31, 2025 and 2024.

**Deferred Income Taxes**

The tax effects of temporary differences that give rise to significant portions of the deferred tax liabilities and deferred tax assets at December 31, 2025 and 2024, are presented below:

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| **Deferred tax liabilities:** |  |  |
| &nbsp;&nbsp;Amortizable intangible | $**69929** | $71414 |
| &nbsp;&nbsp;Deferred acquisition costs | **1871** | 9474 |
| &nbsp;&nbsp;Investments | **—** | 3568 |
| &nbsp;&nbsp;Other | **—** | 787 |
| &nbsp;&nbsp;Total deferred tax liabilities | **71800** | 85243 |
| **Deferred tax assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Federal net operating loss carryforward | **356575** | 349931 |
| &nbsp;&nbsp;Outside basis difference <sup>(1)</sup> | **—** | 17044 |
| &nbsp;&nbsp;Unearned premium reserves | **1714** | 9138 |
| &nbsp;&nbsp;Loss reserves | **1400** | 1102 |
| &nbsp;&nbsp;&nbsp;State capital loss carryforward | **12813** |  |
| &nbsp;&nbsp;State capital loss carryforward | **256665** | 3096 |
| &nbsp;&nbsp;Compensation | **189** | 1423 |
| &nbsp;&nbsp;Investments | **1721** |  |
| &nbsp;&nbsp;Foreign net operating loss carryforward | **4322** |  |
| &nbsp;&nbsp;Other | **1262** | 429 |
| &nbsp;&nbsp;Subtotal deferred tax assets | **636661** | 382163 |
| &nbsp;&nbsp;Valuation allowance <sup>(1)</sup> | **630078** | 367055 |
| &nbsp;&nbsp;Total deferred tax assets | **6583** | 15108 |
| **Net deferred tax liability** | $**65217** | $**70135** |

---

(1)These amounts have been revised from the amounts previously disclosed to accurately reflect the outside basis difference in the subsidiary held for sale.

The Company has adopted an accounting policy to classify the inside tax basis differences in deferred tax assets and liabilities (i.e., inside basis differences) associated with the disposition of shares of a subsidiary as assets or liabilities held for sale on the Consolidated Balance Sheets. For the year ended December 31, 2024, the Company has included net deferred tax liabilities of $20,382 in liabilities held for sale.

In accordance with the Income Tax Topic of the ASC, a valuation allowance is recognized if, based on the weight of available evidence, it is more-likely-than-not that some, or all, of the deferred tax asset will not be realized. As a result of the risks and uncertainties associated with future operating results, management believes it is more likely than not that the Company will not generate sufficient U.S. federal, state and/or local taxable income to recover the deferred tax operating assets and therefore maintains a full valuation allowance on OSG's U.S. net deferred tax assets. The remaining net deferred tax liability of $65,217 is attributable to the amortizing intangible related to the acquisition of Octave Ventures and is classified in Deferred Taxes on the Consolidated Balance Sheet.

**Income Taxes Paid, net of Refunds**

Income taxes paid, net of refunds, exceeds 5% of total income taxes paid, net of refunds, in the following jurisdictions:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| State |  |  |  |
| &nbsp;&nbsp;&nbsp;Texas | $**24** | $18 | $— |
| Foreign |  |  |  |
| &nbsp;&nbsp;&nbsp;United Kingdom | **5528** | 508 |  |
| **Total** | $**5552** | $**526** | $**—** |

---

**Loss Carryforwards**

As of December 31, 2025, the Company has $1,690,842 of U.S. net operating loss carryforwards ("NOLs") that, if not utilized, will begin expiring in 2030. Of the total NOLs $118,910 carry forward indefinitely.

The Company has state net operating loss carryforwards of $231,347 that begin expiring in 2042. The Company also has $3,910,514 of state capital loss carryforwards apportioned to various state jurisdictions primarily resulting from the sale of AAC in 2025. These carryforwards are only available to offset capital gains recognized on state tax returns and, if not utilized, will begin expire in 2026, but the majority will expire in 2030.

The Company also has $17,286 of foreign (UK) net operating losses that carry forward indefinitely.

**Tax Legislative Developments**

On July 4, 2025, President Trump signed into law the 2025 Budget Reconciliation Act ("the Act"). The Act made permanent many of the favorable business tax provisions included in the 2017 Tax Cuts & Jobs Acts ("TCJA"), in addition to several new business tax provisions, the majority of which go into effect for tax years ending after December 31, 2024. This legislation did not have a significant impact on the Company's current operations or financial condition for the year ended December 31, 2025.

**17.&nbsp;&nbsp;&nbsp;&nbsp;EMPLOYMENT BENEFIT PLANS** 

**Incentive Compensation — Stock Units, Stock Options and Cash**

Employees, directors and consultants of Octave are eligible to participate in Octave's 2024 Incentive Plan, which is the successor plan to Octave's 2020 Incentive Plan and 2013 Incentive Plan, subject to the discretion of the Compensation Committee of Octave's Board of Directors. There are 4,350,000, 1,475,000 and 4,000,000 shares of Octave's common stock authorized for awards under the 2024 Plan, 2020 Plan and 2013 Plan, respectively. Awards may also be made under the 2024 Plan with respect to the shares that remained available for grant under the 2020 Plan. In addition, shares subject to outstanding awards granted under the 2020 Plan that subsequently terminate by expiration or forfeiture, cancellation, or otherwise without the issuance of such shares become available for awards under the 2024 Plan.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **87** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

On June 24, 2021, the Compensation Committee of Octave's Board of Directors adopted the Octave Specialty Group, Inc. Executive Stock Deferral Plan (the "Stock Deferral Plan"). Under the Stock Deferral Plan, certain executives of OSG and its subsidiaries who are designated by the compensation committee as eligible to participate in the Stock Deferral Plan may elect to defer the settlement of all or a portion of the RSU and PSU (as defined below) awards that are granted to the executives to a future date(s) selected by the executive. Deferred awards under the Stock Deferral Plan (and any related dividend equivalents) will continue to be paid in shares of common stock of OSG, which will be issued under the relevant incentive compensation plan pursuant to which the underlying award was first granted, provided that any dividend equivalents credited on a participant's deferred awards in respect of cash dividends paid by OSG will be paid to the participant in cash. The sale of AAC triggered a change in control provision under the Stock Deferral Plan and immediately prior to closing all deferred shares were settled in stock. The Stock Deferral Plan is not funded, and deferred awards under the Stock Deferral Plan are not segregated from the Company's general assets. At the discretion of the Compensation Committee of the Board of Directors, RSU and PSU awards may be settled in cash based on the closing price of OSG's common stock on the last business day prior to the settlement date.

The amount of stock-based compensation expense arising from awards under the Incentive Plans and corresponding after-tax expense continuing operations are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Restricted stock units | $**6792** | $3144 | $3462 |
| Performance awards | **3581** | 6212 | 8804 |
| Performance stock options | **303** |  |  |
| Total stock-based compensation | $**10676** | $9356 | $12266 |
| **Total stock-based compensation (after-tax)** <sup>(1)</sup> | $**10676** | $**9356** | $**12266** |

---

(1)Excludes stock-based compensation expense of $36 related to stock options issued by a majority owned subsidiary to buy shares of the subsidiary's stock. Refer to "Other Incentive Plans" below.

***Restricted Stock Units ("RSUs")***

RSUs can be awarded to certain employees for a portion of their STIP compensation, Long-Term Incentive Plan ("LTIP") compensation, sign-on and special awards for exceptional performance or promotion. RSUs can also be awarded to consultants as part of the consideration for their services. The LTIP, sign-on, consultant and special awards generally vest in equal installments over, or cliff-vest at the end of, a two to three year period. Such vesting is expressly conditioned upon continued service with Octave through the applicable vesting date, although vesting may be accelerated in certain circumstances under the awards, including for terminations due to death, disability, eligible retirement, or involuntary termination by Octave other than for cause.

As part of our director compensation program, RSUs are granted quarterly and vest one year from the grant date. These RSUs will

not settle until the respective director's termination from the Board of Directors or, if earlier, upon a change in control. All RSUs provide for accelerated vesting upon a change in control, death or disability or involuntary removal other than for cause (not including removal pursuant to a shareholder vote at a regularly scheduled annual meeting of shareholders). The sale of AAC met the requirements for a change in control and immediately prior to closing, unvested shares vested and settled along with all previously deferred shares. Upon termination (other than for cause), the unvested RSUs shall partially vest as of the date of such termination in an amount equal to the number of then outstanding unvested RSUs multiplied by a fraction, the numerator of which shall be the number of calendar days which have lapsed since the grant date and the denominator of which shall be the number of calendar days from the grant date until the next regularly scheduled quarterly grant date pursuant to Octave's director compensation program.

As of December 31, 2025, 1,096,153 RSUs remained outstanding, of which (i) 1,090,076 units required future service as a condition to the delivery of the underlying shares of common stock and (ii) 6,077 units do not require future service and are deferred for future settlement. As of December 31, 2024, 1,075,025 RSUs remained outstanding, of which (i) 467,705 units required future service as a condition to the delivery of the underlying shares of common stock, and (ii) 608,853 units did not require future service and were deferred for future settlement.

A summary of RSU activity for 2025 is as follows:

---

| | | |
|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Shares** | **Weighted Average**<br>**Grant Date**<br>**Fair Value Per Share** |
| Outstanding at beginning of period | **1075025** | $**15.75** |
| Granted | **1134621** | **8.34** |
| Delivered or returned to plan <sup>(1)</sup> | **(1062983)** | **11.76** |
| Forfeited | **(50510)** | **12.37** |
| **Outstanding at end of period** | **1096153** | $**7.10** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;When restricted stock unit awards issued by Octave become taxable compensation to employees, shares may be withheld to cover the employee's withholding taxes. For the year ended December 31, 2025, Octave withheld 226,045 shares from employees that settled restricted stock units to meet the required tax withholdings.

Octave's closing share price on the grant date was used to estimate the fair value of service condition based RSUs on the grant date. The weighted average grant date fair value per share of RSUs granted during 2025, 2024 and 2023 was $8.34, $15.72 and $12.48, respectively. As of December 31, 2025, there was $7,395 of total unrecognized compensation costs related to unvested RSUs granted. These costs are expected to be recognized over a weighted average period of 1.5 years. The fair value for RSUs vested and delivered during the year ended December 31, 2025, 2024 and 2023 was $4,309, $1,654 and $4,646, respectively.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **88** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

***Performance Stock Awards ("PSUs")***

PSUs are awarded to certain employees for a portion of their LTIP compensation and generally vest after 3 years from grant date. The actual number of shares payable at settlement is subject to performance metrics relative to the companies and segments of Octave. Actual payout can range from 0% to 240% of the number of units granted. Under currently outstanding award agreements, performance will be evaluated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;• In regards to ID business for the 2023 and 2024 PSU awards, (i) cumulative earnings before interest, taxes, depreciation and amortization over the vesting period and (ii) the aggregate of all premiums placed by Octave Partners LLC with any insurance carrier over the vesting period. For the 2025 PSU awards, (i) compounded annual growth rate of cumulative earnings before interest, taxes, depreciation and amortization attributed to Octave shareholders over the vesting period and (ii) Compounded annual growth rate of organic revenues, excluding profit commissions over the vesting period.

&nbsp;&nbsp;&nbsp;&nbsp;• In regards to Everspan: (i) for the 2023 and 2024 PSU awards, cumulative earnings before interest, taxes, depreciation and amortization over the vesting period and (ii) cumulative direct or assumed premiums written (including any from Octave Partners) and fronting fees over the vesting period.

&nbsp;&nbsp;&nbsp;&nbsp;• In regards to AAC: for the 2023 award, reductions in watch list and adversely classified credits, which is intended to reward participants for de-risking the financial guarantee insured portfolio.

&nbsp;&nbsp;&nbsp;&nbsp;• Relative Total Shareholder Return ("rTSR") will cause the payout at the end of the performance period to be increased or decreased 20% for PSU awards granted 2023, 2024 and 2025, if OSG's stock performance compared to a peer group is at or above the 75th percentile or at or below the 25th percentile, respectively.

Pursuant to the LTIP award agreements, if (i) a termination occurred prior to the last day of the performance period by reason of disability, an involuntary termination by the Company other than for "cause," or "retirement," the recipient would be entitled to receive the PSU award at the end of the relevant performance period based on the satisfaction of the performance conditions related to such award at the end of the performance period, and (ii) a termination occurred prior to the last day of the performance period by reason of death, the beneficiaries of the recipient would be entitled to receive the number of PSUs that the recipient would have been entitled to receive at a 100% overall payout multiple regardless of the outcome of any of the performance conditions. The current performance awards shall be settled within 75 days after the end of the performance period, including those with partial or accelerated vesting, subject to any deferrals made pursuant to the Stock Deferral Plan.

A summary of PSU activity for 2025 is as follows:

---

| | | |
|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Shares** | **Weighted Average<br>Grant Date<br>Fair Value Per Share** |
| **Outstanding at beginning of period** | **1263511** | $**17.51** |
| &nbsp;&nbsp;Granted <sup>(1)</sup> | **1016230** | **8.02** |
| &nbsp;&nbsp;Delivered <sup>(2)</sup> | **(1046492)** | **17.60** |
| &nbsp;&nbsp;Forfeited | **(153169)** | **16.53** |
| &nbsp;&nbsp;Performance adjustment <sup>(3)</sup> | **349978** | **14.10** |
| **Outstanding at end of period** | **1430058** | $**10.65** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Represents performance share units at 100% of units granted for LTIP Awards.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Reflects the number of performance shares attributable to the performance goals attained over the completed performance period and for which service conditions have been met. When performance stock unit awards issued by Octave become taxable compensation to employees, shares may be withheld to cover the employee's withholding taxes. For the year ended December 31, 2025, Octave withheld 638,388 of shares from employees that settled performance based restricted stock units to meet the required tax withholdings.

(3)&nbsp;&nbsp;&nbsp;&nbsp;Represents the number of additional shares issued for awards granted in 2022 and partially for awards in 2023 as a result of actual performance during the performance period.

The fair value of PSUs awards are based on the grant date OSG stock price adjusted for the rTSR performance metric using a Monte Carlo simulation of stock performance relative to the peer group over the 3-year performance period. The weighted average grant date fair value per share of PSUs granted during 2025, 2024 and 2023 was $8.02, $15.94 and $17.72, respectively. As of December 31, 2025, there was $3,175 of total unrecognized compensation costs related to the PSU portion of unvested performance awards. These costs are expected to be recognized over a weighted average period of 1.6 years. The fair value for PSUs vested and delivered during the year ended December 31, 2025, 2024 and 2023 was $5,546, $2,663 and $7,665, respectively.

***Performance Stock Options ("PSOs")***

PSOs were issued in 2025 to certain executive officers of Octave. PSOs vest upon the achievement of an explicit one-year service period from grant and OSG stock reaching specified market price hurdles. The market price vesting requirement is based on the Company's achievement of the price hurdles related to the shares of Octave common stock, during the 5.0 year period following the grant date as follows: (i) 40% shall vest on the date on which the sustained stock price first exceeds $18.00 per share; (ii) 20% shall vest on the date on which the sustained stock price first exceeds $21.50 per share; (iii) 20% shall vest on the date on which the sustained stock price first exceeds $25.00 per share; and (iv) 20% shall vest on the date on which the sustained stock price first exceeds $30.00 per share. Compensation costs for PSOs are initially recognized over the period from grant date to the end of the derived service period for each price hurdle tranche estimated from valuation process which range from 2.3 to 3.2 years. The PSOs expire 10.0 years from the date of grant.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **89** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

The fair value of the PSOs was based on a Monte Carlo simulation of stock performance over the 5-year performance period from date of grant. For each iteration that market condition is met, the option is valued at that time using a Black-Scholes model. Inputs and assumptions to the valuation model include the grant date stock price of $8.97, exercise price of $8.97, OSG stock price volatility of 46.9%, risk free rate of 3.7%, and cost of equity 11.8%. The volatility and risk free rate are both commensurate with the 5-year market performance period. Additionally, a discount for lack of marketability of 10.7% was applied to the modeled value.

A summary of PSO activity for 2025 is as follows:

---

| | | |
|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Shares** | **Weighted<br>Average<br>Grant Date<br>Fair Value** |
| **Outstanding at beginning of period** | **—** | $**—** |
| &nbsp;&nbsp;Granted | **1134500** | **8.97** |
| &nbsp;&nbsp;Exercised | **—** | **—** |
| &nbsp;&nbsp;Forfeited or expired | **—** | **—** |
| **Outstanding at end of period** | **1134500** | $**8.97** |

---

None of the PSOs outstanding are vested or exercisable as of December 31, 2025. The weighted average grant date fair value per share of the options granted in 2025 was $2.93. As of as of December 31, 2025, there was $3,025 of total unrecognized compensation cost related to non-vested PSOs which is expected to be recognized over a weighted average period of 2.4 years.

**Other Incentive Plans**

Certain of Octave's majority owned Insurance Distribution subsidiaries have incentive plans that include employee incentive stock options to acquire shares of the subsidiary and management units that allow employee holders to participate in profits of their subsidiary over established targets. Stock-based compensation expense arising from subsidiary stock options was $36, $0 and $0 in 2025, 2024 and 2023, respectively. Profit sharing management units are recognized as cash compensation over the applicable vesting period based on expected payouts. Compensation expense arising from profit sharing units was $331, $0 and $0 in 2025, 2024 and 2023, respectively.

**Postemployment Benefits**

Octave provides discretionary severance benefits. Severance benefits from continuing operations, were $5,046, $416 and $0 for the years ended December 31, 2025, 2024 and 2023, respectively.

**Defined Contribution Plans**

As a result of the acquisitions of All Trans and Capacity Marine effective November 1, 2022, Riverton effective August 1 2023, Octave Ventures effective July 31, 2024, and ArmadaCorp effective October 31, 2025, Octave has multiple savings incentive plans. Substantially all US employees are covered by one of these plans. The Plan sponsored by OSG includes employer matching contributions equal to 100% of the employees' contributions, up to 3% of such participants' compensation, as defined in the plan, plus 50% of contributions up to an additional 2% of compensation, subject to limits set by

the Internal Revenue Code. Xchange and Riverton employees moved to this plan from a previous plan (Xchange during 2022 and Riverton during 2023). Employees of All Trans and Capacity Marine are included in a multiple employer plan that has discretionary contributions for which none were made during Octave's ownership of these entities. The plan for US employees of Octave Ventures includes employer matching contributions equal to 100% of the employees' contributions, up to 5% of such participants' compensation. UK employees of Octave Ventures have a defined contribution pension plan where Octave Ventures contributes 10% of participants' compensation and the assets are held separately from those of the group in an independently administrated fund. The plan for employees of ArmadaCorp includes employer matching contributions equal to 100% of the employees' contributions, up to 6% of such participants' compensation, subject to limits set by the Internal Revenue Code. The plan for employees of Pivix includes employer matching contributions equal to 100% of the employees' contributions, up to 4% of such participants' compensation, as defined in the plan, plus 50% of contributions up to an additional 2% of compensation, subject to limits set by the Internal Revenue Code. The total cost of all the contribution plans were $824, $1,945 and $676 for the years December 31, 2025, 2024 and 2023, respectively.

**18.&nbsp;&nbsp;&nbsp;&nbsp;LEASES** 

Octave is the lessee under certain lease agreements further described below.

**Lessee information**

Octave is the lessee in operating leases for corporate offices. Leases in effect at December 31, 2025, have remaining lease terms ranging from under 2 years to 8 years. Certain of these leases include early termination provisions which Octave does not include in the determination of its lease liabilities and right-of-use assets unless exercise is considered reasonably certain.

Lease costs are included in operating expenses on the Consolidated Statement of Total Comprehensive Income (Loss). The components of lease costs, net of sub-lessor income, is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Operating lease cost | $**9118** | $4247 | $3904 |
| Short-term lease cost | **16** |  | 52 |
| Variable lease cost | **356** | 437 | 404 |
| Sublease income | **407** | (1086) | (1124) |
| **Total lease cost** | $**9897** | $**3598** | $**3236** |

---

Octave is required to make variable lease payments under certain leases which primarily relates to variable costs of the lessor, such as taxes, insurance, maintenance and electricity.

During 2025, Octave terminated an operating lease for office space and incurred a termination payment of $6,481, which is included within operating lease cost. Additionally, costs related to a separate operating lease for office space was transferred to AAC prior to completion of sale, lease cost prior to transfer are included within table above.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **90** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

Supplemental information related to leases is as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Year Ended December 31,** | **2025** | **2024** | **2023** |
| Cash paid for amounts included in the measurement of operating lease liabilities | $**11060** | $4432 | $4155 |
| Right-of-use assets obtained in exchange for operating lease liabilities (non-cash) | **8761** | 2256 | 714 |

---

Supplemental balance sheet information related to leases is as follows:

---

| | | |
|:---|:---|:---|
| **December 31,** | **2025** | **2024** |
| **Operating leases:** |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease right of use assets | $**9192** | $18107 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | **9854** | 21543 |
| **Weighted average remaining lease term:** |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | **4.6 years** | 5.1 years |
| **Weighted average discount rate:** |  |  |
| &nbsp;&nbsp;&nbsp;Operating leases | **6.3%** | 7.8% |

---

Operating lease right of use assets and operating lease liabilities are included in Other assets and Other liabilities, respectively, on the consolidated balance sheet.

Future undiscounted lease payments, gross of sublease receipts, to be made are as follows:

---

| | |
|:---|:---|
| **As of December 31, 2025** | **Operating <br>Leases** |
| 2026 | $**2523** |
| 2027 | **2667** |
| 2028 | **2589** |
| 2029 | **2096** |
| 2030 | **1004** |
| Thereafter | **463** |
| Total lease payments | **11342** |
| Less: imputed interest | **(1488)** |
| **Total** | $**9854** |

---

**19.&nbsp;&nbsp;&nbsp;&nbsp;COMMITMENTS AND CONTINGENCIES** 

The Company periodically receives various regulatory inquiries and requests for information with respect to investigations and inquiries that such regulators are conducting. The Company has complied with all such inquiries and requests for information.

The Company is involved from time to time in various routine legal proceedings, including proceedings related to litigation with present or former employees. Although such litigation is routine and incidental to the conduct of its business, such litigation can potentially result in large monetary awards when a civil jury is allowed to determine compensatory and/or punitive damages.

Everspan may be subject to disputes with policyholders or other third parties regarding the scope and extent of coverage offered under Everspan's policies, including disputes relating to Everspan's course of conduct in the handling of claims and settling or failing to settle claims (which can lead to bad faith and other forms of extra-contractual liability); be required to defend claimants in suits against its policyholders for covered

liability claims; or enter into commercial disputes with its reinsurers, MGA/Us or third party claims administrators regarding their respective contractual obligations and rights. Under some circumstances, the results of such disputes or suits may lead to liabilities beyond those which are anticipated or reserved, including liabilities in excess of applicable policy limits.

Everspan has been, and may from time to time in the future be, threatened with allegations of acting in bad faith in connection with the handling of claims through third-party administrators. Adjudication of any such claims against Everspan could require extensive litigation unless settled or dismissed based on available legal defenses. Damages claimed against Everspan could be material and the outcome of such cases could have an adverse impact on our results of operations and financial condition.

In the ordinary course of their businesses, certain of Octave's subsidiaries assert claims in legal proceedings against third parties to recover losses already paid and/or mitigate future losses. The amounts recovered and/or losses avoided which may result from these proceedings is uncertain, although recoveries and/or losses avoided in any one or more of these proceedings during any quarter or fiscal year could be material to Octave's results of operations in that quarter or fiscal year.

From time to time, Octave is subject to allegations concerning its corporate governance, including the manner in which it exercises control and oversight of its subsidiaries, that may lead to litigation, including derivative litigation. While the monetary impacts of addressing such allegations outside of litigation may not be material, these charges may distract management and the Board of Directors from their principal focus on Octave's business, strategy and objectives.

It is not reasonably possible to predict whether suits in addition to those described below will be filed or whether additional inquiries or requests for information will be made, and it is also not possible to predict the outcome of litigation, inquiries or requests for information. It is possible that there could be unfavorable outcomes in these or other proceedings. Legal accruals for litigation against the Company with losses that are probable and reasonably estimable are not material to the operating results or financial position of the Company. For the litigation matters the Company is defending that do not meet the "probable and reasonably estimable" accrual threshold and where no loss estimates have been provided below, management is unable to make a meaningful estimate of the amount or range of loss that could result from unfavorable outcomes. Under some circumstances, adverse results in any such proceedings could be material to our business, operations, financial position, profitability or cash flows. The Company believes that it has substantial defenses to the claims described below and, to the extent that these actions proceed, the Company intends to defend itself vigorously; however, the Company is not able to predict the outcomes of these actions.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **91** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Notes to Consolidated Financial Statements**

**(Dollar Amounts in Thousands, Except Share Amounts)**

**Litigation against Octave Specialty Group, Inc.**

Dwight Jereczek and Stanley Elliott, individually and on behalf of all others similarly situated v. MBIA Inc., Ambac Financial Group, Inc., Ambac Assurance Corporation, MBIA Insurance Corporation, and National Public Finance Guarantee Corporation (United States District Court for the District of Connecticut, filed on February 12, 2025) (the "COFINA Case"). This putative class action complaint is brought by alleged former holders of bonds issued by the Puerto Rico Sales Tax Financing Corporation ("COFINA") allegedly insured by defendants under financial guaranty insurance policies. On behalf of themselves and all persons and entities that owned such bonds between October 19, 2018, and February 12, 2019, plaintiffs allege that, in connection with the restructuring of COFINA under Title III of the Puerto Rico Oversight, Management, and Economic Stability Act, defendants orchestrated a scheme to improperly use their role in the Title III process to alter contracts with insured COFINA bondholders, resulting in such bondholders receiving less than what they contracted for under the financial guaranty insurance policies. Plaintiffs assert claims for breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment, and bad faith refusal to pay first-party benefits under an insurance contract. Plaintiffs seek an unspecified amount of damages with interest thereon, disgorgement of profits, a declaratory judgment of plaintiffs' rights and defendants' responsibilities, and a permanent injunction against violations of law. On November 14, 2025, the Court found that Defendants were entitled to a stay of discovery. On February 13, 2026, the Court entered an order dismissing Plaintiffs' claims against Ambac Financial Group, Ambac Assurance Corporation, MBIA Insurance Corporation, and National public Finance Guarantee Corporation for lack of personal jurisdiction; Plaintiffs' claims against MBIA Inc. were dismissed for failure to state a claim, with leave to file a second amended complaint on or about March 6, 2026.

**Litigation in Legacy Financial Guarantee Business**

AAC is involved in litigation as described in Note 19. *Commitments and Contingencies* to the Consolidated Financial Statements in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Note 13. *Commitments and Contingencies* to the Unaudited Consolidated Financial Statements in the Company's Report on Form 10-Q for the quarterly period ended June 30, 2025. Following completion of the AAC sale, AFG no longer has any exposure to such matters other than the COFINA Case, in which AFG is a named defendant.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **92** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure** — None.

**Item 9A. &nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures**

**<u>Evaluation of Disclosure Controls and Procedures</u>**. Octave's disclosure controls and procedures are designed to ensure that information required to be disclosed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, including without limitation that information required to be disclosed by Octave in its SEC filings is accumulated and communicated to management, including the Chief Executive Officer (CEO) and Chief Financial Officer (CFO) as appropriate to allow for timely decisions regarding required disclosure.

Octave's Disclosure Committee assists the CEO and CFO in their responsibilities to design, establish, maintain and evaluate the effectiveness of disclosure controls and procedures. The Disclosure Committee is responsible for, among other things, the oversight, maintenance and implementation of the disclosure controls and procedures, subject to the supervision and oversight of the CEO and CFO. Octave's management, with the participation of its CEO and CFO, has evaluated the effectiveness of Octave's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of December 31, 2025 and, the CEO and CFO have concluded that at that date Octave's disclosure controls and procedures were effective at the reasonable assurance level.

**<u>Management's Report on Internal Control Over Financial Reporting</u>**. Management of Octave is responsible for establishing and maintaining adequate internal control over financial reporting. Octave's internal control over financial reporting is a process designed under the supervision of the CEO and CFO and overseen by Octave's Board of Directors to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Octave's financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. Octave's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of Octave; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of Octave; and (iii) provide reasonable assurance regarding the prevention or timely detection and remediation of unauthorized acquisition, use or disposition of Octave's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become

inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Octave management conducted an assessment of the effectiveness of Octave's internal control over financial reporting based on the criteria established in the Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

Octave management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives.

Under guidelines established by the SEC, companies are permitted to exclude certain acquisitions from their first assessment of internal control over financial reporting following the date of acquisition. Based on those guidelines, management's assessment of the effectiveness of Octave Specialty Group Inc.'s internal control over financial reporting at December 31, 2025 excluded certain processes of ArmadaCorp. Limited which were not integrated into the Company's existing internal control over financial reporting environment at December 31, 2025. The excluded ArmadaCorp processes represented approximately 2% of the Company's total assets and approximately 2% of the Company's total revenues, respectively.

Based on its evaluations, Octave's management has concluded that, as of December 31, 2025, our internal control over financial reporting was effective based on the criteria articulated in the 2013 Internal Control - Integrated Framework, excluding the above noted processes of ArmadaCorp. The effectiveness of our internal control over financial reporting as of December 31, 2025 has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report, which expressed an unqualified opinion on the effectiveness of Octave's internal control over financial reporting.

**<u>Changes in Internal Control Over Financial Reporting</u>**. Octave expects to complete the assessment of the design of ArmadaCorp internal controls over financial reporting by October 31, 2026. There were no changes in the Company's internal control over financial reporting that occurred during the fourth quarter of 2025 that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Management has formally incorporated Octave Ventures into Octave's program for internal control over financial reporting effective August 1, 2025. Accordingly, Octave Ventures is included in the scope of management's control assessments beginning with the third quarter of 2025.

The Company completed the sale of AAC on September 29, 2025 (refer to Sale of AAC in the Overview section of Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations). Subsequent to the Sale, AAC continued to perform certain services for the Company under a transition support agreement between the parties. These services included certain accounting and information technology activities that supported the preparation of the Company's

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **93** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

Unaudited Consolidated Financial Statements included in Part 1 of this Form 10-Q.

Effective January 1, 2025, Octave Specialty Group, Inc. changed the general ledger and consolidation system and certain related processes used for a substantial portion of its continuing operations. Additional entities comprising OSG's continuing operations will be converting onto the new general ledger system in 2025 and 2026. As part of its implementation, the Company evaluated the impact of this new system on its internal control over financial reporting and made changes to controls and procedures where necessary.

**Item 9B.&nbsp;&nbsp;&nbsp;&nbsp;Other Information**

In the last fiscal quarter, none of our directors or executive officers adopted, terminated, or modified any contract, instruction or written plan for the purchase or sale of company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) and/or any non-Rule 10b5-1 trading arrangement. No other matters require disclosure.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **94** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**PART III**<br>

**Item 10.&nbsp;&nbsp;&nbsp;&nbsp;Directors, Executive Officers and Corporate Governance**

Information relating to OSG's executive officers and directors, including its audit committee and audit committee financial experts, will be in OSG's definitive Proxy Statement for its 2026 Annual Meeting of Stockholders which will be filed within 120 days of the end of our fiscal year ended December 31, 2025 (the "2026 Proxy Statement") and is incorporated herein by reference.

Octave has a Code of Business Conduct and Ethics which promotes management's commitment to integrity and expresses Octave's standards for ethical behavior by providing guidelines for handling business situations appropriately. This code can be found on Octave's website at <u>www.octavegroup.com</u> on the "Sustainability" page under "Governance Documents." Octave will disclose on its website any amendment to, or waiver from, a provision of its Code of Business Conduct and Ethics that applies to its Chief Executive Officer, Chief Financial Officer or Chief Accounting Officer. Octave's corporate governance guidelines and the charters for the committees of the Board of Directors are also available on our website under the "Governance Documents" page. The reference to our website address does not constitute inclusion or incorporation by reference of the information contained on our website in this Annual Report on Form 10-K or other filings with the SEC and the information contained on our website is not part of this document.

**Item 11.&nbsp;&nbsp;&nbsp;&nbsp;Executive Compensation**

Information relating to Octave's executive officer and director compensation will be in the 2026 Proxy Statement and is incorporated herein by reference.

**Item 12.&nbsp;&nbsp;&nbsp;&nbsp;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

Information relating to security ownership of certain beneficial owners of OSG's common stock and information relating to the security ownership of OSG's management, as well as information related to equity compensation plans, will be in the 2026 Proxy Statement and is incorporated herein by reference.

**Item 13.&nbsp;&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions, and Director Independence**

Information relating to Octave with respect to certain relationships and related transactions and director independence will be in the 2026 Proxy Statement and is incorporated herein by reference.

**Item 14.&nbsp;&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services**

Information relating to principal accountant fees and services will be in the 2026 Proxy Statement and is incorporated herein by reference.

**PART IV**<br>

**Item 15.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits, Financial Statement Schedules**

**(a)&nbsp;&nbsp;&nbsp;&nbsp;Documents filed as a part of this report:** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements</u> 

The consolidated financial statements included in Part II, Item 8 above are filed as part of this Annual Report on Form 10-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statement Schedules</u> 

The financial statement schedules filed herein, which are the only schedules required to be filed, are as follows:

---

| | |
|:---|:---|
| | **Page** |
| <u>[Schedule I — Summary of Investments Other Than Investments in Related Parties](#i9cb0e1a24c9141e0943a78b7b32afc92_280)</u> | [99](#i9cb0e1a24c9141e0943a78b7b32afc92_280) |
| <u>[Schedule II — Condensed Financial Information of Registrant (Parent Company Only)](#i9cb0e1a24c9141e0943a78b7b32afc92_283)</u> | [100](#i9cb0e1a24c9141e0943a78b7b32afc92_283) |
| <u>[Schedule III](#i9cb0e1a24c9141e0943a78b7b32afc92_292)[—](#i9cb0e1a24c9141e0943a78b7b32afc92_283)[Supplementary Insurance Information](#i9cb0e1a24c9141e0943a78b7b32afc92_292)</u> | [105](#i9cb0e1a24c9141e0943a78b7b32afc92_292) |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **95** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| |<br>**Exhibit Description** | **Form** | **Filing Date** | **Exhibit Number** |<br>**Filed Herewith** |
| **(2)&nbsp;&nbsp;&nbsp;&nbsp;Plan of Acquisition/Reorganization:** | **(2)&nbsp;&nbsp;&nbsp;&nbsp;Plan of Acquisition/Reorganization:** | **(2)&nbsp;&nbsp;&nbsp;&nbsp;Plan of Acquisition/Reorganization:** | | | |
| 2.1 | <u>[Second Modified Fifth Amended Plan of Reorganization of Ambac Financial Group, Inc., effective as of May 1, 2013](https://www.sec.gov/Archives/edgar/data/874501/000119312514080373/d656491dex993.htm)</u> | 10-K | 03/03/14 | 99.3 |  |
| **(3)**&nbsp;&nbsp;&nbsp;&nbsp;**Articles of Incorporation and bylaws:** | **(3)**&nbsp;&nbsp;&nbsp;&nbsp;**Articles of Incorporation and bylaws:** | **(3)**&nbsp;&nbsp;&nbsp;&nbsp;**Articles of Incorporation and bylaws:** |  |  |  |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of](https://www.sec.gov/Archives/edgar/data/874501/000087450124000172/a02-033ambcxex3x1x2q24x10q.htm)[Octave Specialty](https://www.sec.gov/Archives/edgar/data/874501/000087450124000172/a02-033ambcxex3x1x2q24x10q.htm)[Group, Inc.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000172/a02-033ambcxex3x1x2q24x10q.htm)</u> | 8-K | 11/10/25 | 3.1 |  |
| 3.2 | <u>[Amended](https://www.sec.gov/Archives/edgar/data/874501/000087450123000018/a04-0634q228xk_exhibit21.htm)[and Restated](https://www.sec.gov/Archives/edgar/data/874501/000087450123000018/a04-0634q228xk_exhibit21.htm)[By-Laws of](https://www.sec.gov/Archives/edgar/data/874501/000087450123000018/a04-0634q228xk_exhibit21.htm)[Octave Specialty](https://www.sec.gov/Archives/edgar/data/874501/000087450123000018/a04-0634q228xk_exhibit21.htm)[Group, Inc.](https://www.sec.gov/Archives/edgar/data/874501/000087450123000018/a04-0634q228xk_exhibit21.htm)</u> | 8-K | 11/10/25 | 3.2 |  |
| **(4)**&nbsp;&nbsp;&nbsp;&nbsp;**Instruments defining the rights of security holders, including indentures:** | **(4)**&nbsp;&nbsp;&nbsp;&nbsp;**Instruments defining the rights of security holders, including indentures:** | **(4)**&nbsp;&nbsp;&nbsp;&nbsp;**Instruments defining the rights of security holders, including indentures:** |  |  |  |
| 4.1 | <u>[Description of Capital Stock](https://www.sec.gov/Archives/edgar/data/874501/000114420413025536/v343212_8a12b.htm)</u> | 8-A | 05/01/13 |  |  |
| 4.2 | <u>[Specimen form of common stock certificate](https://www.sec.gov/Archives/edgar/data/874501/000114420413025536/v343212_ex4-1.htm)</u> | 8-A | 05/01/13 | 4.1 |  |
| 4.3 | <u>[Warrant Agreement, by and between Ambac Financial Group, Inc. and American Acorn Holdings, LLC, dated as of September 29, 2025.](https://www.sec.gov/Archives/edgar/data/874501/000162828025043087/a04-0843q258xkex41.htm)</u> | 8-K | 09/29/25 | 4.1 |  |
| **(10)**&nbsp;&nbsp;&nbsp;&nbsp;**Material contracts and management compensation plans and arrangements:** | **(10)**&nbsp;&nbsp;&nbsp;&nbsp;**Material contracts and management compensation plans and arrangements:** | **(10)**&nbsp;&nbsp;&nbsp;&nbsp;**Material contracts and management compensation plans and arrangements:** |  |  |  |
| 10.1 | <u>[Ambac Financial Group, Inc.'s Long-Term Incentive Compensation Plan](https://www.sec.gov/Archives/edgar/data/874501/000087450114000044/ex101ambaclong-termincenti.htm)</u> | 10-Q | 08/11/14 | 10.1 |  |
| 10.2 | <u>[Form of Restricted Stock Unit Award Agreement for directors](a01-015ex102x4q25x10xk.htm)</u> |  |  |  | X |
| 10.3 | <u>[Closing Agreement between Ambac Financial, Group, Inc. and Commissioner of Internal Revenue, dated April 30, 2013](https://www.sec.gov/Archives/edgar/data/874501/000114420413026218/v343563_ex10-2.htm)</u> | 8-K | 05/03/13 | 10.2 |  |
| 10.4 | <u>[Lease, dated as of March 1, 2011, by and between One State Street, LLC and Ambac Assurance Corporation](https://www.sec.gov/Archives/edgar/data/874501/000119312511068809/dex1034.htm)</u> | 10-K | 03/16/11 | 10.34 |  |
| 10.5 | <u>[Ambac Financial Group, Inc. Severance Pay Plan (Applicable to termination on or after December 16, 2021)](https://www.sec.gov/Archives/edgar/data/874501/000087450122000019/a01-010ex1010x4q21x10k.htm)</u> | 10-K | 02/24/22 | 10.10 |  |
| 10.6 | <u>[Lease Modification dated as of September 8, 2015 to the Lease dated as of March 1, 2011, by and between One State Street, LLC and Ambac Assurance Corporation](https://www.sec.gov/Archives/edgar/data/874501/000087450116000126/a01-002exhibit1027x4q1510k.htm)</u> | 10-K | 02/29/16 | 10.27 |  |
| 10.7 | <u>[SUBLEASE dated as of January 30, 2019, between Advance Magazine Publishers Inc. (D/B/A CONDE NAST), and Ambac Assurance Group Corporation](https://www.sec.gov/Archives/edgar/data/874501/000087450120000034/a01-008xex1045x4q1910k.htm)</u> | 10-K | 03/02/20 | 10.45 |  |
| 10.8 | <u>[2020 Incentive Compensation Plan](https://www.sec.gov/Archives/edgar/data/874501/000087450120000064/a05-0102020ambacproxystate.htm)</u> | Def 14A | 04/15/20 | Ex. B |  |
| 10.9 | <u>[Purchase Agreement, by and among, Ambac Assurance Corporation, Ambac Financial Group, Inc. and certain funds or accounts affiliated with or managed by CVC Credit Partners, LLC, CVC Credit Partners Investment Management Limited and EJF Capital LLC, dated as of January 19, 2021](https://www.sec.gov/ix?doc=/Archives/edgar/data/874501/000087450121000021/ambc-20210119.htm)</u> | 8-K | 01/25/21 | 1.01 |  |
| 10.10 | <u>[Executive Stock Deferral Plan dated June 24, 2021](https://www.sec.gov/Archives/edgar/data/874501/000087450121000118/a04-0552q21exhibit101.htm)</u> | 8-K | 06/30/21 | 10.1 |  |
| 10.11 | <u>[Employment Agreement dated as of October 5, 2023, by and among Ambac Financial Group, Inc., Ambac Assurance Corporation and Daniel McGinnis](https://www.sec.gov/Archives/edgar/data/874501/000087450123000150/a03-031ambcex10x2x3q23x10q.htm)</u> | 10-Q | 11/07/23 | 10.2 |  |
| 10.12 | <u>[Form of 2023 Restricted Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick and Ksenak.](https://www.sec.gov/Archives/edgar/data/874501/000087450123000092/a02-029xambcxex101x1q23x10q.htm)</u> | 10-Q | 05/09/23 | 10.1 |  |
| 10.13 | <u>[Form of 2023 Restricted Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. Barranco, Eisman, McGinnis and Ms. Smith.](https://www.sec.gov/Archives/edgar/data/874501/000087450123000092/a02-029xambcxex102x1q23x10q.htm)</u> | 10-Q | 05/09/23 | 10.2 |  |
| 10.14 | <u>[Form of 2023 Performance Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick and Ksenak.](https://www.sec.gov/Archives/edgar/data/874501/000087450123000092/a02-029xambcxex103x1q23x10q.htm)</u> | 10-Q | 05/09/23 | 10.3 |  |
| 10.15 | <u>[Form of 2023 Performance Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. Barranco, Eisman, McGinnis and Ms. Smith.](https://www.sec.gov/Archives/edgar/data/874501/000087450123000092/a02-029xambcxex104x1q23x10q.htm)</u> | 10-Q | 05/09/23 | 10.4 |  |
| 10.16 | <u>[Stipulation and Order - Office of the Commissioner of Insurance of the State of Wisconsin, in the Matter of Ambac Assurance Corporation effective as of February 22, 2024](https://www.sec.gov/Archives/edgar/data/874501/000087450124000040/a01-012ex1038x4q23x10k.htm)</u> | 10-K | 02/27/24 | 10.38 |  |
| 10.17 | <u>[2024 Incentive Compensation Plan](https://www.sec.gov/ix?doc=/Archives/edgar/data/874501/000087450124000119/ambc-20240426.htm)</u> | Def 14A | 04/26/24 | Appendix A |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **96** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| |<br>**Exhibit Description** | **Form** | **Filing Date** | **Exhibit Number** |<br>**Filed Herewith** |
| 10.18 | <u>[Form of 2024 Restricted Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick, Ksenak, McGinnis and Ms. Smith.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000128/a02-032ambcxex101x1q24x10q.htm)</u> | 10-Q | 05/06/24 | 10.1 |  |
| 10.19 | <u>[Form of 2024 Restricted Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. Barranco and Eisman.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000128/a02-032ambcxex102x1q24x10q.htm)</u> | 10-Q | 05/06/24 | 10.2 |  |
| 10.20 | <u>[Form of 2024 Performance Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick, Ksenak, McGinnis and Ms. Smith.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000128/a02-032ambcxex103x1q24x10q.htm)</u> | 10-Q | 05/06/24 | 10.3 |  |
| 10.21 | <u>[Form of 2024 Performance Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. Barranco and Eisman.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000128/a02-032ambcxex104x1q24x10q.htm)</u> | 10-Q | 05/06/24 | 10.4 |  |
| 10.22 | <u>[Stock Purchase Agreement, by and between Ambac Financial Group, Inc. and American Acorn Corporation, dated as of June 4, 2024.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000137/a04-070ex21spa.htm)</u> | 8-K | 06/05/24 | 2.2 |  |
| 10.23 | <u>[Shareholders' Agreement by and among Ambac Financial Group, Inc., Cirrata V LLC, Beat Capital Partners Limited and the sellers set forth therein, dated as of August 1, 2024 .](https://www.sec.gov/Archives/edgar/data/874501/000087450124000166/a04-076exhibit101.htm)</u> | 8-K | 08/02/24 | 10.1 |  |
| 10.24 | <u>[Credit Agreement, by and between Ambac Financial Group, Cirrata V LLC, Cirrata Group, LLC, Cirrata V UK Ltd and UBS AG, dated as of August 1, 2024.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000166/a04-076exhibit102.htm)</u> | 8-K | 08/02/24 | 10.2 |  |
| 10.25 | <u>[Share Purchase Agreement, by and among Ambac Financial Group, Inc., Cirrata V LLC, Beat Capital Partners Limited and the sellers set forth therein, dated as of June 4, 2024.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000131/a04-070ex22beatagreement.htm)</u> | 8-K | 06/05/24 | 2.2 |  |
| 10.26 | <u>[Form of Investor Rights Agreement to be entered into at the closing of the sale of Ambac Assurance Corporation to funds managed by Oaktree Capital Management, L.P.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000131/a04-070ex102invagreement.htm)</u> | 8-K | 06/05/24 | 10.2 |  |
| 10.27 | <u>[Form of Shareholders' Agreement by and among Ambac Financial Group, Inc., Cirrata V LLC, Beat Capital Partners Limited and the sellers set forth therein.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000131/a04-070ex104shagreement.htm)</u> | 8-K | 06/05/24 | 10.4 |  |
| 10.28 | <u>[Commitment Letter dated June 4, 2024, by UBS AG, Stamford Branch and UBS Securities LLC to Cirrata V LLC.](https://www.sec.gov/Archives/edgar/data/874501/000087450124000131/a04-070ex105commitletter.htm)</u> | 8-K | 06/05/24 | 10.5 |  |
| 10.29 | <u>[First Amendment to the Stock Purchase Agreement, by and between Ambac Financial Group, Inc. and American Acorn Corporation, dated as of July 3, 2025.](https://www.sec.gov/Archives/edgar/data/874501/000119312525155881/d933600dex21.htm)</u> | 8-K | 07/07/25 | 2.1 |  |
| 10.30 | <u>[Letter Agreement, by and between Ambac Financial Group, Inc. and American Acorn Corporation, dated as of July 3, 2025.\*](https://www.sec.gov/Archives/edgar/data/874501/000119312525155881/d933600dex101.htm)</u> | 8-K | 07/07/25 | 10.1 |  |
| 10.31 | <u>[First Amendment dated as of June 10, 2025 to the Credit Agreement, by and between Ambac Financial Group, Cirrata V LLC, Cirrata Group, LLC, Cirrata V UK Ltd and UBS AG, dated as of August 1, 2024.](https://www.sec.gov/Archives/edgar/data/874501/000087450125000132/a02-036ambcxex103x2q25x10q.htm)</u> | 10-Q | 08/07/25 | 10.3 |  |
| 10.32 | <u>[Form of 2025 Performance Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick, Ksenak, McGinnis and Ms. Smith.](https://www.sec.gov/Archives/edgar/data/874501/000087450125000132/a02-036ambcxex104x2q25x10q.htm)</u> | 10-Q | 08/07/25 | 10.4 |  |
| 10.33 | <u>[Form of 2025 Restricted Stock Unit Award Agreement between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick, Ksenak, McGinnis and Ms. Smith.](https://www.sec.gov/Archives/edgar/data/874501/000087450125000132/a02-036ambcxex105x2q25x10q.htm)</u> | 10-Q | 08/07/25 | 10.5 |  |
| 10.34 | <u>[Investor Rights Agreement, by and between Ambac Financial Group, Inc. and American Acorn Holdings, LLC, dated as of September 29, 2025.](https://www.sec.gov/Archives/edgar/data/874501/000162828025043087/a04-0843q258xkex101.htm)</u> | 8-K | 09/29/25 | 10.1 |  |
| 10.35 | <u>[Membership Interest Purchase Agreement, dated September 29, 2025, by and among Sirius Acquisitions Holding Company, Cirrata VI, LLC, Sirius Re Holdings, Inc., and Ambac Financial Group, Inc.](https://www.sec.gov/Archives/edgar/data/874501/000162828025043137/a04-0863q258xkex1001.htm)</u> | 8-K | 09/29/25 | 10.1 |  |
| 10.36 | <u>[Commitment Letter, dated as of September 29, 2025, by and among Cirrata Group LLC, Cirrata V LLC, Cirrata V UK Limited, Cirrata VI, LLC, Truist Bank and Truist Securities, Inc.](https://www.sec.gov/Archives/edgar/data/874501/000162828025043137/a04-0863q258xkex1002.htm)</u> | 8-K | 09/29/25 | 10.2 |  |
| 10.37 | <u>[Employment Agreement dated as of September 29, 2025 by and among Octave Specialty Group, Inc. (formerly known as Ambac Financial Group, Inc. and Claude LeBlanc.](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q858xkex101.htm)</u> | 8-K | 09/29/25 | 10.1 |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **97** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| |<br>**Exhibit Description** | **Form** | **Filing Date** | **Exhibit Number** |<br>**Filed Herewith** |
| 10.38 | <u>[Employment Agreement dated as of September 29, 2025 by and among Octave Specialty Group, Inc. (formerly known as Ambac Financial Group, Inc.) and David Trick](https://www.sec.gov/Archives/edgar/data/874501/000087450116000286/a02-010ambcex10x2xtrickemp.htm)</u> | 8-K | 09/29/25 | 10.2 | |
| 10.39 | <u>[Employment Agreement dated as of September 29, 2025 by and among Octave Specialty Group, Inc. (formerly known as Ambac Financial Group, Inc.](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q258xkex103.htm)[and](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q258xkex103.htm)[R. Sharon Smith](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q258xkex103.htm)</u> | 8-K | 09/29/25 | 10.3 | |
| 10.40 | <u>[Form of Restricted Stock Unit Agreement for Special RSU Award between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick and Ms. Smith](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q258xkex104.htm)</u> | 8-K | 09/29/25 | 10.4 | |
| 10.41 | <u>[Form of Performance Stock Option Agreement for Special Performance-Based Stock Option Award between Ambac Financial Group, Inc. and Messrs. LeBlanc, Trick and Ms. Smith](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q258xkex105.htm)</u> | 8-K | 09/29/25 | 10.5 | |
| 10.42 | <u>[Amendment No. 1 to 2024 Incentive Compensation Plan, dated as of September 26, 2025](https://www.sec.gov/Archives/edgar/data/874501/000162828025043138/a04-0853q258xkex106.htm)</u> | 8-K | 09/29/25 | 10.6 | |
| 10.43 | <u>[Credit Agreement, dated as of October 31, 2025, by and among Cirrata Group LLC, Cirrata V LLC, Cirrata V UK Limited, Cirrata VI, LLC, ArmadaCorp Capital, LLC, ArmadaCare, LLC, Armada Administrators LLC, the several banks and other financial institutions and lenders from time to time party thereto, and Truist Bank\*](https://www.sec.gov/Archives/edgar/data/874501/000162828025047943/a04-0883q258xkex101.htm)</u> | 8-K | 11/03/25 | 10.1 | |
| 10.44 | <u>[Employment Agreement dated as of August](a01-015ex1044x4q25x10k.htm)[1](a01-015ex1044x4q25x10k.htm)[1](a01-015ex1044x4q25x10k.htm)[, 2025, by and among Ambac Financial Group, Inc. and Lawrence Metz](a01-015ex1044x4q25x10k.htm)</u> | | | | X |
| **(19) Insider Trading Policy** | **(19) Insider Trading Policy** |  |  |  |  |
| 19.1 | <u>[Octave](a01-015ex191x4qx10kr.htm)[Insider Trading Policy](a01-015ex191x4qx10kr.htm)</u> | 10-K |  |  | X |
| **(97)**&nbsp;&nbsp;&nbsp;&nbsp;**Recoupment Policy** | **(97)**&nbsp;&nbsp;&nbsp;&nbsp;**Recoupment Policy** |  |  |  |  |
| 97.1 | <u>[Octave Specialty Group, Inc. - Recoupment Policy](https://www.sec.gov/Archives/edgar/data/874501/000087450124000040/a01-012ex971x4q23x10k.htm)</u> | 10-K | 02/27/24 | 97.1 |  |
| **Other exhibits, filed or furnished, as indicated:** | **Other exhibits, filed or furnished, as indicated:** |  |  |  |  |
| 21.1 | <u>[List of Subsidiaries of](a01-015ex211x4q25x10k.htm)[Octave Specialty](a01-015ex211x4q25x10k.htm)[Group, Inc.](a01-015ex211x4q25x10k.htm)</u> |  |  |  | X |
| 23.1 | <u>[Consent of Independent Registered Public Accounting Firm](a01-015ex231x4q25x10k.htm)</u> |  |  |  | X |
| 24.1 | <u>[Power of Attorney for directors of](a01-015ex241x4q25x10k.htm)[Octave Specialty](a01-015ex241x4q25x10k.htm)[Group, Inc.](a01-015ex241x4q25x10k.htm)</u> |  |  |  | X |
| 31.1 | <u>[Certification of Chief Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) Promulgated under the Securities Exchange Act of 1934, as amended](a01-015ex311x4q25x10k.htm)</u> |  |  |  | X |
| 31.2 | <u>[Certification of Chief Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) Promulgated under the Securities Exchange Act of 1934, as amended](a01-015ex312x4q25x10k.htm)</u> |  |  |  | X |
| 32.1++ | <u>[Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](a01-015ex321x4q25x10k.htm)</u> |  |  |  | X |
| 101.INS | XBRL Instance Document. |  |  |  |  |
| 101.SCH | XBRL Taxonomy Extension Schema Document. |  |  |  |  |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. |  |  |  |  |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. |  |  |  |  |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. |  |  |  |  |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. |  |  |  |  |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |  |  |  |  |
|  | ++ Furnished herewith. |  |  |  |  |
|  | \* Certain schedules and other similar attachments to such agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish a copy of such omitted documents to the SEC upon request. |  |  |  |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **98** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**SCHEDULE I**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Summary of Investments**

**Other Than Investments in Related Parties**

**December 31, 2025**

---

| | | | |
|:---|:---|:---|:---|
| **Type of Investment<br>($ in thousands)** | **Cost** | **Estimated**<br>**Fair Value** | **Amount at Which**<br>**Shown in the**<br>**Balance Sheet** |
| Municipal obligations | $**11697** | $**11590** | $**11590** |
| Corporate obligations | **67881** | **66573** | **66573** |
| U.S. government obligations | **35190** | **35424** | **35424** |
| Residential mortgage-backed securities | **1604** | **1597** | **1597** |
| Commercial mortgage-backed securities | **3307** | **3341** | **3341** |
| Collateralized debt obligations | **1963** | **1975** | **1975** |
| Other asset-backed securities | **1772** | **1795** | **1795** |
| Short-term | **146434** | **146442** | **146442** |
| Other <sup>(1)</sup> | **—** | **7454** | **24971** |
| **Total** | $**269848** | $**276191** | $**293708** |

---

(1) &nbsp;&nbsp;&nbsp;&nbsp;Excluded from the estimated fair value amount are equity securities with a carrying value of $17,517 as of December 31, 2025, that do not have readily determinable fair values and are carried on the balance sheet at cost, less impairment, and adjusted to fair value when observable price changes in identical or similar investments from the same issuer occur, as permitted under the Investments — Equity Securities Topic of the ASC.

See the Report of Independent Registered Public Accounting Firm.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **99** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**SCHEDULE II**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Condensed Financial Information**

**of Registrant (Parent Company Only)**

**Condensed Balance Sheets**

---

| | | |
|:---|:---|:---|
| **($ in thousands, except share data) December 31,** | **2025** | **2024** |
| **Assets:** |  |  |
| Fixed maturity securities, at fair value (amortized cost of $151 and $0) | $**153** | $— |
| Short-term investments, at fair value (amortized cost of $39,344 and $64,439) | **39344** | 64439 |
| Other investments | **24971** | 28117 |
| Total investments (net of allowance for credit losses of $0 and $0) | **64468** | 92556 |
| Cash and cash equivalents | **10127** | 9981 |
| Investment in subsidiaries | **645507** | 679150 |
| Deferred tax asset | **1497** | 1497 |
| Other assets | **8750** | 21476 |
| **Total assets** | $**730349** | $**804660** |
| **Liabilities and Stockholders' Equity:** |  |  |
| **Liabilities:** |  |  |
| Accounts payable and other liabilities | **14559** | 6296 |
| **Total liabilities** | **14559** | **6296** |
| **Stockholders' equity:** |  |  |
| Preferred stock, par value $0.01 per share; 20,000,000 shares authorized shares; issued and outstanding shares—none | **—** |  |
| Common stock, par value $0.01 per share; 130,000,000 shares authorized; issued shares: 48,876,882 and 48,875,167 | **489** | 489 |
| Additional paid-in capital | **369860** | 331007 |
| Accumulated other comprehensive income (loss) | **8483** | (188436) |
| Retained earnings | **370431** | 683643 |
| Treasury stock, shares at cost: 3,871,598 and 2,368,194 | **(33473)** | (28339) |
| **Total Octave Specialty Group, Inc. stockholders' equity** | **715790** | **798364** |
| **Total liabilities and stockholders' equity** | $**730349** | $**804660** |

---

*The condensed financial statements should be read in conjunction with the consolidated financial statements and notes thereto and the following notes.*

See the Report of Independent Registered Public Accounting Firm.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **100** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**SCHEDULE II**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Condensed Financial Information**

**of Registrant (Parent Company Only)**

**Condensed Statement of Comprehensive Income**

---

| | | | |
|:---|:---|:---|:---|
| **($ in thousands) Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Revenues:** |  |  |  |
| Investment income | $**2333** | $7262 | $9298 |
| Other income | **(142)** | (415) | 6 |
| Net gains on derivative contracts |  | 3910 | (348) |
| Net investment gains (losses), including impairments | **(3088)** | (498) | 55 |
| Total revenues | **(897)** | 10259 | 9011 |
| **Expenses:** |  |  |  |
| General and administrative expenses | **82970** | 41519 | 21597 |
| Total expenses | **82970** | 41519 | 21597 |
| Income (loss) before income taxes and net income (loss) of subsidiaries | **(83867)** | (31260) | (12586) |
| Federal income tax provision (benefit) | **(483)** | (1748) | (1193) |
| Income (loss) before net income (loss) of subsidiaries | **(83384)** | (29512) | (11393) |
| Net income (loss) of subsidiaries | **(15020)** | (29770) | (13158) |
| Net income (loss) from continuing operations | **(98404)** | (59282) | (24551) |
| Net income (loss) from discontinued operations | **(163288)** | (497167) | **28183** |
| Net income (loss) | $**(261692)** | $**(556449)** | $**3632** |
| **Other comprehensive income (loss), after tax:** |  |  |  |
| Net income (loss) | $**(261692)** | $(556449) | $3632 |
| &nbsp;&nbsp;Unrealized gains (losses) on securities, net of income tax provision (benefit) of $0, $1,295 and $2,095 | **19643** | (939) | 51184 |
| &nbsp;&nbsp;Gains (losses) on foreign currency translation, net of income tax provision (benefit) of $0, $0 and $0 | **176167** | (22156) | 40132 |
| &nbsp;&nbsp;Credit risk changes of fair value option liabilities, net of income tax provision (benefit) of $0, $(118) and $177 | **1108** | (356) | (88) |
| &nbsp;&nbsp;Changes to postretirement benefit, net of income tax provision (benefit) of $0, $0 and $0 | **—** | (4939) | 1569 |
| &nbsp;&nbsp;Total other comprehensive income (loss) | **196918** | (28390) | 92797 |
| &nbsp;&nbsp;**Total comprehensive income (loss) attributable to Octave Specialty Group, Inc.** | $**(64774)** | $**(584839)** | $**96429** |

---

*The condensed financial statements should be read in conjunction with the consolidated financial statements and notes thereto and the following notes.*

See the Report of Independent Registered Public Accounting Firm.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **101** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**SCHEDULE II**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Condensed Financial Information**

**of Registrant (Parent Company Only)**

**Condensed Statement of Stockholders' Equity**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **($ in thousands)** | **Total** | **Preferred**<br>**Stock** | **Common**<br>**Stock** | **Additional Paid-in**<br>**Capital** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income (Loss)** | **Retained**<br>**Earnings** | **Common**<br>**Stock Held**<br>**in Treasury,**<br>**at Cost** |
| **Balance at January 1, 2023** | $**1252331** | $**—** | $**467** | $**274486** | $**(252843)** | $**1245491** | $**(15270)** |
| &nbsp;&nbsp;Total comprehensive income (loss) | 96430 |  |  |  | 92797 | 3633 |  |
| &nbsp;&nbsp;Stock-based compensation | 17275 |  |  | 17275 |  |  |  |
| &nbsp;&nbsp;Cost of shares (acquired) issued under equity plan | (4665) |  |  |  |  | (7872) | 3207 |
| &nbsp;&nbsp;&nbsp;Cost of shares repurchased | (4510) |  |  |  |  |  | (4510) |
| &nbsp;&nbsp;Changes to NCI | 4797 |  |  |  |  | 4797 |  |
| **Balance at December 31, 2023** | **1361658** | **—** | **467** | **291761** | **(160046)** | **1246048** | **(16573)** |
| &nbsp;&nbsp;Total Comprehensive net income (loss) | (584839) |  |  |  | (28390) | (556449) |  |
| &nbsp;&nbsp;Stock-based compensation | 8995 |  |  | 8995 |  |  |  |
| &nbsp;&nbsp;Cost of shares (acquired) issued under equity plan | (701) |  |  |  |  | (634) | (67) |
| &nbsp;&nbsp;Cost of shares repurchased | (11699) |  |  |  |  |  | (11699) |
| &nbsp;&nbsp;Changes to NCI | (4278) |  |  | 1044 |  | (5322) |  |
| &nbsp;&nbsp;Issuance of common stock | 29229 |  | 22 | 29207 |  |  |  |
| **Balance at December 31, 2024** | **798364** | **—** | **489** | **331007** | **(188436)** | **683642** | **(28339)** |
| &nbsp;&nbsp;&nbsp;Total comprehensive income (loss) | **(64773)** |  |  |  | **196919** | **(261692)** |  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | **9707** |  |  | **9707** |  |  |  |
| &nbsp;&nbsp;&nbsp;Cost of shares (acquired) issued under equity plan | **(8535)** |  |  |  |  | **(33343)** | **24808** |
| &nbsp;&nbsp;&nbsp;Cost of shares repurchased | **(29942)** |  |  |  |  |  | **(29942)** |
| &nbsp;&nbsp;&nbsp;Changes to NCI | **(6031)** |  |  | **12146** |  | **(18177)** | **—** |
| &nbsp;&nbsp;&nbsp;Issuance of warrants in connection with sale of AAC | **17000** | **—** | **—** | **17000** | **—** | **—** | **—** |
| &nbsp;&nbsp;&nbsp;**Balance at December 31, 2025** | $**715790** | $**—** | $**489** | $**369860** | $**8483** | $**370431** | $**(33473)** |

---

*The condensed financial statements should be read in conjunction with the consolidated financial statements and notes thereto and the following notes.*

See the Report of Independent Registered Public Accounting Firm.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **102** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

<u>[**Table of Contents**](#i9cb0e1a24c9141e0943a78b7b32afc92_7)</u>

**SCHEDULE II**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Condensed Financial Information**

**of Registrant (Parent Company Only)**

**Condensed Statements of Cash Flow**

---

| | | | |
|:---|:---|:---|:---|
| **($ in thousands) Year Ended December 31,** | **2025** | **2024** | **2023** |
| **Cash flows from operating activities:** |  |  |  |
| Net income (loss) | $**(261692)** | $(556449) | $3632 |
| Loss from discontinued operations | **163288** | 497167 |  |
| Net income (loss) from continuing operations | $**(98404)** | $(59282) | $3632 |
| Adjustments to reconcile net income loss to net cash used in operating activities: |  |  |  |
| &nbsp;&nbsp;Equity in undistributed net (income) loss of subsidiaries | **15020** | 29770 | (15027) |
| &nbsp;&nbsp;Increase (decrease) in current income taxes payable | **1613** | (1970) | (1674) |
| &nbsp;&nbsp;Share-based compensation | **9707** | 8361 | 9404 |
| &nbsp;&nbsp;(Increase) decrease in other assets and liabilities | **26256** | 7817 | (4660) |
| &nbsp;&nbsp;Distributions received from majority owned subsidiaries | **15343** | 10739 | 8032 |
| &nbsp;&nbsp;Other, net | **(128)** | 2312 | 2337 |
| **Net cash provided by (used in) operating activities** | **(30593)** | **(2253)** | **2044** |
| **Cash flows from investing activities:** |  |  |  |
| Proceeds from sales and matured bonds | **1305** | 5000 |  |
| Purchases of bonds | **(1446)** |  | (795) |
| Change in short-term investments | **25095** | 91249 | 19676 |
| Change in other investments | **3146** | (1749) | (2715) |
| Proceeds from sale, net of cash transferred | **407300** |  |  |
| Other, net | **(7115)** |  |  |
| **Net cash provided by (used in) investing activities** | **428285** | **94500** | **16166** |
| **Cash flows from financing activities:** |  |  |  |
| Capital contribution to subsidiaries | **(384604)** | (70817) | (16050) |
| Cost of shares acquired | **(29942)** | (11699) | (4510) |
| Issuance of warrants | **17000** |  |  |
| **Net cash (used in) financing activities** | **(397546)** | **(82516)** | **(20560)** |
| **Net cash flow** | **146** | **9731** | **(2350)** |
| Cash at beginning of period | **9981** | 250 | 2600 |
| **Cash at end of period** | $**10127** | $**9981** | $**250** |
| **<u>Supplemental disclosure of cash flow information:</u>** |  |  |  |
| **Cash paid during the period for:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Income taxes | $**—** | $— | $— |
| **Non-cash financing activity:** |  |  |  |
| &nbsp;&nbsp;&nbsp;Octave common stock issued as partial consideration to acquire Octave Ventures | $**—** | $29229 | $— |

---

*The condensed financial statements should be read in conjunction with the consolidated financial statements and notes thereto and the following notes.*

See the Report of Independent Registered Public Accounting Firm.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **103** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**<u>**Table of Contents**</u>**

**SCHEDULE II**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Condensed Financial Information**

**of Registrant (Parent Company Only)**

**Notes to Condensed Financial Information**

**(Dollar Amounts in Thousands)**

The condensed financial information of Octave Specialty Group, Inc. ("OSG" or the "Registrant") as of December 31, 2025 and 2024, and for the three years in the period ended December 31, 2025, should be read in conjunction with the consolidated financial statements of Octave Specialty Group, Inc. and Subsidiaries and the notes thereto included in this Annual Report on Form 10-K for the year ended December 31, 2025. Investments in subsidiaries are accounted for using the equity method of accounting.

OSG, headquartered in New York City, is an insurance holding company incorporated in the state of Delaware on April 29, 1991.

**Income Taxes**

OSG files a consolidated U.S. federal income tax return with its 80% or greater owned U.S. subsidiaries. Beat's US subsidiaries file separate U.S. federal income tax returns as they are not directly owned by OSG for tax purposes. OSG and its subsidiaries also file separate or combined income tax returns in various states, local and foreign jurisdictions. As of December 31, 2025, the Company has $1,690,842 of NOLs, which if not utilized will begin expiring in 2030, and $118,910 of NOLs that carryforward indefinitely.

**Sale of AAC**

On September 29, 2025, the Company completed the sale of AAC pursuant to the June 4, 2024, stock purchase agreement (the "Purchase Agreement") with American Acorn Corporation (the "Buyer"), a Delaware corporation owned by funds managed by Oaktree Capital Management, L.P., pursuant to which OSG sold all of the issued and outstanding shares of common stock of AAC, a wholly-owned subsidiary of OSG, to Buyer for $420,000 in cash (the "Sale"). The Buyer also made an additional payment to OSG in an amount of $4,300. In the Sale, Buyer acquired complete common equity ownership of AAC and all of its wholly owned subsidiaries, including Ambac Assurance UK Limited. In connection with and pursuant to the Purchase Agreement, OSG issued to Buyer a warrant exercisable for 5,092,707 shares of common stock, par value $0.01, of OSG. Refer to Note 5. Discontinued Operations of the Notes to the Consolidated Financial Statements under Part II, Item 8 in this Annual Report on Form 10-K for further details on the sale of AAC.

For all periods leading up to the Sale, AAC's results of operations and OSG's loss on sale are reported within Net income (loss) from discontinued operations before tax on the Consolidated Statement of Comprehensive Income (Loss). See Note 5. Discontinued Operations of the Notes to the Consolidated Financial Statements under Part II, Item 8 of this Annual Report on Form 10-K for additional information.

**Acquisition of ArmadaCorp**

On October 31, 2025, the Company closed on the acquisition of ArmadaCorp for a purchase price of $250,000. The Company purchased all of the issued and outstanding limited liability company interests in ArmadaCorp from Sirius Re Holdings, Inc. and Sirius Acquisitions Holding Company, funded in part by $120,000 of loans obtained under new credit facilities. Refer to Note 4. Business Combination in Part II, Item 8 in this Annual Report on Form 10-K for further details on the acquisition of ArmadaCorp.

ArmadaCorp includes an MGA/U that focuses on supplemental health and benefit products for C-suite executives and other key talent. ArmadaCorp creates and distributes supplemental benefit solutions and insurance products. ArmadaCorp's differentiated product offering in the A&H market provides both line of business and product diversification to the Company, while also increasing exposure to non-correlated A&H business lines. ArmadaCorp also provides clients with tools to navigate the healthcare system, including services that help match individuals with physicians suited to their personal needs, and maintains a provider of third-party administration services for insurance carriers that distribute the benefit products and handle claims.

**Pivix**

Effective September 1, 2025, OSG's wholly owned subsidiary, Octave Partners LLC ("Octave Partners"), exercised its option to convert its $3,500 convertible note investment in Pivix Specialty Insurance Services ("Pivix"), an excess and surplus lines MGA/U, into common stock. As a result, Octave Partners now has an approximately 74% controlling stake in Pivix when combined with its previous 17% minority equity interest and includes Pivix in its consolidated financial statements.

**Immaterial Correction of Prior Period Error**

As disclosed in Note 2. Basis of Presentation, the Company identified an immaterial prior period error in the Consolidated Stockholders' Equity statement related to the redeemable non-controlling interest associated with the redemption value adjustment recorded under ASC 810-10. In Schedule II, Condensed Financial Information of Registrant (Parent Company Only) Condensed Balance Sheet, the investment in subsidiaries balance and retained earnings as of December 31, 2024 were corrected by $58,542 to reflect the correction to redeemable non controlling interest, which impacted Total assets and Total liabilities and stockholders equity.

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **104** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**<u>**Table of Contents**</u>**

**SCHEDULE III**

**OCTAVE SPECIALTY GROUP, INC. AND SUBSIDIARIES**

**Supplementary Insurance Information**

**(Dollar Amounts in Thousands)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Segment** | **Deferred Acquisition Costs** | **Loss and Loss Adjustment Expense Reserves** | **Unearned Premium** | **Earned Premiums** | **Net Investment Income** | **Loss and Loss Adjustment Expenses (Benefit)** | **Amortization of Deferred Amortization Costs** | **Other Operating Expenses** | **Net Written Premiums** |
| **2025** |  |  |  |  |  |  |  |  |  |
| Specialty Property and Casualty Insurance | $**9732** | $**459990** | $**187178** | $**67232** | $**6811** | $**47193** | $**15790** | $**22090** | $**73898** |
| **2024** |  |  |  |  |  |  |  |  |  |
| Specialty Property and Casualty Insurance | $8572 | $349062 | $182446 | $99005 | $6400 | $72626 | $23666 | $17802 | $88682 |
| **2023** |  |  |  |  |  |  |  |  |  |
| Specialty Property and Casualty Insurance | $10960 | $197089 | $154878 | $51911 | $3795 | $36712 | $10557 | $16449 | $79824 |

---

See the Report of Independent Registered Public Accounting Firm.

**Item 16. Form 10-K Summary**. — None

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **105** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

------

**<u>**Table of Contents**</u>**

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **OCTAVE SPECIALTY GROUP, INC.** | **OCTAVE SPECIALTY GROUP, INC.** |
| Dated: | March 4, 2026 | By: | **/S/ DAVID TRICK** |
|  |  |  | **David Trick** |
|  |  |  | **Executive Vice President and Chief Financial Officer** |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /S/ JEFFREY S. STEIN\* | Chairman of the Board and Director | March 4, 2026 |
| Jeffrey S. Stein |  |  |
| /S/ CLAUDE LEBLANC | President, Chief Executive Officer and Director | March 4, 2026 |
| Claude LeBlanc | (Principal Executive Officer) |  |
| /S/ DAVID TRICK | Executive Vice President and Chief Financial Officer | March 4, 2026 |
| David Trick | (Principal Financial Officer) |  |
| /S/ CRISTINA AHN | Chief Accounting Officer | March 4, 2026 |
| Cristina Ahn | (Principal Accounting Officer) |  |
| /S/ IAN D. HAFT\* | Director | March 4, 2026 |
| Ian D. Haft |  |  |
| /S/ LISA G. IGLESIAS\* | Director | March 4, 2026 |
| Lisa G. Iglesias |  |  |
| /S/ JOAN LAMM-TENNANT\* | Director | March 4, 2026 |
| Joan Lamm-Tennant |  |  |
| /S/ KRISTI A. MATUS\* | Director | March 4, 2026 |
| Kristi A. Matus |  |  |
| /S/ MICHAEL D. PRICE\* | Director | March 4, 2026 |
| Michael D. Price |  |  |
| /S/ LAWRENCE F. METZ | Attorney-in-fact | March 4, 2026 |
| \*By: Lawrence F. Metz |  |  |

---

---

| | | |
|:---|:---|:---|
| **Octave Specialty Group, Inc.** | **106** | &nbsp;&nbsp;&nbsp;&nbsp;**2025 Form 10-K**  |

---

## Exhibit 10.2

Exhibit 10.2

**OCTAVE SPECIALTY GROUP, INC.**

**DIRECTOR RESTRICTED STOCK UNIT AGREEMENT**

[[FIRSTNAME]] [[LASTNAME]] (the "Participant") has been granted a Full Value Award under the Octave Specialty Group, Inc. 2024 Incentive Compensation Plan (the "Plan") in the form of restricted stock units (the "Award"). The Award shall be effective as of [[GRANTDATE]] (the "Grant Date"). The Award shall be subject to the following terms and conditions (sometimes referred to as this "Agreement").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. &nbsp;&nbsp;&nbsp;&nbsp;<u>Defined Terms</u>. Capitalized terms used in this Agreement which are not otherwise defined herein shall have the meaning specified in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. &nbsp;&nbsp;&nbsp;&nbsp;<u>Grant of Restricted Stock Units</u>. Subject to the terms of this Agreement and the Plan, effective as of the Grant Date the Participant is hereby granted [[SHARESGRANTED]] restricted stock units (the "Restricted Stock Units"). This Award contains the right to dividend equivalents units as described in Section 3 ("Dividend Equivalents"). Each Restricted Stock Unit shall become vested as described in Section 4 and each vested Restricted Stock Unit shall be settled in accordance with Section 5.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. &nbsp;&nbsp;&nbsp;&nbsp;<u>Dividend Equivalents</u>. The Participant shall be entitled to Dividend Equivalents, which may consist of Deferred Cash Dividend Equivalents or Dividend Equivalent Units (each as defined below), in accordance with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;*Cash Dividend*. If a dividend with respect to shares of Common Stock is payable in cash, then, as of the applicable dividend payment date, the Participant shall be credited with a right to receive a "Deferred Cash Dividend Equivalent" equal to (i) the cash dividend payable with respect to a share of Common Stock, multiplied by (ii) the number of Restricted Stock Units outstanding (i.e., the number of Restricted Stock Units granted hereunder less the number of such Restricted Stock Units that have settled in accordance with Section 5 below) on the applicable dividend record date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;*Stock Dividend*. If a dividend with respect to shares of Common Stock is payable in shares of Common Stock, then, as of the dividend payment date, the Participant shall be credited with that number of "Dividend Equivalent Units" equal to (i) the number of shares Common Stock distributed in the dividend with respect to a share of Common Stock, multiplied by (ii) the number of Restricted Stock Units outstanding on the applicable dividend record date.

Dividend Equivalents shall be subject to the same vesting provisions as the Restricted Stock Units to which they relate and shall be settled in accordance with Section 5. No Dividend Equivalent Units shall be credited with respect to previously credited Dividend Equivalent Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. &nbsp;&nbsp;&nbsp;&nbsp;<u>Vesting and Forfeiture of Awards</u>. All Restricted Stock Units and Dividend Equivalents shall be unvested unless and until they become vested and nonforfeitable in accordance with this Section 4.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;*Service Vesting*. Subject to the Participant's continuing service on the Board of Directors, and the terms and conditions of this Agreement and the Plan, all of the Restricted Stock Units and associated Dividend Equivalents awarded hereunder shall vest one year after the Grant Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;*Accelerated Vesting*. All Awards and associated Dividend Equivalents

&nbsp;&nbsp;&nbsp;&nbsp;shall vest (i) upon a Change in Control (as defined below), or (ii) in the event of the death of Participant, upon Participant's death. For purposes of this Agreement, "Change in Control" shall mean a change in the ownership or effective control of Octave, or a change in the ownership of a substantially all of the assets of Octave within the meaning of Regs. Section 1.409A-3(i)(5) under Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;*Voluntary Resignation or Termination of Service*. If Participant's service on the Board of Directors terminates by reason of voluntary resignation by Participant or a termination of service (other than for cause), then the Awards and associated Dividend Equivalents under this Agreement shall vest as of the date of such termination equal to (x) the number of then outstanding Awards subject to this Agreement multiplied by (y) a fraction, the numerator of which shall be the number of calendar days which have lapsed since the Grant Date and the denominator of which shall be the number of calendar days from the Grant Date until the next regularly scheduled quarterly grant date pursuant to Octave's director compensation program.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;*Removal For Cause*. All Awards and associated Dividend Equivalents under this Agreement, whether or not vested, shall immediately terminate and shall be forfeited and the Participant shall have no further rights with respect to such Awards upon the removal of the Participant from the Board of Directors for cause.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. &nbsp;&nbsp;&nbsp;&nbsp;<u>Settlement</u>. Subject to the terms and conditions of this Agreement, Restricted Stock Units and associated Dividend Equivalents that have become vested in accordance with Section 4 shall be settled within 30 days of the earliest of (i) the first anniversary of the Grant Date, (ii) Participant's termination of service or (iii) a Change in Control, provided that if such 30-day settlement period begins in one taxable year and ends in a second taxable year, the payment will always be made in the second taxable year. Settlement of the vested Restricted Stock Units and associated Dividend Equivalent Units shall be made in the form of shares of Common Stock with one share of Common Stock being issued in settlement of each Restricted Stock Unit and associated Dividend Equivalent Unit (any fractional share being rounded up to the next whole unit). Settlement of Deferred Cash Dividend Equivalents shall be paid in cash. Upon the settlement of any vested Restricted Stock Units and Dividend Equivalent Units, such Restricted Stock Units and Dividend Equivalent Units shall be cancelled.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. &nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u>. It is expressly understood and agreed that during the term of this Agreement the Participant's relationship to the Company will be that of an independent contractor. The Participant shall have sole and exclusive responsibility for the payment of all of

------

the Participant's (a) federal, state and local income taxes, (b) employment and disability insurance, and (c) Social Security and other similar taxes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. &nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. This Award is not transferable except as designated by the Participant by will or by the laws of descent and distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. &nbsp;&nbsp;&nbsp;&nbsp;<u>Heirs and Successors</u>. If any benefits deliverable to the Participant under this Agreement have not been delivered at the time of the Participant's death, such rights shall be delivered to the Participant's estate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. &nbsp;&nbsp;&nbsp;&nbsp;<u>Administration</u>. The authority to administer and interpret this Agreement shall be vested in the Company's Governance and Nominating Committee, and such Committee shall have all the powers with respect to this Agreement as the "Committee" has under the Plan. Any interpretation of the Agreement by the Governance and Nominating Committee and any decision made by it with respect to the Agreement is final and binding on all persons.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. &nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustment of Award</u>. The number of Restricted Stock Units and Dividend Equivalent Units awarded pursuant to this Agreement may be adjusted (subject to the requirements and limitations of the Code) in accordance with the terms of the Plan to reflect certain corporate transactions which affect the number, type or value of the Common Stock, Restricted Stock Units or Dividend Equivalents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. &nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. The validity, construction and effect of this Agreement shall be determined in accordance with the laws of the State of New York and applicable federal law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. &nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments</u>. The Board of Directors may, at any time, amend or terminate the Plan, and the Board of Directors may amend this Agreement, provided that no amendment or termination may, in the absence of written consent to the change by the affected Participant (or, if the Participant is not then living, the affected beneficiary), adversely affect the rights of any Participant or beneficiary under this Agreement prior to the date such amendment or termination is adopted by the Board of Directors, as the case may be.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp; <u>Deferral</u>. Subject to approval by the Committee, the Participant may be permitted to elect to defer settlement of the vested Restricted Stock Units and associated Dividend Equivalent Units awarded under this Agreement, subject further to the terms of the applicable deferral plan and the applicable deferral election form evidencing such deferral.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp; <u>Severability</u>. If a provision of this Agreement is held invalid by a court of competent jurisdiction, the remaining provisions will nonetheless be enforceable according to their terms. Further, if any provision is held to be overbroad as written, that provision shall be amended to narrow its application to the extent necessary to make the provision enforceable according to applicable law and enforced as amended.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. &nbsp;&nbsp;&nbsp;&nbsp;<u>Plan Governs</u>. The Award evidenced by this Agreement is granted pursuant to the Plan, and the Restricted Stock Units, and Dividend Equivalent Units and this Agreement are in

------

all respects governed by the Plan and subject to all of the terms and provisions thereof, whether such terms and provisions are incorporated in this Agreement by reference or are expressly cited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. &nbsp;&nbsp;&nbsp;&nbsp;<u>Code Section 409A Rules</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;*Compliance*. Notwithstanding anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payments and benefits set forth herein either shall either be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the "Code"), or shall comply with the requirements of Code Section 409A, and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be exempt from or in compliance with Code Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;*Separate Payments*. Notwithstanding anything in this Agreement to the contrary, the right to receive installment payments hereunder shall be treated as a right to receive a series of separate payments in accordance with Code Section 409A and Final Treasury Regulation Section 1.409A-2(b)(2)(iii).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;*Short-Term Deferral*. Except as otherwise specifically provided, amounts payable under this Agreement, other than those expressly payable on a deferred or installment basis, will be paid as promptly as practicable following the date they are earned and vested and, in any event, on or prior to March 15 of the year following the first calendar year in which such amounts are no longer subject to a substantial risk of forfeiture, as such term is defined in Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;*Separation from Service*. Notwithstanding anything in this Agreement or elsewhere to the contrary, a termination of Participant's service with the Board of Directors shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that constitute "non-qualified deferred compensation" within the meaning of Code Section 409A upon or following a termination of Participant's service unless such termination is also a "separation from service" within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a "termination," "termination of service" or like terms shall mean "separation from service" and the date of such separation from service shall be the "Termination Date" for purposes of any such payment or benefits.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;*No Designation*. In no event may Participant, directly or indirectly, designate the calendar year of any payment to be made under this Agreement or otherwise that constitutes a "deferral of compensation" within the meaning of Code Section 409A.

## Exhibit 10.44

Exhibit 10.44

**EMPLOYMENT AGREEMENT** 

This EMPLOYMENT AGREEMENT ("Agreement") is entered into as of August 11, 2025, by and among Ambac Financial Group, Inc., a Delaware corporation ("AFG" or the "Company"), and Lawrence Metz, an individual (the "Executive").

WHEREAS, the Executive is currently employed as the Senior Managing Director & General Counsel of AFG pursuant to that certain offer letter dated August 4, 2025 (the "Offer Letter");

WHEREAS, the Company and the Executive have agreed to enter into this Agreement on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Employment Agreement.</u> On the terms and conditions set forth in this Agreement, AFG agrees to employ the Executive and the Executive agrees to be employed by AFG for the Employment Period set forth in Section 2 and in the position and with the duties set forth in Section 3.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Term.</u> The term of employment under this Agreement shall be for a period beginning on August 11, 2025 (the "Effective Date") and ending on the first anniversary thereof, unless sooner terminated as hereinafter set forth; provided that, on such first anniversary of the Effective Date and on each annual anniversary thereafter (such date and each annual anniversary thereof, a "Renewal Date"), the Agreement shall be deemed to be automatically extended upon the same terms and conditions (except for such terms and conditions that expire prior to any extension period), for successive periods of one year, unless either the Company or the Executive provides written notice of its intention not to extend the term of the Agreement at least ninety (90) days' prior to the applicable Renewal Date. For the avoidance of doubt, a failure to extend the term of the Agreement by a party as described in this Agreement shall require affirmative action of such party. The period during which the Executive is employed by AFG hereunder is hereinafter referred to as the "Employment Period."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Position and Duties</u>. During the Employment Period, the Executive shall serve as the Senior Managing Director & General Counsel of AFG. In such capacity, the Executive shall report directly to the Chief Executive Officer of AFG. During the Employment Period, the Executive shall have the duties, responsibilities and authority as shall be consistent with the Executive's position and such other duties, responsibilities and authority consistent with the Executive's position as may be assigned to the Executive by the Chief Executive Officer of AFG. The Executive shall devote substantially all of the Executive's business efforts to the performance of the Executive's duties hereunder and the advancement of the business and affairs of the Company, provided that in no event shall this sentence prohibit the Executive from creating and managing his personal and family investments or participating in charitable activities, so long as such personal or family investments and charitable activities do not interfere with the Executive's duties under this Agreement and comply with the Company's Code of Business Conduct and Ethics and other policies of the Company as in effect from time to time.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Compensation and Benefits.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Base Salary.</u> Commencing as of the Effective Date and during the Employment Period, the Company shall pay to the Executive a base salary at the rate of four hundred and fifty thousand dollars ($450,000) per calendar year (the "Base Salary"), less applicable deductions, and prorated for any partial month or year, as applicable. The Base Salary shall be reviewed by the Compensation Committee (the "Compensation Committee") of the Board of Directors of AFG (the "Board") no less frequently than annually and may be adjusted in the discretion of the Compensation Committee (but subject to the Executive's right to resign for Good Reason in the event of certain reductions). Any such adjusted Base Salary shall constitute the "Base Salary" for purposes of this Agreement. The Base Salary shall be paid in substantially equal installments in accordance with AFG's regular payroll procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Annual Bonus.</u> For each calendar year that ends during the Employment Period, the Executive shall be eligible to receive an annual bonus pursuant to the Company's annual bonus plan for senior executives. The amount of any such annual bonus paid to the Executive during the Employment Period shall be based on the achievement of pre-established performance goals that are established by the Compensation Committee. With respect to any performance goals that are subjective in nature, the Compensation Committee shall determine, in their discretion, whether and to what extent such performance goals are achieved. The Executive's target annual bonus amount shall be seventy percent (70%) of the Base Salary, as determined by the Compensation Committee, in its discretion; provided, however, that for calendar year 2025, the amount, if any, of the Executive's annual bonus will be pro-rated to reflect the time of service for such year. For the avoidance of doubt, such target annual bonus opportunity does not constitute a guarantee of any bonus payment. Any annual bonus payable to the Executive hereunder shall be paid at the time bonuses are otherwise paid to other executive officers of AFG, but in any event, no later than March 15 of the calendar year following the year with respect to which such annual bonus is earned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Long-Term Incentives</u>. During the Employment Period, the Executive shall be eligible to participate in the AFG 2024 Incentive Compensation Plan (the "Incentive Plan") or any successor plan or additional plan of the Incentive Plan, subject to the terms of any such plan, as determined by the Compensation Committee, in its discretion and subject to the terms of this Agreement. Annual equity awards granted to the Executive under the Incentive Plan shall be similar in form and shall have similar terms and conditions (other than amount) as annual equity awards granted to other senior executives of AFG and shall be granted to the Executive during the annual compensation cycle applicable generally to senior executives of AFG. With respect to each calendar year that commences during the Employment Period, commencing with calendar year 2026, the Executive shall receive an annual long-term incentive ("LTI") award with a target amount of five hundred thousand dollars ($500,000), as determined by the Compensation Committee in its discretion. For the avoidance of doubt, such target annual LTI award opportunity does not constitute a guarantee of any LTI payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Employee Benefits; Perquisites.</u> During the Employment Period, the Executive shall be entitled to participate in all employee benefit plans, practices and programs maintained by the Company, as in effect from time to time, that are generally made available to senior executives of the Company. During the Employment Period, the Executive shall be entitled to fringe benefits and perquisites consistent with the practices and policies of the Company, and to the extent such fringe benefits or perquisites (or both) are generally made available to senior executives of the Company. The Company reserves the right to amend, modify or cancel any employee benefit plans, practices and programs, and any fringe benefits and perquisites, at any time and without the consent of the Executive.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Company Compensation Plans</u>. Except as otherwise provided herein, all compensation provided to the Executive pursuant to Section 4 shall be in accordance with the Company's and Company Affiliates' compensation plans and policies. For purposes of this Agreement, "Company Affiliate" means any entity controlled by, in control of, or under common control with, AFG, including without limitation its direct and indirect subsidiaries.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Clawback/Recoupment</u>. Notwithstanding any other provision in this Agreement to the contrary, any compensation paid to the Executive pursuant to this Agreement or any other agreement or arrangement with the Company shall be subject to (i) any "clawback" or recoupment policy that is applicable to all senior executives of AFG or that is adopted to comply with any applicable law, rule or regulation, or any other requirement, or (ii) any law, rule, requirement or regulation which imposes mandatory recoupment, under circumstances set forth in such law, rule, requirement or regulation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Stock Ownership Guidelines</u>. The Executive shall be required to hold shares of AFG's common stock as required by any stock ownership policy adopted by the Board (or any committee thereof) from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Treatment of Equity and Equity-related Awards</u>. Notwithstanding any provision of this Agreement to the contrary, an equity or equity-related award, as applicable, granted to the Executive following the Effective Date shall be governed by the whichever is more favorable of the terms of the applicable plan or award agreement or this Agreement (including for purposes of determining the Executive rights pursuant to Section 7(d)). For the avoidance of doubt, upon and following vesting of any equity or equity-related awards granted to the Executive at any time, except for recoupment pursuant to clause (i) of Section 4(f), such equity and equity-related awards shall remain vested regardless of the Executive's termination of employment following vesting of the applicable awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Expenses.</u> The Executive is expected and is authorized to incur reasonable expenses in the performance of his duties hereunder. The Company shall reimburse the Executive for all such expenses reasonably and actually incurred in accordance with reasonable policies which may be adopted from time to time by the Company promptly upon periodic presentation by the Executive of an itemized account, including reasonable substantiation, of such expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Termination of Employment.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Permitted Terminations.</u> The Executive's employment is "at will" and may be terminated by either the Executive or the Company at any time and for any or no reason, subject to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Death.</u> The Executive's employment hereunder shall terminate upon the Executive's death;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) <u>By the Company.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) <u>Disability</u>. The Company may terminate the Executive's employment due to the Executive's Disability while such Disability exists. For purposes of this Agreement, "Disability" means a "disability" that entitles the Executive to benefits under the applicable Company long-term disability plan covering the Executive and, in the absence of such a plan, that the Executive shall have been unable, due to physical or mental incapacity, to substantially perform the Executive's duties and responsibilities hereunder for one hundred eighty (180) days out of any three hundred sixty-five (365) day period or for one hundred twenty (120) consecutive days. The Executive agrees, in the event of any question as to the existence, extent or potentiality of the Executive's Disability upon which the Company and the Executive cannot agree shall be resolved by a qualified, independent physician mutually agreed to by the Company and the Executive, the cost of such examination to be paid by the Company. The written

------

medical opinion of such physician shall be conclusive and binding upon each of the parties hereto as to whether a Disability exists and the date when such Disability arose. This section shall be interpreted and applied so as to comply with the provisions of the Americans with Disabilities Act (to the extent applicable) and any applicable state or local laws. Until such termination, the Executive shall continue to receive his compensation and benefits hereunder, reduced by any benefits actually paid to him under any Company-provided disability insurance policy or plan applicable to him; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) <u>Cause.</u> The Company may terminate the Executive's employment for Cause or without Cause.

For purposes of this Agreement, "Cause" shall be limited to the following events: (i) the Executive's gross negligence or willful misconduct in the performance of his duties, (ii) the Executive's conviction of, or plea of guilty or nolo contendere to, a misdemeanor involving moral turpitude that has a substantial adverse effect on the Executive's qualifications or ability to perform his duties, or any felony, (iii) the Executive's failure to attempt to perform lawfully assigned duties consistent with his position or to materially comply with the Company's written material policies, including the Company's Code of Business Conduct and Ethics and any Delegation of Authority Policy of AFG, or (iv) the Executive's material breach of this Agreement. Termination of the Executive's employment shall not be deemed to be for Cause unless and until the Company delivers to the Executive a copy of the resolution duly adopted by the affirmative vote of not less than a majority of the Board (after reasonable written notice is provided to the Executive and the Executive is given a reasonable opportunity, together with counsel, to be heard before the Board), finding that the Executive has engaged in the conduct described in any of (i)-(iv) above. Except for a failure, breach or refusal which, by its nature, cannot reasonably be expected to be cured, or for a termination under clause (ii), the Executive shall have thirty (30) days from the delivery of written notice by the Company within which to cure any acts constituting Cause.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) <u>By the Executive.</u> The Executive may terminate his employment for any reason (including Good Reason) or for no reason. If the Executive terminates his employment without Good Reason, then he shall provide written notice to the Company at least forty-five (45) days prior to the Date of Termination.

For purposes of this Agreement, "Good Reason" means (i) any material diminution in the Executive's title or reporting relationships, (ii) a substantial diminution in the Executive's duties or responsibilities, (iii) the relocation of the Executive's principal place of employment by more than thirty-five (35) miles, (iv) a reduction of the Executive's Base Salary or target annual bonus, other than a uniform reduction applied to substantially all senior executive officers of AFG that does not result in a reduction of more than five percent (5%) of any of the Executive's Base Salary or reduction of the Executive's grant date target value of the annual LTI award below three hundred thousand dollars ($300,000), (v) a material decrease in the employee benefits made available to the Executive, in the aggregate, other than in connection with an across-the-board reduction applicable to substantially all senior executives, (vi) a material breach by AFG of this Agreement, or (vii) non-renewal of the Agreement by the Company regardless of whether the Executive's employment terminates. In order to invoke a termination for Good Reason, the Executive must deliver a written notice of the grounds for such termination within ninety (90) days of the initial existence of the event giving rise to Good Reason and the Company shall have thirty (30) days to cure the circumstances, provided, however, that there shall be no cure for a non-renewal of the Employment Agreement as described in the immediately foregoing clause (vii) of this definition. In order to terminate his employment, if at all, for Good Reason, the Executive must terminate employment within sixty (60) days of the end of the cure period if the circumstances giving rise to Good Reason have not been cured. The Executive acknowledges that, as of the Effective Date, no event that would constitute Good Reason has occurred. The Executive further

------

acknowledges that in the event the Executive is on a period of leave due to a disability and the Company promotes or hires on an interim basis an individual who has a title, if any, that is designated, and who is identified, as "interim" to complete the duties and responsibilities set forth herein solely during the period of such disability, the Executive shall not be permitted to claim "Good Reason" under subsections (i) or (ii) herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Termination</u>. Any termination of the Executive's employment by the Company or the Executive (other than because of the Executive's death) shall be communicated by a written Notice of Termination to the other party hereto in accordance with the requirements of this Agreement. For purposes of this Agreement, a "Notice of Termination" shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon, if any, and shall, in the case of termination for "Cause" or for "Good Reason" set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive's employment. Termination of the Executive's employment shall take effect on the Date of Termination.

For purposes of this Agreement, "Date of Termination" means (i) if the Executive's employment is terminated due to the Executive's death, the date of the Executive's death; (ii) if the Executive's employment is terminated because of the Executive's Disability pursuant to Section 6(a)(ii)(A), thirty (30) days after Notice of Termination, provided that the Executive shall not have returned to the performance of the Executive's duties on a full-time basis during such thirty (30)-day period with reasonable accommodation; (iii) if the Executive's employment is terminated due to the Company's or the Executive's failure to extend the term of the Agreement pursuant to Section 2, the applicable Renewal Date notwithstanding a termination of the Executive's employment by the Company following the date of notice of nonrenewal and prior to the applicable Renewal Date; or (iv) if the Executive's employment is terminated by the Company pursuant to Section 6(a)(ii)(B) or by the Executive pursuant to Section 6(a)(iii), the date specified in the Notice of Termination. Notwithstanding any provision of this Agreement to the contrary, for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered deferred compensation under Section 409A of the Internal Revenue Code of 1986, as amended (the "Code") and the regulations and guidance promulgated thereunder (collectively "Section 409A"), references to the Executive's termination of employment (and corollary terms) with the Company shall be construed to refer to the Executive's "separation from service" (within the meaning of Treas. Reg. Section 1.409A-1(h)) with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Resignation of All Other Positions</u>. Upon termination of the Executive's employment for any reason, the Executive shall be deemed to have resigned from all positions that the Executive holds as a director, officer or employee of AFG or any Company Affiliate and as a fiduciary with respect to any benefit plan (or related trust) sponsored by AFG or any Company Affiliate. The Executive agrees to execute any letter consistent with the foregoing that AFG or any Company Affiliate may reasonably request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Compensation Upon Termination.</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Death.</u> If the Executive's employment is terminated during the Employment Period as a result of the Executive's death, this Agreement and the Employment Period shall terminate without further notice or any action required by the Company or the Executive's legal representatives. Upon the Executive's death, the Company shall pay to the Executive's legal representative or estate, as applicable, (i) the Executive's Base Salary due through the Date of Termination, (ii) all Accrued Benefits, if any, to which the Executive is entitled as of the Date of Termination at the time such payments are due and (iii) subject to execution by the Executive's surviving spouse or in the absence thereof by an individual

------

holding a Power of Attorney from the Executive upon the date of the Executive's death, or by the Executive's estate, a general release of claims substantially in the form of the release attached hereto as <u>Exhibit A</u> (except as may be revised to reasonably reflect changes in applicable law) within the Release Period as defined in Section 7(f): (x) an annual bonus for the year of termination, based on actual full-year performance (with any individual factor being rated at one hundred percent (100%)), pro-rated to reflect the time of service for such year through the Date of Termination, payable at the time the Company pays bonuses to active employees, but in any event, no later than March 15 of the calendar year following the year with respect to which such annual bonus may have been earned; (y) one hundred percent (100%) accelerated vesting of any unvested restricted stock unit awards or performance share unit awards, with such vested restricted stock unit awards and performance share unit awards to be settled within sixty (60) days of the Date of Termination with performance-based awards settled based on the greater of target or actual performance (if measurable) through the Date of Termination ((x) and (y) referred to herein as the "Death/Disability Severance Benefits"). Except as set forth herein, the rights of the Executive's legal representative or estate, as applicable, with respect to the Executive's equity or equity-related awards shall be governed by the applicable terms of the related plan or award agreement. Except as set forth herein, the Company and Company Affiliates shall have no further obligation to the Executive or his legal representatives, estate or heirs upon his death under this Agreement other than such obligations which by their terms continue following termination of the Executive's employment. For purposes of this Agreement, "Accrued Benefits" means (i) any compensation deferred by the Executive prior to the Date of Termination and not paid by the Company or otherwise specifically addressed by this Agreement; (ii) any earned but unpaid annual bonus for the year preceding the year of termination, (iii) any amounts or benefits owing to the Executive or to the Executive's beneficiaries under the then applicable benefit plans of the Company; (iv) any amounts owing to the Executive for reimbursement of expenses properly incurred by the Executive prior to the Date of Termination and which are reimbursable in accordance with Section 5; and (v) any other benefits or amounts due and owing to the Executive under the terms of any plan, program or arrangement of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Disability.</u> If the Company terminates the Executive's employment during the Employment Period because of the Executive's Disability pursuant to Section 6(a)(ii)(A), (A) the Company shall pay to the Executive (i) the Executive's Base Salary due through the Date of Termination, (ii) all Accrued Benefits, if any, to which the Executive is entitled as of the Date of Termination at the time such payments are due and subject to the Executive (or the Executive's personal representative or an individual holding a Power of Attorney from the Executive upon the Date of Termination) executing a general release of claims substantially in the form of the release attached hereto as <u>Exhibit A</u> (except as may be revised to reasonably reflect changes in applicable law) within the Release Period as defined in Section 7(f), the Death/Disability Severance Benefits. Except as set forth herein, the rights of the Executive with respect to the Executive's equity or equity-related awards shall be governed by the applicable terms of the Incentive Plan or award agreement evidencing such award. Except as set forth herein, the Company and Company Affiliates shall have no further obligations to the Executive under this Agreement upon the Executive's termination due to Disability pursuant to Section 6(a)(ii)(A) other than such obligations which by their terms continue following termination of the Executive's employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Termination by the Company for Cause or by the Executive without Good Reason or by the Executive's Failure to Extend the Term.</u> If, during the Employment Period, the Company terminates the Executive's employment for Cause pursuant to Section 6(a)(ii)(B) or the Executive terminates his employment without Good Reason pursuant to Section 6(a)(iii) or the Executive fails to extend the term of the Agreement pursuant to Section 2, the Company shall pay to the Executive the Executive's Base Salary due through the Date of Termination and all Accrued Benefits, if any, to which the Executive is entitled as of the Date of Termination, at the time such payments are due, provided that if the Company

------

terminates the Executive's employment for Cause or the Executive terminates his employment without Good Reason, the Executive's Accrued Benefits shall not include any earned but unpaid annual bonus for the year preceding the year of termination unless otherwise determined by the Compensation Committee. Upon a termination of the Executive's employment by the Company for Cause or by the Executive without Good Reason, or due to the Executive's failure to extend the term of the Agreement, the Executive will forfeit the Executive's rights with respect to all outstanding unvested equity or equity-related awards. Except as set forth herein, the Company and Company Affiliates shall have no further obligations to the Executive under this Agreement upon such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Termination by the Company without Cause or by the Company's Failure to Extend the Term or by the Executive with Good Reason.</u> If, during the Employment Period, other than as set forth in Section 7(e), the Company terminates the Executive's employment other than for Cause pursuant to Section 6(a)(ii)(B) or fails to extend the term of the Agreement pursuant to Section 2 (assuming no Cause then exists) or the Executive terminates his employment with Good Reason pursuant to Section 6(a)(iii), the Company shall pay to the Executive (i) the Executive's Base Salary due through the Date of Termination and (ii) all Accrued Benefits, if any, to which the Executive is entitled as of the Date of Termination, in each case at the time such payments are due. The Executive shall also be entitled to receive, subject to his compliance with the restrictive covenants in Section 8 and the other requirements of this Agreement and his execution and non-revocation of the release described in Section 7(f), the following severance payments and benefits: (1) a lump sum payment equal to one and one half (1.5) times the sum of (i) the Executive's Base Salary and (ii) the amount of the Executive's annual target bonus for the calendar year in which the Date of Termination occurs or if no target bonus has been approved by the Company for the year in which such Date of Termination occurs, then the amount of the Executive's target bonus for the immediately preceding year (as applicable, the "Target Bonus"), (2) a lump sum payment equal to the product of (x) the Executive's annual bonus for the calendar year in which the Date of Termination occurs, based on actual performance through the full performance period, and (y) a fraction, the numerator of which is the number of days the Executive was employed by the Company during the year of termination and the denominator of which is the number of days in such year, with such payment to be made on the same date that other senior executives of the Company receive their annual bonuses, but to be made no later than March 15 of the year following the Executive's Date of Termination (the "Termination Year Bonus"), (3) for up to twelve (12) months following the Date of Termination, the Company shall provide the Executive with the customary outplacement services provided to senior executives of the Company whose employment terminates, which shall be provided by the Company's approved outplacement services vendor and (4) provided the Executive and his eligible dependents timely and properly elect to continue health care coverage under COBRA, with regard to the medical program, the Executive and such eligible dependents shall be entitled to continue to participate in such basic medical and life insurance programs of the Company as in effect from time to time, on the same terms and conditions as applicable to active senior executives of the Company, for twenty-four (24) months or, if earlier, until the date the Executive becomes eligible to receive comparable coverage from another Company or is otherwise no longer eligible to receive COBRA continuation coverage whether under applicable law or otherwise; provided, however, if such medical plan is "self-funded" within the meaning of Code Section 105(h) at the time of termination of employment, then, in lieu of such continued participation in the medical program, the Executive shall be entitled to receive a lump sum payment equal to the portion of the Executive's COBRA premiums equal to twenty-four (24) months of the Company subsidy of group health plan premiums for the Executive and his eligible dependents, subject to applicable withholdings. The lump sum payments described in items (1) and (2), and, if applicable, (4) in the preceding sentence shall be made within ten (10) business days of the Release Effective Date; provided, however, that if the Release Period spans two calendar years, no such amounts subject to Section 409A shall be paid prior to January 1 of the second calendar year. The Executive's rights with

------

respect to equity or equity-related awards shall be governed by the applicable terms of the related plan or award agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Termination by the Company without Cause or by the Executive with Good Reason in connection with a Change in Control</u>. If, during the Employment Period, the Company terminates the Executive's employment other than for Cause pursuant to Section 6(a)(ii)(B) or fails to extend the term of the Agreement pursuant to Section 2 (unless coincidental with a termination for Cause), or the Executive terminates his employment with Good Reason pursuant to Section 6(a)(iii), in each case either (i) in contemplation of and no more than ninety (90) days prior to a Change in Control (as defined below) or (ii) within one (1) year following the occurrence of a Change in Control, then, subject to his compliance with the restrictive covenants in Section 8 and the other requirements of this Agreement and his execution and non-revocation of the release described in Section 7(f), the Executive shall receive the benefits set forth in Section 7(d)(1) – (4) above, except that (i) the lump payment set forth in Section 7(d)(1) shall instead equal two (2) times the sum of (x) the Executive's Base Salary and (y) the amount of the Executive's Target Bonus; (ii) the Termination Year Bonus set forth in Section 7(d)(2) shall be measured at the Target Bonus level rather than actual performance level and to be paid within sixty (60) days of the Date of Termination. Further, (x) to the extent that the Executive's restricted stock unit awards, if any, are not assumed, replaced or continued, such awards shall immediately vest in full and shall be settled within sixty (60) days of the Change in Control; (y) to the extent that the Executive's performance share unit awards, if any, are not assumed, replaced or continued, then such awards shall immediately vest based on the greater of the target or actual performance (or if actual performance cannot be measured at such time, at target performance) as of the date of the Change in Control, to be settled within sixty (60) days of the Change in Control, and (z) notwithstanding the foregoing, if the Incentive Plan (or a successor plan) and applicable award agreement provides for more favorable treatment, such restricted stock unit awards and performance share unit awards shall be governed by the plan and the respective applicable award agreement. With respect to the Executive's outstanding restricted stock unit awards or performance share awards, if any, which are assumed, replaced or continued in connection with the Change in Control, such an award shall continue to have terms applicable upon the Executive's termination of employment with the Company (or with a successor or the successor's parent or affiliate, as applicable) which are no less favorable to the Executive than the terms of the Incentive Plan (or a successor plan) and respective award agreement in effect immediately prior to the Change in Control.

For purposes of this Agreement, "Change in Control" means the occurrence of one or more of the following events: (i) any "person" (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934 as amended (the "Act")) or "group" (as such term is used in Section 13(d)(3) of the Act) is or becomes a "beneficial owner" (as such term is used in Rule 13d-3 promulgated under the Act) of more than thirty percent (30%) of the Voting Stock of AFG; (ii) within any twenty-four (24) month period the majority of the Board consists of individuals other than "Incumbent Directors," which term means the members of the Board on the Effective Date; provided that any person becoming a director subsequent to such date whose election or nomination for election was supported by a majority of the directors who then comprised the Incumbent Directors shall be considered to be an Incumbent Director; (iii) AFG transfers all or substantially all of its assets or business (unless the shareholders immediately prior to such transaction beneficially own, directly or indirectly, in substantially the same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of AFG or AFG's ultimate parent company if AFG is a subsidiary of another corporation); or (iv) any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of AFG immediately prior to the transaction hold, directly or indirectly, more than fifty percent (50%) of the Voting Stock of AFG or AFG's ultimate parent company if AFG is a subsidiary of another corporation

------

(there being excluded from the number of shares held by such shareholders, but not from the Voting Stock of the combined company, any shares received by affiliates of such other company in exchange for stock of such other company). For purposes of this Change in Control definition, AFG shall include any entity that succeeds to all or substantially all of the business of AFG and "Voting Stock" shall mean securities or ownership interests of any class or classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Liquidated Damages.</u> The parties acknowledge and agree that damages which will result to the Executive for termination of the Executive's employment by the Company due to death or disability under Sections 6(a)(i) and 6(b)(ii)(A), without Cause under Section 6(a)(ii)(B) or by the Executive for Good Reason under Section 6(a)(iii) shall be extremely difficult or impossible to establish or prove, and agree that the severance payments and benefits pursuant to Sections 7(a), (b), (d) and (e) (the "Severance Payments"), shall constitute liquidated damages for any such termination. The Executive agrees that, except for such other payments and benefits to which the Executive may be entitled as expressly provided by the terms of this Agreement or any other applicable benefit plan, such liquidated damages shall be in lieu of all other claims that the Executive may make by reason of any such termination of his employment, other than with respect to the Executive's outstanding equity or equity-related awards, any vested payments or benefits under any plan, program or arrangement of AFG in which the Executive participated and any claim for coverage under AFG's indemnification and directors and officers liability coverage, and that, as a condition to receiving the Severance Payments, the Executive will execute a release of claims substantially in the form of the release attached hereto as <u>Exhibit A</u> (except as may be revised to reasonably reflect changes in applicable law) and such other instruments or documents as are required by the terms of this Agreement. Within two (2) business days of the Date of Termination, the Company shall deliver to the Executive the release for the Executive to execute. The Executive will forfeit all rights to the Severance Payments unless, within forty-five (45) days of delivery of the release by the Company to the Executive, the Executive (or his estate or spouse as set forth in Section 7(a) or 7(b), as applicable) executes and delivers the release to the Company, and such release has become irrevocable by virtue of the expiration of the revocation period without the release having been revoked (the first such date, the "Release Effective Date" and the forty-five day consideration period plus the applicable revocation period, the "Release Period"). The Company's obligation to pay the Severance Payments is subject to the occurrence of the Release Effective Date, and if the Release Effective Date does not occur, then the Company shall have no obligation to pay the Severance Payments. If the Executive fails to materially comply with his obligations under Sections 6(c) or 8 and has not cured (if curable) any such failure within ten (10) days after being provided written notice of such failure in reasonable detail, the Executive shall, to the extent such amounts are paid, vested or distributed pursuant to Section 7 hereof, (i) forfeit outstanding equity awards, (ii) transfer the shares underlying any equity awards that were accelerated pursuant to the terms of the related plan or award agreements and settled in shares to AFG for no consideration and (iii) repay the after-tax amount of the Severance Payments and any equity awards that were accelerated pursuant to the terms of the related plan or award agreements and settled in cash or sold.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>No Offset.</u> In the event of termination of his employment, the Executive shall be under no obligation to seek other employment or take any other action to mitigate any amounts owed to the Executive under this Agreement and, except as otherwise expressly provided herein, there shall be no offset against amounts due to him on account of any remuneration or benefits provided by any subsequent employment he may obtain. The Company's and Company Affiliates' obligation to make any payment pursuant to, and otherwise to perform its obligations under, this Agreement shall not be affected by any offset, counterclaim or other right that the Company or its affiliates may have against him for any reason.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Section 409A</u>. The payments and benefits to be provided to the Executive pursuant to this Agreement are intended to comply with, or be exempt from, Section 409A and will be interpreted, administered and operated in a manner consistent with that intent. If the Executive notifies the Company (with specificity as to the reason therefor) that the Executive believes that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause the Executive to incur any additional tax or interest under Section 409A, and the Company concurs with such belief or the Company independently makes such determination, the Company shall, after consulting with the Executive, reform such provision to try to comply with Section 409A through good faith modification to the maximum extent reasonably appropriate to comply with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to the Executive and the Company of the applicable provision without violating the provisions of Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) For purposes of Section 409A, the Executive's right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Executive will be deemed to have a Date of Termination for purposes of determining the timing of any payments or benefits hereunder that are classified as deferred compensation only upon a "separation from service" within the meaning of Section 409A.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) Notwithstanding any other provision of this Agreement to the contrary, if at the time of the Executive's separation from service, (x) the Executive is a specified employee (within the meaning of Section 409A and using the identification methodology selected by the Company from time to time), and (y) the Company makes a good faith determination that an amount payable on account of such separation from service to the Executive constitutes deferred compensation (within the meaning of Section 409A) the payment of which is required to be delayed pursuant to the six-month delay rule set forth in Section 409A in order to avoid taxes or penalties under Section 409A (the "Delay Period"), then the Company will not pay such amount on the otherwise scheduled payment date but will instead pay it in a lump sum on the first business day after such six-month period (or upon the Executive's death, if earlier), together with interest for the period of delay, compounded annually, equal to the prime rate (as published in the Wall Street Journal) in effect as of the dates the payments should otherwise have been provided. To the extent that any benefits to be provided during the Delay Period are considered deferred compensation under Section 409A provided on account of a "separation from service," and such benefits are not otherwise exempt from Section 409A, the Executive shall pay the cost of such benefit during the Delay Period, and the Company shall reimburse the Executive, to the extent that such costs would otherwise have been paid by the Company or to the extent that such benefits would otherwise have been provided by the Company at no cost to the Executive, the Company's share of the cost of such benefits upon expiration of the Delay Period, and any remaining benefits shall be reimbursed or provided by the Company in accordance with the procedures specified herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) (A) Any amount that the Executive is entitled to be reimbursed under this Agreement will be reimbursed to the Executive as promptly as practical and in any event not later than the last day of the calendar year after the calendar year in which the expenses are incurred, (B) any right to reimbursement or in kind benefits will not be subject to liquidation or exchange for another benefit, and (C) the amount of the expenses eligible for reimbursement during any taxable year will not affect the amount of expenses eligible for reimbursement in any other taxable year.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., "payment shall be made within thirty (30) days following the date of termination"), the actual date of payment within the specified period shall be within the sole discretion of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Confidentiality, Non-Disclosure and Non-Competition Agreement.</u> The Company and the Executive acknowledge and agree that during the Executive's employment with the Company, the Executive will have access to and may assist in developing Company Confidential Information and will occupy a position of trust and confidence with respect to the Company's affairs and business and the affairs and business of Company Affiliates. For purposes of this Agreement, "Company Confidential Information" means information known to the Executive to constitute confidential or proprietary information belonging to the Company or Company Affiliates or other non-public information, trade secrets, intellectual property, confidential financial information, operating budgets, strategic plans or research methods, personnel data, projects or plans, or non-public information regarding the terms of any existing or pending transaction between Company or any Company Affiliate and an existing or pending client or customer or other person or entity, in each case, received by the Executive in the course of his employment by the Company or in connection with his duties with the Company and Company Affiliates. Notwithstanding anything to the contrary contained herein, the general skills, knowledge and experience gained during the Executive's employment with the Company, information publicly available or generally known within the industry or trade in which the Company or any Company Affiliate operates and information or knowledge possessed by the Executive prior to his employment by the Company, shall not be considered Company Confidential Information. The Executive agrees that the following obligations are necessary to preserve the confidential and proprietary nature of Company Confidential Information and to protect the Company and Company Affiliates against harmful solicitation of employees and customers, harmful effects on operations and other actions by the Executive that would result in serious adverse consequences for the Company and Company Affiliates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Non-Disclosure.</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) During and after the Executive's employment with the Company or Company Affiliates, the Executive will not knowingly, directly or indirectly through an intermediary, use, disclose or transfer any Company Confidential Information other than as authorized in writing by the Company or Company Affiliates, or if such use, disclosure or transfer is during such employment and within the scope of the Executive's duties with the Company or Company Affiliates as determined reasonably and in good faith by the Executive. Anything herein to the contrary notwithstanding, the provisions of this Section 8(a) shall not apply (i) when disclosure is required by law or by any court, arbitrator, mediator or administrative or legislative body (including any committee thereof) with actual or apparent jurisdiction to order the Executive to disclose or make accessible any information; (ii) with respect to any other litigation, arbitration or mediation involving this Agreement, including, but not limited to, the enforcement of this Agreement; (iii) as to information that becomes generally known to the public or within the relevant trade or industry other than due to the Executive's violation of this Section 8(a); (iv) as to information that is or becomes available to the Executive on a non-confidential basis from a source which is entitled to disclose it to the Executive; or (v) as to information that the Executive possessed prior to the commencement of employment with the Company. In the event the Executive is required or compelled by legal process to disclose any Company Confidential Information, to the extent the Executive is legally permitted to do so, he will promptly inform the Company so that the Company may, at its own expense, present and preserve any objections that it may have to such disclosure and/or seek an appropriate protective order. Notwithstanding the foregoing, nothing contained in this Agreement shall prohibit the Executive from reporting possible violations of federal law or regulation to any governmental agency or entity, including but not limited to the Department of Justice, the Securities and Exchange

------

Commission, the Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. The Executive does not need the prior authorization of AFG's legal department to make any such reports or disclosures and the Executive is not required to notify AFG that the Executive has made such reports or disclosures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Pursuant to 18 U.S.C. § 1833(b), an individual may not be held liable under any criminal or civil federal or state trade secret law for disclosure of a trade secret: (A) made in confidence to a government official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law or (B) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Additionally, an individual suing an employer for retaliation based on the reporting of a suspected violation of law may disclose a trade secret to his or her attorney and use the trade secret information in the court proceeding, so long as any document containing the trade secret is filed under seal and the individual does not disclose the trade secret except pursuant to court order.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Materials.</u> The Executive will not remove, directly or indirectly through an intermediary, any Company Confidential Information or any other property of the Company or any Company Affiliate from the Company's or Company Affiliate's premises or make copies of such materials except for normal and customary use in the Company's or Company Affiliate's business as determined reasonably and in good faith by the Executive. The Executive will return to the Company all Company Confidential Information and copies thereof and all other property of the Company or any Company Affiliate at any time upon the request of the Company and in any event promptly after termination of the Executive's employment. The Executive agrees to attempt in good faith to identify and return to the Company any copies of any Company Confidential Information after the Executive ceases to be employed by the Company. Anything to the contrary notwithstanding, nothing in this Section 8(b) shall prevent the Executive from retaining a home computer, papers and other materials of a personal nature, including diaries, calendars and Rolodexes (including his electronic address books), information relating to his compensation or relating to reimbursement of expenses, information that he reasonably believes may be needed for tax purposes, and copies of plans, programs and agreements relating to his employment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>No Solicitation.</u> During the period commencing on the Effective Date and ending twenty-four (24) months after the Executive's Date of Termination (the "Non-Solicit Period"), the Executive shall not, directly or indirectly through an intermediary, solicit, entice, persuade or induce any individual who is employed by, or who is an independent contractor or consultant to, the Company or any Company Affiliate (or who was so employed or retained within one (1) year prior to the Executive's action, other than any such individual whose employment or engagement was involuntarily terminated by the Company or any Company Affiliate) to terminate or refrain from continuing such employment or engagement or to become employed by or enter into contractual relations with any other individual or entity other than the Company or Company Affiliates, and the Executive shall not hire, directly or indirectly, as an employee, consultant or otherwise, any such person. Anything to the contrary notwithstanding, the Company agrees that (i) the Executive's responding to an unsolicited request from any former employee, independent contractor or consultant of the Company or any Company Affiliate for advice on employment matters, (ii) the Executive's responding to an unsolicited request for a reference regarding any former employee, independent contractor or consultant of the Company or any Company Affiliate from such former employee, independent contractor or consultant, or from a third party, by providing a reference setting forth his personal views about such former employee, independent contractor or consultant, or (iii) hiring or retaining any current or former employee, independent contractor or consultant of the Company or any Company Affiliate who responds to a general advertisement for employment that was not specifically directed at such employees, independent contractors or consultants of the Company or any Company Affiliate, shall not be deemed a violation of

------

this Section 8(c). Additionally, the Executive shall not, directly or indirectly through an intermediary, solicit or encourage any client, customer, supplier or vendor of the Company or any Company Affiliate, or any person or entity who was a client, customer, supplier or vendor within one year prior to Executive's action, to terminate, reduce or alter in a manner adverse to the Company or any Company Affiliate any existing business arrangements with the Company or any Company Affiliate or to transfer existing business from the Company or any Company Affiliate to any other person or entity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Non-Competition</u>. During the period commencing on the Effective Date and ending twelve (12) months after the Executive's Date of Termination (the "Non-Compete Period"), the Executive shall not, directly or indirectly through an intermediary without the prior written consent of the Board, which consent shall not be unreasonably withheld, directly or indirectly own any interest in, manage, control, participate in, consult with, or render services similar to those that the Executive performed on behalf of the Company or Company Affiliates during the last two (2) years of the Executive's employment, or otherwise be or be connected in any manner directly or indirectly, with, (i) any person or entity that is engaged in the same business as the business in which the Company or any Company Affiliate is engaged or (ii) any person or entity that is engaged in a business which otherwise materially competes with any business that the Company or any Company Affiliate conducts or has taken substantial measures to conduct within the next six (6) months (as determined at the Date of Termination) in any state in the United States of America and the District of Columbia or any other jurisdiction in which such business is conducted or in which the Company has taken substantial measures to conduct within the next six (6) months (as applicable) at the Date of Termination and with respect to which the Executive provided services or Company Confidential Information; provided, however, that the Executive may own, as a passive investor, securities of any such entity that has outstanding publicly traded securities or is passively owned through an interest in a hedge fund or private equity fund, so long as his direct holdings in any such entity shall not in the aggregate constitute more than five percent (5%) of the voting power of such entity and, while employed by the Company does not otherwise violate any Company or Company Affiliate policy applicable to the Executive. The Executive agrees that, before providing services, whether as an employee or consultant, to any entity during the Non-Compete Period, he will provide a copy of this Agreement to such entity. The Executive acknowledges that this covenant has a unique, very substantial and immeasurable value to the Company and Company Affiliates, that the Executive has sufficient assets and skills to provide a livelihood for the Executive while such covenant remains in force and that, as a result of the foregoing, in the event that the Executive breaches such covenant, monetary damages would be an insufficient remedy for the Company and equitable enforcement of the covenant would be proper.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Compliance with Company's Policies</u>. The Executive agrees to observe and comply with the policies and rules of the Company and Company Affiliates unless such compliance is inconsistent with the terms of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Non-Disparagement</u>. During the period commencing on the Effective Date and continuing thereafter, the Executive, other than in the good faith performance of his duties for the Company, shall not initiate, participate or engage in any communication whatsoever that could reasonably be interpreted as derogatory or disparaging to the Company or any Company Affiliate, as applicable, including but not limited to the business, practices, policies, or, as such, shareholders, partners, members, directors, managers, officers and employees of the Company or any Company Affiliate. Similarly, the senior executives and directors of the Company shall not initiate, participate or engage in any communication whatsoever that could reasonably be interpreted as derogatory or disparaging to the Executive. The foregoing shall not be violated by (i) truthful statements by the Executive or the senior executives or directors of the Company in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such

------

proceedings) or (ii) the Executive or the senior executives and directors of the Company rebutting false or misleading statements made by others.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Publicity</u>. During the Employment Period, the Executive hereby grants to the Company the right to use, in a reasonable and appropriate manner, the Executive's name and likeness, without additional consideration, on, in and in connection with technical, marketing or disclosure materials, or any combination thereof, published by or for the Company or any Company Affiliate, and any documents or other matters to the extent legally required. If, in connection with the Executive's termination of employment with the Company, the Company determines to issue a press release, the Company agrees to consult with the Executive in good faith as to the wording of the press release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Cooperation</u>. The parties agree that certain matters in which the Executive will be involved during the Employment Period may necessitate the Executive's cooperation in the future. Accordingly, during the five (5) year period following the termination of the Executive's employment for any reason, to the extent reasonably requested by AFG, the Executive shall cooperate with the Company, Company Affiliates and its or their counsel, including information requests relating to the business or affairs of the Company, as well as any investigation, litigation, arbitration or other proceeding related to the business or affairs of the Company, other than in connection with any dispute between the Executive and the Company or any Company Affiliate; provided that, the Company shall make reasonable efforts to minimize disruption of the Executive's business or personal affairs, including limiting the Executive's travel to the extent reasonably possible. The cooperation includes the Executive making himself available for reasonable periods of time (with due regard for his other commitments) upon reasonable notice to the Executive in any such litigation or investigation and providing testimony before or during such litigation or investigation. The Company shall reimburse the Executive for reasonable out-of-pocket expenses incurred in connection with such cooperation (including legal counsel selected by the Executive and reasonably acceptable to the Company); provided that, if the Company requires the Executive to devote significant time to such cooperation, the Company and the Executive will establish in good faith a reasonable hourly or daily rate for the time spent by the Executive on such cooperation, based on the Executive's Base Salary as of the termination date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Enforcement.</u> The Executive acknowledges that in the event of any breach of this Section 8, the business interests of the Company and the Company Affiliates will be irreparably injured, the full extent of the damages to the Company and the Company Affiliates will be impossible to ascertain, monetary damages will not be an adequate remedy for the Company and the Company Affiliates, and the Company will be entitled to enforce this Agreement by a temporary, preliminary and/or permanent injunction or other equitable relief, without the necessity of posting bond or security, which the Executive expressly waives. The Company and the Company Affiliates each acknowledge that in the event of any breach of this Agreement, the interests of the Executive will be irreparably injured, the full extent of damages to the Executive will be impossible to ascertain, monetary damages will not be an adequate remedy for the Executive, and the Executive will be entitled to enforce this Agreement by a temporary, preliminary and/or permanent injunction or other equitable relief, without the necessity of posting bond or security, which the Company expressly waives. If the Executive violates this Section 8, and not withstanding any language to the contrary in any LTI award agreement, it is agreed that (a) any compensation or benefits due to be received by the Executive pursuant to this Agreement or any other agreement, plan or instrument of or with the Company after such violation will immediately cease; (b) the Executive shall forfeit all outstanding, unvested equity awards; (c) the Executive shall repay the Company the after-tax amount of any severance payment or benefit received by him; (d) despite the cessation, forfeiture or repayment of such payment or benefits, the release provided by the Executive in connection with such benefits will remain in full force and effect; and (e) the Company's or any Company Affiliate's remedy of cessation or recoupment of severance payments or benefits to the Executive does not preclude

------

any additional remedies available to the Company or Company Affiliates, including but not limited to injunctive relief. The Company and the Executive each understand that the other may waive some of the requirements expressed in this Agreement, but that such a waiver to be effective must be made in writing and should not in any way be deemed a waiver of the right of either party to enforce any other requirements or provisions of this Agreement. The Company and the Executive agree that each of their obligations specified in this Agreement are separate and independent covenants and that the unenforceability of any of them shall not preclude the enforcement of any other covenants in this Agreement. The Executive further agrees that any breach of this Agreement by the Company prior to the Date of Termination shall not release the Executive from compliance with his obligations under this Section 8, as long as the Company fully complies with Sections 7 and 10. The Company further agrees that any breach during the Employment Period of this Agreement by the Executive that does not result in the Executive being terminated for Cause shall not release the Company from compliance with its obligations under this Agreement. Notwithstanding the foregoing two sentences, neither the Company nor the Executive shall be precluded from pursuing judicial remedies as a result of any such breaches.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) <u>Severability</u>. If any of the restrictions or obligations contained in Section 8 shall be determined by any court of competent jurisdiction to be unenforceable by reason of their extending for too great a period of time or over too great a geographical area or by reason of their being too extensive in any other respect, such provision shall be modified to be effective for the maximum period of time for which it may be enforceable and over the maximum geographical area as to which it may be enforceable and to the maximum extent in all other respects as to which it may be enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Section 280G.</u> If any payment or benefit (including payments and benefits pursuant to this Agreement) that the Executive would receive in connection with a transaction ("Transaction Payment") would (i) constitute a "parachute payment" within the meaning of Section 280G of the Code, and (ii) but for this Section 9, be subject to the excise tax imposed by Section 4999 of the Code (the "Excise Tax"), then the Company shall cause to be determined, before any amounts of the Transaction Payment are paid to the Executive, which of the following two alternative forms of payment would result in the Executive's receipt, on an after-tax basis, of the greater amount of the Transaction Payment notwithstanding that all or some portion of the Transaction Payment may be subject to the Excise Tax: (1) payment in full of the entire amount of the Transaction Payment (a "Full Payment"), or (2) payment of only a part of the Transaction Payment so that the Executive receives the largest payment possible without the imposition of the Excise Tax (a "Reduced Payment"), and the Company shall pay the Executive the greater of the Full Payment or the Reduced Payment.

For purposes of determining whether to make a Full Payment or a Reduced Payment, the Company shall cause to be taken into account all applicable federal, state and local income and employment taxes and the Excise Tax. If a Reduced Payment is made, (x) the Executive shall have no rights to any additional payments and/or benefits constituting the Transaction Payment, and (y) reduction in payments and/or benefits shall occur in the manner that results in the greatest economic benefit to the Executive as determined in this paragraph. If more than one method of reduction will result in the same economic benefit, the portions of the Transaction Payment shall be reduced pro rata.

The independent registered public accounting firm engaged by AFG as of the day prior to the effective date of the transaction shall make all determinations required to be made under this Section 9. If the independent registered public accounting firm so engaged by AFG is serving as accountant or auditor for the individual, entity or group effecting the transaction, AFG shall appoint a nationally recognized independent registered public accounting firm that is reasonably acceptable to the Executive (and such acceptance shall not be unreasonably withheld) to make the determinations required hereunder. The Company shall bear all reasonable expenses with respect to the determinations by such independent

------

registered public accounting firm required to be made hereunder. The independent registered public accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and the Executive within fifteen (15) calendar days after the date on which the Executive's right to a Transaction Payment is triggered or such other time as reasonably requested by the Company or the Executive. If the independent registered public accounting firm determines that no Excise Tax is payable with respect to the Transaction Payment, either before or after the application of the Reduced Amount, it shall furnish the Company and the Executive with detailed supporting calculations of its determinations that no Excise Tax will be imposed with respect to such Transaction Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and the Executive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Indemnification.</u> The Company shall indemnify the Executive to the maximum extent that its officers and employees are entitled to indemnification pursuant to the Company's certificate of incorporation and bylaws (which shall not be less than currently exists, except as required by applicable law), subject to applicable law, and such indemnification shall continue after termination of employment with regard to actions or inactions prior to termination at a level that is no less than currently exists for officers and employees under the Company's certificate of incorporation and bylaws, subject to applicable law. In addition, both during the Employment Period and following his termination of employment, the Executive shall be entitled to liability insurance coverage pursuant to any directors' and officers' liability insurance policy maintained by AFG as of the Effective Date or put in place following the Effective Date on the same basis as other current or former officers of AFG with regard to actions or inactions during the period of service as an officer notwithstanding any ceasing of such service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Notices.</u> All notices, demands, requests, or other communications which may be or are required to be given or made by any party to any other party pursuant to this Agreement shall be in writing and shall be hand delivered, mailed by first-class registered or certified mail, return receipt requested, postage prepaid, delivered by overnight air courier, addressed as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) If to AFG:

Ambac Financial Group, Inc.<br>One World Trade Center, 41st Floor<br>New York, New York 10007<br>Attn: Chief Executive Officer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) If to the Executive:

Lawrence Metz<br>Address last shown on the Company's records

Each party may designate by notice in writing a new address to which any notice, demand, request or communication may thereafter be so given, served or sent. Each notice, demand, request, or communication that shall be given or made in the manner described above shall be deemed sufficiently given or made for all purposes at such time as it is delivered to the addressee (with the return receipt, the delivery receipt, or the affidavit of messenger being deemed conclusive but not exclusive evidence of such delivery) or at such time as delivery is refused by the addressee upon presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Severability.</u> The invalidity or unenforceability of any one or more provisions of this Agreement shall not affect the validity or enforceability of the other provisions of this Agreement, which shall remain in full force and effect.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Effect on Other Agreements.</u> This Agreement constitutes the entire agreement between the parties respecting the employment of the Executive and supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with respect to such subject matter, including, but not limited to, the Offer Letter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Survival.</u> It is the express intention and agreement of the parties hereto that the provisions of Sections 4(f), 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 19, 20 and 22 hereof and this Section 14 shall survive the termination of employment of the Executive.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Assignment.</u> The rights and obligations of the parties to this Agreement shall not be assignable or delegable, except that (i) in the event of the Executive's death, the personal representative or legatees or distributees of the Executive's estate, as the case may be, shall have the right to receive any amount owing and unpaid to the Executive hereunder, (ii) the rights and obligations of the Company hereunder shall be assignable and delegable in connection with any subsequent merger, consolidation, sale of all or substantially all of the assets or equity interests of the Company or similar transaction involving the Company or a successor entity, and (iii) the rights and obligations of the Company hereunder shall be assignable and delegable to AFG. The Company shall require any successor to the Company to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>Binding Effect.</u> Subject to any provisions hereof restricting assignment, this Agreement shall be binding upon the parties hereto and shall inure to the benefit of the parties and their respective heirs, devisees, executors, administrators, legal representatives and permitted successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. <u>Amendment; Waiver.</u> This Agreement shall not be amended, altered or modified except by an instrument in writing duly executed by the party against whom enforcement is sought. Neither the waiver by either of the parties hereto of a breach of or a default under any of the provisions of this Agreement, nor the failure of either of the parties, on one or more occasions, to enforce any of the provisions of this Agreement or to exercise any right or privilege hereunder, shall thereafter be construed as a waiver of any subsequent breach or default of a similar nature, or as a waiver of any such provisions, rights or privileges hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. <u>Headings.</u> Section and subsection headings contained in this Agreement are inserted for convenience of reference only, shall not be deemed to be a part of this Agreement for any purpose, and shall not in any way define or affect the meaning, construction or scope of any of the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. <u>Governing Law.</u> This Agreement, the rights and obligations of the parties hereto, and any claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of New York (but not including any choice of law rule thereof that would cause the laws of another jurisdiction to apply).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. <u>Arbitration</u>. Any dispute, controversy or claim arising out of or related to this Agreement or any breach of this Agreement shall be submitted to and decided by binding arbitration in the County of New York, New York before a single arbitrator selected jointly by the parties, or, if the parties cannot agree on the selection of the arbitrator, as selected by the American Arbitration Association. Arbitration shall be administered exclusively by the American Arbitration Association and shall be conducted in accordance with the rules for the resolution of employment disputes (previously titled the National Rules for the Resolution of Employment Disputes) as well as any requirements imposed by state law. Any arbitral award determination shall be final and binding upon the parties.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21. <u>Counterparts.</u> This Agreement may be executed in two counterparts, each of which shall be an original and all of which shall be deemed to constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22. <u>Withholding.</u> The Company may withhold from any benefit payment or any other payment or amount under this Agreement all federal, state, city or other taxes as shall be required pursuant to any law or governmental regulation or ruling.

------

IN WITNESS WHEREOF, the undersigned have duly executed and delivered this Agreement, or have caused this Agreement to be duly executed and delivered on their behalf.

---

| |
|:---|
| AMBAC FINANCIAL GROUP, INC. |
| /s/ Claude LeBlanc |
| Claude LeBlanc<br>President and Chief Executive Officer  |
| EXECUTIVE |
| /s/ Lawrence Metz |
| Lawrence Metz |

---

------

EXHIBIT A

**<u>General Release of Claims</u>** 

Consistent with Section 7 of the Employment Agreement dated August 11, 2025 among me, Ambac Financial Group, Inc. (the "Employment Agreement") and in consideration for and contingent upon my receipt of the Severance Payments set forth in Section 7 of the Employment Agreement, I, for myself, my attorneys, heirs, executors, administrators, successors, and assigns, do hereby fully and forever release and discharge Ambac Financial Group, Inc. ("Ambac") and their past, current and future affiliated entities, as well as their predecessors, successors, assigns, and their past, current and former directors, officers, partners, agents, employees, attorneys, and administrators from all suits, causes of action, and/or claims, demands or entitlements of any nature whatsoever, whether known, unknown, or unforeseen, which I have or may have against any of them arising out of or in connection with my employment by Ambac, the Employment Agreement, the termination of my employment with Ambac, or any event, transaction, or matter occurring or existing on or before the date of my signing of this General Release related to Ambac, except that I am not releasing (i) any claims arising under Section 10 of the Employment Agreement, any other right to indemnification or director and officer liability insurance coverage that I may otherwise have, (ii) any claims that I may have to vested payments or benefits pursuant to the Employment Agreement or any plan, program or arrangement of Ambac in which I participated, (iii) any claims relating to any rights I may have to payments pursuant to Section 7 of the Employment Agreement, (iv) any claims relating to any rights I may have pursuant to equity and equity-related awards granted to me by Ambac, provisions of the Employment Agreement that survive termination of employment, (v) any claims made under state unemployment compensation insurance or workers compensation laws and/or any claims that cannot be waived by law, or (vi) any claims arising after the date of my signing this General Release. I agree not to file or otherwise institute any claim, demand or lawsuit seeking damages or other relief and not to otherwise assert any claims, demands or entitlements that are released herein. I further hereby irrevocably and unconditionally waive any and all rights to recover any relief or damages concerning the claims, demands or entitlements that are released herein. I represent and warrant that I have not previously filed or joined in any such claims, demands or entitlements against Ambac or the other persons or entities released herein and that I will indemnify and hold them harmless from all liabilities, claims, demands, costs, expenses and/or attorney's fees incurred as a result of any such claims, demands or lawsuits.

This General Release specifically includes, but is not limited to, all claims of breach of contract, employment discrimination (including any claims coming within the scope of Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Equal Pay Act, the Americans with Disabilities Act, and the Family and Medical Leave Act, all as amended, or any other applicable federal, state, or local law), claims under the Employee Retirement Income Security Act, as amended, claims under the Fair Labor Standards Act, as amended (or any other applicable federal, state or local statute relating to payment of wages), wage orders, claims concerning recruitment, hiring, termination, salary rate, severance pay, stock options, wages or benefits due, sick leave, holiday pay, vacation pay, life insurance, group medical insurance, any other fringe benefits, worker's compensation, termination, employment status, libel, slander, defamation, intentional or negligent misrepresentation and/or infliction of emotional distress, together with any and all tort, contract, or other claims which might have been asserted by me or on my behalf in any suit, charge of discrimination, or claim against Ambac or the persons or entities released herein.

Ambac and I acknowledge that different or additional facts may be discovered in addition to what we now know or believe to be true with respect to the matters released in this General Release, and we

------

agree that this General Release shall be and remain in effect in all respects as a complete and final release of the matters released, notwithstanding any different or additional facts.

**<u>Claims Excluded from this Release:</u>** However, notwithstanding the foregoing, nothing in this General Release shall be construed to waive any right that is not subject to waiver by private agreement, including, without limitation, any claims arising under state unemployment insurance or workers compensation laws. I understand that rights or claims under the Age Discrimination in Employment Act that may arise after I execute this General Release are not waived. Likewise, nothing in this General Release shall be construed to prohibit me from filing a charge with or participating in any investigation or proceeding conducted by the EEOC, NLRB, or any comparable state or local agency. Notwithstanding the foregoing, I agree to waive my right to recover individual relief in any charge, complaint, or lawsuit filed by me or anyone on my behalf. Notwithstanding the foregoing, to the extent that Ambac makes any claims against me, nothing in this General Release shall be construed to prohibit me from asserting counterclaims, making cross-claims, or otherwise defending myself, in any case solely with respect to such claims. Moreover, nothing herein shall prohibit me from reporting possible violations of federal or state law or regulation or cooperating with the Securities and Exchange Commission without notice to the Company (and to receive a whistleblower award provided by law for providing such information).

I acknowledge that I have been given an opportunity of twenty-one (21) days to consider this General Release and that I have been encouraged by Ambac to discuss fully the terms of this General Release with legal counsel of my own choosing. Moreover, for a period of seven (7) days following my execution of this General Release, I shall have the right to revoke the waiver of claims arising under the Age Discrimination in Employment Act, a federal statute that prohibits employers from discriminating against employees who are age 40 or over. If I elect to revoke this General Release in whole or in part within this seven-day period, I must inform Ambac by delivering a written notice of revocation to the Chief Executive Officer, One World Trade Center, 41st Floor, New York, New York 10007, no later than 11:59 p.m. on the seventh calendar day after I sign this General Release. I understand that, if I elect to exercise this revocation right, this General Release shall be voided in its entirety at the election of Ambac and Ambac shall be relieved of all obligations to make the Severance Payments described in Section 7 of the Employment Agreement. I may, if I wish, elect to sign this General Release prior to the expiration of the twenty-one (21)-day consideration period, and I agree that if I elect to do so, my election is made freely and voluntarily and after having an opportunity to consult counsel.

---

| | |
|:---|:---|
| AGREED: | |
| _________________<br>Lawrence Metz | _______________<br>Date |

---

## Exhibit 19.1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Octave Specialty Group, Inc.**

**Insider Trading Policy**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**You are responsible for seeing that you do not violate federal or state securities laws or this Policy. We designed this Policy to promote compliance with the federal securities laws and protect you and Octave Specialty Group, Inc. and its affiliates (collectively, "*Octave"*) from the serious liabilities and penalties that can result from violations of these laws.** <br>**The guidelines and procedures set forth in this Policy apply to all directors, officers and employees of Octave and anyone associated with Octave (i.e., not just the traditional "insiders" of Octave). You may, because of your position with Octave or one of its affiliates, be subject to more restrictive trading policies and procedures than are described in this Policy. If so, the General Counsel or the Corporate Secretary of Octave Specialty Group, Inc. will notify you directly.** <br>**The best way to protect each of us, as well as Octave, is to follow the Insider Trading Policy at all times.** <br>

**Revision Date: November 2025** 

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Table of Contents**

**<u>Section</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Page</u>**

1.&nbsp;&nbsp;&nbsp;&nbsp;What are the consequences for violating federal insider trading laws?&nbsp;&nbsp;&nbsp;&nbsp;3

2. What is our policy?&nbsp;&nbsp;&nbsp;&nbsp;3

3. How do I identify "*Material Nonpublic Information*?"&nbsp;&nbsp;&nbsp;&nbsp;4

&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;Is the information "*material*?"&nbsp;&nbsp;&nbsp;&nbsp;4

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;What is "*material"* information?&nbsp;&nbsp;&nbsp;&nbsp;4

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;&nbsp;&nbsp;What are some examples of "*material"* information?&nbsp;&nbsp;&nbsp;&nbsp;5

&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Is the information considered "*non-public*?"&nbsp;&nbsp;&nbsp;&nbsp;5

&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;If the information is *material* but has been publicly disclosed,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;has the marketplace had the opportunity to absorb the information?&nbsp;&nbsp;&nbsp;&nbsp;5

4. Who is a "*Related Person*?"&nbsp;&nbsp;&nbsp;&nbsp;6

5. Are there times during the year when I may <u>not</u> trade in Octave Related Securities?&nbsp;&nbsp;&nbsp;&nbsp;6

6.&nbsp;&nbsp;&nbsp;&nbsp;Am I prohibited from engaging in certain types of transactions

in Octave Related Securities, such as short sales, puts, calls and equity swaps? &nbsp;&nbsp;&nbsp;&nbsp;7&nbsp;&nbsp;&nbsp;&nbsp;

7.&nbsp;&nbsp;&nbsp;&nbsp;How should I respond to requests for information?&nbsp;&nbsp;&nbsp;&nbsp;7

8.&nbsp;&nbsp;&nbsp;&nbsp;What should I be concerned about in my dealings with

financial analysts, investors and the press?&nbsp;&nbsp;&nbsp;&nbsp;8

9.&nbsp;&nbsp;&nbsp;&nbsp;What steps should I take to preserve confidential information?&nbsp;&nbsp;&nbsp;&nbsp;9

10.&nbsp;&nbsp;&nbsp;&nbsp;What happens if I become aware of a violation of Octave's Insider Trading Policy?&nbsp;&nbsp;&nbsp;&nbsp;10

11.&nbsp;&nbsp;&nbsp;&nbsp;What are the consequences if I violate Octave's Insider Trading Policy?&nbsp;&nbsp;&nbsp;&nbsp;10

12.&nbsp;&nbsp;&nbsp;&nbsp;Do these policies and procedures affect me after I retire or if my

employment terminates?&nbsp;&nbsp;&nbsp;&nbsp;11

13.&nbsp;&nbsp;&nbsp;&nbsp;Do I have to acknowledge my understanding and acceptance of Octave's policies?&nbsp;&nbsp;&nbsp;&nbsp;11

14.&nbsp;&nbsp;&nbsp;&nbsp;What happens if I do not sign or acknowledge the Certification?&nbsp;&nbsp;&nbsp;&nbsp;11

15.&nbsp;&nbsp;&nbsp;&nbsp;What if I do not fully understand something in the Policy?&nbsp;&nbsp;&nbsp;&nbsp;11

16. &nbsp;&nbsp;&nbsp;&nbsp;Are there additional restrictions and requirements for Directors and Executive Officers?&nbsp;&nbsp;&nbsp;&nbsp;12

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**<u>Appendix A:</u>**

Form of Certification

***1.&nbsp;&nbsp;&nbsp;&nbsp;What are the consequences for violating federal insider trading laws?***

The Securities and Exchange Commission ("*SEC"*) and federal prosecutors are very aggressive in enforcing the federal insider trading and anti-fraud rules. After the enactment of the Sarbanes-Oxley Act of 2002, the penalties for violations increased significantly.

If you violate the insider trading laws, you may have to pay civil fines of up to three times the profit gained or loss avoided by such trading, as well as criminal fines of up to $5 million. You also may have to serve a jail sentence of up to 20 years. In addition, Octave may face civil penalties up to the greater of $1 million, or three times the profit gained or loss avoided as a result of your insider trading violations, as well as criminal fines of up to $25 million. The civil penalties may extend personal liability to the Octave's directors, officers and other supervisory personnel if they fail to take appropriate steps to prevent insider trading.

You should understand that the above penalties apply even if you have derived no benefit from another's actions. The SEC has imposed large penalties on tippers -- even though they neither traded themselves nor received any money from the friends or relations to whom they tipped inside information.

***2.&nbsp;&nbsp;&nbsp;&nbsp;What is our policy?***

**Neither you nor your "Related Persons" (defined below) may (i) buy or sell Octave Related Securities (defined below) while in possession of "Material Nonpublic Information" as described below or (ii) convey Material Nonpublic Information about Octave or suggest that anyone purchase or sell any Octave Related Securities while you are aware of Material Nonpublic Information ("tipping").** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By **"Octave Related Securities,"** we mean securities that include Octave's common stock, debentures, warrants, options to purchase common stock and any other form of securities issued by Octave, whether under the Octave Specialty Group Incentive Compensation Plans or otherwise.<br>Octave's "no trading" and "no tipping" policy also applies if you possess Material Nonpublic Information about an issuer of securities other than Octave that you have obtained in the course of your employment at Octave. This would, of course, include any company whose securities are publicly traded and with which Octave's officers and employees may have access to Material Nonpublic Information.<br>

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***3.&nbsp;&nbsp;&nbsp;&nbsp;How do I identify "Material Nonpublic Information?"***

Before trading in Octave Related Securities (*or securities of another issuer*) when you may have potential inside information, you should ask yourself the following three questions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)&nbsp;&nbsp;&nbsp;&nbsp;Is the information "*material?"***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)&nbsp;&nbsp;&nbsp;&nbsp;Is the information "*non-public?"***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)&nbsp;&nbsp;&nbsp;&nbsp;If the information is "*material"* but has been** 

**&nbsp;&nbsp;&nbsp;&nbsp;publicly disclosed, has the marketplace had the opportunity to absorb the information?** 

If, after consideration of the above three questions, you believe that the information is "*material"* and "*nonpublic,"* or that it is "*material"* and has been disclosed but the marketplace has not had the time to absorb it:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Do <u>not</u> purchase or sell the securities; and**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Do <u>not</u> communicate the information to anyone inside or outside Octave unless you have first received clearance to disclose such information from the General Counsel or the Corporate Secretary.** 

***If you are not sure of the answers to any of the above questions, you should discuss them with the General Counsel of Octave Specialty Group, Inc. at 212.208.3257 or the Corporate Secretary of Octave Specialty Group, Inc. at 212.658.7456.***

**\* \* \* \***

**a)&nbsp;&nbsp;&nbsp;&nbsp;Is the information "*material?"***

*The explanation that follows should help you identify what Material Nonpublic Information is, and when material information that has been disclosed to the public has been sufficiently absorbed by the marketplace.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(i) What is "material" information?***

*"Material"* information is any information, either positive or negative, that a reasonable investor would consider important in deciding whether to buy, hold or sell a security (e.g., stock, bonds, notes)**.** In practice, any important development affecting the business or financial condition of an issuer or that would affect the market price of its securities is most likely material.

Whether information is material depends upon the circumstances. Information may be material even if it relates to future, speculative or contingent events and even if it is significant only when considered in combination with publicly available information.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(ii) What are some examples of "*material"* information?**

Information about the following subjects is often regarded as material:

---

| | |
|:---|:---|
| *• earnings estimates* | *• dividend changes* |
| *• additions to reserves* | *• expansion or curtailment of operations* |
| *• new products* | *• major litigation* |
| *• liquidity problems* | *• contests for corporate control* |
| *• proposed transactions such as tender offers, acquisitions, mergers, restructurings, or sales of assets or subsidiaries or joint ventures* | *• anticipated public offerings of securities* |
| *• government, regulatory or court actions that are likely to have an effect on the issuer* | *• changes in ratings of debt securities* |
| | *• breaches of covenants in financing documents* |

---

*Remember, if your securities transactions become the subject of scrutiny, the SEC and others will decide what is material after-the-fact, with the clarity of 20/20 hindsight. Therefore, before engaging in any transaction, you should carefully consider how regulators and others might view your transaction in hindsight.*

***If you have any questions about what is and is not considered "material information," you should discuss them with the General Counsel of Octave Specialty Group, Inc. at 212.208.3257 or the Corporate Secretary of Octave Specialty Group, Inc. at 212.658.7456.***

***&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;Is the information considered "non-public?"***

*"Non-public"* information is any information that has not yet been disclosed to the public. This includes confidential analyses, financial information, business data and plans of Octave or another issuer, as well as information received from a client or third party with the expectation that it will be kept confidential and used solely for business purposes.

As a rule, you should be able to point to some fact to show that the information has been publicly disclosed. For example, an announcement in the Wall Street Journal or other major news publication, disclosure on the Dow Jones broad tape or other major news wire service such as Reuters, or its public filing with the SEC. However, mere rumors printed in the trade press or an announcement by a client or government agency may <u>not</u> be enough.

*Remember that your good faith belief that material information has been made public at the time you trade does <u>not</u> relieve you from liability if you are wrong.*

***If you have any questions regarding whether certain information is considered "non-public" you should discuss them with the General Counsel of Octave Specialty Group, Inc. at 212.208.3257 or the Corporate Secretary of Octave Specialty Group, Inc. at 212.658.7456.***

***&nbsp;&nbsp;&nbsp;&nbsp;(c) &nbsp;&nbsp;&nbsp;&nbsp;If the information is material but has been publicly disclosed, &nbsp;&nbsp;&nbsp;&nbsp;has the marketplace had the opportunity to absorb the information?***

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**It is improper for you to enter a trade immediately after Octave has made a public announcement of material information, including earnings releases.** Octave's stockholders and the investing public must be afforded time to receive the information and act upon it.

**<u>Trading after the regular quarterly earnings are released</u>.** As discussed in Section 5 below, you are prohibited from trading in Octave Related Securities during each of the approximately five week "*blackout periods"* that begin following the third business day of the new quarter and end on the second business day after each regular quarterly publication of financial information.

**<u>Trading after other material developments are disclosed</u>**. If material information other than regular quarterly financial information is announced (*and you would otherwise be allowed to trade because it is not a blackout period*), Octave requires that you follow **the two-day rule**: you may not trade and you may not communicate the information to others who may trade until the second business day after the information has been released to the public. Thus, if an announcement were made on a Monday, Wednesday would be the first day on which you may trade. If an announcement were made on a Friday, Tuesday would be the first day.

**<u>Trading in the securities of other issuers</u>**. If you obtain "*material"* information about a client, a transaction or third party as a result of your employment at Octave, Octave also requires that you follow the two-day rule and refrain from trading in the securities of such issuer, whether trading on behalf of yourself or Octave, or communicating information to others who may trade until the second business day after such information has been released to the public by such issuer.

***If you are not sure about when you can and cannot make a trade in Octave Related Securities, you should discuss them with the General Counsel of Octave Specialty Group, Inc. at 212.208.3257 or the Corporate Secretary of Octave Specialty Group, Inc. at 212.658.7456.***

***4.Who is a "Related Person?"***

For the purposes of this Policy, a "Related Person," includes your spouse, minor children and anyone else living in your household; partnerships in which you are a general partner; trusts of which you are a trustee; and estates of which you are an executor. Your parents, children or siblings who do not live in the same household with you may be considered Related Persons if their transactions in Octave Related Securities are directed by the insider or are subject to your influence or control (such as parents, children or siblings who consult with you before they trade in Octave Related Securities).

**You are expected to be responsible for the compliance of a Related Person as well as your own.**

***5. &nbsp;&nbsp;&nbsp;&nbsp;Are there times during the year when I may <u>not</u> trade in Octave Related Securities?***

**Yes. Octave imposes four mandatory no-trading periods each year. They are called "*blackout periods."***

Each blackout period runs for approximately five to six weeks and commences following the third business day of a calendar quarter until the <u>second business day</u> after the publication of financial information for the preceding quarterly/annual period. Each blackout period effectively incorporates the two-day rule.

The purpose of blackout periods is to help prevent inadvertent violations and to avoid even the appearance of an improper transaction when material information has not yet been disclosed to the public.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**You and Related Persons are prohibited from engaging in any transactions in Octave Related Securities during the four blackout periods. These transactions include:** *buying or selling Octave Related Securities in the open market; exercising stock options; and buying, selling or otherwise transacting in Octave Related Securities.*

***Again, as mentioned earlier, Octave Related Securities mean not only Octave common stock, but also Octave debt securities, any other securities issued by Octave.***

Periodically, Octave Specialty Group, Inc.'s Corporate Secretary Office will provide all employees with a schedule of the four (4) blackout periods for the current or upcoming year.

***6.&nbsp;&nbsp;&nbsp;&nbsp;Am I prohibited from engaging in certain types of transactions in Octave Related Securities, such as short sales, puts, calls and equity swaps?***

Yes. You and your Related Persons are prohibited from making short sales or engaging in transactions involving puts, calls and other types of options in Octave Related Securities, including equity swaps and similar derivative transactions. Investing in Octave Related Securities provides an opportunity to share in the future growth of the company. Investment in Octave and sharing in its growth, however, does not mean short-range speculation based on fluctuations in the market. These activities may put your personal gain in conflict with the best interests of Octave and its stockholders. However, it is perfectly proper for you to exercise your Octave employee stock options -- assuming, of course, that we are not in a blackout period and that you do not possess Material Nonpublic Information. The purpose of this restriction is to avoid even the appearance that Octave's employees are speculating in Octave Related Securities for personal gain.

Because securities held in a margin account or pledged as collateral may be sold without your consent if you fail to meet a margin call or if you default on a loan, a margin or foreclosure sale may result in unlawful insider trading. Because of this danger, Octave Related Securities should not be included in a margin account or be pledged as collateral for a loan.

***7.&nbsp;&nbsp;&nbsp;&nbsp;How should I respond to requests for information?***

You may find yourself the recipient of questions concerning various activities of Octave. Such inquiries can come from the media, securities analysts and others regarding Octave's business, rumors, trading activity, current and future prospects and plans, acquisition or divestiture activities and other similar important information. Under no circumstances should you attempt to handle these inquiries without prior authorization from the CEO, the CFO, or the Managing Director of Investor Relations and Corporate Communications. Only Octave individuals specifically authorized to do so by Octave's Regulation FD Policy may answer questions about or disclose information concerning Octave.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Refer requests for information regarding Octave from the financial community, such as securities analysts, brokers or investors, to the Managing Director of Investor Relations and Corporate Communications.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Refer requests for information regarding Octave from the media or press to Octave's Managing Director of Investor Relations and Corporate Communications.

Refer requests for information from the SEC or other regulators to Octave's General Counsel or Corporate Secretary.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***8.&nbsp;&nbsp;&nbsp;&nbsp;What should I be concerned about in my dealings with financial analysts, investors, and the press?***

**Regulation FD.** Octave is committed to fair disclosure to investors in compliance with all applicable securities laws and regulations, including SEC Regulation FD. Regulation FD prohibits public corporations from selectively disclosing Material Nonpublic Information to securities analysts, broker-dealers, other securities market professionals and stockholders who may trade on the basis of the information ("*Securities Professionals*").

Whenever Octave (or person acting on its behalf) discloses Material Nonpublic Information to Securities Professionals, Octave, under Regulation FD must simultaneously make public disclosure of the information in question. If Octave learns that it has unintentionally disclosed Material Nonpublic Information, it must issue a press release making the information public within 24 hours.

To avoid violation of Regulation FD, Octave must strictly adhere to disciplined procedures and recordkeeping with respect to formal and informal contacts with Securities Professionals.

Responses to inquiries by financial analysts, stockholders, the press and others who have a legitimate interest in our affairs should only be given in accordance with Octave's Regulation FD Policy. Unless specifically authorized to respond to such inquiries, you should refer such inquiries to the Managing Director of Investor Relations and Corporate Communications.

***If you inadvertently disclose Material Nonpublic Information, or discover that someone else inside or outside Octave has, you should immediately report the facts to the General Counsel or the Corporate Secretary of Octave Specialty Group, Inc. for a decision regarding appropriate remedial steps.***

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***9.&nbsp;&nbsp;&nbsp;&nbsp;What steps should I take to preserve confidential information?***

There are some very simple, common sense steps that you can take to preserve the confidentiality of information related to Octave's business:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Don't discuss business or office matters in elevators, hallways, restaurants, airplanes, taxicabs or any place where you can be overheard.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Don't gossip about Octave affairs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Don't read documents containing confidential information in public places or discard them where they can be retrieved by others.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Don't carry documents containing confidential information in elevators, hallways, etc., in an exposed manner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Beware of the carrying quality of conversations conducted on cell phones and speaker telephones in offices, or on airplane telephones, etc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Do not give your computer IDs and passwords to any other person. Password protect computers and log off when they are not in use.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Be aware that the Internet and other external electronic mail carriers are not secure environments for the transmission of confidential information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Don't leave documents containing confidential information in unattended conference rooms; don't leave documents behind when the meeting is over.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cover documents containing confidential information on your desk before you leave your office or work area and don't leave confidential papers lying where visitors can see them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Don't give out the whereabouts of personnel not in the office or reveal the presence of specific visitors to the office except when authorized. The mere fact of a meeting or the destination of a trip may reveal something confidential.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Comply with the specific terms of any confidentiality agreements of which you are aware.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Upon termination of your employment, you must return to the Company all physical (including electronic) copies of confidential information as well as all other material embodied in any physical or electronic form that is based on or derived from such information, without retaining any copies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• You may not bring the confidential information of any former employer to the Company.

Obviously, a list such as this can only be suggestive. It is the responsibility of each employee to take whatever practicable steps are appropriate to preserve the confidentiality of Octave information.

In the normal course of your duties, you will often receive information about Octave's plans, prospects or operations and operating results. Remember that such information is not your personal property but is an asset of Octave. It must not be used or passed on to others except

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

through regular Octave channels, which assure fair access to all persons interested in the prospects of Octave and Octave Related Securities.

***10.&nbsp;&nbsp;&nbsp;&nbsp;What happens if I become aware of a violation of Octave's Insider Trading Policy?***

You should refer any suspected violations of Octave's Insider Trading Policy to Octave's Group Compliance Officer, General Counsel or Corporate Secretary. In addition, if you:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• receive Material Nonpublic Information that you are not authorized to receive or that you do not legitimately need to know to perform your employment responsibilities, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• receive confidential information and are unsure if it is within the definition of Material Nonpublic Information or whether its release might be contrary to a fiduciary or other duty or obligation,

you should not share it with anyone. To seek advice about what to do under those circumstances, you should contact Octave's General Counsel or Corporate Secretary. Consulting your colleagues can have the effect of exacerbating the problem. Containment of the information, until the legal implications of possessing it are determined, is critical.

***11.&nbsp;&nbsp;&nbsp;&nbsp;What are the consequences if I violate Octave's Insider Trading Policy?***

Octave will monitor compliance with the guidelines and procedures set forth in this Policy.

Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are no exception to Octave policy. Even the appearance of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.

If you violate Octave's Insider Trading Policy, we will treat it very seriously and impose sanctions, including suspension without pay or dismissal for cause. Of course, if you fail to comply, you also risk the substantial personal liability and criminal penalties described in Section 1. Any of the legal consequences of violating the insider trading laws -- even an SEC investigation that does not result in prosecution -- can drain your financial resources, tarnish your reputation and irreparably damage your career.

Every insider has the individual responsibility to comply with this Policy against insider trading. An insider may, from time to time, have to forego a proposed transaction in Octave Related Securities even if he or she planned to make the transaction before learning of the Material Nonpublic Information and even though the insider believes he or she may suffer an economic loss or forego anticipated profit by waiting. Prior to effecting a transaction in Octave Related Securities, one should consider potential future trading restrictions as part of his or her investment decision. Octave believes that such lost opportunities are a necessary consequence of its commitment to compliance with laws and to fair and equitable trading markets.

***12.&nbsp;&nbsp;&nbsp;&nbsp;Do these policies and procedures affect me after I retire or if my employment terminates?***

No. Once you have retired or if your employment terminates, you may exercise options (and sell the shares resulting from such option exercise) or buy and sell Octave Related Securities at any time including during a blackout period.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

However, if you retire or leave the employment of Octave, you will still be bound by federal securities laws that prohibit you from trading in securities on the basis of Material Non-Public Information. (*And, if you are an "insider," you will be subject for some period of time to the special Section 16 rules as well*.)

***13.&nbsp;&nbsp;&nbsp;&nbsp;Do I have to acknowledge my understanding and acceptance of Octave's policies?***

Yes. You are required to certify to Octave that you have read and understand Octave's Insider Trading Policy and that you will comply with the guidelines and procedures set forth therein. Every director, officer and employee must either sign the Certification which accompanies this Policy, and return it within five (5) business days of receipt or electronically acknowledge the Certification. This Certification will be kept as a permanent part of your personnel file. ***See <u>Appendix A</u> for the form of the Certification***.

***14.&nbsp;&nbsp;&nbsp;&nbsp;What happens if I do not sign or acknowledge the Certification?***

It is necessary for each of us to sign or electronically acknowledge the Certification. If anyone does not, it will be considered a very serious matter and will result in suspension or discharge.

***15.&nbsp;&nbsp;&nbsp;&nbsp;What if I do not fully understand something in the Policy?***

We want you to clearly understand our policies and procedures. So, if you have any questions at all about any of them -- or about what you should do in a particular situation -- **you should discuss it with the General Counsel of Octave Specialty Group, Inc. 212.208.3257 or the Corporate Secretary of Octave Specialty Group, Inc. 212.658.7456.**

***Remember, however, that the ultimate responsibility for adhering to these policies and procedures and avoiding improper transactions rests with you.***

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***16.&nbsp;&nbsp;&nbsp;&nbsp;Are there additional restrictions and requirements for Directors and Executive Officers?***

**Yes. First, directors and executives officers need to complete Form A to pre-clear any proposed securities transaction which are subject to the Insider Trading Policy. Form A may be obtained from the Corporate Secretary. In addition, there are two reports that Directors and Executive Officers may have to file with the SEC when they are engaging in a transaction in any security issued by Octave Specialty Group, Inc. These are Section 16 Reports and Form 144 Reports. <u>Section 16 Reports</u>.** Executive officers and all of Octave's directors (as well as certain large stockholders) are obligated to file reports under Section 16 promulgated under the Exchange Act in connection with most transactions conducted by such persons in Octave equity securities. Although the General Counsel's office may assist reporting persons in preparing and filing the required reports, the reporting persons retain full responsibility for the preparation and filing of such reports. Reporting persons must advise and receive prior approval from the Corporate Secretary or General Counsel before engaging in any such transactions. Failure of such persons to make the required filings in a timely manner must be reported by the Company in its proxy statement filed with the SEC and sent to the Company's stockholders, in addition to other penalties.

The following individuals and entities are obligated to file Section 16 reports:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• directors of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• officers of the Company designated as "executive officers" for SEC reporting purposes by the Board of Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• persons or entities with beneficial ownership, directly or indirectly, of more than ten percent (10%) of any class of equity securities of Octave that is registered with the SEC.

Persons and entities subject to Section 16 must also comply with the limitations on short-swing transactions set forth therein. Generally, the effect of these provisions is that persons and entities that are subject to Section 16 who purchase and sell Octave equity securities within a six-month period <u>must</u> disgorge all profits to Octave whether or not they had knowledge of any material nonpublic information. Under these provisions, so long as certain other criteria are met, neither the receipt of an equity-based award or option under Octave's Incentive Compensation Plans, nor the exercise of those awards or options, nor the receipt of stock under any Octave employee stock option plan is deemed a purchase under Section 16. However, the sale of any shares acquired pursuant to the exercise of options, or the settlement of Restricted Stock Units (RSUs), is a sale under Section 16.

**<u>Form 144 Reports</u>**. Directors and executive officers of Octave are required to file a Form 144 before making an open market sale of Octave equity securities. A Form 144 notifies the SEC of one's intent to sell certain Octave equity securities. This form is generally prepared and filed by the seller's broker and is in addition to any required Section 16 reports. Octave's General Counsel or Corporate Secretary will be available to answer any questions regarding the need to file a Form 144.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**<u>Appendix A</u>**

**Form of Certification**

I have read and understand Octave's Insider Trading Policy (the "Policy").

I agree that I will comply with the guidelines and procedures set forth in the Policy. I understand and agree that, if I am an employee of Octave or one of its subsidiaries or other affiliates, my failure to comply in all respects with the Octave's policies, including the Policy, is a basis for termination for cause of my employment with Octave and any subsidiary or other affiliate to which my employment now relates or may in the future relate.

I am aware that this signed Certification will be filed with my personal records in the Octave's Human Resources Department.

Signature:__________________________________________

Print Name:________________________________________

Title:______________________________________________

Company:__________________________________________

Department:________________________________________

Date:______________________________________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>***If you are signing this Certification in lieu of submitting an electronic confirmation, please return the executed Certification within***<br>***five (5) business days of receipt to:***<br>Office of the Corporate Secretary<br>Octave Specialty Group, Inc.<br>One World Trade Center, 41st Floor<br>New York, New York 10007<br>Attention: William White<br>Telephone: 212.658.7456<br>Fax Number: 212.208.3442<br>

## Exhibit 21.1

**Exhibit 21.1**

**<u>List of Subsidiaries of Octave Specialty Group, Inc.</u>**

The following is a list of significant and other subsidiaries of Octave Specialty Group, Inc. The state of incorporation of each subsidiary is included in parentheses after its name.

---

| | |
|:---|:---|
| **Name** | **State of Incorporation** |
| **All Trans Risk Solutions, LLC** | (New Jersey) |
| **Ambac Asset Management, Inc.** | (Delaware) |
| **Capacity Marine Corporation** | (New Jersey) |
| **Octave Partners LLC** | (Delaware) |
| **Cirrata Partners Insurance Agency, LLC** | (Delaware) |
| **Cirrata IV, LLC** | (Delaware) |
| **Cirrata V LLC** | (Delaware) |
| **Cirrata V UK Limited** | (United Kingdom private limited company) |
| **Cirrata VI LLC** | (Delaware) |
| **ArmadaCorp Capital, LLC** | (Maryland) |
| **ArmadaCare, LLC** | (Maryland) |
| **ArmadaAdministrators, LLC** | (Maryland) |
| **Pivix Specialty Insurance Services, Inc.** | (Arizona) |
| **Octave Specialty Limited** | (United Kingdom corporation) |
| **Everspan Holdings, LLC** | (Delaware) |
| **Everspan Indemnity Insurance Company** | (Arizona) |
| **Everspan Insurance Company** | (Arizona) |
| **Greenwood Insurance Company** | (Pennsylvania) |
| **Providence Washington Insurance Company** | (Rhode Island) |
| **PWIC Holdings, Inc.** | (Delaware) |
| **Consolidated Specialty Insurance Company** | (Arizona) |
| **Redgrove Capital Group LLC** | (Delaware) |
| **Riverton Insurance Agency, Corp.** | (New Jersey) |
| **Tara Hill Insurance Services, LLC** | (Delaware) |
| **22 Degrees Business Services LLC** | (Delaware) |
| **Xchange Benefits, LLC** | (Delaware) |
| **Xchange Re Underwriting Agency, LLC** | (Delaware) |
| **Distribution Re LLC** | (Tennessee) |
| **Beat Capital Partners Limited** | (United Kingdom corporation) |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of lndependent Registered Public Accounting Firm**

We consent to the incorporation by reference in the registration statements Nos. 333-245008 and 333-281432 on Form S-8, and registration statement No. 333-281188 on Form S-3ASR of our reports dated March 4, 2026, with respect to the consolidated financial statements of Octave Specialty Group, Inc. and the effectiveness of internal control over financial reporting.

/s/ **KPMG LLP**

New York, New York

March 4, 2026

## Exhibit 24.1

**Exhibit 24.1**

**<u>POWER OF ATTORNEY</u>**

KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below constitutes and appoints each of Lawrence Metz and William J. White, as such person's true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, for such person and in their name, place and stead, in any and all capacities, to sign Octave Specialty Group, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025 to be filed with the Securities and Exchange Commission and any and all amendments thereto, and any and all instruments and documents filed as a part of or in connection with said Form 10-K or amendments thereto, and does hereby grant unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that each said attorney-in-fact and agent shall do or cause to be done by virtue hereof.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /S/ JEFFREY S. STEIN | Chairman of the Board and Director | March 4, 2026 |
| Jeffrey S. Stein |  |  |
| /S/ CLAUDE LeBLANC | President, Chief Executive Officer and Director | March 4, 2026 |
| Claude LeBlanc | (Principal Executive Officer) |  |
| /S/ DAVID TRICK | Executive Vice President and Chief Financial Officer | March 4, 2026 |
| David Trick | (Principal Financial Officer) |  |
| /S/ CRISTINA AHN | Chief Accounting Officer | March 4, 2026 |
| Cristina Ahn | (Principal Accounting Officer) |  |
| /S/ IAN D. HAFT | Director | March 4, 2026 |
| Ian D. Haft |  |  |
| /S/ LISA G. IGLESIAS | Director | March 4, 2026 |
| Lisa G. Iglesias |  |  |
| /S/ JOAN LAMM - TENNANT | Director | March 4, 2026 |
| Joan Lamm-Tennant |  |  |
| /S/ KRISTI A. MATUS | Director | March 4, 2026 |
| Kristi A. Matus |  |  |
| /S/ MICHAEL D. PRICE | Director | March 4, 2026 |
| Michael D. Price |  |  |

---

## Exhibit 31.1

**EXHIBIT 31.1** 

**Ambac Financial Group, Inc.** 

**Certifications** 

I, Claude LeBlanc, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025 of Ambac Financial Group, Inc. (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a—15(e) and 15d—15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Dated: | March 4, 2026 | By: | /s/ Claude LeBlanc |
|  |  |  | Claude LeBlanc |
|  |  |  | President and Chief Executive Officer |

---

## Exhibit 31.2

**EXHIBIT 31.2** 

**Ambac Financial Group, Inc.** 

**Certifications** 

I, David Trick, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025 of Ambac Financial Group, Inc (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a—15(e) and 15d—15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Dated: | March 4, 2026 | By: | /s/ David Trick |
|  |  |  | David Trick |
|  |  |  | Executive Vice President and Chief Financial Officer |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**Certification of CEO Pursuant to** 

**18 U.S.C. Section 1350,** 

**as Adopted Pursuant to** 

**Section 906 of the Sarbanes-Oxley Act of 2002** 

In connection with the **Annual** Report on Form **10-K** of Ambac Financial Group, Inc. (the "Company") for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Claude LeBlanc, as Chief Executive Officer of the Company, and David Trick, as Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| | | By: | /s/ Claude LeBlanc |
| | | Name: | |
| | | Title: | |
| | | By: | Claude LeBlanc<br>President and Chief Executive Officer<br>/s/ David Trick |
| | | Name: | David Trick |
| | | Title: | Executive Vice President and Chief Financial Officer |
| Dated: | March 4, 2026 |  |  |

---

<br>